U.S. patent number 9,598,427 [Application Number 14/797,532] was granted by the patent office on 2017-03-21 for pyrrole compounds, a process for their preparation and pharmaceutical compositions containing them.
This patent grant is currently assigned to LES LABORATOIRES SERVIER, VERNALIS (R&D) LTD. The grantee listed for this patent is LES LABORATOIRES SERVIER, VERNALIS (R&D) LTD. Invention is credited to I-Jen Chen, James Edward Paul Davidson, Guillaume De Nanteuil, Didier Durand, Imre Fejes, Olivier Geneste, Anne-Francoise Guillouzic, Jean-Michel Henlin, Thierry Le Diguarher, Arnaud Le Tiran, James Brooke Murray, Miklos Nyerges, Jerome-Beno t Starck, Janos Tatai.
United States Patent |
9,598,427 |
Le Tiran , et al. |
March 21, 2017 |
Pyrrole compounds, a process for their preparation and
pharmaceutical compositions containing them
Abstract
Compounds of formula (I): ##STR00001## wherein A.sub.1, A.sub.2,
R.sub.a, R.sub.b, R.sub.c, R.sub.d, R.sub.3, R.sub.4, R.sub.5 and T
are as defined in the description. Medicinal products containing
the same which are useful in treating pathologies involving a
deficit in apoptosis, such as cancer, auto-immune diseases, and
diseases of the immune system.
Inventors: |
Le Tiran; Arnaud (Croissy sur
Seine, FR), Le Diguarher; Thierry (Saint Denis de
l'Hotel, FR), Starck; Jerome-Beno t (Rueil-Malmaison,
FR), Henlin; Jean-Michel (Suresnes, FR),
Guillouzic; Anne-Francoise (Nanterre, FR), De
Nanteuil; Guillaume (Suresnes, FR), Geneste;
Olivier (Rueil-Malmaison, FR), Fejes; Imre
(Budapest, HU), Tatai; Janos (Budapest,
HU), Nyerges; Miklos (Leanyfalu, HU),
Davidson; James Edward Paul (Great Shelford, GB),
Murray; James Brooke (Linton, GB), Chen; I-Jen
(Cambridge, GB), Durand; Didier (Chambourcy,
FR) |
Applicant: |
Name |
City |
State |
Country |
Type |
LES LABORATOIRES SERVIER
VERNALIS (R&D) LTD |
Suresnes
Winnersh |
N/A
N/A |
FR
GB |
|
|
Assignee: |
LES LABORATOIRES SERVIER
(Suresnes, FR)
VERNALIS (R&D) LTD (Winnersh, GB)
|
Family
ID: |
50023639 |
Appl.
No.: |
14/797,532 |
Filed: |
July 13, 2015 |
Prior Publication Data
|
|
|
|
Document
Identifier |
Publication Date |
|
US 20150313907 A1 |
Nov 5, 2015 |
|
Related U.S. Patent Documents
|
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
Issue Date |
|
|
14336311 |
Jul 21, 2014 |
9108983 |
|
|
|
Foreign Application Priority Data
|
|
|
|
|
Jul 23, 2013 [FR] |
|
|
13 57258 |
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61K
31/4725 (20130101); A61P 37/00 (20180101); C07D
498/04 (20130101); A61K 31/496 (20130101); A61K
45/06 (20130101); A61K 9/2059 (20130101); A61P
37/02 (20180101); C07D 491/10 (20130101); A61K
31/5377 (20130101); A61K 31/5383 (20130101); C07D
405/14 (20130101); C07D 471/04 (20130101); A61P
25/28 (20180101); C07D 498/14 (20130101); A61P
37/06 (20180101); A61K 31/506 (20130101); C07D
401/14 (20130101); A61P 35/02 (20180101); A61P
43/00 (20180101); C07D 401/10 (20130101); A61P
35/00 (20180101); C07D 491/107 (20130101); A61K
31/5377 (20130101); A61K 2300/00 (20130101); A61K
31/4725 (20130101); A61K 2300/00 (20130101) |
Current International
Class: |
C07D
401/14 (20060101); A61K 9/20 (20060101); C07D
498/14 (20060101); A61K 31/506 (20060101); A61K
31/5383 (20060101); A61K 31/496 (20060101); A61K
31/5377 (20060101); A61K 31/4725 (20060101); A61K
45/06 (20060101); C07D 498/04 (20060101); C07D
491/10 (20060101); C07D 471/04 (20060101); C07D
401/10 (20060101); C07D 405/14 (20060101); C07D
491/107 (20060101); A61K 31/47 (20060101) |
References Cited
[Referenced By]
U.S. Patent Documents
Foreign Patent Documents
|
|
|
|
|
|
|
2009105195 |
|
Aug 2010 |
|
RU |
|
WO 02/46171 |
|
Jun 2002 |
|
WO |
|
WO 2006/023778 |
|
Mar 2006 |
|
WO |
|
WO 2008/008912 |
|
Jan 2008 |
|
WO |
|
WO 2009/073545 |
|
Jun 2009 |
|
WO |
|
WO 2010/080503 |
|
Jul 2010 |
|
WO |
|
WO2012/162365 |
|
Nov 2012 |
|
WO |
|
WO 2013/096060 |
|
Jun 2013 |
|
WO |
|
WO 2013/110890 |
|
Aug 2013 |
|
WO |
|
Other References
Ashkenazi, Nature Reviews Drug Discovery, Focus on Apoptosis, vol.
7, Dec. 2008, pp. 1001-1012. cited by examiner .
French Preliminary Search Report for FR 13/57258 of Feb. 17, 2014.
cited by applicant .
Deng, et al., Cancer Cell, 2007, 12, 171-185. cited by applicant
.
Hanada, et al., Blood, 1993, 82, 1820-1828. cited by applicant
.
Hockenbery, et al., Proc. Natl. Acad. Sci. USA, 1991, 88,
6961-6965. cited by applicant .
Juin, et al., Nature Reviews Cancer, 2013, 13, 455-465. cited by
applicant .
Kelly, et al., Cell Death and Differentiation, 2011, 18, 1414-1424.
cited by applicant .
Kirkin, et al., Biochimica at Biophysica Acta, 2004, 1644, 229-249.
cited by applicant .
Letai, et al., Blood, 2005, 106, 5008. cited by applicant .
Monni, et al., Blood, 1997, 90, 1168-1174. cited by applicant .
Slavov, et al., Proc. Natl. Acad. Sci. USA, 2009, 106, 4079-4084.
cited by applicant .
Tsujimoto, et al., Science, 1985, 228, 1440-1443. cited by
applicant .
Vaux, et al., Nature, 1988, 335, 440-442. cited by applicant .
Yip, et al., Oncogene, 2008, 27, 6398-6406. cited by
applicant.
|
Primary Examiner: Davis; Zinna Northington
Attorney, Agent or Firm: Hueschen and Sage
Claims
The invention claimed is:
1. A method of treating cancer in a subject in need thereof,
wherein the cancer is selected from the group consisting of cancers
of the bladder, brain, breast and uterus, chronic lymphoid
leukaemias, colorectal cancer, cancers of the esophagus and liver,
lymphoblastic leukaemias, non-Hodgkin lymphomas, melanomas,
malignant haemopathies, myelomas, ovarian cancer, non-small-cell
lung cancer, prostate cancer, and small-cell lung cancer,
comprising administration of an effective amount of a compound of
formula (I): ##STR00015## wherein: A.sub.1 and A.sub.2, each
independently of the other, represent a hydrogen atom, a halogen
atom, a linear or branched (C.sub.1-C.sub.6)polyhaloalkyl group, a
linear or branched (C.sub.1-C.sub.6)alkyl group or a cycloalkyl
group; T represents a hydrogen atom, a linear or branched
(C.sub.1-C.sub.6)alkyl group optionally substituted by from one to
three halogen atoms, a (C.sub.1-C.sub.4)alkyl-NR.sub.1R.sub.2
group, or a (C.sub.1-C.sub.4)alkyl-OR.sub.6 group; R.sub.1 and
R.sub.2, each independently of the other, represent a hydrogen atom
or a linear or branched (C.sub.1-C.sub.6)alkyl group, or R.sub.1
and R.sub.2 form with the nitrogen atom carrying them a
heterocycloalkyl; R.sub.3 represents a linear or branched
(C.sub.1-C.sub.6)alkyl group, a linear or branched
(C.sub.2-C.sub.6)alkenyl group, a linear or branched
(C.sub.1-C.sub.6)alkynyl group, a cycloalkyl group, a
(C.sub.3-C.sub.10)cycloalkyl-(C.sub.1-C.sub.6)alkyl group wherein
the alkyl moiety is linear or branched, a heterocycloalkyl group,
an aryl group or a heteroaryl group, wherein one or more of the
carbon atoms of the preceding groups, or of their possible
substituents, may be deuterated; R.sub.4 represents an aryl group,
a heteroaryl group, a cycloalkyl group or a linear or branched
(C.sub.1-C.sub.6)alkyl group, wherein one or more of the carbon
atoms of the preceding groups, or of their possible substituents,
may be deuterated; R.sub.5 represents a hydrogen or halogen atom, a
linear or branched (C.sub.1-C.sub.6)alkyl group, or a linear or
branched (C.sub.1-C.sub.6)alkoxy group; R.sub.6 represents a
hydrogen atom or a linear or branched (C.sub.1-C.sub.6)alkyl group;
R.sub.a, R.sub.b, R.sub.c and R.sub.d, each independently of the
others, represent a hydrogen atom, a linear or branched
(C.sub.1-C.sub.6)alkyl group, a linear or branched
(C.sub.2-C.sub.6)alkenyl group, a linear or branched
(C.sub.2-C.sub.6)alkynyl group, an aryl group, a heteroaryl group,
a halogen atom, a linear or branched (C.sub.1-C.sub.6)alkoxy group,
a hydroxy group, a linear or branched
(C.sub.1-C.sub.6)polyhaloalkyl group, a trifluoromethoxy group,
--NR.sub.7R.sub.7', nitro, R.sub.7--CO--(C.sub.0-C.sub.6)alkyl-,
R.sub.7--CO--NH--(C.sub.0-C.sub.6)alkyl-,
NR.sub.7R.sub.7'--CO--(C.sub.0-C.sub.6)alkyl-,
NR.sub.7R.sub.7'--CO--(C.sub.0-C.sub.6)alkyl-O--,
R.sub.7--SO.sub.2--NH--(C.sub.0-C.sub.6)alkyl-,
R.sub.7--NH--CO--NH--(C.sub.0-C.sub.6)alkyl-,
R.sub.7--O--CO--NH--(C.sub.0-C.sub.6)alkyl-, a heterocycloalkyl
group, or the substituents of one of the pairs (R.sub.a,R.sub.b),
(R.sub.b,R.sub.c), or (R.sub.c,R.sub.d) form together with the
carbon atoms carrying them a ring composed of from 5 to 7 ring
members, which ring may have from one to 2 hetero atoms selected
from oxygen and sulphur, wherein one or more carbon atoms of the
ring defined hereinbefore may be deuterated or substituted by from
one to 3 groups selected from halogen and linear or branched
(C.sub.1-C.sub.6)alkyl; R.sub.7 and R.sub.7', each independently of
the other, represent a hydrogen atom, a linear or branched
(C.sub.1-C.sub.6)alkyl group, a linear or branched
(C.sub.2-C.sub.6)alkenyl group, a linear or branched
(C.sub.2-C.sub.6)alkynyl group, an aryl group or a heteroaryl
group, or R.sub.7 and R.sub.7', together with the nitrogen atom
carrying them, form a heterocycle composed of from 5 to 7 ring
members; it being understood that: "aryl" means a phenyl, naphthyl,
biphenyl or indenyl group, "heteroaryl" means any mono- or
bi-cyclic group composed of from 5 to 10 ring members, having at
least one aromatic moiety and having from 1 to 4 hetero atoms
selected from oxygen, sulphur and nitrogen (including quaternary
nitrogens), "cycloalkyl" means any mono- or bi-cyclic,
non-aromatic, carbocyclic group having from 3 to 10 ring members,
"heterocycloalkyl" means any mono- or bi-cyclic, non-aromatic,
condensed or Spiro group composed of from 3 to 10 ring members and
having from 1 to 3 hetero atoms selected from oxygen, sulphur, SO,
SO.sub.2 and nitrogen, wherein the aryl, heteroaryl, cycloalkyl and
heterocycloalkyl groups so defined and the alkyl, alkenyl, alkynyl
and alkoxy groups may be optionally substituted by from 1 to 3
groups selected from optionally substituted, linear or branched
(C.sub.1-C.sub.6)alkyl, (C.sub.3-C.sub.6)spiro, optionally
substituted, linear or branched (C.sub.1-C.sub.6)alkoxy,
(C.sub.1-C.sub.6)alkyl-S--, hydroxy, oxo (or N-oxide where
appropriate), nitro, cyano, --COOR', --OCOR', NR'R'', linear or
branched (C.sub.1-C.sub.6)polyhaloalkyl, trifluoromethoxy,
(C.sub.1-C.sub.6)alkylsulphonyl, halogen, optionally substituted
aryl, heteroaryl, aryloxy, arylthio, cycloalkyl, heterocycloalkyl
optionally substituted by one or more halogen atoms or alkyl
groups, wherein R' and R'', each independently of the other,
represent a hydrogen atom or an optionally substituted, linear or
branched (C.sub.1-C.sub.6)alkyl group, or an enantiomer, a
diastereoisomer, or an addition salt thereof with a
pharmaceutically acceptable acid or base.
2. The method according to claim 1, wherein A.sub.1 represents a
hydrogen atom or a methyl group.
3. The method according to claim 1, wherein A.sub.2 represents a
linear or branched (C.sub.1-C.sub.6)alkyl group optionally
substituted by a group selected from halogen, hydroxy, linear or
branched (C.sub.1-C.sub.6)alkoxy, NR'R'' and morpholine.
4. The method according to claim 1, wherein A.sub.2 represents a
linear or branched (C.sub.1-C.sub.6)polyhaloalkyl group or a
cyclopropyl group.
5. The method according to claim 1, wherein A.sub.1 and A.sub.2
both represent a methyl group.
6. The method according to claim 1, wherein T represents methyl,
aminomethyl, (morpholin-4-yl)methyl,
(4-methylpiperazin-1-yl)methyl, 2-(morpholin-4-yl)ethyl,
[2-(morpholin-4-yl)ethoxy]methyl, hydroxymethyl,
[2-(dimethylamino)ethoxy]methyl,
hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-ylmethyl,
1-oxa-6-azaspiro[3.3]hept-6-ylmethyl, 3-(morpholin-4-yl)propyl or
trifluoromethyl.
7. The method according to claim 1, wherein R.sub.a and R.sub.d
each represent a hydrogen atom and (R.sub.b,R.sub.c), together with
the carbon atoms carrying them, form a 1,3-dioxolane group or a
1,4-dioxane group; or R.sub.a, R.sub.c and R.sub.d each represent a
hydrogen atom and R.sub.b represents a hydrogen atom, a halogen
atom, or a methoxy group.
8. The method according to claim 1, wherein R.sub.a and R.sub.d
each represent a hydrogen atom, R.sub.b represents a hydrogen or
halogen atom and R.sub.c represents a hydroxy or methoxy group; or
R.sub.a and R.sub.d each represent a hydrogen atom, R.sub.b
represents a hydroxy or methoxy group and R.sub.c represents a
halogen atom.
9. The method according to claim 1, wherein R.sub.a, R.sub.b and
R.sub.d each represent a hydrogen atom and R.sub.c represents a
group selected from R.sub.7--CO--NH--(C.sub.0-C.sub.6)alkyl-,
R.sub.7--SO.sub.2--NH--(C.sub.0-C.sub.6)alkyl-,
R.sub.7--NH--CO--NH--(C.sub.0-C.sub.6)alkyl- and
R.sub.7--O--CO--NH--(C.sub.0-C.sub.6)alkyl-.
10. The method according to claim 1, wherein R.sub.4 represents
phenyl, 4-hydroxyphenyl, 3-fluoro-4-hydroxyphenyl,
2-hydroxypyrimidine or 3-hydroxypyridine.
11. The method according to claim 1, wherein R.sub.3 represents an
aryl or heteroaryl group.
12. The method according to claim 1, wherein R.sub.3 represents a
group selected from methyl, phenyl, 1H-pyrazole, 1H-indole,
1H-indazole, pyridine, pyrimidine, 1H-pyrrolo[2,3-b]pyridine,
2,3-dihydro-1H-pyrrolo[2,3-b]pyridine, 1H-benzimidazole,
1H-pyrrole, 1H-pyrrolo[2,3-c]pyridine, 1H-pyrrolo[3,2-b]pyridine,
5H-pyrrolo[3,2-d]pyrimidine, thiophene, pyrazine,
1H-pyrazolo[3,4-b]pyridine, 1,2-oxazole, and
1H-pyrazolo[1,5-a]pyrimidine those groups optionally having one or
more substituents selected from halogen, linear or branched
(C.sub.1-C.sub.6)alkyl, linear or branched (C.sub.1-C.sub.6)alkoxy,
cyano, cyclopropyl, oxetane, tetrahydrofuran, --CO--O--CH.sub.3,
trideuteriomethyl, 2-(morpholin-4-yl)ethyl and
2-(morpholin-4-yl)ethoxy.
13. The method according to claim 10, wherein R.sub.3 represents a
linear or branched (C.sub.1-C.sub.6)alkyl or a heteroaryl
optionally substituted by a linear or branched
(C.sub.1-C.sub.6)alkyl, and R.sub.4 represents a 4-hydroxyphenyl
group.
14. The method according to claim 1, wherein the compound of
formula (I) is selected from:
5-(5-chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H-
)-yl]-carbonyl}phenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-(1-methyl-1H-pyr-
azol-4-yl)-1H-pyrrole-3-carboxamide,
5-(5-chloro-2-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}ph-
enyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-(pyridin-4-yl)-1H-pyrrole-3-carbo-
xamide,
N-(4-hydroxyphenyl)-1,2-dimethyl-N-(1-methyl-1H-pyrazol-4-yl)-5-(6-
-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-
-1,3-benzodioxol-5-yl)-1H-pyrrole-3-carboxamide,
N-(4-hydroxyphenyl)-1,2-dimethyl-5-(6-{[(3R)-3-methyl-3,4-dihydroisoqulin-
olin-2(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-N-(pyridin-4-yl)-1H-pyrrole--
3-carboxamide,
5-(5-fluoro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H-
)-yl]-carbonyl}phenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-(1-methyl-1H-pyr-
azol-4-yl)-1H-pyrrole-3-carboxamide,
5-(5-chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H-
)-yl]-carbonyl}phenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-(1-methyl-1H-pyr-
rolo[2,3-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide,
5-(5-chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H-
)-yl]-carbonyl}phenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-(pyridin-4-yl)-1-
H-pyrrole-3-carboxamide,
5-(5-chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H-
)-yl]-carbonyl}phenyl)-N-(5-cyano-1-methyl-1H-pyrrol-3-yl)-N-(4-hydroxyphe-
nyl)-1,2-dimethyl-1H-pyrrole-3-carboxamide,
N-(5-cyano-1-methyl-1H-pyrrol-3-yl)-5-(5-fluoro-2-{[(3S)-3-(morpholin-4-y-
l-methyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}phenyl)-N-(4-hydroxyphe-
nyl)-1,2-dimethyl-1H-pyrrole-3-carboxamide,
5-(5-chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H-
)-yl]-carbonyl}phenyl)-N-(5-cyano-1,2-dimethyl-1H-pyrrol-3-yl)-N-(4-hydrox-
yphenyl)-1,2-dimethyl-1H-pyrrole-3-carboxamide,
5-(5-chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H-
)-yl]-carbonyl}phenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-(1-methyl-2,3-di-
hydro-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide,
N-(5-cyano-1,2-dimethyl-1H-pyrrol-3-yl)-5-(5-fluoro-2-{[(3S)-3-(morpholin-
-4-yl-methyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}phenyl)-N-(4-hydrox-
yphenyl)-1,2-dimethyl-1H-pyrrole-3-carboxamide, and
5-(5-chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H-
)-yl]-carbonyl}phenyl)-N-[5-cyano-2-methyl-1-(trideuteriomethyl)-1H-pyrrol-
-3-yl]-N-(4-hydroxyphenyl)-1,2-dimethyl-1H-pyrrole-3-carboxamide,
or an enantiomer, a diastereoisomer, or an addition salt thereof
with a pharmaceutically acceptable acid or base.
15. The method according to claim 1, wherein the compound of
formula (I) is administered as a pharmaceutical composition
comprising a compound of formula (I) in combination with one or
more pharmaceutically acceptable excipients.
16. The method according to claim 1, wherein the compound of
formula (I) is administered in combination with an anti-cancer
agent selected from genotoxic agents, mitotic poisons,
anti-metabolites, proteasome inhibitors, kinase inhibitors and
antibodies.
17. The method according to claim 1, wherein the compound of
formula (I) is administered in combination with radiotherapy.
18. The method according to claim 14 wherein the cancer is chronic
lymphoid leukaemia.
19. The method according to claim 14 wherein the cancer is
non-Hodgkin lymphoma.
Description
The present invention relates to new pyrrole compounds, to a
process for their preparation and to pharmaceutical compositions
containing them.
The compounds of the present invention are new and have very
valuable pharmacological characteristics in the field of apoptosis
and cancerology.
Apoptosis, or programmed cell death, is a physiological process
that is crucial for embryonic development and maintenance of tissue
homeostasis.
Apoptotic-type cell death involves morphological changes such as
condensation of the nucleus, DNA fragmentation and also biochemical
phenomena such as the activation of caspases which cause damage to
key structural components of the cell, so inducing its disassembly
and death. Regulation of the process of apoptosis is complex and
involves the activation or repression of several intracellular
signalling pathways (Cory S. et al., Nature Review Cancer, 2002, 2,
647-656).
Deregulation of apoptosis is involved in certain pathologies.
Increased apoptosis is associated with neurodegenerative diseases
such as Parkinson's disease, Alzheimer's disease and ischaemia.
Conversely, deficits in the implementation of apoptosis play a
significant role in the development of cancers and their
chemoresistance, in auto-immune diseases, inflammatory diseases and
viral infections. Accordingly, absence of apoptosis is one of the
phenotypic signatures of cancer (Hanahan D. et al., Cell 2000, 100,
57-70).
The anti-apoptotic proteins of the Bcl-2 family are associated with
numerous pathologies. The involvement of proteins of the Bcl-2
family is described in numerous types of cancer, such as colorectal
cancer, breast cancer, small-cell lung cancer, non-small-cell lung
cancer, bladder cancer, ovarian cancer, prostate cancer, chronic
lymphoid leukaemia, follicular lymphoma, myeloma, etc.
Overexpression of the anti-apoptotic proteins of the Bcl-2 family
is involved in tumorigenesis, in resistance to chemotherapy and in
the clinical prognosis of patients affected by cancer. There is,
therefore, a therapeutic need for compounds that inhibit the
anti-apoptotic activity of the proteins of the Bcl-2 family.
In addition to being new, the compounds of the present invention
have pro-apoptotic properties making it possible to use them in
pathologies involving a defect in apoptosis, such as, for example,
in the treatment of cancer, auto-immune diseases and diseases of
the immune system.
The present invention relates more especially to compounds of
formula (I):
##STR00002## wherein: A.sub.1 and A.sub.2, each independently of
the other, represent a hydrogen or halogen atom, a linear or
branched (C.sub.1-C.sub.6)polyhaloalkyl group, a linear or branched
(C.sub.1-C.sub.6)alkyl group or a cycloalkyl group, T represents a
hydrogen atom, a linear or branched (C.sub.1-C.sub.6)alkyl group
optionally substituted by from one to three halogen atoms, a group
(C.sub.1-C.sub.4)alkyl-NR.sub.1R.sub.2, or a group
(C.sub.1-C.sub.4)alkyl-OR.sub.6, R.sub.1 and R.sub.2, each
independently of the other, represent a hydrogen atom or a linear
or branched (C.sub.1-C.sub.6)alkyl group, or R.sub.1 and R.sub.2
form with the nitrogen atom carrying them a heterocycloalkyl,
R.sub.3 represents a linear or branched (C.sub.1-C.sub.6)alkyl
group, a linear or branched (C.sub.2-C.sub.6)alkenyl group, a
linear or branched (C.sub.2-C.sub.6)alkynyl group, a cycloalkyl
group, a (C.sub.3-C.sub.10)cycloalkyl-(C.sub.1-C.sub.6)alkyl group
wherein the alkyl moiety is linear or branched, a heterocycloalkyl
group, an aryl group or a heteroaryl group, it being understood
that one or more of the carbon atoms of the preceding groups, or of
their possible substituents, may be deuterated, R.sub.4 represents
an aryl group, a heteroaryl group, a cycloalkyl group or a linear
or branched (C.sub.1-C.sub.6)alkyl group, it being understood that
one or more of the carbon atoms of the preceding groups, or of
their possible substituents, may be deuterated, R.sub.5 represents
a hydrogen or halogen atom, a linear or branched
(C.sub.1-C.sub.6)alkyl group, or a linear or branched
(C.sub.1-C.sub.6)alkoxy group, R.sub.6 represents a hydrogen atom
or a linear or branched (C.sub.1-C.sub.6)alkyl group, R.sub.a,
R.sub.b, R.sub.c and R.sub.d, each independently of the others,
represent R.sub.7, a halogen atom, a linear or branched
(C.sub.1-C.sub.6)alkoxy group, a hydroxy group, a linear or
branched (C.sub.1-C.sub.6)polyhaloalkyl group, a trifluoromethoxy
group, --NR.sub.7R.sub.7', nitro,
R.sub.7--CO--(C.sub.0-C.sub.6)alkyl-,
R.sub.7--CO--NH--(C.sub.0-C.sub.6)alkyl-,
NR.sub.7R.sub.7'--CO--(C.sub.0-C.sub.6)alkyl-,
NR.sub.7R.sub.7'--CO--(C.sub.0-C.sub.6)alkyl-O--,
R.sub.7--SO.sub.2--NH--(C.sub.0-C.sub.6)alkyl-,
R.sub.7--NH--CO--NH--(C.sub.0-C.sub.6)alkyl-,
R.sub.7--O--CO--NH--(C.sub.0-C.sub.6)alkyl-, a heterocycloalkyl
group, or the substituents of one of the pairs (R.sub.a,R.sub.b),
(R.sub.b,R.sub.c) or (R.sub.c,R.sub.d) form together with the
carbon atoms carrying them a ring composed of from 5 to 7 ring
members, which may contain from one to 2 hetero atoms selected from
oxygen and sulphur, it also being understood that one or more
carbon atoms of the ring defined hereinbefore may be deuterated or
substituted by from one to 3 groups selected from halogen and
linear or branched (C.sub.1-C.sub.6)alkyl, R.sub.7 and R.sub.7',
each independently of the other, represent a hydrogen, a linear or
branched (C.sub.1-C.sub.6)alkyl, a linear or branched
(C.sub.2-C.sub.6)alkenyl, a linear or branched
(C.sub.2-C.sub.6)alkynyl, an aryl or a heteroaryl, or R.sub.7 and
R.sub.7', together with the nitrogen atom carrying them, form a
heterocycle composed of from 5 to 7 ring members, it being
understood that: "aryl" means a phenyl, naphthyl, biphenyl or
indenyl group, "heteroaryl" means any mono- or bi-cyclic group
composed of from 5 to 10 ring members, having at least one aromatic
moiety and containing from 1 to 4 hetero atoms selected from
oxygen, sulphur and nitrogen (including quaternary nitrogens),
"cycloalkyl" means any mono- or bi-cyclic, non-aromatic,
carbocyclic group containing from 3 to 10 ring members,
"heterocycloalkyl" means any mono- or bi-cyclic, non-aromatic,
condensed or spiro group composed of from 3 to 10 ring members and
containing from 1 to 3 hetero atoms selected from oxygen, sulphur,
SO, SO.sub.2 and nitrogen, it being possible for the aryl,
heteroaryl, cycloalkyl and heterocycloalkyl groups so defined and
the groups alkyl, alkenyl, alkynyl and alkoxy to be substituted by
from 1 to 3 groups selected from optionally substituted, linear or
branched (C.sub.1-C.sub.6)alkyl, (C.sub.3-C.sub.6)spiro, optionally
substituted, linear or branched (C.sub.1-C.sub.6)alkoxy,
(C.sub.1-C.sub.6)alkyl-S--, hydroxy, oxo (or N-oxide where
appropriate), nitro, cyano, --COOR', --OCOR', NR'R'', linear or
branched (C.sub.1-C.sub.6)polyhaloalkyl, trifluoromethoxy,
(C.sub.1-C.sub.6)alkylsulphonyl, halogen, optionally substituted
aryl, heteroaryl, aryloxy, arylthio, cycloalkyl, heterocycloalkyl
optionally substituted by one or more halogen atoms or alkyl
groups, it being understood that R' and R'', each independently of
the other, represent a hydrogen atom or an optionally substituted,
linear or branched (C.sub.1-C.sub.6)alkyl group, to their
enantiomers and diastereoisomers, and to addition salts thereof
with a pharmaceutically acceptable acid or base.
Among the pharmaceutically acceptable acids there may be mentioned,
without implying any limitation, hydrochloric acid, hydrobromic
acid, sulphuric acid, phosphonic acid, acetic acid, trifluoroacetic
acid, lactic acid, pyruvic acid, malonic acid, succinic acid,
glutaric acid, fumaric acid, tartaric acid, maleic acid, citric
acid, ascorbic acid, oxalic acid, methanesulphonic acid, camphoric
acid etc.
Among the pharmaceutically acceptable bases there may be mentioned,
without implying any limitation, sodium hydroxide, potassium
hydroxide, triethylamine, tert-butylamine etc.
Advantageously, A.sub.1 represents a hydrogen atom or a methyl
group.
Furthermore, A.sub.2 preferably represents a linear or branched
(C.sub.1-C.sub.6)alkyl group optionally substituted by a group
selected from halogen, hydroxy, linear or branched
(C.sub.1-C.sub.6)alkoxy, NR'R'' and morpholine.
In another embodiment of the invention, A.sub.2 represents a linear
or branched (C.sub.1-C.sub.6)polyhaloalkyl group or a cyclopropyl
group.
Even more preferably, A.sub.1 and A.sub.2 both represent a methyl
group.
In a preferred embodiment of the invention, T represents a linear
or branched (C.sub.1-C.sub.6)alkyl.
In another preferred embodiment, T represents a group
alkyl(C.sub.1-C.sub.4)--NR.sub.1R.sub.2, and more particularly a
group alkyl(C.sub.1-C.sub.4)--NR.sub.1R.sub.2 wherein R.sub.1 and
R.sub.2 form with the nitrogen atom carrying them a
heterocycloalkyl.
In preferred compounds of the invention, T represents a methyl,
aminomethyl, (morpholin-4-yl)methyl,
(4-methylpiperazin-1-yl)methyl, 2-(morpholin-4-yl)ethyl,
[2-(morpholin-4-yl)ethoxy]methyl, hydroxymethyl,
[2-(dimethylamino)ethoxy]methyl,
hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-ylmethyl,
1-oxa-6-azaspiro[3.3]hept-6-yl-methyl, 3-(morpholin-4-yl)propyl or
trifluoromethyl group. Even more preferably, T represents a
(morpholin-4-yl)methyl, methyl or 3-(morpholin-4-yl)propyl
group.
Preferably, R.sub.a and R.sub.d each represent a hydrogen atom and
(R.sub.b,R.sub.c), together with the carbon atoms carrying them,
form a 1,3-dioxolane group or a 1,4-dioxane group; or R.sub.a,
R.sub.c and R.sub.d each represent a hydrogen atom and R.sub.b
represents a hydrogen or halogen atom or a methoxy group. Even more
preferably, R.sub.a and R.sub.d each represent a hydrogen atom and
(R.sub.b,R.sub.c), together with the carbon atoms carrying them,
form a 1,3-dioxolane group; or R.sub.a, R.sub.c and R.sub.d each
represent a hydrogen atom and R.sub.b represents a halogen,
preferably a chlorine or fluorine atom.
In another embodiment of the invention, R.sub.a and R.sub.d each
represent a hydrogen atom, R.sub.b represents a hydrogen or halogen
atom and R.sub.c a hydroxy or methoxy group, or: R.sub.a and
R.sub.d each represent a hydrogen atom, R.sub.b represents a
hydroxy or methoxy group and R.sub.c a halogen atom.
Alternatively, R.sub.a, R.sub.b and R.sub.d advantageously each
represent a hydrogen atom and R.sub.c represents a group selected
from R.sub.7--CO--NH--(C.sub.0-C.sub.6)alkyl-,
R.sub.7--SO.sub.2--NH--(C.sub.0-C.sub.6)alkyl-,
R.sub.7--NH--CO--NH--(C.sub.0-C.sub.6)alkyl- and
R.sub.7--O--CO--NH--(C.sub.0-C.sub.6)alkyl-. For those specific
compounds, R.sub.3 preferably represents a linear or branched
(C.sub.1-C.sub.6)alkyl or a heteroaryl optionally substituted by a
linear or branched (C.sub.1-C.sub.6)alkyl, and R.sub.4 represents a
4-hydroxyphenyl group. Even more preferably, R.sub.3 represents a
methyl.
Preferred R.sub.4 groups are as follows: phenyl; 4-hydroxyphenyl;
3-fluoro-4-hydroxyphenyl; 2-hydroxypyrimidine; 3-hydroxypyridine.
Even more preferably, R.sub.4 represents a 4-hydroxyphenyl
group.
In preferred compounds of the invention, R.sub.3 represents a
linear or branched (C.sub.1-C.sub.6)alkyl group (preferably
methyl), aryl or heteroaryl, all being optionally substituted. The
groups aryl and heteroaryl are more especially preferred. Finally,
R.sub.3 preferably represents a group selected from phenyl,
1H-pyrazole, 1H-indole, 1H-indazole, pyridine, pyrimidine,
1H-pyrrolo[2,3-b]pyridine, 2,3-dihydro-1H-pyrrolo[2,3-b]pyridine,
1H-benzimidazole, 1H-pyrrole, 1H-pyrrolo[2,3-c]pyridine,
1H-pyrrolo[3,2-b]pyridine, 5H-pyrrolo[3,2-d]pyrimidine, thiophene,
pyrazine, 1H-pyrazolo[3,4-b]pyridine, 1,2-oxazole, and
1H-pyrazolo[1,5-a]pyrimidine, those groups optionally having one or
more substituents selected from halogen, linear or branched
(C.sub.1-C.sub.6)alkyl, linear or branched (C.sub.1-C.sub.6)alkoxy,
cyano, cyclopropyl, oxetane, tetrahydrofuran, --CO--O--CH.sub.3,
trideuteriomethyl, 2-(morpholin-4-yl)ethyl and
2-(morpholin-4-yl)ethoxy. More preferably, R.sub.3 represents a
group 1-methyl-1H-pyrazol-4-yl, pyridin-4-yl,
1-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl,
5-cyano-1-methyl-1H-pyrrol-3-yl,
5-cyano-1,2-dimethyl-1H-pyrrol-3-yl,
1-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-5-yl,
5-cyano-2-methyl-1-(trideuteriomethyl)-1H-pyrrol-3-yl.
Preferred compounds according to the invention are included in the
following group:
5-(5-chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H-
)-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-(1-methyl-1H-pyra-
zol-4-yl)-1H-pyrrole-3-carboxamide,
5-(5-chloro-2-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}ph-
enyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-(pyridin-4-yl)-1H-pyrrole-3-carbo-
xamide,
N-(4-hydroxyphenyl)-1,2-dimethyl-N-(1-methyl-1H-pyrazol-4-yl)-5-(6-
-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-
-1,3-benzodioxol-5-yl)-1H-pyrrole-3-carboxamide,
N-(4-hydroxyphenyl)-1,2-dimethyl-5-(6-{[(3R)-3-methyl-3,4-dihydroisoquino-
lin-2(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-N-(pyridin-4-yl)-1H-pyrrole-3-
-carboxamide,
5-(5-fluoro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H-
)-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-(1-methyl-1H-pyra-
zol-4-yl)-1H-pyrrole-3-carboxamide,
5-(5-chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H-
)-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-(1-methyl-1H-pyrr-
olo[2,3-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide,
5-(5-chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H-
)-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-(pyridin-4-yl)-1H-
-pyrrole-3-carboxamide,
5-(5-chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H-
)-yl]carbonyl}phenyl)-N-(5-cyano-1-methyl-1H-pyrrol-3-yl)-N-(4-hydroxyphen-
yl)-1,2-dimethyl-1H-pyrrole-3-carboxamide,
N-(5-cyano-1-methyl-1H-pyrrol-3-yl)-5-(5-fluoro-2-{[(3S)-3-(morpholin-4-y-
l-methyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}phenyl)-N-(4-hydroxyphe-
nyl)-1,2-dimethyl-1H-pyrrole-3-carboxamide,
5-(5-chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H-
)-yl]-carbonyl}phenyl)-N-(5-cyano-1,2-dimethyl-1H-pyrrol-3-yl)-N-(4-hydrox-
yphenyl)-1,2-dimethyl-1H-pyrrole-3-carboxamide,
5-(5-chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H-
)-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-(1-methyl-2,3-dih-
ydro-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide,
N-(5-cyano-1,2-dimethyl-1H-pyrrol-3-yl)-5-(5-fluoro-2-{[(3S)-3-(morpholin-
-4-yl-methyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}phenyl)-N-(4-hydrox-
yphenyl)-1,2-dimethyl-1H-pyrrole-3-carboxamide,
5-(5-chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H-
)-yl]carbonyl}phenyl)-N-[5-cyano-2-methyl-1-(trideuteriomethyl)-1H-pyrrol--
3-yl]-N-(4-hydroxyphenyl)-1,2-dimethyl-1H-pyrrole-3-carboxamide,
their enantiomers and diastereoisomers, and addition salts thereof
with a pharmaceutically acceptable acid or base.
The invention relates also to a process for the preparation of
compounds of formula (I), which process is characterised in that
there is used as starting material the compound of formula
(II):
##STR00003## wherein R.sub.a, R.sub.b, R.sub.c and R.sub.d are as
defined for formula (I), which compound of formula (II) is
subjected to a Heck reaction, in an aqueous or organic medium, in
the presence of a palladium catalyst, of a base, of a phosphine and
of the compound of formula (III):
##STR00004## wherein the groups A.sub.1 and A.sub.2 are as defined
for formula (I) and Alk represents a linear or branched
(C.sub.1-C.sub.6)alkyl, to obtain the compound of formula (IV):
##STR00005## wherein A.sub.1, A.sub.2, R.sub.a, R.sub.b, R.sub.c
and R.sub.d are as defined for formula (I) and Alk is as defined
hereinbefore, the aldehyde function of which compound of formula
(IV) is oxidised to a carboxylic acid to form the compound of
formula (V):
##STR00006## wherein A.sub.1, A.sub.2, R.sub.a, R.sub.b, R.sub.c
and R.sub.d are as defined for formula (I) and Alk is as defined
hereinbefore, which compound of formula (V) is then subjected to
peptide coupling with a compound of formula (VI):
##STR00007## wherein T and R.sub.5 are as defined for formula (I),
to yield the compound of formula (VII):
##STR00008## wherein A.sub.1, A.sub.2, R.sub.a, R.sub.b, R.sub.c,
R.sub.d, T and R.sub.5 are as defined for formula (I) and Alk is as
defined hereinbefore, the ester function of which compound of
formula (VII) is hydrolysed to yield the corresponding carboxylic
acid or carboxylate, which may be converted into an acid derivative
such as the corresponding acyl chloride or anhydride before being
coupled with an amine NHR.sub.3R.sub.4 wherein R.sub.3 and R.sub.4
have the same meanings as for formula (I), to yield the compound of
formula (I), which compound of formula (I) may be purified
according to a conventional separation technique, which is
converted, if desired, into its addition salts with a
pharmaceutically acceptable acid or base and which is optionally
separated into its isomers according to a conventional separation
technique, it being understood that, at any time considered
appropriate in the course of the above-described process, certain
groups (hydroxy, amino . . . ) of the reagents or intermediates of
synthesis may be protected and then deprotected according to the
requirements of synthesis.
More particularly, when one of the groups R.sub.3 or R.sub.4 of the
amine NHR.sub.3R.sub.4 is substituted by a hydroxy function, the
latter may be subjected beforehand to a protection reaction prior
to any coupling with the carboxylic acid formed from the compound
of formula (VII), or with a corresponding acid derivative thereof,
the resulting protected compound of formula (I) subsequently
undergoes a deprotection reaction and is then optionally converted
into one of its addition salts with a pharmaceutically acceptable
acid or base.
The present invention relates also to an alternative process for
the preparation of compounds of formula (I'), which are particular
cases of the compounds of formula (I) as defined hereinbefore:
##STR00009## wherein: A.sub.1, A.sub.2, R.sub.a, R.sub.d, R.sub.3,
R.sub.4, T and R.sub.5 are as defined for formula (I), R.sub.b and
R.sub.c are such that one represents a hydrogen and the other a
group selected from R.sub.7--CO--NH--(C.sub.0-C.sub.6)alkyl-,
R.sub.7--SO.sub.2--NH--(C.sub.0-C.sub.6)alkyl-,
R.sub.7--NH--CO--NH--(C.sub.0-C.sub.6)alkyl- and
R.sub.7--O--CO--NH--(C.sub.0-C.sub.6)alkyl-, which preparation
process uses as starting material a compound of formula (II'):
##STR00010## wherein: R.sub.a and R.sub.d are as defined for
formula (I), Hal represents a halogen atom, X.sub.1 and X.sub.2 are
such that one represents a (C.sub.0-C.sub.6)alkyl-NH.sub.2 group
while the other represents a hydrogen atom, which compound of
formula (II') is then subjected to peptide coupling with a compound
of formula (VI):
##STR00011## wherein T and R.sub.5 are as defined for formula (I),
to yield the compound of formula (III'):
##STR00012## wherein: R.sub.a, R.sub.d, T and R.sub.5 are as
defined for formula (I), Hal represents a halogen atom, X.sub.1 and
X.sub.2 are such that one represents a
(C.sub.0-C.sub.6)alkyl-NH.sub.2 group while the other represents a
hydrogen atom, which compound of formula (III') is subjected to a
Heck reaction, in an aqueous or organic medium, in the presence of
a palladium catalyst, of a base, of a phosphine and of a compound
of formula (IV'):
##STR00013## wherein A.sub.1, A.sub.2, R.sub.3 and R.sub.4 are as
defined for formula (I), to form the compound of formula (V'):
##STR00014## wherein: A.sub.1, A.sub.2, R.sub.a, R.sub.d, R.sub.3,
R.sub.4, T and R.sub.5 are as defined for formula (I), X.sub.1 and
X.sub.2 are such that one represents a
(C.sub.0-C.sub.6)alkyl-NH.sub.2 group while the other represents a
hydrogen atom, which compound of formula (V') is then subjected to
an acylation or sulphonylation reaction to yield the compound of
formula (I'), which compound of formula (I') may be purified
according to a conventional separation technique, which is
converted, if desired, into its addition salts with a
pharmaceutically acceptable acid or base and which is optionally
separated into its isomers according to a conventional separation
technique, it being understood that, at any time considered
appropriate in the course of the above-described process, certain
groups (hydroxy, amino . . . ) of the reagents or intermediates of
synthesis may be protected and then deprotected according to the
requirements of synthesis.
The compounds of formulae (II), (III), (II'), (IV'), (VI) and the
amine NHR.sub.3R.sub.4 are either commercially available or can be
obtained by the person skilled in the art using conventional
chemical reactions described in the literature.
Pharmacological study of the compounds of the invention has shown
that they have pro-apoptotic properties. The ability to reactivate
the apoptotic process in cancerous cells is of major therapeutic
interest in the treatment of cancers, auto-immune diseases and
diseases of the immune system.
More especially, the compounds according to the invention will be
useful in the treatment of chemo- or radio-resistant cancers, and
in malignant haemopathies and small-cell lung cancer.
Among the cancer treatments envisaged there may be mentioned,
without implying any limitation, cancers of the bladder, brain,
breast and uterus, chronic lymphoid leukaemias, colorectal cancer,
cancers of the sophagus and liver, lymphoblastic leukaemias,
non-Hodgkin lymphomas, melanomas, malignant haemopathies, myelomas,
ovarian cancer, non-small-cell lung cancer, prostate cancer and
small-cell lung cancer. Among non-Hodgkin lymphomas, there may be
mentioned more preferably follicular lymphomas, mantle cell
lymphomas, diffuse large B-cell lymphomas, small lymphocytic
lymphomas and marginal zone B-cell lymphomas.
The present invention relates also to pharmaceutical compositions
comprising at least one compound of formula (I) in combination with
one or more pharmaceutically acceptable excipients.
Among the pharmaceutical compositions according to the invention
there may be mentioned more especially those that are suitable for
oral, parenteral, nasal, per- or trans-cutaneous, rectal,
perlingual, ocular or respiratory administration, especially
tablets or dragees, sublingual tablets, sachets, paquets, capsules,
glossettes, lozenges, suppositories, creams, ointments, dermal
gels, and drinkable or injectable ampoules.
The dosage varies according to the sex, age and weight of the
patient, the administration route, the nature of the therapeutic
indication, or of any associated treatments, and ranges from 0.01
mg to 1 g per 24 hours in one or more administrations.
Furthermore, the present invention relates also to the association
of a compound of formula (I) with an anticancer agent selected from
genotoxic agents, mitotic poisons, anti-metabolites, proteasome
inhibitors, kinase inhibitors and antibodies, and also to
pharmaceutical compositions comprising that type of association and
their use in the manufacture of medicaments for use in the
treatment of cancer.
The compounds of the invention may also be used in association with
radiotherapy in the treatment of cancer.
Finally, the compounds of the invention may be linked to monoclonal
antibodies or fragments thereof or linked to scaffold proteins that
can be related or not to monoclonal antibodies.
Antibody fragments must be understood as fragments of Fv, scFv,
Fab, F(ab')2, F(ab'), scFv-Fc type or diabodies, which generally
have the same specificity of binding as the antibody from which
they are descended. According to the present invention, antibody
fragments of the invention can be obtained starting from antibodies
by methods such as digestion by enzymes, such as pepsin or papain,
and/or by cleavage of the disulfide bridges by chemical reduction.
In another manner, the antibody fragments comprised in the present
invention can be obtained by techniques of genetic recombination
likewise well known to the person skilled in the art or else by
peptide synthesis by means of, for example, automatic peptide
synthesizers such as those supplied by the company Applied
Biosystems, etc.
Scaffold proteins that can be related or not to monoclonal
antibodies are understood to mean a protein that contains or not an
immunoglobulin fold and that yields a binding capacity similar to a
monoclonal antibody. The man skilled in the art knows how to select
the protein scaffold. More particularly, it is known that, to be
selected, such a scaffold should display several features as follow
(Skerra A., J. Mol. Recogn., 13, 2000, 167-187): phylogenetically
good conservation, robust architecture with a well-known
three-dimensional molecular organization (such as, for example,
crystallography or NMR), small size, no or only a low degree of
post-translational modifications, easy to produce, express and
purify. Such a protein scaffold can be, but without limitation, a
structure selected from the group consisting in fibronectin and
preferentially the tenth fibronectin type III domain (FNfn10),
lipocalin, anticalin (Skerra A., J. Biotechnol., 2001,
74(4):257-75), the protein Z derivative from the domain B of
staphylococcal protein A, thioredoxin A or any protein with a
repeated domain such as an "ankyrin repeat" (Kohl et al., PNAS,
2003, vol. 100, No. 4, 1700-1705), "armadillo repeat",
"leucine-rich repeat" or "tetratricopeptide repeat". There could
also be mentioned a scaffold derivative from toxins (such as, for
example, scorpion, insect, plant or mollusc toxins) or protein
inhibitors of neuronal nitric oxide synthase (PIN).
The following Preparations and Examples illustrate the invention
without limiting it in any way.
Preparation 1:
4-Chloro-2-[4-(ethoxycarbonyl)-1,5-dimethyl-1H-pyrrol-2-yl]benzoic
acid
Step A: Ethyl 1,2-dimethyl-1H-pyrrole-3-carboxylate
To a solution of 10 g of ethyl 2-methyl-1H-pyrrole-3-carboxylate
(65.3 mmol) and 8.95 mL (130.6 mmol) of methyl iodide in 70 mL of
dimethylformamide placed at 0.degree. C. there are added, in three
portions, 2.61 g (65.3 mmol) of sodium hydride (NaH) 60%. The batch
is then stirred at 0.degree. C. for 1 hour. Then, the reaction
mixture is hydrolysed by the addition of 420 mL of ice-cold water.
The reaction mixture is then diluted with ethyl acetate,
successively washed with 0.1M aqueous hydrochloric acid (HCl)
solution, saturated aqueous LiCl solution and then brine. The
organic phase is then dried over MgSO.sub.4, filtered, concentrated
to dryness and purified by chromatography over silica gel
(petroleum ether/AcOEt gradient).
.sup.1H NMR: .delta. (400 MHz; dmso-d6; 300K): 6.65 (d, 1H
pyrrole); 6.3 (1d, 1H pyrrole); 4.1 (1q, 2H, OCH.sub.2CH.sub.3);
3.5 (s, 3H N-pyrrole); 2.4 (s, 3H pyrrole); 1.5 (1t, 3H
OCH.sub.2CH.sub.3)
IR: .nu.: >C.dbd.O: 1688 cm.sup.-1; .nu.: C--O--C: 1172
cm.sup.-1
Step B: Ethyl
5-(5-chloro-2-formylphenyl)-1,2-dimethyl-1H-pyrrole-3-carboxylate
To a solution of 10.5 g of the compound obtained in Step A (62.8
mmol) in 65 mL of N,N-dimethylacetamide there are successively
added 15.2 g of 2-bromo-4-chlorobenzaldehyde (69 mmol), 12.3 g of
potassium acetate (125.6 mmol) and then the batch is stirred under
argon for 20 minutes. There are then added 2.2 g of palladium
catalyst PdCl.sub.2(PPh.sub.3).sub.2 (3.14 mmol). The reaction
mixture is then heated at 130.degree. C. overnight. The mixture is
allowed to return to ambient temperature and it is then diluted
with dichloromethane. Animal charcoal is added (2 g per g of
product) and the batch is stirred at ambient temperature for 1 hour
and then filtered. The organic phase is then washed with water,
dried over MgSO.sub.4 and concentrated to dryness. The crude
product thereby obtained is purified by chromatography over silica
gel (petroleum ether/AcOEt gradient). The title product is obtained
in the form of a solid.
.sup.1H NMR: .delta. (400 MHz; dmso-d6; 300K): 9.8 (s, 1H, formyl);
7.91-7.69-7.61 (d, 3H, aromatic Hs); 6.5 (s, 1H pyrrole); 4.2 (q,
2H, OCH.sub.2CH.sub.3); 3.4 (s, 3H, CH.sub.3--N-pyrrole); 2.55 (s,
3H pyrrole); 1.28 (t, 3H, OCH.sub.2CH.sub.3)
Step C:
4-Chloro-2-[4-(ethoxycarbonyl)-1,5-dimethyl-1H-pyrrol-2-yl]benzoic
acid
A solution is prepared containing 12.85 g of the compound obtained
in Step B (42 mmol) and 35.7 mL (336 mmol) of 2-methyl-2-butene in
a mixture containing 20 mL of acetone and 20 mL of tetrahydrofuran.
There are added, dropwise, 200 mL of an aqueous solution containing
a mixture of 13.3 g of sodium chlorite (NaClO.sub.2) (147 mmol) and
14.5 g of sodium hydrogen phosphate (NaHPO.sub.4) (105 mmol). The
batch is then vigorously stirred at ambient temperature for 7
hours. The reaction mixture is then concentrated to remove the
acetone. Ethyl acetate is added, and the organic phase is washed
with water, dried over MgSO.sub.4 and then concentrated to dryness.
The residue is then taken up in a minimum of ethyl ether. The solid
then obtained is filtered off, washed with ether and then dried in
vacuo at 40.degree. C. overnight. The title product is obtained in
the form of a solid, which is subsequently used without being
otherwise purified.
.sup.1H NMR: .delta. (400 MHz; dmso-d6; 300K): 13 (m, 1H COOH);
7.85-7.6-7.41 (d, dd, wd, 3H, aromatic Hs); 6.3 (s, 1H, H pyrrole);
4.15 (q, 2H, OCH.sub.2CH.sub.3); 3.25 (s, 3H, CH.sub.3--N-pyrrole);
2.5 (s, 3H, CH.sub.3-pyrrole); 1.25 (t, 3H, OCH.sub.2CH.sub.3)
IR: .nu.: --OH: 3100-2500 cm.sup.-1 acid; .nu.: >C.dbd.O: 1681
cm.sup.-1 ester+acid
Preparation 2:
2-[4-(Ethoxycarbonyl)-1-methyl-1H-pyrrol-2-yl]benzoic acid
The procedure is in accordance with the process of Preparation 1,
replacing, on the one hand, the ethyl
2-methyl-1H-pyrrole-3-carboxylate used in Step A by ethyl
1H-pyrrole-3-carboxylate and, on the other hand, the
2-bromo-4-chlorobenzaldehyde used in Step B by
2-bromo-benzaldehyde.
Preparation 3:
4-Chloro-2-[4-(ethoxycarbonyl)-1-methyl-1H-pyrrol-2-yl]benzoic
acid
The procedure is in accordance with the process of Preparation 1,
replacing the ethyl 2-methyl-1H-pyrrole-3-carboxylate used in Step
A by ethyl 1H-pyrrole-3-carboxylate.
Preparation 4:
6-[4-(Ethoxycarbonyl)-1-methyl-1H-pyrrol-2-yl]-1,3-benzodioxole-5-carboxy-
lic acid
The procedure is in accordance with the process of Preparation 1,
replacing, on the one hand, the ethyl
2-methyl-1H-pyrrole-3-carboxylate used in Step A by ethyl
1H-pyrrole-3-carboxylate and, on the other hand, the
2-bromo-4-chlorobenzaldehyde used in Step B by
6-bromo-1,3-benzodioxole-5-carbaldehyde.
IR: .nu.: --OH: 3500-2300 cm.sup.-1 acid; .nu.: >C.dbd.O:
1688-1670 cm.sup.-1 ester+acid
Preparation 5:
4-Chloro-2-[4-(ethoxycarbonyl)-1-ethyl-1H-pyrrol-2-yl]benzoic
acid
The procedure is in accordance with the process of Preparation 1,
replacing in Step A, on the one hand, the ethyl
2-methyl-1H-pyrrole-3-carboxylate by ethyl 1H-pyrrole-3-carboxylate
and, on the other hand, the methyl iodide by ethyl iodide (see the
protocol described in U.S. Pat. No. 6,258,805 B1).
Preparation 6:
4-Chloro-2-[1-cyclopropyl-4-(ethoxycarbonyl)-1H-pyrrol-2-yl]benzoic
acid
The procedure is in accordance with the process of Preparation 1,
replacing in Step A, on the one hand, the ethyl
2-methyl-1H-pyrrole-3-carboxylate by ethyl 1H-pyrrole-3-carboxylate
and, on the other hand, the methyl iodide by cyclopropylboronic
acid (see the protocol described in Benard S. et al, Journal of
Organic Chemistry 73(16), 6441-6444, 2008).
Preparation 7:
4-Chloro-2-[4-(ethoxycarbonyl)-1-(propan-2-yl)-1H-pyrrol-2-yl]-benzoic
add
The procedure is in accordance with the process of Preparation 1,
replacing in Step A, on the one hand, the ethyl
2-methyl-1H-pyrrole-3-carboxylate by ethyl 1H-pyrrole-3-carboxylate
and, on the other hand, the methyl iodide by isopropyl iodide (see
the protocol described in Okada E. et al, Heterocycles 34(7),
1435-1441, 1992).
Preparation 8:
4-Fluoro-2-[4-(methoxycarbonyl)-1,5-dimethyl-1H-pyrrol-2-yl]benzoic
acid
The procedure is in accordance with the process of Preparation 1,
replacing, in Step A, the ethyl 2-methyl-1H-pyrrole-3-carboxylate
by methyl 2-methyl-1H-pyrrole-3-carboxylate and also the
2-bromo-4-chlorobenzaldehyde used in Step B by
2-bromo-4-fluorobenzaldehyde.
IR: .nu.: --OH: 2727-2379 cm.sup.-1 acid; .nu.: >C.dbd.O: 1687
cm.sup.-1
Preparation 9:
6-{1-[2-(Benzyloxy)ethyl]-4-(ethoxycarbonyl)-5-methyl-1H-pyrrol-2-yl}-1,3-
-benzodioxole-5-carboxylic acid
Step A: Ethyl
1-[2-(benzyloxy)ethyl]-2-methyl-1H-pyrrole-3-carboxylate
The procedure is in accordance with the process of Step A of
Preparation 1, replacing the methyl iodide used as alkylating agent
by benzyl 2-bromoethyl ether.
.sup.1H NMR: .delta. (400 MHz; dmso-d6; 300K): 7.32 (t, 2H,
aromatic Hs, H meta benzyl ether); 7.3 (t, 1H, aromatic H, H para
benzyl ether); 7.23 (d, 2H, aromatic Hs, H ortho benzyl ether);
6.72 (d, 1H, H-- pyrrole); 6.35 (d, 1H, H-- pyrrole); 4.48 (s, 2H,
aliphatic Hs, O--CH.sub.2-Ph); 4.15 (q, 2H, aliphatic Hs,
O--CH.sub.2--CH.sub.3); 4.1 (t, 2H, aliphatic Hs,
CH.sub.2--O--CH.sub.2-Ph); 3.7 (t, 2H, aliphatic Hs,
CH.sub.2--CH.sub.2--O--CH.sub.2-Ph); 2.45 (s, 3H,
CH.sub.3-pyrrole); 1.25 (t, 3H, aliphatic Hs,
O--CH.sub.2--CH.sub.3)
IR: .nu.: >C.dbd.O: 1689 cm.sup.-1
Step B:
6-{1-[2-(Benzyloxy)ethyl]-4-(ethoxycarbonyl)-5-methyl-1H-pyrrol-2--
yl}-1,3-benzodioxole-5-carboxylic acid
The procedure is in accordance with the processes of Steps B and C
of Preparation 1, replacing the 2-bromo-4-chlorobenzaldehyde by
6-bromo-1,3-benzodioxole-5-carbaldehyde.
.sup.1H NMR: .delta. (400 MHz; dmso-d6; 300K): 7.35 (s, 1H,
aromatic H, H benzodioxole); 7.30 (m, 3H, aromatic Hs, H benzyl
ether); 7.25 (s, 1H, aromatic H, H benzodioxole); 7.10 (d, 2H,
aromatic Hs, H ortho benzyl ether); 12.55 (broad s, 1H, COOH); 6.75
(s, 1H, H-pyrrole); 6.15 (broad s, 2H, aliphatic Hs,
O--CH.sub.2--O); 4.30 (s, 2H, aliphatic Hs, O--CH.sub.2-Ph); 4.15
(q, 2H, aliphatic Hs, O--CH.sub.2--CH.sub.3); 3.9 (m, 2H, aliphatic
Hs, CH.sub.2--CH.sub.2--O--CH.sub.2-Ph); 3.40 (t, 2H, aliphatic Hs,
CH.sub.2--CH.sub.2--O--CH.sub.2-Ph); 2.50 (s, 3H, CH.sub.3--
pyrrole); 1.25 (t, 3H, aliphatic Hs, O--CH.sub.2--CH.sub.3)
IR: .nu.: --OH: 3200-2300 cm.sup.-1 acid; .nu.: >C.dbd.O: 1687
cm.sup.-1 acid
Preparation 10:
2-{1-[3-(Benzyloxy)propyl]-4-(ethoxycarbonyl)-5-methyl-1H-pyrrol-2-yl}-4--
fluorobenzoic acid
The procedure is in accordance with the process of Preparation 9,
replacing the benzyl 2-bromoethyl ether used in Step A by benzyl
3-bromopropyl ether and also the
6-bromo-1,3-benzodioxole-5-carbaldehyde used in Step B by
2-bromo-4-fluorobenzaldehyde.
IR: .nu.: --OH: 3200-2305 cm.sup.-1 acid; .nu.: >C.dbd.O: 1690
cm.sup.-1 acid
Preparation 11:
6-[4-(Ethoxycarbonyl)-1,5-dimethyl-1H-pyrrol-2-yl]-1,3-benzodioxole-5-car-
boxylic acid
The procedure is in accordance with the process of Preparation 1,
replacing the 2-bromo-4-chlorobenzaldehyde used in Step B by
6-bromo-1,3-benzodioxole-5-carbaldehyde.
Preparation 12:
4-Methoxy-2-[4-(methoxycarbonyl)-1,5-dimethyl-1H-pyrrol-2-yl]-benzoic
acid
The procedure is in accordance with the process of Preparation 1,
replacing the ethyl 2-methyl-1H-pyrrole-3-carboxylate used in Step
A by methyl 2-methyl-1H-pyrrole-3-carboxylate and also the
2-bromo-4-chlorobenzaldehyde used in Step B by
2-bromo-4-methoxybenzaldehyde.
IR: .nu.: --OH: 3000-2500 cm.sup.-1 acid; .nu.: >C.dbd.O:
1693+1670 cm.sup.-1 acid+ester
Preparation 13:
7-[4-(Methoxycarbonyl)-1,5-dimethyl-1H-pyrrol-2-yl]-2,3-dihydro-1,4-benzo-
dioxin-6-carboxylic acid
The procedure is in accordance with the process of Preparation 1,
replacing in Step A the ethyl 2-methyl-1H-pyrrole-3-carboxylate by
methyl 2-methyl-1H-pyrrole-3-carboxylate and also the
2-bromo-4-chlorobenzaldehyde used in Step B by
7-bromo-2,3-dihydro-1,4-benzodioxin-6-carbaldehyde.
IR: .nu.: --OH: 3100-2500 cm.sup.-1 acid; .nu.: >C.dbd.O:
1690+1674 cm.sup.-1 acid+ester
Preparation 14:
4-Fluoro-5-methoxy-2-[4-(methoxycarbonyl)-1,5-dimethyl-1H-pyrrol-2-yl]ben-
zoic acid
The procedure is in accordance with the process of Preparation 1,
replacing in Step A the ethyl 2-methyl-1H-pyrrole-3-carboxylate by
methyl 2-methyl-1H-pyrrole-3-carboxylate and also the
2-bromo-4-chlorobenzaldehyde used in Step B by
2-bromo-4-fluoro-5-methoxybenzaldehyde.
Preparation 15:
4-Fluoro-5-hydroxy-2-[4-(methoxycarbonyl)-1,5-dimethyl-1H-pyrrol-2-yl]ben-
zoic acid
The procedure is in accordance with the process of Preparation 1,
replacing in Step A the ethyl 2-methyl-1H-pyrrole-3-carboxylate by
methyl 2-methyl-1H-pyrrole-3-carboxylate and also the
2-bromo-4-chlorobenzaldehyde used in Step B by
2-bromo-4-fluoro-5-hydroxy-benzaldehyde.
Preparation 16:
6-[4-(Ethoxycarbonyl)-1-methyl-5-trifluoromethyl-1H-pyrrol-2-yl]-1,3-benz-
odioxole-5-carboxylic acid
The procedure is in accordance with the process of Preparation 1,
replacing in Step A the ethyl 2-methyl-1H-pyrrole-3-carboxylate by
ethyl 2-(trifluoromethyl)-1H-pyrrole-3-carboxylate and also the
2-bromo-4-chlorobenzaldehyde used in Step B by
6-bromo-1,3-benzodioxole-5-carbaldehyde.
Preparation 17:
6-[4-(Ethoxycarbonyl)-1-ethyl-5-methyl-1H-pyrrol-2-yl]-1,3-benzodioxole-5-
-carboxylic acid
The procedure is in accordance with the process of Preparation 11,
replacing the methyl iodide by ethyl iodide (see the protocol
described in U.S. Pat. No. 6,258,805 B1).
Preparation 18:
6-[4-(Ethoxycarbonyl)-1-methyl-5-(trifluoromethyl)-1H-pyrrol-2-yl]-1,3-be-
nzodioxole-5-carboxylic acid
Step A: Ethyl 1-methyl-2-(trifluoromethyl)pyrrole-3-carboxylate
Ethyl 4,4,4-trifluoro-3-oxo-butanoate (29 ml, 0.219 mmol) is added
to methylamine (40% solution in water) (50 ml, 0.580 mmol) cooled
to 10.degree. C.; a white precipitate forms. 1,2-Dibromoethyl
acetate (prepared according to Molecules, 16, 9368-9385; 2011) is
added dropwise. The reactor is then sealed and heated at 70.degree.
C. for 45 minutes. The reaction mixture is cooled, then extracted
with ethyl acetate, dried over sodium sulphate (Na.sub.2SO.sub.4)
and evaporated to dryness. The crude reaction product obtained is
purified by chromatography over silica gel using heptane and ethyl
acetate as eluants. The expected compound is obtained in the form
of crystals.
.sup.1H NMR (400 MHz, dmso-d6) .delta. ppm: 7.11 (d, 1H), 6.52 (d,
1H), 4.21 (quad, 2H), 3.8 (s, 3H), 1.27 (t, 3H)
.sup.19F NMR (400 MHz, dmso-d6) .delta. ppm: -53.9
IR (ATR) cm.sup.-1: 3145+3128 .nu. --CH, 1711 .nu. >C.dbd.O,
1183+1117+1078 .nu. --CF3
Step B:
6-[4-(Ethoxycarbonyl)-1-methyl-5-(trifluoromethyl)-1H-pyrrol-2-yl]-
-1,3-benzodioxole-5-carboxylic acid
The procedure is in accordance with the protocol described in Steps
B and C of Preparation 1, replacing the
2-bromo-4-chlorobenzaldehyde used in Step B by
6-bromo-1,3-benzodioxole-5-carbaldehyde.
Preparation 19:
6-[1-(2-Benzyloxyethyl)-4-ethoxycarbonyl-5-methyl-1H-pyrrol-2-yl]-1,3-ben-
zodioxole-5-carboxylic acid
Step A: Ethyl
1-(2-benzyloxyethyl)-2-methyl-pyrrole-3-carboxylate
Ethyl 2-methyl-1H-pyrrole-3-carboxylate (10 g, 65.3 mmol) is
dissolved in 100 mL of dimethylformamide under argon cooled to
0.degree. C., and then 2-bromoethoxymethylbenzene (28.1 g, 130.6
mmol) is added all at once. The reaction mixture is placed under
stirring. There is then added thereto, at 0.degree. C., in three
portions, NaH (1.72 g, 71.83 mmol) over a period of 15 minutes. The
reaction mixture is stirred for 15 minutes at 0.degree. C., and
then for 15 hours at ambient temperature. It is then poured into an
ice bath and then extracted 3 times with ethyl acetate. The organic
phase is washed 3 times with saturated aqueous lithium chloride
solution, dried over MgSO.sub.4, filtered and then evaporated to
dryness. The residue thereby obtained is purified by chromatography
over silica gel using petroleum ether and ethyl acetate as eluants.
The expected compound is obtained in the form of an oil.
.sup.1H NMR (400 MHz, dmso-d6) .delta. ppm: 7.32 (t, 2H), 7.3 (t,
1H), 7.23 (d, 2H), 6.72 (d, 1H), 6.35 (d, 1H), 4.48 (s, 2H), 4.15
(quad., 2H), 4.1 (t, 2H), 3.7 (t, 2H), 2.45 (s, 3H), 1.25 (t,
3H)
IR (ATR) cm.sup.-1: 1689 .nu. --C.dbd.O
Step B: Ethyl
1-(2-benzyloxyethyl)-5-(6-formyl-1,3-benzodioxol-5-yl)-2-methyl-pyrrole-3-
-carboxylate
The procedure is in accordance with the process of Step B of
Preparation 1, replacing the 2-bromo-4-chlorobenzaldehyde by
6-bromo-1,3-benzodioxole-5-carbaldehyde.
.sup.1H NMR (400 MHz, dmso-d6) .delta. ppm: 9.5 (s, 1H), 7.3 (s,
1H), 7.25 (m, 3H), 7.05 (m, 2H), 7 (s, 1H), 6.4 (s, 1H), 6.2 (bs,
2H), 4.25 (s, 2H), 4.2 (quad., 2H), 4.05 (m, 2H), 3.4 (m, 2H), 2.55
(s, 3H), 1.25 (t, 3H)
Step C:
6-[1-(2-Benzyloxyethyl)-4-ethoxycarbonyl-5-methyl-1H-pyrrol-2-yl]--
1,3-benzodioxole-5-carboxylic acid
The procedure is in accordance with the process of Step C of
Preparation 1.
.sup.1H NMR (400 MHz, dmso-d6) .delta. ppm: 12.55 (bs, 1H), 7.35
(s, 1H), 7.3 (m, 3H), 7.2 (m, 3H), 6.75 (s, 1H), 6.15 (s, 2H), 4.3
(s, 2H), 4.15 (quad., 2H), 3.9 (m, 2H), 3.4 (t, 2H), 2.5 (s, 3H),
1.25 (t, 3H)
IR (ATR) cm.sup.-1: 3200-2300 .nu. --OH, 1687 (+shoulder)
.nu.-C.dbd.O carboxylic acid+conjugated ester
Preparation 20:
6-[4-(Ethoxycarbonyl)-1-ethyl-5-methyl-1H-pyrrol-2-yl]-1,3-benzodioxole-5-
-carboxylic acid
The procedure is in accordance with the protocol described in
Preparation 11, replacing the methyl iodide by ethyl iodide.
.sup.1H NMR (400 MHz, dmso-d6) .delta. ppm: 12.49 (bs, 1H), 7.33
(s, 1H), 6.89 (s, 1H), 6.17 (s, 2H), 6.13 (s, 1H), 4.15 (quad, 2H),
3.69 (quad, 2H), 2.51 (s, 3H), 1.24 (t, 3H), 1.01 (t, 3H)
Preparation 21:
6-[4-(Ethoxycarbonyl)-1-(2-fluoroethyl)-5-methyl-1H-pyrrol-2-yl]-1,3-benz-
odioxole-5-carboxylic acid
The procedure is in accordance with the process of Preparation 11,
replacing the methyl iodide by 1-bromo-2-fluoroethane.
.sup.1H NMR (400 MHz, dmso-d6, 300K) .delta. ppm: 12.53 (bs, 1H),
7.34 (s, 1H), 6.9 (s, 1H), 6.16 (s, 1H), 6.16 (s, 2H), 4.4 (dt,
2H), 4.15 (quad, 2H), 4.01 (m, 2H), 2.51 (s, 3H), 1.24 (t, 3H)
.sup.19F NMR (400 MHz, dmso-d6, 300 K) .delta. ppm: -222
IR: .nu.: --OH: 3700-2400 cm.sup.-1 acid; .nu.: >C.dbd.O: 1689
cm.sup.-1 acid; .nu.: >CF: 1213 cm.sup.-1
Preparation 22:
6-{4-(Ethoxycarbonyl)-1-methyl-5-[2-(morpholin-4-yl)ethyl]-1H-pyrrol-2-yl-
}-1,3-benzodioxole-5-carboxylic acid
Step A: 3,3-Diethoxypropanoic acid
To a solution of 25 g of ethyl 3,3-diethoxypropionate (131 mmol) in
79 mL of methanol there are added 13.1 mL of aqueous 35% sodium
hydroxide solution (452 mmol). The reaction mixture is stirred at
ambient temperature for 3 hours. The reaction mixture is then
concentrated to remove the methanol. After dissolving the
undissolved material by adding water, aqueous 5N HCl solution is
added to obtain a pH of 5. Dichloromethane is added and then the
organic phase is washed with brine. After drying over MgSO.sub.4
and concentrating to dryness, the title product is obtained in the
form of an oil which is used in the next Step without being
otherwise purified.
.sup.1H NMR (400 MHz, dmso-d6) .delta. ppm: 12.2 (s, 1H), 4.8 (t,
1H), 3.58/3.47 (2m, 4H), 2.5 (d, 2H), 1.09 (t, 6H)
Step B: Ethyl 5,5-diethoxy-3-oxo-pentanoate
To a solution of 16 mL of 3-ethoxy-3-oxomalonic acid (135 mmol) in
40 mL of tetrahydrofuran there are added, under argon, 21.9 g of
powdered magnesium (90.4 mmol). The mixture obtained is then heated
at 80.degree. C. for 7 hours. After returning to ambient
temperature, this mixture is transferred by cannula to a solution
of 10 g of the compound obtained in Step A (61.7 mmol) in 64 mL of
tetrahydrofuran to which there has previously been added, in
portions, 11 g of carbonyldiimidazole (66 mmol). The reaction
mixture is stirred for 3 days at ambient temperature. After
concentration, the residue is taken up in a mixture of ethyl
acetate and aqueous sodium hydrogen sulphate (NaHSO.sub.4)
solution. The mixture is stirred vigorously until no more gas is
evolved. After separation of the phases, the organic phase is
washed successively with water, saturated aqueous NaHCO.sub.3
solution and finally brine. After drying over MgSO.sub.4 and
concentrating to dryness, the title product is obtained in the form
of an oil which is used in the next Step without being otherwise
purified.
.sup.1H NMR (400 MHz, dmso-d6) .delta. ppm: 4.84 (t, 1H), 4.08 (q,
2H), 3.59 (s, 2H), 3.56/3.46 (2m, 4H), 2.8 (d, 2H), 1.18 (t, 3H),
1.09 (t, 6H)
Step C: Ethyl
2-(2,2-diethoxyethyl)-1-methyl-pyrrole-3-carboxylate
To a solution of 11.8 g of the compound obtained in Step B (50.8
mmol) in 76 mL of water there are added, dropwise at 0.degree. C.,
6.6 ml of aqueous 40% methylamine solution (76.2 mmol). The
reaction mixture is stirred and gently reheated to ambient
temperature over 5 hours. After returning to 0.degree. C., 8.8 mL
of aqueous 40% methylamine solution (102 mmol) and then 16.6 mL of
aqueous 50% chloroacetaldehyde solution (127 mmol) are each added
dropwise at a temperature of less than 10.degree. C. The reaction
mixture is stirred at ambient temperature for 16 hours and then
diluted with ethyl acetate. The organic phase is washed with brine,
dried over MgSO.sub.4 and concentrated to dryness. The crude
product thereby obtained is purified by chromatography over silica
gel using petroleum ether and ethyl acetate as eluants. The title
product is obtained in the form of an oil.
.sup.1H NMR (400 MHz, dmso-d6) .delta. ppm: 6.7 (d, 1H), 6.33 (d,
1H), 4.55 (t, 1H), 4.15 (q, 2H), 3.6 (m, 2H), 3.6 (s, 3H), 3.3 (m,
2H), 3.15 (d, 2H), 1.25 (t, 3H), 1.05 (t, 6H)
Step D: Ethyl
1-methyl-2-(2-morpholinoethyl)pyrrole-3-carboxylate
To a solution of 3.8 g of the compound obtained in Step C (14.05
mmol) in 28 mL of tetrahydrofuran there are added 58 mL of aqueous
10% sulphuric acid solution. The reaction mixture is stirred at
ambient temperature for 2 hours and then diluted with a mixture of
ethyl acetate and water. After separation, the organic phase is
washed with brine, dried over MgSO.sub.4 and concentrated to
dryness. To a solution of the residue thereby obtained in 70 mL of
dichloroethane there are added a solution of 13.5 mL of morpholine
(14.5 mmol) in a mixture composed of 30 mL of dichloroethane and
3.6 mL of 4N aqueous HCL solution in dioxane (14.5 mmol), and then
7.4 g of sodium triacetoxyborohydride (NaBH(OAc).sub.3) (35.13
mmol). The reaction mixture is stirred at ambient temperature for 3
hours and then diluted with a mixture of dichloromethane and
saturated aqueous NaHCO.sub.3 solution. After separation of the
phases and extraction of the aqueous phase with dichloromethane,
the organic phases are dried over MgSO.sub.4 and concentrated to
dryness.
The crude product thereby obtained is purified by chromatography
over silica gel using dichloromethane and methanol as eluants. The
title product is isolated in the form of an oil.
.sup.1H NMR (400 MHz, dmso-d6) .delta. ppm: 6.66 (d, 1H), 6.31 (d,
1H), 4.14 (q, 2H), 3.58 (s, 3H), 3.57 (m, 4H), 3.05 (m, 2H),
2.45-2.38 (m, 6H), 1.24 (t, 3H)
Step E:
6-{4-(Ethoxycarbonyl)-1-methyl-5-[2-(morpholin-4-yl)ethyl]-1H-pyrr-
ol-2-yl}-1,3-benzodioxole-5-carboxylic acid
The procedure is in accordance with Steps B and C of Preparation, 1
replacing the 2-bromo-4-chlorobenzaldehyde used in Step B by
6-bromo-1,3-benzodioxole-5-carbaldehyde.
Preparation 23:
6-[4-(Ethoxycarbonyl)-1-methyl-5-(morpholin-4-ylmethyl)-1H-pyrrol-2-yl]-1-
,3-benzodioxole-5-carboxylic acid
Step A: Ethyl 4,4-diethoxy-3-oxo-butanoate
To a solution of 40 g of ethyl diethoxyacetate (227 mmol) in 67 mL
of ethyl acetate there are added under argon, in portions, 6 g of
sodium (261 mmol). The reaction mixture is then stirred at ambient
temperature for 48 hours. There are added 10 mL of methanol, and
then the mixture is hydrolysed with 65 mL of water. The pH of the
reaction mixture is adjusted to pH 6 by adding 1N aqueous HCl
solution. The mixture is separated and then extracted with ethyl
acetate. The organic phases are combined, washed with brine, dried
over MgSO.sub.4, filtered and concentrated to dryness. The title
product is obtained in the form of an oil which is used in the next
Step without being otherwise purified.
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. ppm: 3.6 (s, 2H), 1.28
(t, 9H), 3.7-3.6 (2m, 4H), 4.7 (s, 1H), 4.2 (quad, 2H)
Step B: Ethyl
2-(2,2-diethoxymethyl)-1-methyl-pyrrole-3-carboxylate
The title compound is obtained in accordance with the process
described in Step C of Preparation 22, starting from the ethyl
4,4-diethoxy-3-oxo-butanoate obtained in the preceding Step.
.sup.1H NMR (400 MHz, dmso-d6) .delta. ppm: 6.73 (d, 1H), 6.32 (d,
1H), 6.23 (s, 1H), 4.17 (q, 2H), 3.7 (s, 3H), 3.68/3.43 (2m, 4H),
1.26 (t, 3H), 1.13 (t, 6H)
Step C: Ethyl
1-methyl-2-(2-morpholinomethyl)pyrrole-3-carboxylate
The title compound is obtained in accordance with the process
described in Step D of Preparation 22, starting from the ethyl
2-(2,2-diethoxymethyl)-1-methyl-pyrrole-3-carboxylate obtained in
the preceding Step.
.sup.1H NMR (400 MHz, dmso-d6) .delta. ppm: 6.74 (d, 1H), 6.32 (d,
1H), 4.15 (q, 2H), 3.8 (s, 2H), 3.65 (s, 3H), 3.5 (m, 4H), 2.32 (m,
4H), 1.22 (t, 3H)
Step D:
6-[4-(Ethoxycarbonyl)-1-methyl-5-(morpholin-4-ylmethyl)-1H-pyrrol--
2-yl]-1,3-benzodioxole-5-carboxylic acid
The procedure is in accordance with the protocol described in Steps
B and C of Preparation 1, replacing the
2-bromo-4-chlorobenzaldehyde used in Step B by
6-bromo-1,3-benzodioxole-5-carbaldehyde.
Preparation 24:
6-[4-(Methoxycarbonyl)-5-(2-methoxyethyl)-1-methyl-1H-pyrrol-2-yl]-1,3-be-
nzodioxole-5-carboxylic acid
Step A: Methyl
2-(2-methoxyethyl)-1-methyl-pyrrole-3-carboxylate
The title compound is obtained in accordance with the protocol of
Step C of Preparation 22, using methyl 5-methoxy-3-oxovalerate.
.sup.1H NMR (400 MHz, dmso-d6) .delta. ppm: 6.69 (wd, 1H), 6.31
(wd, 1H), 3.69 (s, 3H), 3.59 (s, 3H), 3.49 (t, 2H), 3.2 (s, 3H),
3.11 (t, 2H)
Step B:
6-[4-(Methoxycarbonyl)-5-(2-methoxyethyl)-1-methyl-1H-pyrrol-2-yl]-
-1,3-benzodioxole-5-carboxylic acid
The procedure is in accordance with the protocol described in Steps
B and C of Preparation 1, replacing the
2-bromo-4-chlorobenzaldehyde used in Step B by
6-bromo-1,3-benzodioxole-5-carbaldehyde.
Preparation 25:
2-[4-(Ethoxycarbonyl)-1,5-dimethyl-1H-pyrrol-2-yl]benzoic acid
The procedure is in accordance with the process of Preparation 1,
replacing the 2-bromo-4-chlorobenzaldehyde used in Step B by
2-bromobenzaldehyde.
.sup.1H NMR (400 MHz, dmso-d6) .delta. ppm: 12.81 (m, 1H), 7.84 (m,
1H), 7.59 (m, 1H), 7.51 (m, 1H), 7.35 (m, 1H), 6.23 (s, 1H), 4.16
(q, 2H), 3.24 (s, 3H), 2.5 (s, 3H), 1.25 (t, 3H)
Preparation 26:
5-Fluoro-2-[4-(methoxycarbonyl)-1,5-dimethyl-1H-pyrrol-2-yl]-benzoic
acid
The procedure is in accordance with the process of Preparation 1,
replacing in Step A the ethyl 2-methyl-1H-pyrrole-3-carboxylate by
methyl 2-methyl-1H-pyrrole-3-carboxylate and also the
2-bromo-4-chlorobenzaldehyde used in Step B by
2-bromo-5-fluorobenzaldehyde.
.sup.1H NMR (400 MHz, dmso-d6) .delta. ppm: 7.6 (dd, 1H), 7.42 (m,
2H), 6.22 (s, 1H), 4.15 (q, 2H), 3.21 (s, 3H), 2.5 (s, 3H), 1.23
(t, 3H)
.sup.19F NMR (400 MHz, dmso-d6) .delta. ppm: -113
Preparation 27:
2-[4-(Ethoxycarbonyl)-1,5-dimethyl-1H-pyrrol-2-yl]-5-fluoro-4-methoxybenz-
oic acid
The procedure is in accordance with the process of Preparation 1,
replacing in Step A the ethyl 2-methyl-1H-pyrrole-3-carboxylate by
methyl 2-methyl-1H-pyrrole-3-carboxylate and also the
2-bromo-4-chlorobenzaldehyde used in Step B by
2-bromo-4-methoxy-5-fluorobenzaldehyde.
.sup.1H NMR (400 MHz, dmso-d6) .delta. ppm: 9.65 (d, 1H), 7.67 (d,
1H), 7.24 (d, 1H), 6.48 (s, 1H), 4.19 (q, 2H), 3.97 (s, 3H), 3.38
(s, 3H), 2.56 (s, 3H), 1.26 (t, 3H).
Preparation 28:
2-(4-Ethoxycarbonyl-1,5-dimethyl-1H-pyrrol-2-yl)-4-fluoro-5-methoxybenzoi-
c acid
The procedure is in accordance with Preparation 1, replacing the
2-bromo-4-chlorobenzaldehyde used in Step B by
4-fluoro-5-methoxybenzaldehyde.
.sup.1H NMR (400 MHz, dmso-d6) .delta. ppm: 12.9 (m, 1H), 7.6 (d,
1H), 7.22 (d, 1H), 6.23 (s, 1H), 4.2 (quad, 2H), 3.95 (s, 3H), 3.25
(s, 3H), 2.5 (s, 3H), 1.25 (t, 3H)
Preparation 29:
5-Chloro-2-[4-(ethoxycarbonyl)-1,5-dimethyl-1H-pyrrol-2-yl]benzoic
acid
The procedure is in accordance with the process of Preparation 1,
replacing the 2-bromo-4-chlorobenzaldehyde used in Step B by
2-bromo-5-chlorobenzaldehyde.
Preparation 30:
2-{1-[2-(Benzyloxy)ethyl]-4-(ethoxycarbonyl)-5-methyl-1H-pyrrol-2-yl}-4-c-
hlorobenzoic acid
The procedure is in accordance with the process of Preparation 19,
replacing the 6-bromo-1,3-benzodioxole-5-carbaldehyde by
2-bromo-4-chlorobenzaldehyde.
Preparation 31:
5-Methoxy-2-[4-(methoxycarbonyl)-1,5-dimethyl-1H-pyrrol-2-yl]-benzoic
add
The procedure is in accordance with the process of Preparation 1,
replacing in Step A the ethyl 2-methyl-1H-pyrrole-3-carboxylate by
methyl 2-methyl-1H-pyrrole-3-carboxylate and also the
2-bromo-4-chlorobenzaldehyde used in Step B by
2-bromo-5-methoxybenzaldehyde.
.sup.1H NMR (400 MHz, dmso-d6) .delta. ppm: 12.8 (bs, 1H), 7.34
(wd, 1H), 7.26 (d, 1H), 7.15 (dd, 1H), 6.19 (s, 1H), 3.84 (s, 3H),
3.69 (s, 3H), 3.22 (s, 3H), 2.5 (s, 3H)
Preparation 32:
6-[1-(2,2-Difluoroethyl)-4-(ethoxycarbonyl)-5-methyl-1H-pyrrol-2-yl]-1,3--
benzodioxole-5-carboxylic acid
The procedure is in accordance with the protocol of Preparation 19,
replacing the 2-bromoethoxymethylbenzene used in Step A by
2-bromo-1,1-difluoro-ethane.
Preparation 1': (3R)-3-Methyl-1,2,3,4-tetrahydroisoquinoline
hydrochloride
Step A:
{(3S)-2-[(4-Methylphenyl)sulphonyl]-1,2,3,4-tetrahydroisoquinolin--
3-yl}methyl 4-methylbenzenesulphonate
To a solution of 30.2 g of
[(3S)-1,2,3,4-tetrahydroisoquinolin-3-yl]methanol (185 mmol) in 750
mL of dichloromethane there are successively added 91.71 g of tosyl
chloride (481 mmol) and then, dropwise, 122.3 mL of
N,N,N-triethylamine (740 mmol). The reaction mixture is then
stirred at ambient temperature for 20 hours. It is then diluted
with dichloromethane, washed successively with 1M HCl solution,
saturated aqueous NaHCO.sub.3 solution and then brine until
neutral. The organic phase is then dried over MgSO.sub.4, filtered
and concentrated to dryness. The solid obtained is then dissolved
in a minimum volume of dichloromethane and then cyclohexane is
added until a precipitate is formed. This precipitate is then
filtered off and washed with cyclohexane. After drying, the title
product is obtained in the form of crystals.
.sup.1H NMR: .delta. (400 MHz; dmso-d6; 300K): 7.75 (d, 2H,
aromatic Hs, ortho O-tosyl); 7.6 (d, 2H, aromatic Hs, ortho
N-tosyl); 7.5 (d, 2H, aromatic Hs, meta O-tosyl); 7.3 (d, 2H,
aromatic Hs, meta N-tosyl); 7.15-6.9 (m, 4H, aromatic Hs,
tetrahydroisoquinoline); 4.4-4.15 (dd, 2H, aliphatic Hs,
tetrahydroisoquinoline); 4.25 (m, 1H, aliphatic H,
tetrahydroisoquinoline); 4.0-3.8 (2dd, 2H, aliphatic Hs,
CH.sub.2--O-tosyl); 2.7 (2dd, 2H, aliphatic Hs,
tetrahydroisoquinoline); 2.45 (s, 3H, O--SO.sub.2-Ph-CH.sub.3);
2.35 (s, 3H, N--SO.sub.2-Ph-CH.sub.3)
IR: .nu.: --SO.sub.2: 1339-1165 cm.sup.-1
Step B:
(3R)-3-Methyl-2-[(4-methylphenyl)sulphonyl]-1,2,3,4-tetrahydroisoq-
uinoline
To a suspension of 8.15 g (214.8 mmol) of lithium aluminium hydride
(LiAlH.sub.4) in 800 mL of methyl tert-butyl ether (MTBE) there are
added 101.2 g of the ditosyl compound obtained in Step A (214.8
mmol) dissolved in 200 mL of MTBE. The batch is then heated at
50.degree. C. for 2 hours. It is allowed to cool and placed at
0.degree. C., and there are then added, dropwise, 12 mL of 5N NaOH
solution. The batch is stirred at ambient temperature for 45
minutes. The solid thereby obtained is then filtered off and washed
with MTBE and then with dichloromethane. The filtrate is then
concentrated to dryness. The title product is then obtained in the
form of a solid.
.sup.1H NMR: .delta. (400 MHz; dmso-d6; 300K): 7.70 (d, 2H,
aromatic Hs, ortho N-tosyl); 7.38 (d, 2H, aromatic Hs, meta
N-tosyl); 7.2-7.0 (m, 4H, aromatic Hs, tetrahydroisoquinoline); 4.4
(m, 2H, aliphatic Hs, tetrahydroisoquinoline); 4.3 (m, 1H,
aliphatic H, tetrahydroisoquinoline); 2.85-2.51 (2dd, 2H, aliphatic
Hs, tetrahydroisoquinoline); 2.35 (s, 3H, N--SO.sub.2-Ph-CH.sub.3);
0.90 (d, 3H, tetrahydroisoquinoline-CH.sub.3)
IR: .nu.: --SO.sub.2: 1332-1154 cm.sup.-1
Step C: (3R)-3-Methyl-1,2,3,4-tetrahydroisoquinoline
To a solution of 31.15 g (103.15 mmol) of the monotosyl compound
obtained in Step B in 500 mL of anhydrous methanol there are added,
in portions, 3.92 g (161 mmol) of magnesium turnings. The batch is
stirred in the presence of ultrasound for 96 hours. The reaction
mixture is then filtered and the solid is washed several times with
methanol. The filtrate is then concentrated to dryness. After
purification by chromatography over silica gel using
dichloromethane and ammonia-in-ethanol as eluants, the title
product is obtained in the form of an oil.
.sup.1H NMR: .delta. (400 MHz; dmso-d6; 300K): 7.05 (m, 4H,
aromatic Hs, tetrahydroisoquinoline); 3.90 (m, 2H, aliphatic Hs,
tetrahydroisoquinoline); 2.85 (m, 1H, aliphatic H,
tetrahydroisoquinoline); 2.68-2.4 (2dd, 2H, aliphatic Hs,
tetrahydroisoquinoline); 1.12 (d, 3H,
tetrahydroisoquinoline-CH.sub.3); 2.9-2.3 (m, broad, 1H, HN
(tetrahydroisoquinoline))
IR: .nu.: --NH: 3248 cm.sup.-1
Step D: (3R)-3-Methyl-1,2,3,4-tetrahydroisoquinoline
hydrochloride
To a solution of 14.3 g (97.20 mmol) of the compound obtained in
Step C in 20 mL of anhydrous ethanol there are added, dropwise, 100
mL of a 1M solution of HCl in ether. The batch is stirred at
ambient temperature for 1 hour and then filtered. The crystals
thereby obtained are washed with ethyl ether. After drying, the
title product is obtained in the form of crystals.
.sup.1H NMR: .delta. (400 MHz; dmso-d6; 300K): 9.57 (m, broad, 2H,
NH.sub.2.sup.+ (tetrahydroisoquinoline); 7.22 (m, 4H, aromatic Hs,
tetrahydroisoquinoline); 4.27 (s, 2H, aliphatic Hs,
tetrahydroisoquinoline); 3.52 (m, 1H, aliphatic H,
tetrahydroisoquinoline); 3.03-2.85 (2dd, 2H, aliphatic Hs,
tetrahydroisoquinoline); 1.39 (d, 3H,
tetrahydroisoquinoline-CH.sub.3)
IR: .nu.: --NH.sub.2.sup.+: 3000-2300 cm.sup.-1; .nu.: aromatic
--CH: 766 cm.sup.-1
Preparation 2': tert-Butyl
[(3S-1,2,3,4-tetrahydroisoquinolin-3-ylmethyl]-carbamate
Step A: Benzyl
(3S)-3-(hydroxymethyl)-3,4-dihydro-1H-isoquinoline-2-carboxylate
This compound is obtained using a protocol from the literature (R.
B. Kawthekar et al South Africa Journal of Chemistry 63, 195, 2009)
starting from 15 g of
(3S)-1,2,3,4-tetrahydroisoquinolin-3-ylmethanol (91.9 mmol) in the
presence of benzyl chloroformate and triethylamine in solution in
dichloromethane. After purification by chromatography over silica
gel using petroleum ether and ethyl acetate as eluants, the title
product is obtained in the form of an oil.
.sup.1H NMR: .delta. (300 MHz; DMSO-d6; 300K): 7.33 (m, 5H,
aromatic Hs, O-benzyl); 7.15 (s, 4H, aromatic Hs, H
tetrahydroisoquinoline); 5.13 (s, 2H, CH.sub.2-Ph); 4.73 (d, 1H, H
tetrahydroisoquinoline); 4.47 (m, H, CH.sub.2OH); 4.36 (m, 1H, H
tetrahydroisoquinoline); 4.28 (d, 1H, H tetrahydroisoquinoline);
3.39 (dd, 1H, CH.sub.2OH); 3.23 (dd, 1H, CH.sub.2OH); 2.93 (dd, 1H,
H tetrahydroisoquinoline); 2.86 (dd, 1H, H
tetrahydroisoquinoline)
IR: .nu.: OH: 3416 cm.sup.-1; .nu.: <C.dbd.O 1694 cm.sup.-1;
.nu.: aromatic >C--H: 754 cm.sup.-1
Step B: Benzyl
(3S)-3-(azidomethyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate
This compound is obtained using a protocol from the literature (D.
Page et al J. Med. Chem, 44, 2387, 2001) starting from 23 g of the
compound obtained in Step A (77.3 mmol) in the presence of
diphenylphosphoryl azide and triphenylphosphine in solution in THF.
After purification by chromatography over silica gel using
petroleum ether and ethyl acetate as eluants, the title product is
obtained in the form of an oil.
.sup.1H NMR: .delta. (400 MHz; DMSO-d6; 300K): 7.36 (m, 5H,
aromatic Hs, O-benzyl); 7.19 (m, 4H, aromatic Hs, H
tetrahydroisoquinoline); 5.16 (s, 2H, CH.sub.2-Ph); 4.76 (d, 1H, H
tetrahydroisoquinoline); 4.53 (m, 1H, H tetrahydroisoquinoline);
4.30 (m, 1H, H tetrahydroisoquinoline); 3.28 (m, 2H,
CH.sub.2N.sub.3); 3.06 (dd, 1H, H tetrahydroisoquinoline); 2.78
(dd, 1H, H tetrahydroisoquinoline)
IR: .nu.: N.sub.3: 2095 cm.sup.-1; .nu.: <C.dbd.O: 1694
cm.sup.-1; .nu.: aromatic >C--H: 754 cm.sup.-1
Step C: Benzyl
(3S)-3-(aminomethyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate
To a solution of 20.9 g (64.5 mmol) of the azido compound obtained
in Step B in 650 mL of THF, there are successively added 25.5 g
(97.2 mmol) of triphenylphosphine and 157 mL of water. The batch is
refluxed for 2 hours 30 minutes. The reaction mixture is then
concentrated to dryness and the residue oil is then taken up in
isopropyl ether. A white precipitate appears; it is filtered off
and washed with isopropyl ether. The filtrate is then concentrated
to dryness and then purified by chromatography over silica gel
using dichloromethane and methanol as eluants. The title product is
obtained in the form of an oil.
.sup.1H NMR: .delta. (400 MHz; DMSO-d6; 300K): 7.40 (m, 5H,
aromatic Hs, O-benzyl); 7.20 (m, 4H, aromatic Hs, H
tetrahydroisoquinoline); 5.15 (s, 2H, CH.sub.2-Ph); 4.75-4.3 (m,
2H, H tetrahydroisoquinoline); 4.30 (d, 1H, H
tetrahydroisoquinoline); 2.90 (m, 2H, CH.sub.2NH.sub.2); 2.45 (m,
2H, H tetrahydroisoquinoline); 1.40 (m, 2H, NH.sub.2)
IR: .nu.: NH.sub.2: 3400-3300 cm.sup.-1; .nu.: <C.dbd.O: 1688
cm.sup.-1
Step D: Benzyl
(3S)-3-{[(tert-butoxycarbonyl)amino]methyl}-3,4-dihydroisoquinoline-2(1H)-
-carboxylate
To a solution of 18.4 g (62.1 mmol) of the compound obtained in
Step C in 630 mL of dichloromethane there are successively added
17.5 mL (124 mmol) of triethylamine and, in portions, 14.9 g (68.3
mmol) of di-tert-butyl dicarbonate. The batch is stirred at ambient
temperature for 2 h. The reaction mixture is then concentrated and
ethyl acetate is then added. The organic phase is successively
washed with 1M HCl solution, brine, saturated aqueous NaHCO.sub.3
solution and then brine. After drying, concentrating to dryness and
purifying by chromatography over silica gel using petroleum ether
and ethyl acetate as eluants, the title product is obtained in the
form of an oil.
.sup.1H NMR: .delta. (400 MHz; DMSO-d6; 300K): 7.35 (m, 5H,
aromatic Hs, O-benzyl); 7.15 (m, 4H, aromatic Hs, H
tetrahydroisoquinoline); 6.51 (m, 1H, NHBoc); 5.12 (s, 2H,
CH.sub.2-Ph); 4.76 (d, 1H, H tetrahydroisoquinoline); 4.51 (m, 1H,
H tetrahydroisoquinoline); 4.36 (d, 1H, H tetrahydroisoquinoline);
2.95 (m, 3H, H tetrahydroisoquinoline+CH.sub.2NHBoc); 2.71 (d, 1H,
H tetrahydroisoquinoline); 1.34 (s, 9H, NHBoc)
IR: .nu.: NH: 3351 cm.sup.-1; .nu.: <C.dbd.O: 1686 cm.sup.-1
Step E: tert-Butyl
[(3S)-1,2,3,4-tetrahydroisoquinolin-3-ylmethyl]carbamate
To a solution of 21 g (53 mmol) of the compound obtained in Step D
in 600 mL of ethyl acetate there are added 2.1 g of
palladium-on-carbon 10%. The batch is stirred at ambient
temperature under a pressure of 1.3 bars of dihydrogen for 5 hours.
The reaction mixture is then filtered and then concentrated to
dryness. The title product is obtained in the form of a solid.
.sup.1H NMR: .delta. (400 MHz; DMSO-d6; 300K): 7.15 (m, 4H,
aromatic Hs, H tetrahydroisoquinoline); 6.85 (t, 1H, NHBoc); 3.90
(m, 2H, H tetrahydroisoquinoline); 3.00 (m, 2H, CH.sub.2NHBoc);
2.80 (m, 1H, H tetrahydroisoquinoline); 2.65 (dd, 1H, H
tetrahydroisoquinoline); 2.40 (dd, 1H, H tetrahydroisoquinoline);
1.40 (s, 9H, NHBoc)
IR: .nu.: NH: 3386-3205 cm.sup.-1 (NH amide); .nu.: <C.dbd.O:
1688 cm.sup.-1; .nu.: NH: 1526 cm.sup.-1 (NH amine)
Preparation
(3S)-3-(4-Morpholinylmethyl)-1,2,3,4-tetrahydroisoquinoline
Step A: Benzyl
(3S)-3-(4-morpholinylcarbonyl)-3,4-dihydro-2(1H)-isoquinolinecarboxylate
To a solution of 5 g of
(3S)-2-[(benzyloxy)carbonyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic
acid (16 mmol) in 160 mL of dichloromethane there are added 1.5 mL
of morpholine (17.6 mmol), then 9 mL of N,N,N-triethylamine (64
mmol), 3.3 g of 1-ethyl-3-(3'-dimethylaminopropyl)-carbodiimide
(EDC) (19.2 mmol) and 2.6 g of hydroxybenzotriazole (HOBt) (19.2
mmol). The reaction mixture is stirred at ambient temperature
overnight; it is then poured into ammonium chloride solution and
extracted with ethyl acetate. The organic phase is then dried over
MgSO.sub.4, and then filtered and evaporated to dryness. The crude
product thereby obtained is then purified by chromatography over
silica gel using dichloromethane and methanol as eluants. The
product is obtained in the form of a foam.
.sup.1H NMR: .delta. (400 MHz; dmso-d6; 353K): 7.30 (m, 5H benzyl);
7.15 (m, 4H, aromatic Hs); 5.2-5.0 (m, 3H, 2H benzyl, 1H
dihydroisoquinoline); 4.75-4.5 (2d, 2H dihydroisoquinoline);
3.55-3.3 (m, 8H morpholine); 3.15-2.9 (2dd, 2H
dihydroisoquinoline)
IR: .nu.: >C.dbd.O: 1694; 1650 cm.sup.-1
Step B: Benzyl
(3S)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1H)-isoquinolinecarboxylate
To a solution of 5.3 g of the product obtained in Step A (13.9
mmol) in 278 mL of tetrahydrofuran there are added 14 mL of
borane-dimethylsulphide complex (BH.sub.3Me.sub.2S) (27.8 mmol) at
ambient temperature. The batch is heated for 4 hours at 80.degree.
C. It is allowed to return to ambient temperature and there are
then added 7 mL (14 mmol) of BH.sub.3Me.sub.2S. The reaction
mixture is again heated at 80.degree. C. for 2 hours. The
tetrahydrofuran is then evaporated off and then there is slowly
added methanol and then 5.6 mL of 5N aqueous HCl solution (27.8
mmol). The mixture is stirred at ambient temperature overnight, and
then at 80.degree. C. for 1 hour. Saturated aqueous NaHCO.sub.3
solution is then added to the reaction mixture placed at 0.degree.
C. until a pH of 8 is obtained, and extraction with ethyl acetate
is then carried out. The organic phase is then dried over
MgSO.sub.4, and then filtered and evaporated to dryness. The title
product is obtained in the form of an oil.
.sup.1H NMR: .delta. (400 MHz; dmso-d6; 353K): 7.43-7.30
(unresolved peak, 5H benzyl); 7.19 (m, 4H, aromatic Hs); 5.16 (m,
2H, 2H benzyl); 4.79-4.29 (d, 2H dihydroisoquinoline); 4.58 (m, 1H
dihydroisoquinoline); 3.50 (m, 4H morpholine); 3.02-2.80 (dd, 2H
dihydroisoquinoline); 2.42-2.28 (unresolved peak, 5H, 4H
morpholine, 1H morpholine); 2.15 (dd, 1H morpholine)
IR: .nu.: >CH: 2810 cm.sup.-1; .nu.: >C.dbd.O: 1694
cm.sup.-1; .nu.: >C--O--C<: 1114 cm.sup.-1; .nu.: >CH--Ar:
751; 697 cm.sup.-1
Step C:
(3S)-3-(4-Morpholinylmethyl)-1,2,3,4-tetrahydroisoquinoline
To a solution of 4.9 g of the compound of Step B (13.4 mmol) in 67
mL of ethanol there is added 0.980 g of palladium dihydroxide (20%
by weight) at ambient temperature. The reaction mixture is placed
under 1.2 bars of hydrogen at ambient temperature for 4 hours. It
is then passed through a Whatman filter and the palladium is then
rinsed several times with ethanol. The filtrate is evaporated to
dryness. The title product is obtained in the form of an oil.
.sup.1H NMR: .delta. (400 MHz; dmso-d6; 300K): 7.12-7.0 (unresolved
peak, 4H, aromatic Hs); 3.92 (s, 2H tetrahydroisoquinoline); 3.60
(t, 4H morpholine); 2.98 (m, 1H tetrahydroisoquinoline); 2.68 (dd,
1H tetrahydroisoquinoline); 2.5-2.3 (unresolved peak, 8H, 1H
tetrahydroisoquinoline, 6H morpholine, 1H NH)
IR: .nu.: >NH: 3322 cm.sup.-1; .nu.: >C--O--C<: 1115
cm.sup.-1; .nu.: >CH--Ar: 742 cm.sup.-1
Preparation 4':
(3S)-3-[(4-Methyl-1-piperazinyl)methyl]-1,2,3,4-tetrahydroisoquinoline
The procedure is in accordance with the process of Preparation 3',
replacing the morpholine used in Step A by 1-methyl-piperazine.
Preparation 5':
(3S)-3-[2-(Morpholin-4-yl)ethyl]-2,3,4-tetrahydroisoquinoline
hydrochloride
Step A: tert-Butyl
(3S)-3-(2-morpholino-2-oxo-ethyl)-3,4-dihydro-1H-isoquinoline-2-carboxyla-
te
To a solution of 3 g (10.30 mmol) of
[(3S)-2-(tert-butoxycarbonyl)-1,2,3,4-tetrahydroisoquinolin-3-yl]acetic
acid in 100 mL of dichloromethane, there are added dropwise 1.10 mL
(11.32 mmol) of morpholine, still dropwise 4.3 mL (30.9 mmol) of
triethylamine, 2.20 g (12.40 mmol) of EDC and 1.70 g (1.68 mmol) of
HOBt (hydroxybenzotriazole). The batch is stirred at ambient
temperature for 15 hours. The reaction mixture is then diluted with
dichloromethane, successively washed with 1M HCl solution,
saturated aqueous NaHCO.sub.3 solution and then brine until
neutral. The organic phase is then dried over MgSO.sub.4, filtered
and concentrated to dryness. After purification by chromatography
over silica gel using dichloromethane and methanol as eluants, the
title product is obtained in the form of an oil.
.sup.1H NMR: .delta. (400 MHz; dmso-d6; 300K): 7.20-7.10 (m, 4H,
aromatic Hs, tetrahydroisoquinoline); 4.70 (m, 1H, aliphatic Hs, CH
tetrahydroisoquinoline); 4.75-4.20 (2m, 2H, aliphatic Hs, CH.sub.2
alpha to N tetrahydroisoquinoline); 3.60 (m, 8H, aliphatic Hs,
morpholine); 3.00 and 2.70 (2dd, 2H, aliphatic H,
tetrahydroisoquinoline); 2.50-2.20 (2d, 2H, aliphatic Hs,
CH.sub.2CO); 1.40 (s, 9H, .sup.tBu)
IR: .nu.: C.dbd.O: 1687; 1625 cm.sup.-1
Step B:
1-(Morpholin-4-yl)-2-[(3S)-1,2,3,4-tetrahydroisoquinolin-3-yl]etha-
none hydrochloride
To a solution of 2.88 g (7.18 mmol) of the compound obtained in
Step A in 16 mL of dichloromethane, there are added dropwise 80 mL
(80 mmol) of 1M solution of HCl in ether. The batch is stirred at
ambient temperature for 15 hours, and then the suspension is
filtered and the precipitate washed with ether. After drying, the
title product is obtained in the form of a solid.
.sup.1H NMR: .delta. (400 MHz; dmso-d6; 300K): 9.80-9.50 (m, 2H,
NH.sub.2.sup.+); 7.30-7.10 (m, 4H, aromatic Hs,
tetrahydroisoquinoline); 4.30 (m, 2H, aliphatic Hs, CH.sub.2 alpha
to N tetrahydroisoquinoline); 3.80 (m, 1H, aliphatic Hs, CH
tetrahydroisoquinoline); 3.70-3.40 (2m, 8H, aliphatic Hs,
morpholine); 3.15 and 2.8 (m, 4H, aliphatic H, CH.sub.2
tetrahydroisoquinoline and CH.sub.2CO)
IR: .nu.: --NH.sub.2.sup.+: 2800-1900 cm.sup.-1; .nu.: C.dbd.O:
1620 cm.sup.-1
Step C:
(3S)-3-[2-(Morpholin-4-yl)ethyl]-1,2,3,4-tetrahydroisoquinoline
hydrochloride
A solution of 2.2 g (7.44 mmol) of the compound obtained in Step B
in 22 mL of MTBE and 5 mL of dichloromethane is prepared. After
cooling in an ice bath at 0.degree. C., there are added thereto,
dropwise, 15 mL (15 mmol) of 1M LiAlH.sub.4 solution in
tetrahydrofuran. The batch is then stirred at ambient temperature
for 6 hours. It is placed at 0.degree. C., and there is then added,
dropwise, 1 mL of 5N NaOH solution. The batch is stirred at ambient
temperature for 45 minutes. The solid is then filtered off and
washed with MTBE and then with dichloromethane and the filtrate is
concentrated to dryness. The oil thereby obtained is diluted with
dichloromethane and there are added, dropwise, 6.3 mL of a 1M
solution of HCl in ether. The batch is stirred at ambient
temperature for 1 hour and then filtered. The crystals thereby
obtained are washed with ethyl ether. After drying, the title
product is obtained in the form of a solid.
.sup.1H NMR: .delta. (400 MHz; dmso-d6; 300K): 11.35+9.80 (2m, 2H,
NH.sub.2.sup.+); 10.00 (m, H, NH.sup.+); 7.20 (m, 4H, aromatic Hs,
tetrahydroisoquinoline); 4.30 (s, 2H, aliphatic Hs, CH.sub.2 alpha
to N tetrahydroisoquinoline); 4.00+3.85 (2m, 4H, aliphatic Hs,
CH.sub.2 alpha to N morpholine); 3.70 (m, 1H, aliphatic Hs, CH
tetrahydroisoquinoline); 3.55-3.30 (m, 4H, aliphatic Hs, CH alpha
to O morpholine and CH.sub.2-morpholine); 3.15 (dd, 1H, aliphatic
H, CH.sub.2 tetrahydroisoquinoline); 3.10 (m, 2H, aliphatic H, CH
alpha to O morpholine); 2.90 (dd, 1H, aliphatic H, CH.sub.2
tetrahydroisoquinoline); 2.30+2.15 (2m, 2H, aliphatic H,
CH.sub.2-tetrahydroisoquinoline)
IR: .nu.: NH.sup.+/--NH.sub.2.sup.+: between 3500 and 2250
cm.sup.-1; .nu.: C.dbd.C: weak 1593 cm.sup.-1; .nu.: aromatic C--H:
765 cm.sup.-1
Preparation 6':
(3R)-3-[3-(Morpholin-4-yl)propyl]-1,2,3,4-tetrahydroisoquinoline
Step A:
{(3S)-2-[(4-Methylphenyl)sulphonyl]-1,2,3,4-tetrahydroisoquinolin--
3-yl}methyl 4-methylbenzenesulphonate
The process is the same as that of Step A of Preparation 1'.
Step B: tert-Butyl
2-({(3R)-2-[(4-methylphenyl)sulphonyl]-1,2,3,4-tetrahydroisoquinolin-3-yl-
}methyl)-3-(morpholin-4-yl)-3-oxopropanoate
To a suspension of 1 g of NaH (60%) (25.08 mmol) in 30 mL of MTBE
there are added, dropwise, a solution of 5 g of tert-butyl
3-morpholino-3-oxopropanoate (21.81 mmol) in 20 mL of anhydrous
MTBE. This suspension stirred at ambient temperature for 1 hour and
then the compound obtained in Step A is added in the form of a
powder. The batch is stirred at 60.degree. C. for 30 hours. 100 mL
of saturated aqueous ammonium chloride solution are added. The
resulting solution is extracted with dichloromethane. The organic
phase is then dried over MgSO.sub.4, filtered and concentrated to
dryness. After purification by chromatography over silica gel using
dichloromethane and MeOH as eluants, the expected product is
obtained in the form of an oil.
.sup.1H NMR (500 MHz, dmso-d6) .delta. ppm: 7.63/7.59 (2d, 2H),
7.3/7.26 (2d, 2H), 7.13 (m, 2H), 7.09/6.97 (2t, 2H),
4.64/4.55/4.36/4.28 (2AB, 2H), 4.25/4.11 (2m, 1H), 3.81 (m, 1H),
3.73-3.48 (m, 4H), 3.57-3.32 (m, 4H), 2.51 (m, 2H), 2.32/2.31 (2s,
3H), 1.88/1.79 (2m, 2H), 1.39/1.38 (2s, 9H)
IR (ATR) cm.sup.-1: .nu.: >C.dbd.O: 1731 (ester); .nu.:
>C.dbd.O: 1644 (amide); .nu.: --SO2: 1334-1156; .nu.:
>C--O--C<: 1115; .gamma.: >CH--Ar: 815-746-709
Step C:
2-({(3R)-2-[(4-Methylphenyl)sulphonyl]-1,2,3,4-tetrahydroisoquinol-
in-3-yl}methyl)-3-(morpholin-4-yl)-3-oxopropanoic acid
To a solution of 9.5 g (17.97 mmol) of the compound obtained in
Step B in 40 mL of dioxane there are added, dropwise, 20 mL of a 4M
solution of HCl in dioxane. The batch is stirred at ambient
temperature for 48 hours and then the solution is concentrated to
dryness. After drying, the expected product is obtained in the form
of an oil.
.sup.1H NMR (400 MHz, dmso-d6) .delta. ppm: 12.75 (m, 1H), 7.6
(2*d, 2H), 7.3 (2*d, 2H), 7.1/6.95 (2*m, 4H), 4.7-4.2 (d, 2H),
4.25/4.12 (2*m, 1H), 3.9-3.3 (m, 9H), 2.55 (d, 2H), 2.3 (2*s, 3H),
1.8 (t, 2H)
IR (ATR) cm.sup.-1: .nu.: --OH: 3500 to 2000; .nu.: >C.dbd.O:
1727 (acid); .nu.: >C.dbd.O: 1634 (amide); .nu.: --SO2:
1330-1155
Step D:
3-{(3R)-2-[(4-Methylphenyl)sulphonyl]-1,2,3,4-tetrahydroisoquinoli-
n-3-yl}-1-(morpholin-4-yl)propan-1-one
To a solution of 7.80 g (16.51 mmol) of the compound obtained in
Step C in 100 mL of DMSO there are added 1.16 g (19.83 mmol) of
solid sodium chloride (NaCl) and then, dropwise, 5 mL of water. The
batch is stirred at 130.degree. C. for 1 hour and then the solution
is concentrated to 3/4. The reaction mixture is then diluted with
dichloromethane and washed successively with saturated aqueous
lithium chloride solution and then with brine. The organic phase is
then dried over MgSO.sub.4, filtered and concentrated to dryness.
After purification by chromatography over silica gel using
cyclohexane and ethyl acetate as eluants, the expected product is
obtained in the form of an oil.
.sup.1H NMR (400 MHz, dmso-d6) .delta. ppm: 7.65 (d, 2H), 7.3 (d,
2H), 7.15/7 (2 m, 4H), 4.6 (d, 1H), 4.25 (d, 1H), 4.2 (m, 1H), 3.5
(m, 4H), 3.4 (2 m, 4H), 2.6 (2 dd, 2H), 2.35 (s, 3H), 2.3 (m, 2H),
1.5 (quad., 2H)
IR (ATR) cm.sup.-1: .nu.: >C.dbd.O: 1639; .nu.: --SO2:
1331-1156; .gamma.: >CH--Ar: 815-675
Step E:
(3R)-2-[(4-Methylphenyl)sulphonyl]-3-[3-(morpholin-4-yl)propyl]-1,-
2,3,4-tetrahydroisoquinoline
To a solution of 6.0 g (14.0 mmol) of the compound obtained in Step
D in 60 mL of MTBE and 14 mL of dichloromethane there are added
1.06 g (28 mmol) of LAH in portions over 5 minutes. The batch is
stirred at ambient temperature for 15 hours. There are added,
dropwise, 1.5 mL of water and stirring is carried out for 15
minutes. There are then added, dropwise, 1.5 mL of 5M sodium
hydroxide solution and stirring is carried out for 15 minutes. The
reaction mixture is then diluted with MTBE and dichloromethane. The
suspension is then filtered and the precipitate is washed with MTBE
and dichloromethane. The organic phase is then dried over
MgSO.sub.4, filtered and concentrated to dryness. After
purification by chromatography over silica gel using
dichloromethane and ammonia-in-ethanol as eluants, the expected
product is obtained in the form of an oil.
.sup.1H NMR (400 MHz, dmso-d6) .delta. ppm: 7.68 (d, 2H), 7.32 (d,
2H), 7.1 (unresolved peak, 4H), 4.65/4.23 (AB, 2H), 4.2 (m, 1H),
3.55 (t, 4H), 2.7/2.6 (ABX, 2H), 2.35 (s, 3H), 2.25 (t, 4H), 2.2
(t, 2H), 1.4/1.3 (2m, 4H).
IR (ATR) cm.sup.-1: .nu.: --SO2: 1333-1158
Step F:
(3R)-3-[3-(Morpholin-4-yl)propyl]-1,2,3,4-tetrahydroisoquinoline
To a solution of 1.50 g (3.62 mmol) of the compound obtained in
Step E in 20 mL of anhydrous methanol there are added 2.0 g (82.3
mmol), in portions, of magnesium turnings. The batch is stirred in
the presence of ultrasound for 96 hours. The reaction mixture is
then filtered, the solid is washed several times with methanol, and
the filtrate is concentrated to dryness. After purification by
chromatography over silica gel using dichloromethane and
ammonia-in-ethanol as eluants, the expected product is obtained in
the form of an oil.
.sup.1H NMR (400 MHz, dmso-d6) .delta. ppm: 7.3 (d, 2H), 7.1 (t,
2H), 7.1 (d+t, 3H), 7 (d, 2H), 3.9 (s, 2H), 3.55 (t, 4H), 2.75 (m,
1H), 2.72/2.45 (dd, 2H), 2.35 (t, 4H), 2.25 (t, 2H), 1.6 (m, 2H),
1.45 (m, 2H)
IR (ATR) cm.sup.-1: .nu.: >NH2+/NH+: 3500-2300; .nu.:
>C--O--C<: 1115
High-Resolution Mass Spectrometry (ESI+-/FIA/HR):
Empirical formula: C.sub.16H.sub.24N.sub.2O
[M+H].sup.+ calculated: 261.1961
[M+H].sup.+ measured: 261.1959
Preparation 7':
(3S)-3-[(9aS)-Octahydropiperazino[2,1-c]morpholin-8-ylmethyl]-1,2,3,4-tet-
rahydroisoquinoline trihydrochloride
Step A: tert-Butyl
(9aS)-4-oxo-octahydropiperazino[2,1-c]morpholine-8-carboxylate
The synthesis of this compound is known in the literature (J. Med.
Chem. 2012, 55, 5887 for the opposite enantiomer).
Step B: (9aS)-Octahydropiperazino[2,1-c]morpholin-4-one
hydrochloride
A 4M solution of HCl in dioxane (60 mL, 240 mmol) is added to the
compound tert-butyl
(9aS)-4-oxo-octahydropiperazino[2,1-c]morpholine-8-carboxylate
(11.8 g, 46.0 mmol) cooled using an ice bath. The solution is then
stirred at ambient temperature for 2 hours, and then at
50-60.degree. C. for 1.5 hours. The solution is then evaporated to
dryness. The residue is co-evaporated with dioxane (3.times.20 mL)
and then dried in vacuo to obtain the expected compound in the form
of a solid.
.sup.1H NMR (400 MHz, dmso-d6) .delta. ppm: 2.80-2.94 (m, 2H),
2.94-3.05 (m, 1H), 3.23-3.37 (m, 2H), 3.59-3.69 (m, 1H), 3.83-3.93
(m, 1H), 3.95-4.04 (m, 1H), 4.02-4.13 (m, 2H), 4.45-4.55 (m, 1H),
9.58 (br s, 2H)
Step C: tert-Butyl
(3S)-3-[(9aS)-4-oxo-octahydropiperazino[2,1-c]morpholine-8-carbonyl]-1,2,-
3,4-tetrahydroisoquinoline-2-carboxylate
EDC (3.90 g, 20.3 mmol) is added to a solution of the compound of
Step B (3.02 g, 15.7 mmol),
(3S)-2-[(tert-butoxy)carbonyl]-1,2,3,4-tetrahydroisoquinoline-3-carboxyli-
c acid (4.6 g, 16.6 mmol), triethylamine (8.0 mL, 57.4 mmol) and
HOBt (2.72 g, 20.1 mmol) in dichloromethane (150 mL). The mixture
is stirred at ambient temperature for 21 hours. 1N aqueous HCl
solution (105 mL) is added and the precipitate formed is filtered
off using a Buchner funnel. The phases of the filtrate are
separated. The aqueous phase is extracted with dichloromethane
(2.times.10 mL). The combined organic phases are washed with 3N
aqueous HCl solution (35 mL), then with aqueous 5% potassium
bicarbonate solution (2.times.35 mL) and finally with brine (35
mL). The organic phase is dried over Na.sub.2SO.sub.4, filtered and
then concentrated under reduced pressure. The product is purified
by chromatography over silica gel using ethyl acetate and heptane
as eluants to obtain the expected compound in the form of a
solid.
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. ppm: 1.38-1.57 (m, 9H),
2.39-2.89 (m, 2H), 2.89-3.34 (m, 3H), 3.34-3.70 (m, 2H), 3.90-4.06
(m, 1H), 4.09-4.27 (m, 2H), 4.30-5.00 (m, 5H), 5.20-5.37 (m, 1H),
7.03-7.24 (m, 4H)
Step D:
(3S)-3-[(9aS)-Octahydropiperazino[2,1-c]morpholin-8-ylmethyl]-1,2,-
3,4-tetrahydroisoquinoline trihydrochloride
4M HCl solution in dioxane (45 mL, 180 mmol) is added to the
compound of Step C (6.6 g, 46.0 mmol) cooled in an ice bath. The
suspension is then stirred at ambient temperature for 24 hours and
then it is evaporated to dryness. The residue is co-evaporated with
MTBE and then dried in vacuo. The solid thereby obtained is
suspended in tetrahydrofuran (160 mL), and then LiAlH.sub.4 (3.0 g,
79.1 mmol) is added. The suspension is refluxed for 6.5 hours, and
it is then cooled in an ice bath. Water (3 mL) is then added over a
period of 7 minutes. After 0.5 hours, 2N aqueous sodium hydroxide
solution (6 mL) is added. Water (6 mL) is again added 0.25 hours
later. Finally, Celite (7 g) and Na.sub.2SO.sub.4 (25 g) are added
0.5 hours later. The suspension is filtered over Celite and rinsed
with tetrahydrofuran (2.times.100 mL). The filtrate is concentrated
to dryness. The oil thereby obtained is dissolved in MTBE (50 mL).
The resulting solution is filtered and the filtrate concentrated.
The residue is dissolved in methanol (60 mL), and then 4M HCl
solution in dioxane (20 mL) is added. The solution is heated to
40.degree. C. and treated with activated charcoal (0.66 g), with
stirring, for 1 hour. The suspension is filtered over Celite and
rinsed with warm methanol. The filtrate is concentrated until the
product starts to crystallise out. Crystallisation is allowed to
continue for 16 hours at ambient temperature. The solid obtained is
filtered off and rinsed with a mixture of 2-propanol/MTBE (4/6)
(2.times.20 mL), and then with MTBE (2.times.20 mL). After drying,
the expected compound is obtained.
.sup.1H NMR (400 MHz, D.sub.2O) .delta. ppm: 2.28-2.44 (m, 1H),
2.74-3.00 (m, 4H), 3.08-3.27 (m, 3H), 3.27-3.42 (m, 2H), 3.43-3.56
(m, 2H), 3.56-3.69 (m, 2H), 3.76-3.95 (m, 2H), 4.00-4.22 (m, 2H),
4.35-4.50 (m, 2H), 7.20-7.41 (m, 4H)
.sup.13C NMR (100 MHz, D.sub.2O) .delta. ppm: 29.00, 44.58, 50.30,
51.08, 51.17, 52.75, 53.17, 58.08, 61.60, 64.61, 66.37, 127.14,
127.71, 128.00, 128.77, 129.55, 131.15
MS (ESI): [M+H].sup.+ 288.16
Preparation 8':
(3S)-3-(1-Oxa-6-azaspiro[3.3]hept-6-ylmethyl)-1,2,3,4-tetrahydroisoquinol-
ine
Step A:
(3S)-3-(Iodomethyl)-2-[(4-methylphenyl)sulphonyl]-1,2,3,4-tetrahyd-
roisoquinoline
The compound of Step A of Preparation 6' (4.0 g; 8.48 mmol) in
acetonitrile (10 mL) is placed in a 27-ml microwave tube and then
sodium iodide (1.40 g; 9.33 mmol) is added. The reaction mixture is
heated for 5 hours at 100.degree. C. using microwaves (200 W). It
is then filtered and the solid is washed with dichloromethane. The
filtrate is evaporated to dryness and then the residue is purified
by chromatography over silica gel using heptane and ethyl acetate
as eluants. The title compound is obtained in the form of an
oil.
.sup.1H NMR (400 MHz, dmso-d6) .delta. ppm: 7.64 (d, 2H), 7.28 (d,
2H), 7.15-7 (m, 4H), 4.5/4.3 (2d, 2H), 4.14 (m, 1H), 3.22 (m, 2H),
2.82 (m, 2H), 2.31 (s, 3H)
IR (ATR) cm.sup.-1: 1897 .nu. --Ar, 1333+1156 .nu. --SO2
Step B:
(3S)-2-[(4-Methylphenyl)sulphonyl]-3-(1-oxa-6-azaspiro[3.3]hept-6--
ylmethyl)-1,2,3,4-tetrahydroisoquinoline
The iodinated compound (2.5 g; 5.85 mmol) obtained in the preceding
Step is dissolved in acetonitrile (50 mL).
1-Oxa-6-azaspiro[3.3]heptane oxalate (1.21 g; 6.36 mmol) is added,
followed by potassium carbonate (1.61 g; 11.7 mmol). The reaction
mixture is heated for 15 hours at reflux. The reaction mixture is
filtered and washed with acetonitrile, and then is evaporated to
dryness.
The compound is purified by chromatography over silica gel using
dichloromethane and ammonia-in-methanol as eluants. The title
compound is obtained in the form of an oil.
.sup.1H NMR (400 MHz, dmso-d6) .delta. ppm: 7.68 (d, 2H), 7.32 (d,
2H), 7.14-7 (m, 4H), 4.53/4.2 (dd, 2H), 4.34 (t, 2H), 3.95 (m, 1H),
3.5/3.4/2.98 (3m, 4H), 2.7 (t, 2H), 2.68-2.58 (m, 2H), 2.34 (s,
3H), 2.31-2.24 (m, 2H)
IR (ATR) cm.sup.-1: 1333+1156 .nu. --SO2
Step C:
(3S)-3-(1-Oxa-6-azaspiro[3.3]hept-6-ylmethyl)-1,2,3,4-tetrahydrois-
oquinoline
The tosylated compound of the above Step (1.3 g; 3.26 mmol) is
dissolved in 10 mL of methanol. Powdered magnesium (633 mg; 26.08
mmol) is added in portions of 160 mg every 3 hours. The reaction
mixture is stirred in an ultrasound bath 15 hours. It is then
filtered over Celite, washed with copious amounts of methanol, and
then evaporated to dryness. The compound is purified by
chromatography over silica gel using dichloromethane and
ammonia-in-methanol as eluants. The compound is obtained in the
form of an oil.
.sup.1H NMR (400 MHz, dmso-d6) .delta. ppm: 7.01 (m, 4H), 4.46 (t,
2H), 3.85 (s, 2H), 3.51/3.05 (dd, 2H), 2.73 (t, 2H), 2.61/2.4 (m,
4H), 2.4 (m, 1H), 2.4 (m, 1H)
IR (ATR) cm.sup.-1: 3325 .nu. >NH
Preparation 9':
(3S)-3-[(9aR)-Octahydropiperazino[2,1-c]morpholin-8-ylmethyl]-1,2,3,4-tet-
rahydroisoquinoline trihydrochloride
Step A: tert-Butyl
(9aR)-4-oxo-octahydropiperazino[2,1-c]morpholine-8-carboxylate
Synthesis of this compound is described in the literature (J. Med.
Chem. 2012, 55, 5887).
Step B: (9aR)-Octahydropiperazino[2,1-c]morpholin-4-one
hydrochloride
A 4M solution of HCl in dioxane (39 mL, 154 mmol) is added to the
compound of Step A (11.3 g, 44.1 mmol). The solution is then
stirred at ambient temperature for 5 hours, and then a 4M solution
of HCl in dioxane (12 mL, 48 mmol) is added again. The mixture is
stirred for 16 hours. The solution is then evaporated to dryness to
yield the expected product in the form of a solid.
.sup.1H NMR (400 MHz, dmso-d6) .delta. ppm: 2.79-2.93 (m, 2H), 3.02
(td, J=13.1, 2.7 Hz, 1H), 3.22-3.34 (m, 2H), 3.59-3.67 (m, 1H),
3.86-3.96 (m, 1H), 3.96-4.01 (m, 1H), 4.05 (AB q, J=13.3 Hz, 2H),
4.48 (dd, J=14.1, 2.5 Hz, 1H), 9.71 (br. s, 1H), 9.91 (br. s,
1H)
Step C: tert-Butyl
(3S)-3-[(9aR)-4-oxo-octahydropiperazino[2,1-c]morpholine-8-carbonyl]-1,2,-
3,4-tetrahydroisoquinoline-2-carboxylate
EDC (5.17 g, 27.0 mmol) is added to a solution of the compound of
the above Step (4.0 g, 20.7 mmol),
(3S)-2-[(tert-butoxy)carbonyl]-1,2,3,4-tetrahydroisoquinoline-3-carboxyli-
c acid (6.04 g, 21.8 mmol), triethylamine (11.6 mL, 83.1 mmol) and
HOBt (3.65 g, 27.0 mmol) in dichloromethane (100 mL). The mixture
is stirred at ambient temperature for 16 hours. 1N aqueous HCl
solution (70 mL) is added and the precipitate formed is filtered
off using a Buchner funnel. The phases of the filtrate are
separated. The organic phase is washed with saturated aqueous
potassium carbonate solution and is then concentrated under reduced
pressure. The residue is pre-absorbed onto silica gel and is
purified by chromatography over silica gel using ethyl acetate and
heptane as eluants to yield the expected compound in the form of a
solid.
.sup.1H NMR (400 MHz, dmso-d6) .delta. ppm: 1.25-1.58 (m, 9H),
2.50-2.76 (m, 2H), 2.76-3.25 (m, 3H), 3.37-3.76 (m, 2H), 3.92-4.50
(m, 5H), 4.06 (s, 2H), 4.66 (d, J=15.6 Hz, 1H), 4.76-5.28 (m, 1H),
7.05-7.31 (m, 4H)
Step D:
(3S)-3-[(9aR)-Octahydropiperazino[2,1-c]morpholin-8-ylmethyl]-1,2,-
3,4-tetrahydroisoquinoline trihydrochloride
A 4M solution of HCl in dioxane (24.0 mL, 96.2 mmol) is added to a
solution of the compound of Step C (8.00 g, 12.25 mmol) in
dichloromethane (25 mL). The mixture is stirred at ambient
temperature for 16 hours and is then concentrated to dryness. The
crude product obtained is added to a suspension of LiAlH.sub.4
(1.97 g, 51.91 mmol) in tetrahydrofuran (140 mL). The mixture is
refluxed until the reaction (monitored by LC-MS) is complete and it
is then cooled to 0.degree. C. Water (2.5 mL) is added dropwise.
After stirring for 10 minutes, aqueous 2M sodium hydroxide solution
(5 mL) is added dropwise. Water (5 mL) is again added after
stirring for 10 minutes. There are finally added Celite (4 g) and
Na.sub.2SO.sub.4 (12 g) after stirring for an additional 10
minutes. The suspension is filtered over Celite and the filtrate is
concentrated to dryness. The crude residue thereby obtained is
dissolved in methanol (80 mL), and then a 4M solution of HCl in
dioxane (16.75 mL, 67.0 mmol) is added. The mixture is stirred at
ambient temperature for 3 hours, and then concentrated to dryness.
The residue is dissolved in a minimum of warm methanol (70 mL), and
then MTBE (3-5 mL) is added. The solution is cooled at 0.degree. C.
for 1 hour in an ice-cold water bath, and the product precipitates
out. A little MTBE (2-3 mL) is again added and the mixture is
allowed to stand for a further 1 hour at 0.degree. C. The solid
obtained is filtered over a Buchner funnel and dried in vacuo to
yield the expected compound in the form of a solid.
.sup.1H NMR (400 MHz, CD.sub.3OD) .delta. ppm: 2.65 (t, J=11.1 Hz,
1H), 2.74-2.97 (m, 4H), 3.10 (d, J=12.5 Hz, 1H), 3.19 (dd, J=17.6,
4.8 Hz, 1H), 3.25-3.55 (m, 5H), 3.59-3.74 (m, 2H), 3.82-4.15 (m,
4H), 4.45 (AB q, J=15.9 Hz, 2H), 7.21-7.35 (m, 4H).
.sup.13C NMR (100 MHz, CD.sub.3OD) .delta. ppm: 30.21, 45.67,
50.22, 51.99, 52.90, 53.58, 53.71, 59.25, 62.58, 65.30, 67.07,
127.76, 128.40, 129.08, 129.36, 130.16, 131.95
MS (ESI): [M+H].sup.+ 288.2
Preparation 1'':
N-[4-[tert-Butyl(dimethyl)silyl]oxyphenyl]-1-methyl-pyrazol-4-amine
Step A: 4-{[tert-Butyl(dimethyl)silyl]oxy}aniline
The title compound is obtained starting from 4-aminophenol in THF
in the presence of imidazole and tert-butyl(dimethyl)silyl chloride
in accordance with the protocol described in the literature (S.
Knaggs et al, Organic & Biomolecular Chemistry, 3(21),
4002-4010; 2005).
.sup.1H NMR: .delta. (400 MHz; dmso-d6; 300K): 6.45-6.55 (dd, 4H,
aromatic Hs); 4.60 (m, 2H, NH.sub.2-Ph); 0.90 (s, 9H, Si
(CH.sub.2).sub.2CH(CH.sub.3).sub.2); 0.10 (s, 6H, Si
(CH.sub.2).sub.2CH(CH.sub.3).sub.2)
IR: .nu.: --NH.sub.2.sup.+: 3300-3400 cm.sup.-1
Step B:
N-[4-[tert-Butyl(dimethyl)silyl]oxyphenyl]-1-methyl-pyrazol-4-amin-
e
To a solution of 30.8 g (0.137 mol) of the compound of Step A in
525 mL of anhydrous toluene there are successively added 29.8 g of
sodium tert-butylate (0.310 mol), 4.55 g of Pd.sub.2(dba).sub.3
(also referred to as tris(dibenzylideneacetone)dipalladium(0))
(4.96 mmol), 4.81 g of
2-di-tert-butylphosphino-2',4',6'-tri-isopropyl-1,1'-biphenyl (9.91
mmol) and 12.8 mL of 4-bromo-1-methyl-1H-pyrazole (0.124 mol). The
batch is degassed under argon for 30 minutes and then refluxed for
3 hours. It is allowed to cool. The reaction mixture is
concentrated to dryness and then taken up in dichloromethane,
filtered over Celite and then concentrated to dryness again. The
residue is then purified by chromatography over silica gel using
dichloromethane and ethyl acetate as eluants to provide the
expected product in the form of a solid.
.sup.1H NMR: .delta. (400 MHz; dmso-d6; 300K): 7.55 (s, 1H,
pyrazole); 7.23 (s, 1H, pyrazole); 7.18 (broad s, 1H, NH.sub.2-Ph);
6.64 (m, 4H, aromatic Hs); 3.77 (s, 3H, CH.sub.3-pyrazole); 0.90
(s, 9H, Si (CH.sub.2).sub.2CH(CH.sub.3).sub.2); 0.12 (s, 6H, Si
(CH.sub.2).sub.2CH(CH.sub.3).sub.2)
IR: .nu. --NH.sup.+: 3275 cm.sup.-1; .nu. Ar and C.dbd.N: 1577 and
1502 cm.sup.-1; .nu. --Si--C--: 1236 cm.sup.-1; .nu. --Si--O--: 898
cm.sup.-1; .nu. --Si--C--: 828, 774 cm.sup.-1
Preparation 2'':
4-{[tert-Butyl(dimethyl)silyl]oxy}-N-phenylaniline
To a solution of 12 g of 4-anilinophenol (64.7 mmol) in 200 mL of
acetonitrile there are added, at ambient temperature, 6.7 g of
imidazole (97.05 mmol) and 11.7 g of tert-butyl(dimethyl)silyl
chloride (77.64 mmol). The batch is stirred at 70.degree. C. for 4
hours. The reaction mixture is then poured into water and extracted
with ether. The organic phase is then dried over MgSO.sub.4, then
filtered and evaporated to dryness. The crude product thereby
obtained is then purified by chromatography over silica gel using
petroleum ether and dichloromethane as eluants. The title product
is obtained in the form of a powder.
.sup.1H NMR: .delta. (400 MHz; dmso-d6; 300K): 7.84 (s, 1H NH);
7.17 (t, 2H aniline); 6.98 (d, 2H phenoxy); 6.94 (d, 2H aniline);
6.76 (d, 2H phenoxy); 6.72 (t, 1H aniline); 0.95 (s, 9H
tert-butyl); 0.15 (s, 6H dimethyl)
IR: .nu.: >NH: 3403 cm.sup.-1; .nu.: >Ar: 1597 cm.sup.-1
Preparation 3'': tert-Butyl
5-[(4-{[tert-butyl(dimethyl)silyl]oxy}phenyl)amino]-1H-indole-1-carboxyla-
te
The procedure is in accordance with the process of Preparation 1'',
replacing the 4-bromo-1-methyl-1H-pyrazole used in Step B by
tert-butyl 5-bromo-1H-indole-1-carboxylate.
.sup.1H NMR: .delta. (400 MHz; dmso-d6; 300K): 7.85 (d, 1H); 7.78
(s, 1H); 7.55 (d, 1H); 7.15 (d, 1H); 6.95 (m, 3H); 6.75 (d, 2H);
6.58 (d, 1H); 1.65 (s, 9H); 1.00 (s, 9H); 0.2 (s, 6H)
Preparation 4'':
N-(4-{[tert-Butyl(dimethyl)silyl]oxy}phenyl)-1-methyl-1H-indol-5-amine
The procedure is in accordance with the process of Preparation 1'',
replacing the 4-bromo-1-methyl-1H-pyrazole used in Step B by
5-bromo-1-methyl-1H-indole.
Preparation 5'':
N-(4-{[tert-Butyl)dimethyl)silyl]oxy}phenyl)-1-methyl-1H-indazol-5-amine
The procedure is in accordance with the process of Preparation 1'',
replacing the 4-bromo-1-methyl-1H-pyrazole used in Step B by
5-bromo-1-methyl-1H-indazole.
Preparation 6'':
N-(4-{[tert-Butyl(dimethyl)silyl]oxy}phenyl)-3-fluoro-4-methylaniline
The procedure is in accordance with the process of Preparation
1''', replacing the 4-bromo-1-methyl-1H-pyrazole used in Step B by
4-bromo-2-fluoro-1-methylbenzene.
Preparation 7'':
N-(4-{[tert-Butyl(dimethyl)silyl]oxy}phenyl)-3-fluoroaniline
The procedure is in accordance with the process of Preparation 1'',
replacing the 4-bromo-1-methyl-1H-pyrazole used in Step B by
1-bromo-3-fluorobenzene.
Preparation 8'': 4-Benzyloxy-N-phenyl-aniline
To a solution of 4-hydroxy-N-phenyl-aniline (30 g; 162 mmol) in
acetonitrile (400 mL) there are added 58 g of Cs.sub.2CO.sub.3 (178
mmol) and stirring is carried out for 15 minutes at ambient
temperature. Benzyl bromide (22.5 mL; 178 mmol) is then added
dropwise and then the reaction mixture is refluxed for 4 hours.
After filtering and rinsing with acetonitrile, the filtrate is
concentrated and purified by chromatography over silica gel using
petroleum ether and ethyl acetate as eluants. The title product is
then obtained in the form of a colourless solid.
.sup.1H NMR: .delta. (400 MHz; dmso-d6; 300K): 7.80 (m, 1H, NH);
7.45 (m, 2H, aryl); 7.40 (m, 2H, aryl); 7.30 (m, 1H, aryl); 7.15
(s, 2H, aryl); 7.05 (d, 2H, aryl); 6.9-7.0 (m, 4H, aryl); 6.70 (t,
1H, aryl); 5.05 (s, 2H, benzyl).
IR: .nu.: >NH: 3408 cm.sup.-1
Preparation 9'':
N-(4-{[tert-Butyl(dimethyl)silyl]oxy}phenyl)pyridin-4-amine
The procedure is in accordance with the process of Preparation 1'',
replacing the 4-bromo-1-methyl-1H-pyrazole used in Step B by
4-bromopyridine.
IR: .nu. --NH--: 3200 and 2500 cm.sup.-1; .nu.: --Si--O--: 902
cm.sup.-1; .nu.: --Si--C--: 820 cm.sup.-1
Preparation 10'':
N-(4-{[tert-Butyl(dimethyl)silyl]oxy}phenyl)-4-fluoroaniline
The procedure is in accordance with the process of Preparation 1'',
replacing the 4-bromo-1-methyl-1H-pyrazole used in Step B by
1-bromo-4-fluorobenzene.
Preparation 11'':
N-(4-{[tert-Butyl(dimethyl)silyl]oxy}phenyl)-1-methyl-1H-pyrrolo[2,3-b]py-
ridin-5-amine
The procedure is in accordance with the process of Preparation 1'',
replacing the 4-bromo-1-methyl-1H-pyrazole used in Step B by
5-bromo-1-methyl-1H-pyrrolo[2,3-b]pyridine (obtained in accordance
with a protocol from the literature: Heterocycles, 60(4), 865,
2003).
IR: .nu.: --NH--: 3278 cm.sup.-1; .nu.: aromatic --C.dbd.C--
moieties: 1605 cm.sup.-1
Preparation 12'':
N-(4-{[tert-Butyl(dimethyl)silyl]oxy}phenyl)-2-methoxypyrimidin-5-amine
The procedure is in accordance with the process of Preparation 1'',
replacing the 4-bromo-1-methyl-1H-pyrazole used in Step B by
5-bromo-2-methoxypyrimidine.
Preparation 13'':
N-(4-{[tert-Butyl(dimethyl)silyl]oxy}phenyl)-1-methyl-2,3-dihydro-1H-pyrr-
olo[2,3-b]pyridin-5-amine
The procedure is in accordance with the process of Preparation 1'',
replacing the 4-bromo-1-methyl-1H-pyrazole used in Step B by
5-bromo-1-methyl-2,3-dihydro-1H-pyrrolo-[2,3-b]pyridine.
Preparation 14'':
N-(4-{[tert-Butyl(dimethyl)silyl]oxy}phenyl)-1-methyl-1H-benzimidazol-5-a-
mine
The procedure is in accordance with the process of Preparation 1'',
replacing the 4-bromo-1-methyl-1H-pyrazole used in Step B by
5-bromo-1-methyl-1H-benzimidazole.
Preparation 15'':
N.sup.4-(4-{[tert-Butyl(dimethyl)silyl]oxy}phenyl)-N.sup.2,N.sup.2-dimeth-
yl-pyridine-2,4-diamine
The procedure is in accordance with the process of Preparation 1'',
replacing the 4-bromo-1-methyl-1H-pyrazole used in Step B by
4-bromo-N,N-dimethylpyridin-2-amine.
Preparation 16'':
N-(4-{[tert-Butyl(dimethyl)silyl]oxy}phenyl)pyrazolo[1,5-a]-pyrimidin-6-a-
mine
The procedure is in accordance with the process of Preparation 1'',
replacing the 4-bromo-1-methyl-1H-pyrazole used in Step B by
6-bromopyrazolo[1,5-a]pyrimidine.
IR: .nu. --NH--: 3272 cm.sup.-1; .nu. --C.dbd.N--: 1634 cm.sup.-1;
.nu. --C.dbd.C--: 1616 cm.sup.-1
Preparation 17'';
N-[4-[tert-Butyl(dimethyl)silyl]oxyphenyl]-1-methyl-pyrazolo-[3,4-b]pyrid-
in-5-amine
The procedure is in accordance with the process of Preparation 1'',
replacing the 4-bromo-1-methyl-1H-pyrazole used in Step B by
5-bromo-1-methyl-pyrazolo[3,4-b]pyridine (obtained in accordance
with a protocol from the literature: WO 2006/052568 starting from
2-methyl-pyrazol-3-amine and 2-bromopropanedial).
Preparation 18'':
4-({4-[(tert-Butyldimethylsilyl)oxy]phenyl}amino)-1,5-dimethyl-1H-pyrrole-
-2-carbonitrile
Step A: 4-Bromo-1,5-dimethyl-1H-pyrrole-2-carbonitrile
A solution of bromine (6.58 mL, 0.13 mol) in acetic acid (60 mL) is
added dropwise, with the aid of a dropping funnel, to a solution of
1,5-dimethyl-1H-pyrrole-2-carbonitrile (15.0 g, 0.12 mol) in acetic
acid (300 mL). The batch is stirred at ambient temperature for 24
hours. The reaction mixture is then poured into a beaker containing
300 mL of water. The solid formed is filtered off and rinsed with
water. It is then dissolved in dichloromethane (300 mL) and the
organic phase is washed with brine, dried over Na.sub.2SO.sub.4,
filtered and concentrated in vacuo to yield the expected product in
the form of a solid.
.sup.1H NMR (CDCl.sub.3) .delta. ppm: 2.25 (s, 3H), 3.67 (s, 3H),
6.74 (s, 1H)
Step B:
4-({4-[(tert-Butyldimethylsilyl)oxy]phenyl}amino)-1,5-dimethyl-1H--
pyrrole-2-carbonitrile
A solution of the compound of the above Step (1.5 g, 7.53 mmol),
4-[(tert-butyldimethylsilyl)oxy]aniline (2.02 g, 9.04 mmol), sodium
tert-butylate (1.45 g, 15.06 mmol) and
2-di-tert-butylphosphino-2',4',6'-triisopropylbiphenyl (0.13 g,
0.30 mmol) in toluene (20 mL) is purged with nitrogen.
Tris(dibenzylideneacetone)-dipalladium(0) (0.28 g, 0.30 mmol) is
added, and then the reaction mixture is heated at 90.degree. C.
until the reaction is complete (monitored by TLC). Heating is
stopped and the mixture is allowed to return to ambient
temperature. Water (75 mL) is added and the mixture is extracted
with ethyl acetate (3.times.75 mL). The combined organic phases are
washed with brine and then concentrated. The crude product is
absorbed onto silica gel and purified by chromatography over silica
gel using ethyl acetate and heptane as eluants. The product thereby
obtained is dissolved in heptane in the warm state and is allowed
to precipitate, with stirring, at ambient temperature, and then at
0.degree. C. The solid is filtered off and the operation is
repeated on the filtrate to yield the expected compound in the form
of a solid.
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. ppm: 0.15 (s, 6H), 0.97
(s, 9H), 2.13 (s, 3H), 3.66 (s, 3H), 4.68 (br. s, 1H), 6.49 (d,
J=8.5 Hz, 2H), 6.64 (s, 1H), 6.66 (d, J=8.7 Hz, 2H)
.sup.13C NMR (100 MHz, CDCl.sub.3) .delta. ppm: 4.34, 9.72, 18.30,
25.88, 32.94, 101.27, 114.37, 114.70, 116.41, 120.73, 124.52,
131.23, 141.54, 148.27
MS (ESI+): [M+H].sup.+ measured: 342.3
Preparation 19'':
4-[(4-{[tert-Butyl(dimethyl)silyl]oxy}phenyl)amino]-1-methyl-1H-pyrrole-2-
-carbonitrile
Step A: 1-Methyl-1H-pyrrole-2-carbonitrile
N,N-Dimethylformamide (3 mL) and 1,4-diazabicyclo[2.2.2]octane
(0.49 g, 4.3 mmol) are added to a solution of
pyrrole-2-carbonitrile (4 g, 43.4 mmol) in dimethyl carbonate (56
mL). The solution is stirred at 90.degree. C. for 15 hours, and is
then heated at 110.degree. C. for 8 hours. The mixture is cooled to
ambient temperature, and then ethyl acetate (80 mL) is added. The
phases are separated and the organic phase is washed with water
(2.times.80 mL) and 1N aqueous HCl solution (1.times.80 mL). The
combined aqueous phases are extracted again with ethyl acetate
(1.times.80 mL). The combined organic phases are washed with brine
(1.times.80 mL), dried over MgSO.sub.4, filtered and concentrated
in vacuo to obtain the expected product in the form of a
liquid.
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. ppm: 3.78 (m, 2H),
6.12-6.18 (m, 1H), 6.74-6.82 (m, 1H)
Step B: 4-Bromo-1-methyl-1H-pyrrole-2-carbonitrile
N-Bromosuccinimide (6.2 g, 34.9 mmol) is added to a solution of
1-methyl-1H-pyrrole-2-carbonitrile (3.7 g, 34.9 mmol) in
N,N-dimethylformamide (150 mL). The solution is stirred for 15
hours at ambient temperature. Another amount of N-bromosuccinimide
(2.0 g, 11 mmol) is added and the mixture is stirred for 3 hours.
Silica (7 g) is then added and the suspension is then evaporated to
dryness. The material pre-absorbed onto the silica is placed on a
silica gel column and the product is purified by chromatography
over silica gel using ethyl acetate and heptane as eluants to
obtain the expected product in the form of a solid.
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. ppm: 3.77 (s, 3H), 6.75
(d, J=1.7 Hz, 1H), 6.80 (d, J=1.7 Hz, 1H)
Step C:
4-[(tert-Butyldimethylsilyl)oxy]phenyl}amino)-1-methyl-1H-pyrrole--
2-carbonitrile
Nitrogen is bubbled through a solution of
4-bromo-1-methyl-1H-pyrrole-2-carbonitrile (2.82 g, 15.2 mmol) and
4-[(tert-butyldimethylsilyl)oxy]aniline (4.08 g, 18.3 mmol) in
toluene (55 mL) for 5 minutes. Sodium tert-butylate (2.92 g, 30.4
mmol), tris(dibenzylideneacetone)dipalladium(0) (556 mg, 0.6 mmol)
and 2-di-tert-butylphosphino-2',4',6'-triisopropylbiphenyl (255 mg,
0.6 mmol) are then added to the reaction mixture. The mixture is
stirred for 1 hour at 80.degree. C. under nitrogen. The suspension
is then cooled to ambient temperature and filtered over Celite. The
Celite cake is then rinsed with ethyl acetate. The filtrate is
washed with water and then with brine. The organic phase is dried
over MgSO.sub.4, filtered and concentrated in vacuo. The product is
purified twice by chromatography over silica gel using ethyl
acetate and heptane as eluants, and then by trituration in heptane
to obtain the expected product in the form of a solid.
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. ppm: 0.16 (s, 6H), 0.97
(s, 9H), 3.73 (s, 3H), 6.57 (d, J=1.9 Hz, 1H), 6.64-6.66 (m, 1H),
6.70 (s, 4H); NMR
.sup.13C NMR (100 MHz, CDCl.sub.3) .delta. ppm: -4.48, 18.17,
25.72, 35.46, 103.01, 113.56, 113.69, 115.92, 119.55, 120.67,
129.04, 139.94, 148.85
MS (ESI+): [M+H].sup.+ 328.25
Preparation 20'':
N-[4-[tert-Butyl(dimethyl)silyl]oxy-3-fluoro-phenyl]-1-methyl-1H-pyrazol--
4-amine
The procedure is in accordance with the protocol of Preparation
1'', replacing the 4-aminophenol used in Step A by
2-fluoro-4-aminophenol.
.sup.1H NMR (400 MHz, dmso-d6) .delta. ppm: 7.59 (bs, 1H), 7.39 (m,
1H), 7.24 (d, 1H), 6.74 (dd, 1H), 6.52 (dd, 1H), 6.42 (ddd, 1H),
3.76 (s, 3H), 0.92 (s, 9H), 0.1 (d, 6H)
Preparation 21'':
2-({4-[(tert-Butyldimethylsilyl)oxy]phenyl}amino)pyridine-4-carbonitrile
A solution composed of 2-bromo-4-pyridinecarbonitrile (5.00 g, 36.1
mmol), 4-[(tert-butyldimethylsilyl)oxy]aniline (8.06 g, 36.1 mmol),
sodium tert-butylate (4.50 g, 46.9 mmol) and
2-di-tert-butylphosphino-2',4',6'-triisopropylbiphenyl (0.458 g,
1.08 mmol) in toluene (50 mL) is purged with nitrogen.
Tris(dibenzylideneacetone)-dipalladium(0) (0.99 g, 1.08 mmol) is
then added to the reaction mixture, and then the batch is heated at
50.degree. C. for 1.5 hours. The mixture is then allowed to cool to
ambient temperature. Water is added and the reaction mixture is
extracted with ethyl acetate (3.times.20 mL). The combined organic
phases are washed with brine, and then concentrated under reduced
pressure. The crude product is absorbed onto silica gel and
purified by chromatography over silica gel using ethyl acetate and
heptane as eluants. The product obtained is dissolved in the warm
state in heptane and precipitates, with stirring, at ambient
temperature, and then at 0.degree. C. After filtration, the
expected compound is obtained in the form of a solid.
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. ppm: 0.22 (s, 6H), 1.00
(s, 9H), 6.61 (br. s, 1H), 6.81-6.84 (m, 2H), 6.84-6.89 (m, 2H),
7.12-7.17 (m, 2H), 8.26 (dd, J=5.1, 0.9 Hz, 1H)
.sup.13C NMR (100 MHz, CDCl.sub.3) .delta. ppm: -4.29, 18.31,
25.78, 109.11, 114.73, 117.23, 121.17, 121.74, 124.93, 132.12,
149.79, 153.45, 158.00
MS (ESI+): [M+H].sup.+ 326.19
Preparation 22'':
N-[4-[tert-Butyl(dimethyl)silyl]oxyphenyl]-1-tetrahydrofuran-3-yl-pyrazol-
-4-amine
4-[tert-Butyl(dimethyl)silyl]oxyaniline (0.92 g, 3.48 mmol) and
4-iodo-1-tetrahydrofuran-3-yl-pyrazole (0.78 g, 3.48 mmol)
dissolved in anhydrous tetrahydrofuran (20 mL) are stirred for one
hour at ambient temperature in the presence of sodium tert-butylate
(1.7 mL, 2M solution in THF) and
chloro(2-di-tert-butylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2-
-aminoethyl)phenyl]palladium(II) (84 mg, 0.122 mmol). The reaction
mixture is filtered over Celite and then evaporated to dryness. The
residue is crystallised from a mixture of heptane/ethyl acetate,
filtered and washed with heptane and then purified by
chromatography over silica gel using dichloromethane and methanol
as eluants to yield the expected product.
.sup.1H NMR (500 MHz, dmso-d6, 300 K) .delta. ppm: 7.62 (d, 1H,
pyrazole-H5), 7.29 (d, 1H, pyrazole-H3), 7.26 (s, 1H, NH), 6.68 (d,
2H, Ar--H), 6.64 (d, 2H, Ar--H), 4.93 (m, 1H, THF-3'H), 3.95 (m,
1H, THF-5'H), 3.94 (m, 1H, THF-2'H), 3.87 (m, 1H, THF-2'H), 3.80
(m, 1H, THF-5'H), 2.33 (m, 1H, THF-4'H), 2.27 (m, 1H, THF-4'H),
0.93 (s, 9H, .sup.tBu), 0.12 (s, 6H, Me)
IR: .nu. C--H: 2857 cm.sup.-1; .nu. aromatic: 1505 cm.sup.-1; .nu.
Si--C: 1249 cm.sup.-1
Preparation 23'':
6-({4-[(tert-Butyldimethylsilyl)oxy]phenyl}amino)pyridine-2-carbonitrile
4-Aminophenol (3.3 g, 30.2 mmol) is added to a solution of
6-chloropyridine-2-carbonitrile (3.5 g, 25.3 mmol) in
1-methyl-2-pyrrolidinone (70 mL). The reaction mixture is heated at
140-150.degree. C. for 16 hours in a sealed flask. The batch is
then cooled to ambient temperature. Imidazole (3.4 g, 49.9 mmol)
and tert-butyl(dimethyl)silyl chloride (7.6 g, 50.4 mmol) are
subsequently added and the mixture is stirred for 16 hours at
ambient temperature. The mixture is diluted with water (140 mL) and
the product is extracted with AcOEt (4.times.50 mL). The organic
phases are combined and washed with water (3.times.50 mL), and then
brine (1.times.50 mL). The organic phase is then dried over
MgSO.sub.4, filtered and concentrated in vacuo. The crude product
is purified by chromatography over silica gel using ethyl acetate
and heptane as eluants to obtain the title product.
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. ppm: 0.20 (s, 6H), 0.99
(s, 9H), 6.74 (dd, J=7.6, 4.9 Hz, 1H), 6.81-6.88 (m, 3H), 7.36-7.42
(m, 2H), 7.74 (dd, J=7.6, 1.9 Hz, 1H), 8.34 (dd, J=4.9, 1.9 Hz,
1H)
.sup.13C NMR (100 MHz, CDCl.sub.3) .delta. ppm: -4.38, 18.21,
25.73, 92.58, 113.50, 116.53, 120.30, 123.20, 131.97, 141.67,
152.42, 152.45, 156.51
MS (ESI): [M+H].sup.+ 326.24
Preparation 24'':
4-({4-[(tert-Butyldimethylsilyl)oxy]phenyl}amino)pyrimidine-2-carbonitril-
e
Step A:
N-{4-[(tert-Butyldimethylsilyl)oxy]phenyl}-2-chloropyrimidin-4-ami-
ne
4-Aminophenol (8.8 g, 80.6 mmol) and triethylamine (18.6 mL, 133.4
mmol) are added to a solution of 2,4-dichloropyrimidine (10.0 g,
67.1 mmol) in ethanol (150 mL). The reaction mixture is heated at
150.degree. C. for 14 hours in a sealed flask. The batch is then
cooled to ambient temperature and the solvent is evaporated off in
vacuo. Dichloromethane (200 mL) is added to the residue, and then
imidazole (9.1 g, 133.7 mmol) and tert-butyl(dimethyl)silyl
chloride (12.1 g, 80.3 mmol) are added. The mixture is stirred for
15 hours at ambient temperature. The reaction mixture is diluted
with water (200 mL). The phases are separated and the organic phase
is washed with brine (1.times.100 mL). It is then dried over
MgSO.sub.4, filtered and concentrated in vacuo. The residue is
purified by chromatography over silica gel using ethyl acetate and
heptane as eluants to obtain a solid. The latter is triturated in
heptane, filtered off and rinsed with heptane to yield the expected
compound in the form of a solid.
.sup.1H NMR (400 MHz, dmso-d6) .delta. ppm: 0.22 (s, 6H), 0.99 (s,
9H), 6.42 (d, J=5.9 Hz, 1H), 6.81 (br. s, 1H), 6.85-6.90 (m, 1H),
7.13 (d, J=8.7 Hz, 2H), 8.07 (d, J=5.9 Hz, 2H)
Step B:
4-({4-[(tert-Butyldimethylsilyl)oxy]phenyl}amino)pyrimidine-2-carb-
onitrile
Anhydrous N,N-dimethylformamide (10 mL) is placed under nitrogen in
a flask and then the compound of Step A (670 mg, 2.0 mmol) is
added. Zinc cyanide (468 mg, 4.0 mmol) and
tetrakis(triphenylphosphine)palladium(0) (404 mg, 0.3 mmol) are
subsequently added. Nitrogen is bubbled through the solution for 5
minutes and then the reaction mixture is stirred at 120.degree. C.
for 2 hours under a nitrogen atmosphere. The reaction, monitored by
LC-MS, is complete. The mixture is cooled to ambient temperature,
and then water (15 mL) is added thereto. The product is extracted
with AcOEt (3.times.25 mL). The organic phases are combined and
washed with water (4.times.25 mL), and then with brine (1.times.25
mL). The organic phase is dried over MgSO.sub.4, filtered and
concentrated in vacuo. The residue is purified by chromatography
over silica gel using ethyl acetate and heptane as eluants to
obtain the expected compound in the form of a solid.
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. ppm: 0.22 (s, 6H), 0.99
(s, 9H), 6.63 (d, J=6.1 Hz, 1H), 6.86-6.92 (m, 2H), 7.03 (br. s,
1H), 7.17 (d, J=8.5 Hz, 2H), 8.22 (d, J=6.1 Hz, 1H)
.sup.13C NMR (100 MHz, CDCl.sub.3) .delta. ppm: -4.51, 18.10,
25.55, 106.32, 115.92, 121.00, 125.22, 129.73, 144.55, 154.16,
156.07, 161.56
Preparation 25'':
N-{4-[(tert-Butyldimethylsilyl)oxy]phenyl}-1-trideuteriomethyl-1H-pyrazol-
-4-amine
Step A: 4-Bromo-1-trideuteriomethyl-1H-pyrazole
4-Bromo-1H-pyrazole (9.05 g, 61.6 mmol) is added in portions to a
suspension of NaH (60% in oil) (2.83 g, 70.8 mmol) in
tetrahydrofuran (90 mL) cooled in an ice bath. After having taken
away the ice bath, the solution is stirred at ambient temperature
for 0.5 hours. It is again cooled in an ice bath and
iodomethane-d.sub.3 (5.0 mL, 80.3 mmol) is added. The solution is
stirred at ambient temperature for 19 hours. The suspension is then
concentrated. The evaporation residue is triturated with MTBE (90
mL) and filtered. The filtrate is concentrated in vacuo to obtain
the expected compound in the form of an oil.
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. ppm: 7.37 (s, 1H), 7.43
(s, 1H)
Step B:
N-{4-[(tert-Butyldimethylsilyl)oxy]phenyl}-1-trideuteriomethyl-1H--
pyrazol-4-amine
4-Bromo-1-trideuteriomethyl-1H-pyrazole (9.6 g, 58.5 mmol),
4-[(tert-butyldimethyl-silyl)oxy]aniline (14.4 g, 64.6 mmol) and
toluene (150 mL) are added to a 500-ml three-necked flask. The
solution is degassed with nitrogen for 15 minutes, and then sodium
tert-butylate (11.4 g, 0.12 mol),
2-di-tert-butylphosphino-2',4',6'-triisopropylbiphenyl (0.77 g,
1.81 mmol) and tris(dibenzylideneacetone)dipalladium(0) (1.64 g,
1.79 mmol) are successively added. The suspension is heated at
85.degree. C. for 1.5 hours. The reaction mixture is then cooled to
ambient temperature and water (270 mL) is added. The mixture is
stirred for 30 minutes. Celite (30 g) is then added and the
suspension is filtered on a bed of Celite.
The phases of the filtrate are separated and the aqueous phase is
extracted with ethyl acetate (3.times.200 mL). The combined organic
phases are dried over Na.sub.2SO.sub.4 and filtered. Silica (36 g)
is added to the filtrate and the batch is evaporated to dryness.
The product is purified by chromatography over silica gel using
ethyl acetate and heptane as eluants. The product obtained is
recrystallised from heptane (80 mL) to obtain the expected
compound.
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. ppm: 0.16 (s, 6H), 0.97
(s, 9H), 4.92 (s, 1H), 6.61-6.73 (m, 4H), 7.25 (s, 1H), 7.36 (s,
1H)
.sup.13C NMR (100 MHz, CDCl.sub.3) .delta. ppm: -4.37, 18.28,
25.86, 38.67 (sept., .sup.1J.sub.C-D=21.0 Hz), 115.12, 120.73,
123.76, 126.52, 134.74, 141.07, 148.43
MS (ESI): [M+H].sup.+ 307.08
Preparation 26'':
N-[4-[tert-Butyl(dimethyl)silyl]oxyphenyl]-1-(oxetan-3-yl)-1H-pyrazol-4-a-
mine
Step A: 4-Bromo-1-(oxetan-3-yl)-1H-pyrazole
4-Bromo-1H-pyrazole (1.53 g, 10.7 mmol) is dissolved in anhydrous
dimethylformamide (15 mL). 3-Bromooxetane (2.0 g, 14.6 mmol) and
caesium carbonate (4.7 g, 14 mmol) are successively added thereto.
The reaction mixture is heated for 8 hours at 130.degree. C. in a
sealed flask. At the end of the reaction, the solvent is evaporated
off in vacuo and the residue is purified by chromatography over
silica gel using dichloromethane containing diethylamine and
methanol as eluants to yield the expected compound.
Step B:
N-[4-[tert-Butyl(dimethyl)silyl]oxyphenyl]-1-(oxetan-3-yl)-1H-pyra-
zol-4-amine
4-[tert-Butyl(dimethyl)silyl]oxyaniline (1.5 g, 7.2 mmol) and
4-bromo-1-(oxetan-3-yl)-pyrazole (1.6 g, 7.2 mmol) dissolved in
anhydrous tetrahydrofuran (25 mL) are stirred for 3 hours at
ambient temperature in the presence of sodium tert-butylate (3.7
mL, 2M solution in THF) and
chloro(2-di-tert-butylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2-
-aminoethyl)phenyl]palladium(II) (101 mg, 0.145 mmol). The reaction
mixture is filtered over Celite and then evaporated to dryness. The
residue is purified by chromatography over silica gel using
dichloromethane containing diethylamine and ethyl acetate as
eluants to yield the expected product.
.sup.1H NMR (500 MHz, dmso-d6, 300 K) .delta. ppm: 7.76 (s, 1H,
pyrazole-5'H), 7.40 (s, 1H, pyrazole-3'H), 7.34 (br s, 1H, NH),
6.70 (d, 2H, Ar--H), 6.65 (d, 2H, Ar--H), 5.49 (m, 1H, oxetane),
4.89 (d, 4H, oxetane), 0.93 (s, 9H, .sup.tBu), 0.13 (s, 6H, Me)
IR: .nu.: C--H: 2955 cm.sup.-1; aromatic: 1505 cm.sup.-1; Si--C:
1237 cm.sup.-1
Preparation 27'': Mixture of
N-(4-{[tert-butyl(dimethyl)silyl]oxy}phenyl)-1,5-dimethyl-1H-pyrazol-4-am-
ine and
N-(4-{[tert-butyl(dimethyl)silyl]oxy}phenyl)-1,3-dimethyl-1H-pyraz-
ol-4-amine
Step A: Mixture of 4-bromo-1,5-dimethyl-1H-pyrazole and
4-bromo-1,3-dimethyl-1H-pyrazole
To a suspension of NaH 60% in oil (0.3 g; 7.45 mmol) in
tetrahydrofuran (150 mL) there is added, at 10.degree. C.,
4-bromo-3-methyl-1H-pyrazole dissolved in 15 mL of tetrahydrofuran
dropwise, over 15 minutes. After stirring for 40 minutes at ambient
temperature, iodomethane (0.45 mL; 7.45 mmol) is added dropwise,
and then the reaction mixture is stirred overnight. After adding
water, the reaction mixture is evaporated and taken up in
dichloromethane. The organic phase is separated off and dried over
MgSO.sub.4, filtered and concentrated to dryness. The residue is
purified by chromatography over silica gel to yield a mixture of
the title compounds (4-bromo-1,3-dimethyl-pyrazole and
4-bromo-1,5-dimethyl-pyrazole respectively in a ratio of 4:6).
4-bromo-1,5-dimethyl-1H-pyrazole
.sup.1H NMR (500 MHz, dmso-d6) .delta. ppm: 7.41 (s, 1H), 3.76 (s,
3H), 2.22 (s, 3H)
4-bromo-1,3-dimethyl-1H-pyrazole
.sup.1H NMR (500 MHz, dmso-d6) .delta. ppm: 7.81 (s, 1H), 3.74 (s,
3H), 2.09 (s, 3H)
Step B: Mixture of
N-(4-{[tert-butyl(dimethyl)silyl]oxy}phenyl)-1,5-dimethyl-1H-pyrazol-4-am-
ine and
N-(4-{[tert-butyl(dimethyl)silyl]oxy}phenyl)-1,3-dimethyl-1H-pyraz-
ol-4-amine
The procedure is in accordance with Step B of Preparation 1'',
replacing the 4-bromo-1-methyl-1H-pyrazole by the mixture of
isomers from Step A. A mixture of isomers in a ratio of 4:6 is
obtained (respectively
N-(4-{[tert-butyl(dimethyl)silyl]oxy}phenyl)-1,5-dimethyl-1H-pyrazol-4-am-
ine and
N-(4-{[tert-butyl(dimethyl)silyl]oxy}phenyl)-1,3-dimethyl-1H-pyraz-
ol-4-amine).
Preparation 28'':
N-[4-[tert-Butyl(dimethyl)silyl]oxyphenyl]-1-cyclopropyl-1H-pyrazol-4-ami-
ne
Step A: 4-Bromo-1-cyclopropyl-1H-pyrazole
4-Bromo-1H-pyrazole (1.76 g, 12 mmol) is dissolved in anhydrous
dimethylformamide (15 mL). Cyclopropyl bromide (2.9 mL, 36 mmol)
and caesium carbonate (7.8 g, 24 mmol) are successively added
thereto. The reaction mixture is heated for 15 hours at 160.degree.
C. in a sealed flask. At the end of the reaction, the solvent is
evaporated off in vacuo and the residue is purified by
chromatography over silica gel using heptane and dichloromethane as
eluants to yield the expected compound.
Step B:
N-[4-[tert-Butyl(dimethyl)silyl]oxyphenyl]-1-cyclopropyl-1H-pyrazo-
l-4-amine
4-[tert-Butyl(dimethyl)silyl]oxyaniline (1.64 g, 7.3 mmol) and
4-bromo-1-cyclopropyl-1H-pyrazole (1.4 g, 7.3 mmol) dissolved in
anhydrous tetrahydrofuran (30 mL) are stirred for 3 hours at
ambient temperature in the presence of sodium tert-butylate (3.7
mL, 2M solution in THF) and
chloro(2-di-tert-butylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2-
-aminoethyl)phenyl]palladium(II) (101 mg, 0.146 mmol). The reaction
mixture is filtered over Celite and then evaporated to dryness. The
residue is purified by chromatography over silica gel using heptane
and ethyl acetate as eluants to yield the expected product.
.sup.1H NMR (500 MHz, dmso-d6, 300 K) .delta. ppm: 7.61 (s, 1H,
pyrazole-5'H), 7.23 (s, 1H, pyrazole-3'H), 7.22 (br s, 1H, NH),
6.65 (d, 2H, Ar--H), 6.63 (d, 2H, Ar--H), 3.64 (m, 1H,
cyclopropyl-H), 1.00-0.91 (m, 4H, cyclopropyl), 0.93 (s, 9H,
.sup.tBu), 0.12 (s, 6H, Me)
IR: .nu.: C--H: 2930 cm.sup.-1; aromatic: 1504 cm.sup.-1; Si--C:
1237 cm.sup.-1
High-Resolution Mass Spectrometry (ESI+):
Empirical formula: C.sub.18H.sub.27N.sub.3OSi
[M+H].sup.+ calculated: 330.2003
[M+H].sup.+ measured: 330.1989
Preparation 29'':
1,5-Dimethyl-4-(phenylamino)-1H-pyrrole-2-carbonitrile
The procedure is in accordance with the protocol of Preparation
1'', replacing the 4-{[ten-butyl(dimethyl)silyl]oxy}aniline used in
Step B by aniline.
.sup.1H NMR (400 MHz, dmso-d6) .delta. ppm: 7.19 (s, 1H), 7.05 (t,
2H), 6.79 (s, 1H), 6.6 (m, 3H), 3.61 (s, 3H), 2.1 (s, 3H)
Preparation 30'':
1-Methyl-N-phenyl-1H-pyrrolo[2,3-b]pyridin-6-amine
The procedure is in accordance with the protocol of Step B of
Preparation 1'' using aniline and
5-bromo-1-methyl-1H-pyrrolo[2,3-b]pyridine (obtained in accordance
with a protocol from the literature: Heterocycles, 60(4), 865,
2003).
.sup.1H NMR (400 MHz, dmso-d6) .delta. ppm: 8.1 (d, 1H), 7.9 (s,
1H), 7.7 (d, 1H), 7.45 (d, 1H), 7.17 (t, 2H), 6.9 (d, 2H), 6.7 (t,
1H), 6.38 (d, 1H), 3.8 (s, 3H)
Preparation 31'':
N-(4-{[tert-Butyl(dimethyl)silyl]oxy}phenyl)-1-trideuteriomethyl-1H-pyrro-
lo[2,3-b]pyridin-5-amine
The procedure is in accordance with the process of Preparation 1'',
replacing the 4-bromo-1-methyl-1H-pyrazole used in Step B by
5-bromo-1-(trideuteriomethyl)-1H-pyrrolo[2,3-b]pyridine (obtained
in accordance with a protocol from the literature Heterocycles,
60(4), 865, 2003, replacing the methyl iodide by trideuterated
methyl iodide).
.sup.1H NMR (400 MHz, dmso-d6) .delta. ppm: 8.05 (d, 1H), 7.6 (m+d,
2H), 7.4 (d, 1H), 6.85/6.7 (2d, 4H), 6.3 (d, 1H), 0.95 (s, 9H),
0.15 (s, 6H)
Preparation 32'':
4-({4-[(tert-Butyldimethylsilyl)oxy]phenyl}amino)-1-trideuteriomethyl-1H--
pyrrole-2-carbonitrile
Step A: 1-Trideuteriomethyl-1H-pyrrole-2-carbonitrile
NaH (60% in oil) (2.61 g, 65.2 mmol) is suspended in
tetrahydrofuran (110 mL) at 0.degree. C. 1H-Pyrrole-2-carbonitrile
(5 g, 54.3 mmol) is added dropwise over 10 minutes. The reaction
mixture is then warmed up to ambient temperature over 30 minutes.
It is again cooled to 0.degree. C., and then iodomethane-d.sub.3
(10.23 g, 70.6 mmol) is added. The reaction mixture is stirred for
16 hours under nitrogen at ambient temperature. The reaction
mixture is then evaporated under reduced pressure, and then ethyl
acetate (200 mL) and water (200 mL) are added. The phases are
separated, and the aqueous phase is extracted with ethyl acetate
(2.times.200 mL). The combined organic phases are washed with brine
(1.times.80 mL), dried over MgSO.sub.4, filtered and concentrated
in vacuo. The residue is purified by chromatography over silica gel
using ethyl acetate and heptane as eluants. The fractions are
combined and evaporated in vacuo to obtain the expected
compound.
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. ppm: 6.13 (dd, J=2.7, 3.9
Hz, 1H), 6.75 (dd, J=1.5, 4.1 Hz, 1H), 6.79 (dd, J=1.7, 2.6 Hz,
1H)
Step B: 4-Bromo-1-trideuteriomethyl-1H-pyrrole-2-carbonitrile
N-Bromosuccinimide (6.68 g, 37.5 mmol) is added to a solution of
the compound of the above Step (4.09 g, 37.5 mmol) in
N,N-dimethylformamide (188 mL). The solution is stirred for 16
hours at ambient temperature. The residue is purified by
chromatography using ethyl acetate and heptane as eluants to obtain
the expected compound in the form of a solid.
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. ppm: 6.75 (d, J=1.7 Hz,
1H), 6.80 (d, J=1.7 Hz, 1H)
Step C:
4-({4-[(tert-Butyldimethylsilyl)oxy]phenyl}amino)-1-trideuteriomet-
hyl-1H-pyrrole-2-carbonitrile
Nitrogen is bubbled through a solution composed of the compound
obtained in the above Step (5.85 g, 31.1 mmol),
4-[(tert-butyldimethylsilyl)oxy]aniline (8 g, 35.8 mmol), sodium
tert-butylate (3.88 g, 40.4 mmol) and
2-di-tert-butylphosphino-2',4',6'-triisopropylbiphenyl (662 mg,
1.56 mmol) in toluene (260 mL) for 5 minutes.
Tris(dibenzylideneacetone)-dipalladium(0) (1.43 g, 1.56 mmol) is
then added. The mixture is stirred for 1 hour at 70.degree. C.
under nitrogen. The suspension is then cooled to ambient
temperature, diluted with ethyl acetate and filtered over Celite.
The Celite cake is then rinsed with ethyl acetate. The filtrate is
washed with water (3 times), and then brine (once). The organic
phase is dried over Na.sub.2SO.sub.4, filtered and concentrated in
vacuo. The product is purified twice by chromatography over silica
gel using ethyl acetate and heptane as eluants, and then by
reverse-phase chromatography using methanol and water as eluants to
obtain the expected compound in the form of a powder.
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. ppm: 0.17 (s, 6H), 0.98
(s, 9H), 4.96 (br. s, 1H), 6.57 (d, J=1.9 Hz, 1H), 6.64 (d, J=1.8
Hz, 1H), 6.70 (br. s, 4H)
.sup.13C NMR (100 MHz, CDCl.sub.3) .delta. ppm: -4.38, 18.26,
25.83, 34.83, 102.96, 113.69, 113.71, 115.95, 119.58, 120.75,
129.14, 140.10, 148.84
MS (ESI): [M+H].sup.+ 331.09
Preparation 33'':
4-({4-[(tert-Butyldimethylsilyl)oxy]phenyl}amino)-1-trideuteriomethyl-5-m-
ethyl-1H-pyrrole-2-carbonitrile
Step A: 5-Methyl-1H-pyrrole-2-carbonitrile
The compound is prepared in accordance with the protocol described
in Heterocycles 2011, 82, 1503.
Step B: 1-Trideuteriomethyl-5-methyl-1H-pyrrole-2-carbonitrile
A solution of 5-methyl-1H-pyrrole-2-carbonitrile (0.30 g, 2.82
mmol) in N,N-dimethylformamide (5 mL) is cooled to 0.degree. C. NaH
(60% in oil) (0.118 g, 2.96 mmol) is added in portions, and the
reaction mixture is stirred at 0.degree. C. for 30 minutes.
Iodomethane-d.sub.3 (4.15 mL, 67.2 mmol) is added in a single
portion, and the reaction mixture is stirred at ambient temperature
until the reaction is complete. It is then diluted with water (30
mL) and ethyl acetate (15 mL). The phases are separated and the
aqueous phase is extracted a second time with ethyl acetate (15
mL). The combined organic phases are washed with water (1.times.50
mL), and then brine, and dried over Na.sub.2SO.sub.4. After
filtration and concentration under reduced pressure, the residue is
purified by chromatography over silica gel using ethyl acetate and
heptane as eluants to yield the expected compound in the form of a
solid.
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. ppm: 2.25 (s, 3H), 5.91
(dd, J=3.9, 0.6 Hz, 1H), 6.69 (d, J=3.9 Hz, 1H)
Step C:
4-Bromo-1-trideuteriomethyl-5-methyl-1H-pyrrole-2-carbonitrile
A solution of bromine (0.133 mL, 2.60 mmol) in acetic acid (1.5 mL)
is added dropwise to a solution of the compound obtained in the
above Step (0.305 g, 2.48 mmol) in acetic acid (5.5 mL) previously
cooled to 0.degree. C. The reaction mixture is stirred and
gradually warmed up to ambient temperature over a period of 20
hours. The reaction mixture is poured into water (50 mL) and the
mixture is extracted with dichloromethane (2.times.50 mL). The
organic phase is dried over Na.sub.2SO.sub.4, filtered and
concentrated under reduced pressure to yield the expected compound
in the form of a solid.
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. ppm: 2.24 (s, 3H), 6.73
(s, 1H)
Step D:
4-({4-[(tert-Butyldimethylsilyl)oxy]phenyl}amino)-1-trideuteriomet-
hyl-5-methyl-1H-pyrrole-2-carbonitrile
A solution composed of the compound obtained in the above Step
(7.00 g, 34.6 mmol), 4-[(tert-butyldimethylsilyl)oxy]aniline (8.90
g, 39.8 mmol), sodium tert-butylate (4.33 g, 45.0 mmol) and
2-di-tert-butylphosphino-2',4',6'-triisopropylbiphenyl (0.441 g,
1.04 mmol) in toluene (70 mL) is purged with nitrogen.
Tris(dibenzylideneacetone)-dipalladium(0) (0.951 g, 1.04 mmol) is
added, and then the reaction mixture is heated at 65.degree. C.
until the reaction, monitored by TLC, is complete. Heating is
stopped and the mixture is cooled to ambient temperature. Water
(200 mL) is added and the mixture is extracted with ethyl acetate
(3 times). The combined organic phases are washed with brine, and
then concentrated. The crude product is purified by chromatography
over silica gel using ethyl acetate and heptane as eluants. The
product obtained is dissolved in heptane in the warm state; it is
allowed to precipitate out at ambient temperature and then at
0.degree. C. to yield the expected product in the form of
crystals.
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. ppm: 0.15 (s, 6H), 0.96
(s, 9H), 2.12 (s, 3H), 4.66 (br. s, 1H), 6.46-6.51 (m, 2H), 6.64
(s, 1H), 6.64-6.69 (m, 2H)
.sup.13C NMR (100 MHz, CDCl.sub.3) .delta. ppm: -4.37, 9.64, 18.26,
25.84, 31.62-32.87 (m), 101.14, 114.35, 114.66, 116.33, 120.68,
124.51, 131.17, 141.53, 148.18
MS (ESI): [M+H].sup.+ 345.13
Preparation 34'':
5-[(4-{[tert-Butyl(dimethyl)silyl]oxy}phenyl)amino]-1-methyl-1H-pyrazole--
3-carbonitrile
Step A: 5-Amino-1-methyl-1H-pyrazole-3-carbonitrile
To a suspension of 1-methyl-5-nitro-1H-pyrazole-3-carbonitrile (2
g; 13.1 mmol) in a mixture of water (14 mL) and ethanol (120 mL)
there are added HCl 37% (170 .mu.L) and iron filings (5.1 g; 91
mmol). The reaction mixture is heated for 5 hours at 50.degree. C.
After cooling to ambient temperature, the reaction mixture is
filtered. The filtrate is concentrated to dryness and then purified
by chromatography over silica gel using dichloromethane and ethyl
acetate as eluants to yield the expected compound in the form of a
solid.
.sup.1H NMR (400 MHz, dmso-d6) .delta. ppm: 5.8 (s, 1H), 5.7 (m,
2H), 3.6 (s, 3H)
Step B:
5-[(4-{[tert-Butyl(dimethyl)silyl]oxy}phenyl)amino]-1-methyl-1H-py-
razole-3-carbonitrile
The procedure is in accordance with the protocol of Step B of
Preparation 1'', replacing the 4-bromo-1-methyl-1H-pyrazole by
(4-bromophenoxy)-(tert-butyl)dimethyl-silane and the
4-{[tert-butyl(dimethyl)silyl]oxy}aniline by the compound from Step
A.
.sup.1H NMR (400 MHz, dmso-d6) .delta. ppm: 8.15 (s, 1H), 6.9 (d,
2H), 6.75 (d, 2H), 6.45 (s, 1H), 3.75 (s, 3H), 0.95 (s, 9H), 0.15
(s, 6H)
Preparation 35'':
4-[(4-{[tert-Butyl(dimethyl)silyl]oxy}phenyl)amino]-5-methyl-1-[2-(morpho-
lin-4-yl)ethyl]-1H-pyrrole-2-carbonitrile
The procedure is in accordance with the process of Preparation
33'', replacing the iodomethane-d.sub.3 in Step B by
2-(chloroethyl)morpholine hydrochloride.
.sup.1H NMR (400 MHz, dmso-d6) .delta. ppm: 6.85 (s, 1H), 6.75 (s,
1H), 6.6 (d, 2H), 6.5 (d, 2H), 4.1 (t, 2H), 3.55 (t, 4H), 2.6 (t,
2H), 2.4 (t, 4H), 2.1 (s, 3H), 0.9 (s, 9H), 0.1 (s, 6H)
Preparation 36'':
N-(4-{[tert-Butyl(dimethyl)silyl]oxy}phenyl)-2-[2-(morpholin-4-yl)ethoxy]-
pyrimidin-5-amine
Step A: 4-[2-(5-Bromopyrimidin-2-yl)oxyethyl]morpholine
NaH (1.0 g, 25.0 mmol, 60% in oil) suspended in anhydrous
tetrahydrofuran is cooled at 0.degree. C. in an ice bath under
argon, and then 2-morpholinoethanol (2.7 g, 20.7 mmol) is added
dropwise. The ice bath is withdrawn and the suspension is stirred
for 1 hour at ambient temperature. 5-Bromo-2-chloro-pyrimidine (4.0
g, 20.7 mmol) is then added at ambient temperature and the reaction
mixture is stirred for 16 hours at ambient temperature. Saturated
aqueous ammonium chloride solution (10 mL) and water (10 mL) are
added to the reaction mixture; the pH is adjusted to 9 by adding
saturated aqueous NaHCO.sub.3 solution. The resulting solution is
extracted 3 times with ethyl acetate, the organic phase is then
washed with brine, dried over MgSO.sub.4, and then evaporated to
dryness. The expected compound precipitates out by means of the
addition of petroleum ether.
.sup.1H NMR (400 MHz, dmso-d6) .delta. ppm: 8.75 (s, 2H), 4.4 (t,
2H), 3.55 (t, 4H), 2.7 (t, 2H), 2.45 (t, 4H)
IR (ATR) cm.sup.-1: 1562 .nu. >C.dbd.C< and C.dbd.N, 787 .nu.
--C--H Ar
Step B:
N-(4-{[tert-Butyl(dimethyl)silyl]oxy}phenyl)-2-[2-(morpholin-4-yl)-
ethoxy]-pyrimidin-5-amine
The procedure is in accordance with the protocol of Step B of
Preparation 1'', replacing the 4-bromo-1-methyl-1H-pyrazole by the
compound from Step A.
.sup.1H NMR (400 MHz, dmso-d6) .delta. ppm: 8.3 (s, 2H), 7.8 (s,
1H), 6.9/6.75 (2d, 4H), 4.35 (t, 2H), 3.55 (t, 4H), 2.7 (t, 2H),
2.45 (t, 4H), 0.95 (s, 9H), 0.15 (s, 6H)
IR (ATR) cm.sup.-1: 3300 .nu. --NH, 1506 .nu. --NH, 837 .nu.
--Si-Me, 837 and 778 .nu. --CH Ar
Preparation 37'':
4-({4-[(tert-Butyldimethylsilyl)oxy]phenyl}amino)-1,3-dimethyl-1H-pyrrole-
-2-carbonitrile
Step A: 4-Methyl-N-(prop-2-en-1-yl)benzene-1-sulphonamide
Allylamine (10.6 mL, 0.14 mol) is added over a period of 4 minutes
to a solution of tosyl chloride (25.1 g, 0.13 mol) in
dichloromethane (250 mL) cooled in an ice bath. Triethylamine (24
mL, 0.18 mol) is added and then the solution is stirred at ambient
temperature for 1.25 hours. Aqueous 3N HCl solution (60 mL) is
added and the phases are then separated. The organic phase is
washed with another amount of aqueous 3N HCl solution (60 mL) and
then with 5% aqueous sodium bicarbonate solution (60 mL). The
organic phase is dried over Na.sub.2SO.sub.4, filtered and
concentrated to obtain the expected compound in the form of a
solid.
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. ppm: 2.43 (s, 3H),
3.54-3.63 (m, 2H), 4.50 (ls, 1H), 5.05-5.22 (m, 2H), 5.66-5.79 (m,
1H), 7.31 (d, J=8.1 Hz, 2H), 7.76 (d, J=8.1 Hz, 2H)
Step B:
4-Methyl-N-(2-methylprop-2-en-1-yl)-N-(prop-2-en-1-yl)benzene-1-su-
lphonamide
3-Chloro-2-methylpropene (20 mL, 0.20 mol) is added over a period
of 5 minutes to a suspension of
4-methyl-N-(prop-2-en-1-yl)benzene-1-sulphonamide (27.9 g, 0.13
mol) and potassium carbonate (28.1 g, 0.20 mol) in
N,N-dimethylformamide (200 mL) cooled in an ice bath. After 20
minutes, the suspension is stirred at ambient temperature for 18
hours. The suspension is concentrated to dryness. The residue is
taken up in ethyl acetate (250 mL) and water (110 mL). The aqueous
phase is extracted with ethyl acetate (2.times.50 mL). The combined
organic phases are washed successively with aqueous 3N HCl solution
(50 mL), water (3.times.50 mL), aqueous 5% potassium bicarbonate
solution (50 mL), and finally brine (50 mL). The organic phase is
dried over Na.sub.2SO.sub.4, filtered and concentrated to obtain
the expected compound in the form of an oil.
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. ppm: 1.69 (s, 3H), 2.43
(s, 3H), 3.70 (s, 2H), 3.75-3.79 (m, 2H), 4.87 (d, J=25.1 Hz, 1H),
5.04-5.09 (m, 1H), 5.09-5.12 (m, 1H), 5.45-5.59 (m, 1H), 7.29 (d,
J=8.1 Hz, 2H), 7.71 (d, J=8.1 Hz, 2H)
Step C: 3-Methyl-1-(4-methylbenzenesulphonyl)-1H-pyrrole
A solution of the compound obtained in Step B (15.2 g, 57.3 mmol)
in toluene (550 mL) is heated at 80.degree. C. in the presence of
(1,3-bis(2,4,6-trimethylphenyl)-2-imidazolidinylidene)-dichloro(phenylmet-
hylene)(tricyclohexylphosphine)ruthenium (Grubbs' catalyst, 2nd
generation) (150 mg, 0.18 mmol) for 1 hour.
2,3-Dichloro-5,6-dicyano-p-benzoquinone (16.1 g, 70.9 mmol) is then
added in one portion, and the solution is heated at 80.degree. C.
for 24 hours. The solution is filtered over Celite, and the
filtrate is concentrated in vacuo. The product is purified by
chromatography over silica gel using ethyl acetate and heptane as
eluants to obtain the expected compound in the form of a solid.
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. ppm: 2.02 (d, J=1.0 Hz,
3H), 2.39 (s, 3H), 6.09-6.13 (m, 1H), 6.85-6.90 (m, 1H), 7.03-7.07
(m, 1H), 7.27 (d, J=8.4 Hz, 2H), 7.72 (d, J=8.4 Hz, 2H)
Step D:
3-Methyl-1-(4-methylbenzenesulphonyl)-1H-pyrrole-2-carbonitrile
Aluminium chloride (19.4 g, 0.15 mol) is added all at once to a
solution of 3-methyl-1-(4-methylbenzenesulphonyl)-1H-pyrrole (13.0
g, 55.3 mmol) in 1,2-dichloroethane (230 mL) at ambient
temperature. After stirring for 20 minutes, cyanogen bromide (11.11
g, 0.10 mol) is added in portions over a period of 20 minutes.
After 4.5 hours, an additional amount of cyanogen bromide (1.94 g,
18.3 mmol) is added. After stirring for 17 hours at ambient
temperature, the reaction mixture is poured slowly into a mixture
of dichloromethane (300 mL) and water (600 mL) cooled to 0.degree.
C. The resulting mixture is stirred for 1 hour. Subsequently the
phases are separated and the aqueous phase is extracted with
dichloromethane (3.times.150 mL). The combined organic phases are
washed with water (2.times.150 mL) and brine (150 mL). The organic
phase is dried over Na.sub.2SO.sub.4, filtered and concentrated in
vacuo to obtain the expected compound in the form of a solid.
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. ppm: 2.18 (s, 3H), 2.43
(s, 3H), 6.17 (d, J=3.2 Hz, 1H), 7.33-7.39 (m, 3H), 7.90 (d, J=8.5
Hz, 2H)
Step E:
4-Bromo-3-methyl-1-(4-methylbenzenesulphonyl)-1H-pyrrole-2-carboni-
trile
N-Bromosuccinimide (12.0 g, 67.4 mmol) is added all at once to a
suspension of
3-methyl-1-(4-methylbenzenesulphonyl)-1H-pyrrole-2-carbonitrile
(14.45 g, 55.6 mmol) in N,N-dimethylformamide (60 mL) at ambient
temperature. The mixture is stirred at ambient temperature for 29
hours and is then cooled in an ice bath. Saturated aqueous sodium
bisulphite solution (90 mL), water (90 mL) and ethyl acetate (250
mL) are then added. The phases are separated, and then the aqueous
phase is extracted with ethyl acetate (2.times.70 mL). The combined
organic phases are washed with 5% aqueous potassium bicarbonate
solution (90 mL), water (3.times.90 mL), and then brine (3.times.90
mL). The organic phase is dried over Na.sub.2SO.sub.4, filtered and
concentrated in vacuo. The crude product is purified by
chromatography over silica gel using toluene and heptane as eluants
to obtain the expected compound in the form of a solid.
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. ppm: 2.13 (s, 3H), 2.45
(s, 3H), 7.38 (d, J=8.4 Hz, 2H), 7.43 (s, 1H), 7.92 (d, J=8.4 Hz,
2H)
Step F: 4-Bromo-1,3-dimethyl-1H-pyrrole-2-carbonitrile
Potassium hydroxide (3.65 g, 65.1 mmol) is added all at once to a
suspension of
4-bromo-3-methyl-1-(4-methylbenzenesulphonyl)-1H-pyrrole-2-carbonitrile
(4.66 g, 13.7 mmol) in methanol (95 mL) cooled using an ice bath.
After 15 minutes, the suspension is stirred at ambient temperature
for 17 hours. The methanol is evaporated to dryness. The
evaporation residue is taken up in MTBE (25 mL) and washed with
water (25 mL). The aqueous phase is extracted with MTBE (2.times.25
mL). The combined organic phases are dried over Na.sub.2SO.sub.4,
filtered and concentrated in vacuo. The residue obtained is
dissolved in tetrahydrofuran (50 mL) and the solution is cooled
using an ice bath. NaH (60% in oil) (1.02 g, 25.5 mmol) is added.
After 10 minutes, iodomethane (2.4 mL, 38.6 mmol) is also
added.
The mixture is stirred at ambient temperature for 1.5 hours. The
tetrahydrofuran is evaporated to dryness. The residue is taken up
in dichloromethane and washed with water. The aqueous phase is
extracted with dichloromethane. The combined organic phases are
dried over Na.sub.2SO.sub.4, filtered and concentrated in vacuo to
obtain the expected compound in the form of a solid.
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. ppm: 2.16 (s, 3H), 3.71
(s, 3H), 6.74 (s, 1H)
Step G:
4-({4-[(tert-Butyldimethylsilyl)oxy]phenyl}amino)-1,3-dimethyl-1H--
pyrrole-2-carbonitrile
4-Bromo-1,3-dimethyl-1H-pyrrole-2-carbonitrile (2.03 g, 10.2 mmol)
and 4-[(tert-butyldimethylsilyl)oxy]aniline (3.41 g, 15.3 mmol) are
dissolved in toluene (40 mL). The solution is degassed with
nitrogen for 10 minutes. Sodium tert-butylate (1.18 g, 12.2 mmol),
2-di-tert-butylphosphino-2',4',6'-triisopropylbiphenyl (0.17 g,
0.41 mmol) and tris(dibenzylideneacetone)dipalladium(0) (0.187 g,
0.2 mmol) are then added. The mixture is heated at 100.degree. C.
for 30 minutes and then cooled to ambient temperature. Water (50
mL) and Celite (6 g) are added. The suspension is filtered over
Celite, and the filtrate is diluted with MTBE. The phases are
separated and the aqueous phase is extracted with MTBE (2.times.50
mL). The combined organic phases are dried over Na.sub.2SO.sub.4
and filtered. The residue is purified by chromatography over silica
gel using ethyl acetate and heptane as eluants followed by
reverse-phase chromatography using methanol and water as eluants.
The product obtained is lyophilised to provide the expected
compound in the form of a solid.
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. ppm: 0.15 (s, 6H), 0.98
(s, 9H), 2.05 (s, 3H), 3.70 (s, 3H), 4.69 (br. s, 1H), 6.55-6.57
(m, 2H), 6.64-6.69 (m, 3H)
.sup.13C NMR (100 MHz, CDCl.sub.3) .delta. ppm: -4.37, 9.42, 18.27,
25.84, 35.50, 102.59, 113.77, 115.13, 120.72, 121.91, 126.77,
126.94, 140.98, 148.39
Preparation 38'':
4-[(4-{[tert-Butyl(dimethyl)silyl]oxy}phenyl)amino]-1-ethyl-5-methyl-1H-p-
yrrole-2-carbonitrile
The procedure is in accordance with the process of Preparation
33'', replacing the iodomethane-d.sub.3 in Step B by
iodoethane.
.sup.1H NMR (400 MHz, dmso-d6) .delta. ppm: 6.85 (s, 1H), 6.75 (s,
1H), 6.6/6.5 (2d, 4H), 4 (quad, 2H), 2.1 (s, 3H), 1.3 (s, 3H), 0.9
(s, 9H), 0.1 (s, 6H)
Preparation 39'':
N-[4-[tert-Butyl(dimethyl)silyl]oxyphenyl]-2-ethoxy-pyrimidin-5-amine
Step A: 5-Bromo-2-ethoxy-pyrimidine
5-Bromo-2-chloro-pyrimidine (5.0 g, 25 mmol) is dissolved in
ethanol (55 mL) and sodium ethylate (1.81 g, 26.6 mmol) is added in
portions. The reaction mixture is stirred for 15 hours at ambient
temperature. When the reaction is complete, the solvent is
evaporated off, water (200 mL) is added, and then the reaction
mixture is extracted with dichloromethane (2.times.100 mL). The
organic phase is dried over Na.sub.2SO.sub.4, and then evaporated
to dryness to yield 5-bromo-2-ethoxy-pyrimidine.
Step B:
N-[4-[tert-Butyl(dimethyl)silyl]oxyphenyl]-2-ethoxy-pyrimidin-5-am-
ine
4-[tert-Butyl(dimethyl)silyl]oxyaniline (1.8 g, 8 mmol) and
5-bromo-2-ethoxy-pyrimidine (1.6 g, 8 mmol) dissolved in anhydrous
tetrahydrofuran (30 mL) are stirred for 1 hour at ambient
temperature in the presence of sodium tert-butylate (4 mL, 2M
solution in THF) and
chloro(2-di-tert-butylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)
[2-(2-aminoethyl)-phenyl]palladium(II) (111 mg, 0.16 mmol). The
reaction mixture is filtered over Celite and then evaporated to
dryness. The residue is triturated in heptane to obtain the
expected compound after filtration.
.sup.1H NMR (500 MHz, dmso-d6, 300 K) .delta. ppm: 8.31 (s, 2H,
pyrimidine-H), 7.80 (s, 1H, NH), 6.73 (d, 2H, Ar--H), 6.68 (d, 2H,
Ar--H), 4.26 (q, 2H, CH.sub.2CH.sub.3), 1.31 (t, 3H,
CH.sub.2CH.sub.3), 0.94 (s, 9H, .sup.tBu), 0.15 (s, 6H, Me)
IR: .nu.: aromatic: 1504 cm.sup.-1; Si--C: 1247 cm.sup.-1; C--O--C:
1057 cm.sup.-1
Preparation 40'': tert-Butyl
6-[(1-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)amino]-pyridin-3-yl
carbonate
Step A: 6-Bromopyridin-3-yl tert-butyl carbonate
To a solution of 5 g of 6-bromopyridin-3-ol (28.7 mmol) and 7.53 g
of di-tert-butyl dicarbonate (34.5 mmol) in 50 mL of
tetrahydrofuran there is added 0.18 g of 4-dimethylaminopyridine
(1.4 mmol). The mixture is stirred at ambient temperature for 6
hours and then concentrated. The residue obtained is dissolved in a
mixture of ethyl ether and water. After separation of the phases,
the separated-off organic phase is dried over MgSO.sub.4 and
concentrated to dryness. The title product is obtained in the form
of a solid which is used in the next Step without being otherwise
purified.
.sup.1H NMR (400 MHz, dmso-d6) .delta. ppm: 8.4 (s, 1H), 7.71 (s,
2H), 1.5 (s, 9H)
Step B: tert-Butyl
6-[(1-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)amino]pyridin-3-yl
carbonate
To a solution of 2.79 g of the compound obtained in Step A (10.2
mmol) in 15 mL of toluene and 15 mL of tetrahydrofuran there are
added 1.18 g of sodium tert-butylate (12.2 mmol), and then the
batch is stirred under argon for 15 minutes. There is then added
0.35 g of palladium catalyst (0.5 mmol). The reaction mixture is
then stirred at ambient temperature for 16 hours and then filtered.
The filtrate is concentrated and taken up in a mixture of
dichloromethane and water. The organic phase is separated off and
then washed with water, dried over MgSO.sub.4, filtered and
concentrated to dryness. The crude product thereby obtained is
purified by chromatography over silica gel using dichloromethane
and ethyl acetate as eluants. The residue is then taken up in a
minimum of isopropyl ether. The solid then obtained is filtered
off, washed with ether and then dried. The title product is
obtained in the form of a solid, which is subsequently used without
being otherwise purified.
.sup.1H NMR (400 MHz, dmso-d6) .delta. ppm: 9 (s, 1H), 8.35 (wd,
1H), 8.3 (wd, 1H), 8 (wd, 1H), 7.45 (dd, 1H), 7.45 (wd, 1H), 6.8
(d, 1H), 6.4 (wd, 1H), 3.8 (s, 3H), 1.5 (s, 9H)
Preparation 41'':
3-[4-[tert-Butyl(dimethyl)silyl]oxyanilino]benzonitrile
The procedure is in accordance with the process of Preparation 1'',
replacing the 4-bromo-1-methyl-1H-pyrazole used in Step B by
3-bromobenzonitrile.
.sup.1H NMR (400 MHz, dmso-d6) .delta. ppm: 8.3 (s, 1H), 7.3 (t,
1H), 7.2/7.1 (2 dd, 2H), 7.15 (t, 1H), 7.05 (d, 2H), 6.8 (d, 2H),
0.95 (s, 9H), 0.2 (s, 6H)
Preparation 42'':
4-[4-[tert-Butyl(dimethyl)silyl]oxyanilino]thiophene-2-carbonitrile
The procedure is in accordance with the process of Preparation 1'',
replacing the 4-bromo-1-methyl-1H-pyrazole used in Step B by
4-bromothiophene-2-carbonitrile.
.sup.1H NMR (400 MHz, dmso-d6) .delta. ppm: 8.35 (s, 1H), 7.59 (wd,
1H), 7.08 (wd, 1H), 6.95 (d, 2H), 6.75 (d, 2H), 0.94 (s, 9H), 0.16
(s, 6H)
The amines NHR.sub.3R.sub.4 wherein R.sub.3 and R.sub.4, each
independently of the other, represent an aryl or heteroaryl group
are obtained in accordance with processes described in the
literature (Surry D. S. et al., Chemical Science, 2011, 2, 27-50,
Charles M. D. et al., Organic Letters, 2005, 7, 3965-3968). The
reaction protecting the hydroxy function of the 4-anilinophenol
described in Preparation 2'' can be applied to various secondary
amines NHR.sub.3R.sub.4 (as defined hereinbefore) having one or
more hydroxy functions, when they are available commercially.
Alternatively, the secondary amines having at least one hydroxy
substituent may be synthesised directly in a protected form, i.e.
starting from reagents whose hydroxy function has been protected
beforehand. Among the protecting groups,
tert-butyl(dimethyl)silyloxy and benzyloxy are especially
preferred.
Among the amines NHR.sub.3R.sub.4 having a hydroxy substituent that
are used for synthesising the compounds of the invention there may
be mentioned: 4-(4-toluidino)phenol, 4-(4-chloroanilino)phenol,
4-(3-fluoro-4-methylanilino)phenol,
4-[4-(trifluoromethoxy)anilino]-phenol, 4-[4-hydroxyanilino]phenol,
{4-[(1-methyl-1H-indol-6-yl)amino]phenyl}-methanol,
4-(2,3-dihydro-1H-indol-6-ylamino)phenol,
4-[(1-methyl-2,3-dihydro-1H-indol-6-yl)amino]phenol,
4-[(1-methyl-1H-indol-6-yl)amino]phenol,
4-[(1-methyl-1H-indol-6-yl)amino]cyclohexanol,
4-[(1-methyl-1,2,3,4-tetrahydro-6-quinolinyl)amino]phenol,
4-[(4-methyl-3,4-dihydro-2H-1,4-benzoxazin-7-yl)amino]phenol,
4-[4-(diethylamino)anilino]-phenol,
4-(2,3-dihydro-1H-inden-5-ylamino)phenol,
4-[(1-methyl-1H-indazol-5-yl)amino]-phenol,
4-[(1'-methyl-1',2'-dihydrospiro[cyclopropane-1,3'-indol]-5'-yl)amino]phe-
nol, 4-[(1,3,3-trimethyl-2,3-dihydro-1H-indol-5-yl)amino]phenol,
4-[4-methoxy-3-(trifluoromethyl)anilino]phenol,
4-[4-(methylsulphanyl)-3-(trifluoromethyl)anilino]phenol,
2-fluoro-4-[(1-methyl-1H-indol-5-yl)amino]phenol,
4-[(1-ethyl-1H-indol-5-yl)amino]phenol,
4-[(1-ethyl-2,3-dihydro-1H-indol-5-yl)amino]phenol,
4-[(1-isopropyl-2,3-dihydro-1H-indol-5-yl)amino]phenol,
4-(butylamino)phenol, 3-[(1-methyl-1H-indol-5-yl)amino]-1-propanol,
4-[(1-methyl-1H-indol-5-yl)amino]-1-butanol,
4-[(3-fluoro-4-methylphenyl)-amino]phenol,
4-[(3-chloro-4-methylphenyl)amino]phenol,
4-[(4-fluorophenyl)amino]-phenol,
4-[(1-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)amino]phenol,
4-[(4-fluorophenyl)-amino]phenol, 4-[(2-fluorophenyl)amino]phenol,
4-[(3-fluorophenyl)amino]phenol,
4-[(2,4-difluorophenyl)amino]phenol,
4-[(3,4-difluorophenyl)amino]phenol,
3-[(4-hydroxyphenyl)amino]benzonitrile,
4-[(3-methoxyphenyl)amino]phenol,
4-[(3,5-difluorophenyl)-amino]phenol,
4-[(3-methylphenyl)amino]phenol,
4-[(4-hydroxyphenyl)amino]benzonitrile,
4-[(3-chlorophenyl)amino]phenol, 4-(pyrimidin-2-ylamino)phenol,
4-[(cyclobutyl-methyl)amino]phenol,
2-[(4-hydroxyphenyl)amino]benzonitrile,
4-{[(1-methyl-1H-pyrazol-4-yl)methyl]amino}phenol,
4-[(cyclopropylmethyl)amino]phenol,
4-{[(1-methyl-1H-pyrazol-3-yl)methyl]amino}phenol,
4-(but-2-yn-1-ylamino)phenol, 4-(pyrazin-2-yl-amino)phenol,
4-(pyridin-2-ylamino)phenol, 4-(pyridazin-3-ylamino)phenol,
4-(pyrimidin-5-ylamino)phenol, 4-(pyridin-3-ylamino)phenol,
4-[(3,5-difluoro-4-methoxyphenyl)-amino]phenol,
4-(pyridin-4-ylamino)phenol,
4-[(3-fluoro-4-methoxyphenyl)amino]phenol,
2-(phenylamino)pyrimidin-5-ol,
5-[(4-hydroxyphenyl)amino]-2-methoxybenzonitrile,
4-{[3-(trifluoromethyl)phenyl]amino}phenol and
4-(methylamino)phenol.
The hydroxy function(s) of the secondary amines listed above is
(are) protected beforehand by a suitable protecting group prior to
any coupling to an acid derivative of the compound of formula (VII)
as defined in the preceding general process.
Preparation I: tert-Butyl
[2-(3-iodo-4-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}phe-
nyl)ethyl]carbamate
Step A: 4-[2-(tert-Butoxycarbonylamino)ethyl]benzoic acid
tert-Butyl dicarbonate (1.64 g; 7.5 mmol) is dissolved in
1,4-dioxane (5 mL) and the solution is added to a well-stirred
solution of 4-(2-aminoethyl)benzoic acid (1.0 g; 5 mmol) in 1M
aqueous sodium hydroxide solution (25 mL) and 1,4-dioxane (10 mL),
and the mixture is then stirred at ambient temperature for 3 hours.
The 1,4-dioxane is removed by evaporation in vacuo, and then ethyl
acetate (200 mL) is added to the residue. The pH of the aqueous
phase is adjusted to 1.5 with 2M aqueous HCl solution. The organic
phase is separated off and the aqueous phase is then extracted with
ethyl acetate (100 mL). The combined organic extracts are washed
with water, dried over Na.sub.2SO.sub.4 and evaporated to a volume
of 10 mL. Heptane is added to the residue and then the solid
precipitate is filtered off to yield the title compound.
.sup.1H NMR (500 MHz, dmso-d6, 300K): 12.81 (br s, 1H, COOH), 7.85
(m, 2H, Ar-2' and 6'H), 7.31 (m, 2H, Ar-3' and 5'H), 6.91 and 6.51
(2.times.br s, 1H, NH), 3.16 (m, 2H, CH.sub.2), 2.75 (t, 2H,
CH.sub.2), 1.35 and 1.31 (2.times.br s, 9H, Bu.sup.t); .sup.13C NMR
(125 MHz, dmso-d6, 300 K): 167.8 (q), 156.0 (CH), 145.3 (q), 129.8
(2.times.CH), 129.3 (2.times.CH), 129.1 (q), 78.0 (q), 41.5
(CH.sub.2), 35.9 (CH.sub.2), 28.7 (CH.sub.3)
Step B: 4-[2-(tert-Butoxycarbonylamino)ethyl]-2-iodo-benzoic
acid
The compound of the above Step (0.88 g; 3.31 mmol), iodobenzene
diacetate (1.07 g; 3.31 mmol), tetrabutylammonium iodide (1.22 g;
3.31 mmol), iodine (0.84 g; 3.31 mmol) and diacetoxypalladium (0.04
g; 0.165 mmol) are dissolved in 1,2-dichloroethane (8 mL), and the
mixture is then heated in a microwave reactor at 80.degree. C. for
90 minutes. The cooled mixture is partitioned between saturated
aqueous Na.sub.2CO.sub.3 solution (30 mL) and the original solvent.
The organic phase is separated off and the aqueous residue is
extracted with diethyl ether (2.times.15 mL). The pH of the
resulting aqueous solution is adjusted to 2 with 2M aqueous HCl
solution and the product is then extracted with ethyl acetate
(2.times.75 mL). The organic phase is dried over Na.sub.2SO.sub.4
and evaporated. The crude product is purified by chromatography
over silica gel to yield the mixture of regioisomers, which are
separated by preparative HPLC using water-TFA and acetonitrile as
eluants. The pH of the appropriate combined fractions is adjusted
to 5 with NaHCO.sub.3, and then the acetonitrile is evaporated off
under reduced pressure. The precipitate is recovered by filtration
and then dried to yield the title compound.
.sup.1H NMR (500 MHz, dmso-d6, 300K): 13.16 (broad s, 1H, COOH),
7.81 (s, 1H, Ar-3'H), 7.66 (d, 1H, Ar-6'H), 7.29 (d, 1H, Ar-5'H),
6.89 (t, 1H, NH), 3.14 (t, 1H, CH.sub.2), 2.69 (t, 1H, CH.sub.2),
1.35 (s, 9H, Boc)
Step C: tert-Butyl
[2-(3-iodo-4-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]-carbonyl}ph-
enyl)ethyl]carbamate
The compound of the above Step (0.714 g; 1.82 mmol), TBTU (0.73 g;
2.28 mmol), N-ethyl-N-isopropyl-propan-2-amine (0.94 mL; 5.46 mmol)
and N,N-dimethylpyridin-4-amine (22 mg) are stirred in
dichloromethane (20 mL) for 5 minutes, and then
(3R)-3-methyl-1,2,3,4-tetrahydroisoquinoline (0.282 g; 1.92 mmol)
(cf. Preparation 1') is added. The mixture is stirred for three
more hours. The reaction mixture is diluted with dichloromethane
(150 mL) and then washed with water (25 mL), dried over
Na.sub.2SO.sub.4 and evaporated. The crude product is purified by
chromatography over silica gel using dichloromethane and methanol
as eluants to yield the title compound.
High-Resolution Mass Spectrometry (ESI+):
Empirical formula: C.sub.24H.sub.29IN.sub.2O.sub.3
[M+H].sup.+ calculated: 521.1303
[M+H].sup.+ measured: 521.1282
IR: .nu.: C--H: 2931 cm.sup.-1; >C.dbd.O: 1706, 1627 cm.sup.-1;
amide: 1505 cm.sup.-1; C--O--C: 1248, 1166 cm.sup.-1
Preparation II: tert-Butyl
(4-Iodo-3-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}benzyl-
)carbamate
Step A: 2-Iodo-5-methyl-benzoic acid
3-Methylbenzoic acid (6.12 g; 45 mmol), iodobenzene diacetate
(14.49 g; 45 mmol), tetrabutylammonium iodide (16.62 g, 45 mmol),
iodine (11.43 g; 45 mmol) and diacetoxypalladium (0.5 g; 2.2 mmol)
are dissolved in 1,2-dichloroethane, and then the mixture is heated
in a sealed tube at 85.degree. C. for 1 hour and 45 minutes. The
cooled solution is purified by chromatography over silica gel using
dichloromethane and methanol as eluants to yield the title
compound.
Step B: Methyl 2-iodo-5-methyl-benzoate
The compound of the above Step (6.25 g, 23.9 mmol) is dissolved in
anhydrous methanol (100 mL), and then SOCl.sub.2 (3.6 mL, 49 mmol)
is added dropwise to the well-stirred solution. The solution is
refluxed for 18 hours and then evaporated to a volume of 25 mL and
then poured into crushed ice (100 g). The resulting mixture is
extracted with diethyl ether (2.times.75 mL). The organic phase is
washed with saturated aqueous NaHCO.sub.3 solution and then brine,
dried over Na.sub.2SO.sub.4 and evaporated to dryness to yield the
title compound.
Step C: Methyl 5-(bromomethyl)-2-iodo-benzoate
The compound of the above Step (5.7 g; 20.7 mmol),
N-bromo-succinimide (3.67 g; 20.7 mmol) and dibenzoyl peroxide
(0.24 g; 1 mmol) are dissolved in carbon tetrachloride (40 mL) and
then refluxed for 5 hours. New portions of N-bromosuccinimide (1.0
g; 5.6 mmol) and dibenzoyl peroxide (0.05 g; 0.2 mmol) are then
added and heating is continued for 4 more hours. The reaction
mixture is cooled to ambient temperature. The insoluble parts are
removed by filtration, and the concentrated filtrate is then
purified by chromatography over silica gel using heptane and ethyl
acetate as eluants to yield the title compound.
Step D: Methyl 5-(aminomethyl)-2-iodo-benzoate
The compound of the above Step (0.53 g; 1.5 mmol) is dissolved in
7M methanolic ammonia (20 mL) and then stirred at ambient
temperature for 1 hour. The solution is evaporated to dryness to
yield the title compound, which was used in the next Step without
purification.
Step E: 5-[(tert-Butoxycarbonylamino)methyl]-2-iodo-benzoic
acid
Methyl 5-(aminomethyl)-2-iodo-benzoate hydrobromide (0.56 g; 1.5
mmol) was dissolved in pyridine (10 mL), then di-tert-butyl
dicarbonate (0.80 g; 3.6 mmol) is added and the mixture is stirred
at ambient temperature for 30 minutes and then evaporated to
dryness. The residue is redissolved in methanol (10 mL), and then
2M aqueous NaOH solution (3 mL) and 2 mL of water are added. The
resulting solution is stirred for 2 hours at 50.degree. C., then
diluted with water (20 mL), and the methanol is evaporated off
under reduced pressure. The pH of the resulting aqueous solution is
adjusted to 3 with 2M aqueous HCl solution; the product is then
extracted with ethyl acetate. The organic phase is washed with
brine, and then dried over Na.sub.2SO.sub.4 and evaporated to
dryness. The crude product is triturated with DCM. The solid formed
is recovered by filtration to yield the title compound.
.sup.1H NMR (500 MHz, dmso-d6, 300 K): 13.24 (broad s, 1H, COOH),
7.91 (d, 1H, Ar-3'H), 7.58 (d, 1H, Ar-6'H), 7.47 (t, 1H, NH), 7.09
(d, 1H, (Ar-5'H), 4.09 (d, 2H, CH.sub.2), 1.38 (s, 9H, Boc);
.sup.13C NMR (125 MHz, dmso-d6, 300K): 168.6 (q), 156.3 (q), 141.1
(q), 140.9 (CH), 137.1 (q), 131.6 (CH), 129.1 (CH), 92.2 (q), 78.5
(q), 28.7 (CH.sub.3)
Step F: tert-Butyl
(4-iodo-3-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-benzy-
l)carbamate
The compound of the above Step (1.62 g; 4.3 mmol), TBTU (2.76 g;
8.59 mmol), N-ethyl-N-isopropyl-propan-2-amine (1.48 mL; 8.59 mmol)
and N,N-dimethylpyridin-4-amine (10 mg) are stirred in DCM (50 mL)
for 5 minutes; (3R)-3-methyl-1,2,3,4-tetrahydroisoquinoline (0.76
g; 5.15 mmol) (cf. Preparation 1') is then added and the mixture is
stirred for 15 minutes more. The insoluble parts are removed by
filtration, and then the concentrated filtrate is purified by
chromatography over silica gel using dichloromethane and methanol
as eluants to yield the title compound.
Preparation III: tert-Butyl
(3-bromo-4-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}benzy-
l)carbamate
Step A: Methyl 4-(aminomethyl)-2-bromo-benzoate
A solution of methyl 2-bromo-4-(bromomethyl)benzoate (4.57 g; 14.84
mmol) in 50 mL of methanol is added dropwise to a well-stirred
solution of ammonia in methanol (7M; 315 mL) at ambient
temperature, and the solution is then stirred for 3 hours. All the
solvents are evaporated off and the residue is purified by
chromatography over silica gel using dichloromethane-methanol as
eluants to yield the title compound.
Step B: 2-Bromo-4-[(tert-butoxycarbonylamino)methyl]benzoic
acid
The compound of the above Step (4.04 g; 16.6 mmol) is dissolved in
pyridine (55 mL) and then di-tert-butyl dicarbonate (5.43 g; 24.9
mmol) is added and the mixture is stirred at ambient temperature
for 16 hours; it is then evaporated to dryness. The residue is
redissolved in methanol (100 mL), and then 1M aqueous NaOH solution
(54 mL) is added. The resulting solution is stirred for 1.5 hours
at 50.degree. C. and is then allowed to cool to ambient
temperature. The pH of the solution is adjusted to 7 using 2M
aqueous HCl solution; the methanol is then evaporated off under
reduced pressure. The resulting aqueous solution is diluted with
water (50 mL), and then the pH is adjusted to 3 using 2M aqueous
HCl solution. The product is extracted with dichloromethane
(2.times.100 mL). The organic phase is washed with brine, then
dried over Na.sub.2SO.sub.4 and evaporated to dryness to yield the
title compound which is used in the next Step without
purification.
IR: .nu.: N--H: 3359 cm.sup.-1; C--H: 2983 cm.sup.-1; >C.dbd.O:
1685, 1603 cm.sup.-1; amide: 1519 cm.sup.-1; C--O--C: 1248, 1162,
1057 cm.sup.-1
Step C: tert-Butyl
(3-bromo-4-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]-carbonyl}benz-
yl)carbamate
The compound of the above Step (3.7 g; 11.2 mmol), TBTU (7.19 g;
22.4 mmol), N-ethyl-N-isopropyl-propan-2-amine (3.86 mL; 22.4 mmol)
and N,N-dimethylpyridin-4-amine (48 mg) are stirred in
dichloromethane (100 mL) for 5 minutes, and then
(3R)-3-methyl-1,2,3,4-tetrahydroisoquinoline (1.98 g, 13.44 mmol)
(cf. Preparation 1') is added, and the mixture is stirred for 1
hour more. The insoluble parts are removed by filtration, and then
the concentrated filtrate is purified by chromatography over silica
gel using dichloromethane and methanol as eluants to yield the
title compound.
High-Resolution Mass Spectrometry (ESI+):
Empirical formula: C.sub.23H.sub.27BrN.sub.2O.sub.3
[M+H].sup.+ calculated: 459.1285
[M+H].sup.+ measured: 459.1282
.sup.1H NMR (500 MHz, dmso-d6, 300K, presence of amide rotamers):
7.66-6.87 (m, 7H, aromatic), 5.34 and 4.12 (d, 2H,
CH.sub.2-isoquinoline), 5.02 and 4.97 and 3.87 and 3.83 (m, 1H,
CH.sub.2-isoquinoline), 4.17 (d, 2H, CH.sub.2-benzyl), 3.18-2.48
(m, 1H, CH.sub.2-isoquinoline), 1.16 and 1.14 and 1.10 and 0.98 (d,
3H, isoquinoline CH.sub.3), 1.31 and 1.41 (s, 9H, Boc).
EXAMPLE 1
5-(5-Chloro-2-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}phe-
nyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-(1-methyl-1H-pyrazol-4-yl)-1H-pyrr-
ole-3-carboxamide
Step A: Ethyl
5-(5-chloro-2-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}ph-
enyl)-1,2-dimethyl-1H-pyrrole-3-carboxylate
To a solution of 1.4 g of the compound obtained in Preparation 1
(4.35 mmol) in 50 mL of dichloromethane there are successively
added 0.7 g of the compound obtained in Preparation 1' (4.79 mmol),
0.7 g of HOBT (5.22 mmol), 0.81 g of EDC (5.22 mmol) and 1.6 mL of
triethylamine (21.7 mmol). The batch is then stirred overnight at
ambient temperature. The reaction mixture is then diluted with
dichloromethane and washed 3 times with saturated aqueous
NaHCO.sub.3 solution. The organic phase is then dried over
MgSO.sub.4, filtered, concentrated to dryness, and then purified by
chromatography over silica gel using dichloromethane and methanol
as eluants.
.sup.1H NMR: .delta. (500 MHz; dmso-d6; 300K): 7.6-7.3 (m, 3H,
aromatic Hs, 4-chlorophenyl); 7.2-6.85 (m, 4H, aromatic Hs,
tetrahydroisoquinoline); 6.45-6.3 (m, 1H, H pyrrole); 5.0-4.8-3.8
(m, 1H, aliphatic H, tetrahydroisoquinoline); 5.3-3.75 (dd, 2H,
aliphatic Hs tetrahydroisoquinoline); 4.2-4.0 (m, 2H,
OCH.sub.2CH.sub.3); 3.25 (s, 3H, CH.sub.3--N-pyrrole); 3.0-2.2 (m,
2H, aliphatic Hs, tetrahydroisoquinoline); 2.5 (s, 3H,
CH.sub.3-pyrrole); 1.25 (t, 3H, OCH.sub.2CH.sub.3); 1.05 (d, 3H,
tetrahydroisoquinoline-CH.sub.3)
IR: .nu.: >C.dbd.O: 1693 cm.sup.-1 ester; .nu.: >C.dbd.O:
1625 cm.sup.-1 amide
Step B:
5-(5-Chloro-2-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]carb-
onyl}-phenyl)-1,2-dimethyl-1H-pyrrole-3-carboxylic acid
To a solution of 1.7 g of the compound obtained in Step A (3.77
mmol) in 5 mL of dioxane there is added 0.317 g of LiOH (7.5 mmol)
dissolved in 5 mL of water. The batch is heated in a microwave
apparatus for 4 hours at 100.degree. C. (power 140 W). The reaction
mixture is then filtered and concentrated to dryness. The residue
thereby obtained is taken up in dichloromethane (50 mL) and then
saturated aqueous NH.sub.4Cl solution is added thereto. The organic
phase is washed with water and then with brine, dried over
MgSO.sub.4, filtered and concentrated to dryness. The title product
is obtained in the form of a solid and is used directly in the next
Step.
.sup.1H NMR: .delta. (500 MHz; dmso-d6; 300K): 11.05 (broad s, 1H,
COOH), 7.5-7.2 (m, 3H, aromatic Hs, 4-chlorophenyl); 7.2-6.9 (m,
4H, aromatic Hs, tetrahydroisoquinoline); 6.45-6.2 (m, 1H,
aliphatic H, H pyrrole); 5.3-3.75 (dd, 2H, aliphatic Hs,
tetrahydroisoquinoline); 5.0-4.8-3.8 (m, 1H, aliphatic H,
tetrahydroisoquinoline); 3.5-3.2 (s, 3H, CH.sub.3--N-pyrrole);
3.0-2.1 (aliphatic Hs, CH.sub.3-tetraisoquinoline); 2.5-2.4-1.98
(m, 3H, CH.sub.3-pyrrole); 1.05-0.52 (m, 3H, aliphatic Hs,
CH.sub.3-tetraisoquinoline)
IR: .nu.: --OH: 3500-2000 cm.sup.-1 carboxylic acid; .nu.:
>C.dbd.O: 1699+1658 cm.sup.-1 carboxylic acid; .nu.:
>C.dbd.N--: 1625 cm.sup.-1 amide
Step C:
N-(4-{[tert-Butyl(dimethyl)silyl]oxy}phenyl)-5-(5-chloro-2-{[(3R)--
3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}phenyl)-1,2-dimethyl-N-(-
1-methyl-1H-pyrazol-4-yl)-1H-pyrrole-3-carboxamide
To a solution of 0.65 g of the compound obtained in Step B (1.54
mmol) in 15 mL of dichloroethane there is added, dropwise, 0.244 mL
of 1-chloro-N,N,2-trimethyl-prop-1-en-1-amine. The reaction mixture
is stirred at ambient temperature for 1 hour, and there are then
added 0.56 g of the compound of Preparation 1'' (1.84 mmol), 10 mL
of dichloroethane and 0.376 g of 4-dimethylaminopyridine (DMAP)
(3.07 mmol). The batch is stirred at 110.degree. C. overnight. The
reaction mixture is concentrated, dissolved in dichloromethane and
washed with saturated aqueous NaHCO.sub.3 solution. The title
product is obtained in the form of an oil and is used directly in
the next Step.
Step D:
5-(5-Chloro-2-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]carb-
onyl}-phenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-(1-methyl-1H-pyrazol-4-yl-
)-1H-pyrrole-3-carboxamide
To a solution of 0.8 g of the compound obtained in Step C (1.03
mmol) in 2 mL of methanol, there are added 1.55 mL of a 1M solution
of potassium hydroxide in methanol (1.55 mmol). The batch is
stirred at ambient temperature for 30 minutes. The reaction mixture
is then diluted with dichloromethane and successively washed with
1M aqueous HCl solution, saturated aqueous NaHCO.sub.3 solution and
then brine until neutral. The organic phase is then dried over
MgSO.sub.4, filtered and evaporated. The crude product thereby
obtained is purified by chromatography over silica gel using
dichloromethane and methanol as eluants. The solid thereby obtained
is dissolved in a mixture of water/acetonitrile until dissolution
is complete, filtered and then lyophilised.
Elemental Microanalysis: (%, Theoretical:Measured)
% C=68.74:68.25; % H=5.43:5.69; % N=11.79:11.66; % Cl=5.97:5.95
High-Resolution Mass Spectrometry (ESI+):
Empirical formula: C.sub.34H.sub.32ClN.sub.5O.sub.3
[M+H].sup.+ calculated: 594.2266
[M+H].sup.+ measured: 594.2289
EXAMPLE 2
5-(2-{[(3S)-3-(Aminomethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}pheny-
l)-1-methyl-N,N-diphenyl-1H-pyrrole-3-carboxamide
Step A: tert-Butyl
{[(3S)-2-{2-[4-(diphenylcarbamoyl)-1-methyl-1H-pyrrol-2-yl]benzoyl}-1,2,3-
,4-tetrahydroisoquinolin-3-yl]methyl}carbamate
The title compound is obtained in accordance with the process of
Example 1 using the acid of Preparation 2 and tert-butyl
[(3S)-1,2,3,4-tetrahydroisoquinolin-3-ylmethyl]carbamate (see
Preparation 2') in Step A, and N-phenylaniline in Step C.
Step B:
5-(2-{[(3S)-3-(Aminomethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbon-
yl}phenyl)-1-methyl-N,N-diphenyl-1H-pyrrole-3-carboxamide
A solution of the NH-Boc compound of Step A in dichloromethane is
placed at 0.degree. C. 10 molar equivalents of trifluoroacetic acid
are added thereto dropwise. The batch is stirred at ambient
temperature for 4 hours until the starting material has disappeared
completely. The reaction mixture is then concentrated to dryness,
taken up again and co-evaporated twice with toluene, then taken up
in a mixture of acetonitrile/H.sub.2O and finally lyophilised. The
title product is then obtained after a neutralisation step.
Elemental Microanalysis: (%, Theoretical:Measured)
% C=77.75:77.27; % H=5.97:5.73; % N=10.36:10.44
EXAMPLE 3
5-(5-Chloro-2-{[(3S)-3-[(4-methylpiperazin-1-yl)methyl]-3,4-dihydroisoquin-
olin-2(1H)-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-N-(1H-indol-5-yl)-1-met-
hyl-1H-pyrrole-3-carboxamide
Step A: tert-Butyl
5-[(4-{[tert-butyl(dimethyl)silyl]oxy}phenyl){[5-(5-chloro-2-{[(3S)-3-[(4-
-methylpiperazin-1-yl)methyl]-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}phe-
nyl)-1-methyl-1H-pyrrol-3-yl]carbonyl}amino]-1H-indole-1-carboxylate
The title compound is obtained in accordance with the process of
Example 1 using the acid of Preparation 3 and
(3S)-3-[(4-methyl-1-piperazinyl)methyl]-1,2,3,4-tetrahydroisoquinoline
(see Preparation 4') in Step A, and the compound of Preparation 3''
in Step C.
Step B:
5-(5-Chloro-2-{[(3S)-3-[(4-methylpiperazin-1-yl)methyl]-3,4-dihydr-
oisoquinolin-2(1H)-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-N-(1H-indol-5-y-
l)-1-methyl-1H-pyrrole-3-carboxamide
To a solution of 455 mg (0.49 mmol) of the product obtained in Step
A in 5 mL of methanol there are added 135 mg (2.5 mmol) of KOH.
After stirring for 3 hours at ambient temperature, the reaction
mixture is concentrated, treated with saturated aqueous NaHCO.sub.3
solution and extracted with methylene chloride. The organic phase
is then dried over MgSO.sub.4, filtered and evaporated to dryness.
The crude product thereby obtained is then purified by
chromatography over silica gel using dichloromethane and methanol
as eluants to yield the expected product in the form of a foam.
Elemental Microanalysis: (%, Theoretical:Measured)
% C=70.72:68.54; % H=5.79:5.37; % N=11.78:11.41; % Cl=4.97:4.79
High-Resolution Mass Spectrometry (ESI+):
Empirical formula: C.sub.42H.sub.41ClN.sub.6O.sub.3
[M+H].sup.+ calculated: 713.3007
[M+H].sup.+ measured: 713.2973
EXAMPLE 4
N-(4-Hydroxyphenyl)-N-(1H-indol-5-yl)-1-methyl-5-(6-{[(3S)-3-[(4-methylpip-
erazin-1-yl)methyl]-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-1,3-benzodio-
xol-5-yl)-1H-pyrrole-3-carboxamide
The title compound is obtained in accordance with the process of
Example 3 using the compound of Preparation 4 in Step A.
Elemental Microanalysis: (%, Theoretical:Measured)
% C=71.45:69.32; % H=5.86:5.22; % N=11.63:11.08
High-Resolution Mass Spectrometry (ESI+):
Empirical formula: C.sub.43H.sub.42N.sub.6O.sub.5
[M+H].sup.+ calculated: 723.3295
[M+H].sup.+ measured: 723.3262
Unless otherwise mentioned, the compounds of the following Examples
are synthesised in accordance with the process of Example 1 using,
in Step A: (i) the appropriate acid obtained according to one of
Preparations 1 to 32 and (ii) the appropriate
tetrahydroisoquinoline compound obtained according to one of
Preparations 1' to 9' and, in Step C: (iii) the suitable
NHR.sub.3R.sub.4 amine (a non-exhaustive list is proposed in
Preparations 1'' to 42''. The compounds thereby obtained are
optionally subjected to a step of conversion into salt form in the
presence of HCl in ether. After filtration and lyophilisation in a
mixture of acetonitrile/water, the hydrochloride of the expected
compound is obtained.
EXAMPLE 5
5-(5-Chloro-2-{[(3S)-3-[(4-methylpiperazin-1-yl)methyl]-3,4-dihydroisoquin-
olin-2(1H)-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1-methyl-N-(1-methyl-1H-
-indol-5-yl)-1H-pyrrole-3-carboxamide hydrochloride
Elemental Microanalysis: (%, Theoretical:Measured)
% C=64.54:64.9; % H=5.67:5.49; % N=10.5:10.4; % Cl=13.29:12.52; %
Cl--=8.86:7.39
EXAMPLE 6
5-(5-Chloro-2-{[(3S)-3-[(4-methylpiperazin-1-yl)methyl]-3,4-dihydroisoquin-
olin-2(1H)-yl]carbonyl}phenyl)-1-ethyl-N-(4-hydroxyphenyl)-N-(1-methyl-1H--
indol-5-yl)-1H-pyrrole-3-carboxamide
High-Resolution Mass Spectrometry (ESI+):
Empirical formula: C.sub.44H.sub.45ClN.sub.6O.sub.3
[M+H].sup.+ calculated: 741.3320
[M+H].sup.+ measured: 741.3326
EXAMPLE 7
5-(5-Chloro-2-{[(3S)-3-[(4-methylpiperazin-1-yl)methyl]-3,4-dihydroisoquin-
olin-2(1H)-yl]carbonyl}phenyl)-1-cyclopropyl-N-(4-hydroxyphenyl)-N-(1-meth-
yl-1H-indol-5-yl)-1H-pyrrole-3-carboxamide
High-Resolution Mass Spectrometry (ESI+):
Empirical formula: C.sub.45H.sub.45ClN.sub.6O.sub.3
[M+H].sup.+ calculated: 753.3320
[M+H].sup.+ measured: 753.3306
EXAMPLE 8
5-(5-Chloro-2-{[(3S)-3-[(4-methylpiperazin-1-yl)methyl]-3,4-dihydroisoquin-
olin-2(1H)-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-N-(1-methyl-1H-indol-5--
yl)-1-(propan-2-yl)-1H-pyrrole-3-carboxamide
High-Resolution Mass Spectrometry (ESI+):
Empirical formula: C.sub.45H.sub.47ClN.sub.6O.sub.3
[M+H].sup.+ calculated: 755.3476
[M+H].sup.+ measured: 755.3466
EXAMPLE 9
N-(4-Hydroxyphenyl)-1-methyl-N-(1-methyl-1H-indol-5-yl)-5-(6-{[(3S)-3-[(4--
methylpiperazin-1-yl)methyl]-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-1,3-
-benzodioxol-5-yl)-1H-pyrrole-3-carboxamide hydrochloride
Elemental Microanalysis: (%, Theoretical:Measured)
% C=65.26:65.8; % H=5.73:5.47; % N=10.38:10.48; % Cl=8.76:8.46; %
Cl--=8.76:8.02
EXAMPLE 10
5-(5-Fluoro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-phenyl-1H-pyrrole--
3-carboxamide hydrochloride
Elemental Microanalysis: (%, Theoretical:Measured)
% C=69.11:68.56; % H=5.8:5.31; % N=8.06:8.13; % Cl--=5.1:4.68
EXAMPLE 11
5-(5-Fluoro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1-(3-hydroxypropyl)-2-methyl-N-ph-
enyl-1H-pyrrole-3-carboxamide hydrochloride
Step A:
1-[3-(Benzyloxy)propyl]-5-(5-fluoro-2-{[(3S)-3-(morpholin-4-ylmeth-
yl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-2-
-methyl-N-phenyl-1H-pyrrole-3-carboxamide
The title compound is obtained in accordance with the process of
Example 1 using the acid of Preparation 10 and the compound of
Preparation 3' in Step A, and the compound of Preparation 2'' in
Step C.
Step B:
5-(5-Fluoro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinol-
in-2(1H)-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1-(3-hydroxypropyl)-2-met-
hyl-N-phenyl-1H-pyrrole-3-carboxamide hydrochloride
The compound of Step A is subjected to a deprotection reaction in
accordance with a protocol analogous to that described in Step B of
Example 23.
Elemental Microanalysis: (%, Theoretical:Measured)
% C=68.24:67.96; % H=6:5.79; % N=7.58:7.61; % Cl--=4.8:4.75
High-Resolution Mass Spectrometry (ESI+):
Empirical formula: C.sub.42H.sub.43FN.sub.4O.sub.5
[M+H].sup.+ calculated: 703.3296
[M+H].sup.+ measured: 703.33294
EXAMPLE 12
5-(5-Fluoro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-(1-methyl-1H-indaz-
ol-5-yl)-1H-pyrrole-3-carboxamide hydrochloride
Elemental Microanalysis: (%, Theoretical:Measured)
% C=67.33:67.39; % H=5.65:5.18; % N=11.22:11.52; %
Cl--=4.73:3.82
EXAMPLE 13
N-(3-Fluoro-4-methylphenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-5-(6-{[(3S)-3-
-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-1,3-benz-
odioxol-5-yl)-1H-pyrrole-3-carboxamide hydrochloride
Elemental Microanalysis: (%, Theoretical:Measured)
% C=66.97:66.72; % H=5.62:5.21; % N=7.44:7.59; % Cl--=4.71:4.54
EXAMPLE 14
N-(4-Hydroxyphenyl)-1,2-dimethyl-N-(1-methyl-1H-indazol-5-yl)-5-(6-{[(3S)--
3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-1,3-ben-
zodioxol-5-yl)-1H-pyrrole-3-carboxamide hydrochloride
Elemental Microanalysis: (%, Theoretical:Measured)
% C=66.62:66.59; % H=5.59:4.67; % N=10.84:10.85; %
Cl--=4.57:4.24
EXAMPLE 15
N-(4-Hydroxyphenyl)-1,2-dimethyl-5-(6-{[(3S)-3-(morpholin-4-ylmethyl)-3,4--
dihydroisoquinolin-2(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-N-phenyl-1H-py-
rrole-3-carboxamide hydrochloride
Elemental Microanalysis: (%, Theoretical:Measured)
% C=68.28:67.07; % H=5.73:5.09; % N=7.77:7.75; % Cl--=4.92:5.71
High-Resolution Mass Spectrometry (ESI+):
Empirical formula: C.sub.41H.sub.40N.sub.4O.sub.6
[M+H].sup.+ calculated: 685.3026
[M+H].sup.+ measured: 685.3033
EXAMPLE 16
N-(3-Fluorophenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-5-(6-{[(3S)-3-(morphol-
in-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-1,3-benzodioxol-5-
-yl)-1H-pyrrole-3-carboxamide hydrochloride
Elemental Microanalysis: (%, Theoretical:Measured)
% C=66.62:66.11; % H=5.45:5.2; % N=7.58:7.89; % Cl--=4.8:5.59
EXAMPLE 17
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-phenyl-1H-pyrrole--
3-carboxamide hydrochloride
Elemental Microanalysis: (%, Theoretical:Measured)
% C=67.51:66.91; % H=5.66:5.05; % N=7.87:7.88; % Cl--=4.98:5.75
EXAMPLE 18
1-(2-Hydroxyethyl)-N-(4-hydroxyphenyl)-2-methyl-5-(6-{[(3S)-3-[2-(morpholi-
n-4-yl)ethyl]-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-1,3-benzodioxol-5--
yl)-N-phenyl-1H-pyrrole-3-carboxamide hydrochloride
Step A:
1-[2-(Benzyloxy)ethyl]-N-[4-(benzyloxy)phenyl]-2-methyl-5-(6-{[(3S-
)-3-[2-(morpholin-4-yl)ethyl]-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-1,-
3-benzodioxol-5-yl)-N-phenyl-1H-pyrrole-3-carboxamide
The title compound is obtained in accordance with the process of
Example 1 using the acid of Preparation 9 and
(3S)-3-[2-(morpholin-4-yl)ethyl]-1,2,3,4-tetrahydroisoquinoline
(see Preparation 5') in Step A, and 4-(benzyloxy)-N-phenylaniline
(see Preparation 8'') in Step C.
Step B:
1-(2-Hydroxyethyl)-N-(4-hydroxyphenyl)-2-methyl-5-(6-{[(3S)-3-[2-(-
morpholin-4-yl)ethyl]-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-1,3-benzod-
ioxol-5-yl)-N-phenyl-1H-pyrrole-3-carboxamide hydrochloride
The compound of Step A is subjected to a deprotection reaction in
accordance with a protocol analogous to that described in Step B of
Example 23.
High-Resolution Mass Spectrometry (ESI+):
Empirical formula: C.sub.38H.sub.40N.sub.6O.sub.5
[M+H].sup.+ calculated: 729.3283
[M+H].sup.+ measured: 729.3282
EXAMPLE 19
N-(4-Hydroxyphenyl)-5-(5-methoxy-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dih-
ydroisoquinolin-2(1H)-yl]carbonyl}phenyl)-1,2-dimethyl-N-phenyl-1H-pyrrole-
-3-carboxamide hydrochloride
Elemental Microanalysis: (%, Theoretical:Measured)
% C=69.63:69.45; % H=6.13:5.94; % N=7.92:7.79; % Cl--=5.01:4.58
EXAMPLE 20
N-(4-Hydroxyphenyl)-5-(5-methoxy-2-{[(3R)-3-methyl-3,4-dihydroisoquinolin--
2(1H)-yl]carbonyl}phenyl)-1,2-dimethyl-N-(pyridin-4-yl)-1H-pyrrole-3-carbo-
xamide hydrochloride
Elemental Microanalysis: (%, Theoretical:Measured)
% C=69.39:69.66; % H=5.66:5.46; % N=8.99:8.92; % Cl--=5.69:5.29
High-Resolution Mass Spectrometry (ESI+):
Empirical formula: C.sub.36H.sub.35N.sub.4O.sub.4
[M+H].sup.+ calculated: 587.2653
[M+H].sup.+ measured: 587.2649
EXAMPLE 21
N-(4-Hydroxyphenyl)-1,2-dimethyl-N-(1-methyl-1H-pyrazol-4-yl)-5-(7-{[(3S)--
3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-2,3-dih-
ydro-1,4-benzodioxin-6-yl)-1H-pyrrole-3-carboxamide
hydrochloride
Elemental Microanalysis: (%, Theoretical:Measured)
% C=64.99:64.67; % H=5.86:5.67; % N=11.37:11.27; %
Cl--=4.8:4.71
High-Resolution Mass Spectrometry (ESI+):
Empirical formula: C.sub.40H.sub.43N.sub.6O.sub.6
[M+H].sup.+ calculated: 703.3236
[M+H].sup.+ measured: 703.3239
EXAMPLE 22
N-(4-Hydroxyphenyl)-1,2-dimethyl-5-(7-{[(3S)-3-(morpholin-4-ylmethyl)-3,4--
dihydroisoquinolin-2(1H)-yl]carbonyl}-2,3-dihydro-1,4-benzodioxin-6-yl)-N--
phenyl-1H-pyrrole-3-carboxamide hydrochloride
Elemental Microanalysis: (%, Theoretical:Measured)
% C=68.61:67.97; % H=5.89:5.59; % N=7.62:7.55; % Cl--=4.82:4.27
EXAMPLE 23
1-(2-Hydroxyethyl)-N-(4-hydroxyphenyl)-2-methyl-5-(6-{[(3R)-3-methyl-3,4-d-
ihydroisoquinolin-2(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-N-(1-methyl-1H--
pyrazol-4-yl)-1H-pyrrole-3-carboxamide
Step A:
1-[2-(Benzyloxy)ethyl]-N-(4-{[tert-butyl(dimethyl)silyl]oxy}phenyl-
)-2-methyl-5-(6-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}--
1,3-benzodioxol-5-yl)-N-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrole-3-carboxamid-
e
The title compound is obtained in accordance with the process of
Example 1 using the acid of Preparation 9 and the compound of
Preparation 1'' in Step C.
Step B:
N-(4-{[tert-Butyl(dimethyl)silyl]oxy}phenyl)-1-(2-hydroxyethyl)-2--
methyl-5-(6-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-1,3--
benzodioxol-5-yl)-N-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrole-3-carboxamide
To a solution of 6.86 g (8.19 mmol) of the compound of Step A in 70
mL of anhydrous methanol there are added 1.37 g of Pd/C 10%. The
batch is degassed for 0.5 hours and then stirred at ambient
temperature under dihydrogen pressure (1.5 bar) for 12 hours. The
reaction mixture is then filtered and then concentrated to dryness.
The expected product is obtained in the form of a solid.
.sup.1H NMR: .delta. (500 MHz; dmso-d6; 300K): 7.7-7.4 (s, 1H, H
pyrazole); 7.1-6.8 (s, 1H, H pyrazole); 7.3-6.9 (m, 4H, aromatic
Hs, H tetrahydroisoquinoline); 7.0-6.7 (m, 2H, aromatic Hs);
6.9-6.4 (m, 2H, aromatic Hs); 6.8-6.4 (m, 2H, aromatic Hs); 6.1 (m,
2H, OCH.sub.2O); 5.2, 5.0, 4.7 (4s, H, H-pyrrole (presence of
conformational isomers); 5.15 (d, 1H, aliphatic H, H
tetrahydroisoquinoline); 4.9 (m, 1H, aliphatic H, H
tetrahydroisoquinoline); 4.9-4.8 (m, 1H, CH.sub.2OH); 4.7 (m, 1H,
aliphatic H, H tetrahydroisoquinoline); 3.9 (d, 1H, aliphatic H, H
tetrahydroisoquinoline); 3.85 (m, 1H, aliphatic H, H
tetrahydroisoquinoline); 3.7 (m, 2H, aliphatic Hs,
CH.sub.2CH.sub.2OH); 3.75 (2s, 3H); 3.5-3.2 (m, 2H, aliphatic Hs,
CH.sub.2CH.sub.2OH); 3.0-2.4 (m, 2H, aliphatic H, H
tetrahydroisoquinoline); 2.4-2.3 (4s, 3H, CH.sub.3-pyrrole); 1.5,
0.95, 0.75 (4 d, 3H, CH.sub.3-THIQ); 0.85 (broad s, 9H,
Si(CH.sub.3).sub.2(CH(CH.sub.3).sub.2); 0.15 (m, 6H,
Si(CH.sub.3).sub.2(CH(CH.sub.3).sub.2)
IR: .nu.: --OH: 3346 cm.sup.-1 carboxylic acid; .nu.: >C.dbd.O:
1621 cm.sup.-1
Step C:
1-(2-Hydroxyethyl)-N-(4-hydroxyphenyl)-2-methyl-5-(6-{[(3R)-3-meth-
yl-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-N-(1-me-
thyl-1H-pyrazol-4-yl)-1H-pyrrole-3-carboxamide
The phenol function of the compound of Step B is deprotected
following the process of Step D of Example 1.
Elemental Microanalysis: (%, Theoretical:Measured)
% C=68.23:68.12; % H=5.57:5.29; % N=11.05:10.79
High-Resolution Mass Spectrometry (ESI+):
Empirical formula: C.sub.36H.sub.36N.sub.5O.sub.6
[M+H].sup.+ calculated: 634.2662
[M+H].sup.+ measured: 634.2660
EXAMPLE 24
N-(4-Hydroxyphenyl)-5-(5-methoxy-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dih-
ydroisoquinolin-2(1H)-yl]carbonyl}phenyl)-1,2-dimethyl-N-(1-methyl-1H-pyra-
zol-4-yl)-1H-pyrrole-3-carboxamide hydrochloride
Elemental Microanalysis: (%, Theoretical:Measured)
% C=65.86:64.47; % H=6.09:5.88; % N=11.82:11.45; %
Cl--=4.98:6.7
High-Resolution Mass Spectrometry (ESI+):
Empirical formula: C.sub.39H.sub.42N.sub.6O.sub.5
[M+H].sup.+ calculated: 675.3289
[M+H].sup.+ measured: 675.3287
EXAMPLE 25
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-(1-methyl-1H-pyraz-
ol-4-yl)-1H-pyrrole-3-carboxamide hydrochloride
Elemental Microanalysis: (%, Theoretical:Measured)
% C=63.77:62.83; % H=5.63:5.83; % N=11.74:11.29; %
Cl--=4.95:5.42
EXAMPLE 26
N-(4-Hydroxyphenyl)-2-methyl-1-[2-(methylamino)ethyl]-5-(6-{[(3R)-3-methyl-
-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-N-(1-meth-
yl-1H-pyrazol-4-yl)-1H-pyrrole-3-carboxamide hydrochloride
The procedure is in accordance with Steps A, B and C of the process
of Example 30 replacing the sodium azide used in Step B by
methylamine. After purification over silica gel
(CH.sub.2Cl.sub.2/MeOH/NH.sub.3 gradient), the compound obtained,
0.3 g (0.46 mmol), is dissolved in 5 mL of anhydrous methanol and
there is added, dropwise, 0.464 mL (0.47 mmol) of 1M HCl solution
in ether. The batch is stirred for 0.5 hours at ambient
temperature. The precipitate thereby obtained is filtered off and
dried and then dissolved in a mixture of CH.sub.3CN/H.sub.2O before
being lyophilised at low temperature. The expected product is
obtained in the form of a solid.
Elemental Microanalysis: (%, Theoretical:Measured)
% C=65.05:64.64; % H=5.75:5.43; % N=12.3:12.3; % Cl--=5.19:5.39
High-Resolution Mass Spectrometry (ESI+):
Empirical formula: C.sub.37H.sub.38N.sub.6O.sub.5
[M+H].sup.+ calculated: 647.2903
[M+H].sup.+ measured: 647.2922
EXAMPLE 27
1-[2-(Dimethylamino)ethyl]-N-(4-hydroxyphenyl)-2-methyl-5-(6-{[(3R)-3-meth-
yl-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-N-(1-me-
thyl-1H-pyrazol-4-yl)-1H-pyrrole-3-carboxamide hydrochloride
The procedure is in accordance with the process of Example 26,
replacing the methylamine in Step B by dimethylamine.
Elemental Microanalysis: (%, Theoretical:Measured)
% C=65.46:65.07; % H=5.93:5.87; % N=12.05:12.06; %
Cl--=5.08:5.55
High-Resolution Mass Spectrometry (ESI+):
Empirical formula: C.sub.38H.sub.40N.sub.6O.sub.5
[M+H].sup.+ calculated: 661.3060
[M+H].sup.+ measured: 661.3045
EXAMPLE 28
5-(5-Chloro-2-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}phe-
nyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-(pyridin-4-yl)-1H-pyrrole-3-carbox-
amide hydrochloride
Elemental Microanalysis: (%, Theoretical:Measured)
% C=66.99:66.88; % H=5.14:5.28; % N=8.93:8.87; % Cl--=5.65:4.98
High-Resolution Mass Spectrometry (ESI+):
Empirical formula: C.sub.35H.sub.32ClN.sub.4O.sub.3
[M+H].sup.+ calculated: 591.2157
[M+H].sup.+ measured: 591.2178
EXAMPLE 29
5-(5-Chloro-2-{[(3S)-3-{[2-(morpholin-4-yl)ethoxy]methyl}-3,4-dihydroisoqu-
inolin-2(1H)-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-phenyl-
-1H-pyrrole-3-carboxamide hydrochloride
Step A: Methyl
5-(5-chloro-2-{[(3S)-3-(hydroxymethyl)-3,4-dihydroisoquinolin-2(1H)-yl]ca-
rbonyl}phenyl)-1,2-dimethyl-1H-pyrrole-3-carboxylate
To a solution of 4.9 g of the compound of Preparation 1 in a
mixture of 40 mL of dimethylformamide and 40 mL of tetrahydrofuran
there are added 2.73 g (1.1 equivalents) of
(3S)-3-hydroxymethyl-1,2,3,4-tetrahydroisoquinoline, 7.95 mL of
diisopropylethylamine and 9.84 g (1.7 equivalents) of HATU. After
stirring for 2 hours at ambient temperature, the reaction mixture
is dried, taken up in ethyl acetate and then washed with 10%
aqueous citric acid solution and water. The combined aqueous phases
are extracted with ethyl acetate. The organic phases thereby
obtained are combined, dried over Na.sub.2SO.sub.4, filtered and
concentrated under reduced pressure. The crude product obtained is
purified by chromatography over silica gel using dichloromethane
and ethanol as eluants to yield the title compound.
.sup.1H NMR: .delta. (500 MHz; dmso-d6; 300K): 7.6-7.4 (m, 3H,
Cl-Ph); 7.2-6.9 (m, 4H, Ar(THIQ); 6.5-6.15 (broad 4s, 1H, pyrrole);
4.9-3.8 (6 d, 2H, NCH.sub.2 THIQ); 4.85-3.6 (m, 1H, NCH THIQ);
4.2-4.0 (m, 2H, OCH.sub.2 ester), 3.45-3.2 (3s, 3H, N--CH.sub.3);
3.35-3.0 (3m, 2H, HOCH.sub.2); 3.0-2.0 (m, 2H, THIQ); 2.5-2.1 (m,
3H, CH.sub.3 pyrrole); 1.25-1.1 (m, 3H, CH.sub.3 ester)
IR: .nu. --OH: 3388 cm.sup.-1, .nu. >C.dbd.O: 1693 cm.sup.-1
(conjugated ester), .nu. >C.dbd.O: 1620 cm.sup.-1 (amide)
Step B: Methyl
5-(5-chloro-2-{[(3S)-3-{[2-(morpholin-4-yl)ethoxy]methyl}-3,4-dihydroisoq-
uinolin-2(1H)-yl]carbonyl}phenyl)-1,2-dimethyl-1H-pyrrole-3-carboxylate
A solution of 1.7 g (3.2 mmol) of the compound obtained in the
above Step in 20 mL of dimethylformamide is added, dropwise at
0.degree. C., to a suspension of 0.280 g of NaH 60% in oil (2.2
equivalents) in 10 mL of dimethylformamide. After stirring for 5
minutes at ambient temperature, a suspension of 0.68 g of
4-(2-bromoethyl)morpholine hydrobromide (1.1 equivalents) is added
dropwise. The reaction mixture is stirred at ambient temperature
for 45 minutes. There are then added, in two steps over 20 hours,
2.2 equivalents of 4-(2-bromoethyl)morpholine hydrobromide, and
then 3 equivalents of NaH 60% in oil. The reaction mixture is then
poured into a mixture of 10% aqueous ammonium chloride and ethyl
acetate. The resulting organic phase is successively washed with
water, and then with saturated aqueous LiCl solution and brine. It
is then dried over Na.sub.2SO.sub.4, filtered and concentrated
under reduced pressure. The oil obtained is purified by
chromatography over silica gel using dichloromethane and ethanol as
eluants to provide the expected product.
.sup.1H NMR: .delta. (500 MHz; dmso-d6; 300K): 7.6-7.3 (m, 3H,
Cl-Ph); 7.2-6.85 (m, 4H, Ar(THIQ); 6.5-6.15 (broad s, 1H, pyrrole);
5.25-3.8 (m, 2H, NCH.sub.2 THIQ); 5.05-3.75 (m, 1H, NCH THIQ);
4.2-4.0 (m, 2H, OCH.sub.2 ester), 3.5-3.25 (m, 3H, N--CH.sub.3);
3.6-2.75 (m, 8H, OCH.sub.2 morpholinoethoxymethyl); 2.95-2.05 (m,
2H, THIQ); 2.55-2.15 (m, 6H, NCH.sub.2 morpholinoethoxymethyl);
2.55-2.05 (m, 3H, CH.sub.3 pyrrole), 1.25-1.1 (m, 3H, CH.sub.3
ester)
IR: .nu. >C.dbd.O: 1694 cm.sup.-1 (conjugated ester), .nu.
>C.dbd.O: 1629 cm.sup.-1 (amide)
Step C:
5-(5-Chloro-2-{[(3S)-3-{[2-(morpholin-4-yl)ethoxy]methyl}-3,4-dihy-
droisoquinolin-2(1H)-yl]carbonyl}phenyl)-1,2-dimethyl-1H-pyrrole-3-carboxy-
lic acid
To a solution of 1.46 g of the compound of the above Step in 5 mL
of dioxane there are added 5 mL of 1M aqueous LiOH solution. The
batch is heated in a microwave apparatus (100 W) at 100.degree. C.
for 2 hours. The reaction mixture is poured into water and then
extracted with ethyl ether. The ethereal phase is extracted again
with 10 mL of water. The aqueous phases are acidified to pH 5-6 by
adding saturated aqueous ammonium chloride solution and then
extracted twice with dichloromethane. The dichloromethane phase is
dried over Na.sub.2SO.sub.4, filtered and concentrated to dryness.
The title product is obtained in the form of a meringue.
.sup.1H NMR: .delta. (500 MHz; dmso-d6; 300K): 11.4 (broad s, 1H,
CO.sub.2H), 7.6-7.3 (m, 3H, Cl-Ph); 7.2-6.8 (m, 4H, Ar(THIQ);
6.5-6.2 (broad 4s, 1H, pyrrole); 5.25-3.75 (m, 2H, NCH.sub.2 THIQ);
5.05-3.7 (3m, 1H, NCH THIQ); 3.5-3.2 (3s, 3H, N--CH.sub.3); 3.6-2.7
(m, 8H, OCH.sub.2 morpholinoethoxymethyl); 2.5-2.2 (m, 6H,
NCH.sub.2 morpholinoethoxymethyl); 3.0-2.0 (m, 2H, THIQ), 2.5-2.0
(3s, 3H, CH.sub.3 pyrrole)
IR: .nu. --OH: 3300-2200 cm.sup.-1, .nu. >C.dbd.O: 1697-1662
cm.sup.-1 (double band, carboxylic acid), .nu. >C.dbd.O: 1628
cm.sup.-1 (amide)
Step D:
N-(4-{[tert-Butyl(dimethyl)silyl]oxy}phenyl)-5-(5-chloro-2-{[(3S)--
3-{[2-(morpholin-4-yl)ethoxy]methyl}-3,4-dihydroisoquinolin-2(1H)-yl]carbo-
nyl}phenyl)-1,2-dimethyl-N-phenyl-1H-pyrrole-3-carboxamide
The acid obtained in Step C (1.48 g) is suspended in 15 mL of
1,2-dichloroethane. 1.1 equivalents of
1-chloro-N,N,2-trimethylpropenylamine are added thereto. After
stirring for 1 hour at ambient temperature, there are added 15 mL
of toluene and 1.05 equivalents of the compound of Preparation 2''.
The reaction mixture is heated for 14 hours at 110.degree. C. and
then dried. The crude product thereby obtained is purified by
chromatography over silica gel using dichloromethane and ethanol as
eluants to yield the expected product.
.sup.1H NMR: .delta. (500 MHz; dmso-d6; 300K): 7.55-7.25 (m, 3H,
Cl-Ph); 7.25-6.6 (m, 9H, Ar(THIQ)+phenyl); 6.8-6.5 (m, 2H,
phenoxy); 7.0-6.6 (m, 2H, phenoxy); 5.7-5.05 (broad 4s, 1H,
pyrrole); 5.2-3.6 (8d, 2H, THIQ); 5.05-3.6 (4m, 1H, NCH THIQ),
3.6-2.9 (m, 8H, aliphatic morpholinoethoxymethyl); 3.4-3.2 (broad
3s, 3H, N--CH.sub.3); 3.0-2.1 (m, 2H, THIQ), 2.35 (m, 2H, NCH.sub.2
morpholinoethoxymethyl); 2.4-2.2 (m, 4H, NCH.sub.2 morpholine);
2.4-2.15 (broad 3s, 3H, CH.sub.3 pyrrole); 0.8 (broad 2s, 9H,
SiC(CH.sub.3).sub.3); 0.1 (4s, 6H, SiCH.sub.3)
IR: .nu. >C.dbd.O: 1635-1595 cm.sup.-1 (double band), .nu.
Si--O: 1117 cm.sup.-1, .nu. Si--C: 837 cm.sup.-1
Step E:
5-(5-Chloro-2-{[(3S)-3-{[2-(morpholin-4-yl)ethoxy]methyl}-3,4-dihy-
droisoquinolin-2(1H)-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl--
N-phenyl-1H-pyrrole-3-carboxamide hydrochloride
To a solution of 0.7 g of the compound of Step D in 5 mL of
methanol there is added 0.92 mL of a 1M solution of potassium
hydroxide in methanol. After stirring for 1 hour 10 minutes at
ambient temperature, saturated aqueous sodium bicarbonate solution
is added. The product which precipitates is extracted with ethyl
acetate and then washed with water and brine. The resulting aqueous
phases are extracted again with ethyl acetate. The organic phases
thereby obtained are dried over Na.sub.2SO.sub.4, filtered and
concentrated under reduced pressure. The crude product obtained is
purified by chromatography over silica gel using dichloromethane
and ammonia-in-ethanol as eluants to provide 0.536 g of the title
product, in the form of the base. The latter is dissolved in
acetonitrile and converted into salt form using 1M aqueous HCl
solution. After a lyophilisation step, the expected product is
obtained in the form of a solid.
Elemental Microanalysis: (%, Measured(Theoretical))
% C=66.4 (66.75); % H=5.98 (5.87); % N=7.38 (7.41); % Cl=9.42
(9.38); % Cl.sup.-=4.57 (4.69)
EXAMPLE 30
1-(2-Aminoethyl)-N-(4-hydroxyphenyl)-2-methyl-5-(6-{[(3R)-3-methyl-3,4-dih-
ydroisoquinolin-2(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-N-(1-methyl-1H-py-
razol-4-yl)-1H-pyrrole-3-carboxamide hydrochloride
Step A:
2-{3-[(4-{[tert-Butyl(dimethyl)silyl]oxy}phenyl)(1-methyl-1H-pyraz-
ol-4-yl)carbamoyl]-2-methyl-5-(6-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(-
1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-1H-pyrrol-1-yl}ethyl
methanesulphonate
A solution of 4.65 g of the compound obtained in Step B of Example
23 (6.22 mmol) in 100 mL of anhydrous THF is placed at 0.degree. C.
There are successively added thereto 3.5 mL (12.44 mmol) of
triethylamine and then, dropwise, 0.722 mL of methanesulphonic
chloride (9.33 mmol) dissolved in 20 mL of THF. The batch is then
stirred at ambient temperature for 2 hours. The reaction mixture is
hydrolysed by addition of saturated aqueous NaHCO.sub.3 solution
and then extracted twice with ethyl acetate. The organic phases are
combined, dried over MgSO.sub.4 and concentrated to dryness. The
expected compound is obtained in the form of a glassy solid.
.sup.1H NMR: .delta. (500 MHz; dmso-d6; 300K): 7.7-7.45 (s, 1H, H
pyrazole); 7.1-6.9 (s, 1H, H pyrazole); 7.2-6.4 (m, 8H, aromatic
Hs); 6.95-6.65 (m, 2H, aromatic Hs); 6.1 (m, 2H, OCH.sub.2O); 5.2,
4.6 (4s, H, H-pyrrole (presence of conformational isomers); 4.9,
4.6, 3.9, 3.8 (m, 1H), 5.05-3.75 (m, 1H, aliphatic H, H
tetrahydroisoquinoline); 4.3-4.05 (m, 2H, aliphatic Hs,
CH.sub.2CH.sub.2OSO.sub.2CH.sub.3); 4.2-3.95 (m, 2H, aliphatic Hs,
CH.sub.2CH.sub.2OSO.sub.2CH.sub.3); 3.75-2.7 (2s, 3H,
CH.sub.3-pyrazole); 3.0 (several s, 3H, CH.sub.2OSO.sub.2CH.sub.3);
3.05-2.5 (several m, 2H, aliphatic Hs, H tetrahydroisoquinoline);
2.45-2.3 (several s, 3H, CH.sub.3-pyrrole); 1.05, 0.75 (several d,
3H, CH.sub.3-tetraisoquinoline); 0.9 (several s, 9H,
Si(CH.sub.3).sub.2(CH(CH.sub.3).sub.2); 0.1 (m, 6H,
Si(CH.sub.3).sub.2(CH(CH.sub.3).sub.2)
IR: .nu.: >C.dbd.O: 1626 cm.sup.-1, .nu.: --SO.sub.2: 1349 and
1172 cm.sup.-1
Step B:
1-(2-Azidoethyl)-N-(4-{[tert-butyl(dimethyl)silyl]oxy}phenyl)-2-me-
thyl-5-(6-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-1,3-be-
nzodioxol-5-yl)-N-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrole-3-carboxamide
To a solution of 2 g (2.42 mmol) of compound of Step A in 20 mL of
anhydrous DMF there is added 0.472 g (7.26 mmol) of sodium azide.
The batch is stirred at 65.degree. C. for 4 hours 30 minutes. The
reaction mixture is poured into saturated aqueous NaHCO.sub.3
solution and then extracted twice with ethyl acetate. The organic
phases are combined and washed with saturated aqueous LiCl
solution, dried over MgSO.sub.4 and concentrated to dryness. After
purification over silica gel using dichloromethane and
ammonia-in-methanol as eluants, the expected product is obtained in
the form of a foam.
.sup.1H NMR: .delta. (500 MHz; dmso-d6; 300K): 7.65-7.45 (several
s, 1H, H pyrazole); 7.1-6.9 (several s, 1H, H pyrazole); 7.3-6.4
(several m, 6H, aromatic Hs); 7.1-6.9 (several s, 1H, aromatic Hs);
6.8, 6.5 (2m, 2H, aromatic Hs); 6.1 (several s, 2H, OCH.sub.2O);
5.25-4.65 (several s, 1H, H-pyrrole (presence of conformational
isomers); 4.9, 4.6, 3.8 (several m, 1H); 5.05-3.7 (several m, 4H,
aliphatic Hs, H-THIQ+CH.sub.2CH.sub.2N.sub.3); 3.7 (several s, 3H,
H CH.sub.3-pyrazole); 3.5-3.25 (m, 2H, CH.sub.2CH.sub.2N.sub.3);
3.1-2.4 (several m, 3H, CH.sub.3-pyrrole); 2.45-2.3 (several s, 3H,
CH.sub.3-pyrrole); 1.0-0.75 (several d, 3H, CH.sub.3-THIQ); 0.9
(several s, 9H, Si(CH.sub.3).sub.2(CH(CH.sub.3).sub.2); 0.1
(several s, 6H, Si(CH.sub.3).sub.2(CH(CH.sub.3).sub.2)
IR: .nu.: --N.dbd.N.dbd.N: 2100 cm.sup.-1, .nu.: >C.dbd.O: 1630
cm.sup.-1, .nu.: --Si--O--: 1035 cm.sup.-1
Step C:
1-(2-Azidoethyl)-N-(4-hydroxyphenyl)-2-methyl-5-(6-{[(3R)-3-methyl-
-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-N-(1-meth-
yl-1H-pyrazol-4-yl)-1H-pyrrole-3-carboxamide
To a solution of 1.12 g of the compound obtained in Step B (14.49
mmol) in 5 mL of methanol there are added, dropwise, 7.24 mL of 1M
methanolic potassium hydroxide solution (72.45 mmol). The batch is
stirred at ambient temperature for 3 hours. The reaction mixture is
then concentrated to dryness, taken up in dichloromethane,
hydrolysed with saturated aqueous NaHCO.sub.3 solution and then
extracted twice with dichloromethane. The organic phases are then
combined, washed with water, dried over MgSO.sub.4 and concentrated
to dryness. The expected product is obtained in the form of a foam
and used directly in the next Step.
.sup.1H NMR: .delta. (500 MHz; dmso-d6; 300K): 9.60 ((s, 1H,
CH.sub.2CH.sub.2OH); 7.65-7.45 (several s, 1H, H pyrazole); 7.1-6.9
(several s, 1H, H pyrazole); 7.3-6.4 (several m, 6H, aromatic Hs);
7.1-6.9 (several s, 1H, aromatic Hs); 6.8, 6.5 (2m, 2H, aromatic
Hs); 6.15 (several s, 2H, OCH.sub.2O); 5.35-4.8 (several s, 1H,
H-pyrrole (presence of conformational isomers); 4.9, 4.6, 3.8
(several m, 1H, aliphatic H, H tetrahydroisoquinoline); 3.7
(several s, 3H, H CH.sub.3-pyrazole); 3.5-3.25 (m, 2H,
CH.sub.2CH.sub.2N.sub.3); 3.1-2.4 (several m, 3H,
CH.sub.3-pyrrole); 2.45-2.3 (several s, 3H, H THIQ); 2.45-2.3
(several s, 3H, CH.sub.3-pyrrole); 1.0-0.75 (several d, 3H,
CH.sub.3-THIQ)
IR: .nu.: --OH: 3171 cm.sup.-1, .nu.: --N.dbd.N.dbd.N: 2100
cm.sup.-1, .nu.: >C.dbd.O: 1617 cm.sup.-1
Step D:
1-(2-Aminoethyl)-N-(4-hydroxyphenyl)-2-methyl-5-(6-{[(3R)-3-methyl-
-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-N-(1-meth-
yl-1H-pyrazol-4-yl)-1H-pyrrole-3-carboxamide hydrochloride
To a solution of 1.27 g of the compound obtained in the above Step
(1.93 mmol) in 15 mL of anhydrous ethanol there is added 0.154 g of
Pd/C 10%. The batch is degassed for 0.5 hours. It is then stirred
for 12 hours at ambient temperature under hydrogen pressure (1.5
bar). The reaction mixture is then filtered and then concentrated
to dryness. After purification by chromatography over silica gel
(CH.sub.2Cl.sub.2/MeOH/NH.sub.3 gradient), an oily residue is
obtained. The residue is dissolved in 10 mL of anhydrous ethanol
and then converted into salt form by adding two molar equivalents
of a 1N solution of HCl in ethanol. The product is then dried
before being dissolved in a minimum of a mixture of water and
acetonitrile. After a lyophilisation step at low temperature, the
expected product is obtained in the form of a solid.
Elemental Microanalysis: (%, Theoretical:Measured)
% C=64.62:63.84; % H=5.57:5.55; % N=12.56:12.36; %
Cl--=5.3:5.56
High-Resolution Mass Spectrometry (ESI+):
Empirical formula: C.sub.36H.sub.36N.sub.6O.sub.5
[M+H].sup.+ calculated: 633.2820
[M+H].sup.+ measured: 633.2808
EXAMPLE 31
N-(4-Hydroxyphenyl)-5-(5-methoxy-2-{[(3R)-3-methyl-3,4-dihydroisoquinolin--
2(1H)-yl]carbonyl}phenyl)-1,2-dimethyl-N-(1-methyl-1H-pyrazol-4-yl)-1H-pyr-
role-3-carboxamide
Elemental Microanalysis: (%, Theoretical:Measured)
% C=71.29:70.17; % H=5.98:5.98; % N=11.88:11.49
High-Resolution Mass Spectrometry (ESI+):
Empirical formula: C.sub.35H.sub.36N.sub.5O.sub.4
[M+H].sup.+ calculated: 590.2762
[M+H].sup.+ measured: 590.2778
EXAMPLE 32
Phenyl
(4-{4-[(4-hydroxyphenyl)(methyl)carbamoyl]-1,5-dimethyl-1H-pyrrol-2-
-yl}-3-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}benzyl)-ca-
rbamate
Step A:
N-(4-Benzyloxyphenyl)-N,1,2-trimethyl-pyrrole-3-carboxamide
The process is analogous to that described in Step A of Example
45.
Step B: tert-Butyl
[4-(4-{[4-(benzyloxy)phenyl](methyl)carbamoyl}-1,5-dimethyl-1H-pyrrol-2-y-
l)-3-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}benzyl]-carb-
amate
The compound of Preparation II (1.5 g; 2.96 mmol) and the compound
of Step A (1.16 g; 3.44 mmol) are dissolved in dimethylacetamide
(25 mL) and then nitrogen is bubbled through the solution for 5
minutes. Potassium acetate (0.586 g; 5.92 mmol) and
bis(triphenylphosphine)palladium(II) dichloride (0.2 g; 0.295 mmol)
are added to the mixture which is then heated to 100.degree. C.
and, after stirring for 20 minutes, water (10 .mu.L) is added.
Stirring at 100.degree. C. under a nitrogen atmosphere is continued
for 2 hours more. The reaction mixture is allowed to cool to
ambient temperature and is then evaporated to a volume of 15 mL.
The resulting mixture is filtered over a short Celite column and
then purified by preparative HPLC using water-TFA and acetonitrile
as eluants. The pH of the appropriate fractions is adjusted to 7
with NaHCO.sub.3, and then the acetonitrile is evaporated off under
reduced pressure. The aqueous residue is extracted with DCM. The
organic phase is washed with brine, dried over Na.sub.2SO.sub.4 and
evaporated to dryness to yield the title compound.
High-Resolution Mass Spectrometry (ESI+):
Empirical formula: C.sub.40H.sub.41N.sub.5O.sub.4
[M+H].sup.+ calculated: 713.3705
[M+H].sup.+ measured: 713.3709
Step C:
5-[4-(Aminomethyl)-2-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)--
yl]-carbonyl}phenyl]-N-[4-(benzyloxy)phenyl]-N,1,2-trimethyl-1H-pyrrole-3--
carboxamide hydrochloride
The compound of the above Step (1.18 g, 1.66 mmol) is
dissolved/suspended in 4M HCl in dioxane (20 mL). The heterogeneous
mixture is stirred for 30 minutes at ambient temperature and then
evaporated to dryness to yield 1.19 g of the title compound which
is used in the next Step without purification.
Step D: Phenyl
(4-{4-[(4-hydroxyphenyl)(methyl)carbamoyl]-1,5-dimethyl-1H-pyrrol-2-yl}-3-
-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}benzyl)carbamate
The title compound is obtained starting from the compound of the
above Step in accordance with the protocol of Step D of Example
45.
Elemental Microanalysis: (%, Measured(Theoretical))
% C=72.83 (72.88); % H=6.01 (5.96); % N=8.02 (8.72)
High-Resolution Mass Spectrometry (ESI+):
Empirical formula: C.sub.39H.sub.38N.sub.4O.sub.5
[M+H].sup.+ calculated: 643.2922
[M+H].sup.+ measured: 643.2916
EXAMPLE 33
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(4-fluorophenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-1-
H-pyrrole-3-carboxamide hydrochloride
Elemental Microanalysis: (%, Measured(Theoretical))
% C=65.75 (65.84); % H=5.38 (5.39); % N=7.62 (7.68); % Cl=9.77
(9.72); % Cl--=4.84 (4.86)
EXAMPLE 34
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(3-fluorophenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-1-
H-pyrrole-3-carboxamide hydrochloride
Elemental Microanalysis: (%, Measured(Theoretical))
% C=65.61 (65.84); % H=5.09 (5.39); % N=7.76 (7.68); % Cl--=4.83
(4.86)
EXAMPLE 35
N-(4-Hydroxyphenyl)-N,1,2-trimethyl-5-(2-{[(3R)-3-methyl-3,4-dihydroisoqui-
nolin-2(1H)-yl]carbonyl}-4-{[(phenoxyacetyl)amino]methyl}phenyl)-1H-pyrrol-
e-3-carboxamide
The title compound is obtained in accordance with the process of
Example 32 using 2-phenoxyacetyl chloride as acylating agent in
Step D.
Elemental Microanalysis: (%, Measured(Theoretical))
% C=72.53 (73.15); % H=5.76 (6.14); % N=8.31 (8.53)
High-Resolution Mass Spectrometry (ESI+):
Empirical formula: C.sub.40H.sub.40N.sub.4O.sub.5
[M+H].sup.+ calculated: 657.3079
[M+H].sup.+ measured: 657.3061
EXAMPLE 36
5-(4-{[(Ethylcarbamoyl)amino]methyl}-2-{[(3R)-3-methyl-3,4-dihydroisoquino-
lin-2(1H)-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-N,1,2-trimethyl-1H-pyrro-
le-3-carboxamide
The title compound is obtained in accordance with the process of
Example 32 using ethyl isocyanate as acylating agent in Step D.
Elemental Microanalysis: (%, Measured(Theoretical))
% C=70.88 (70.8); % H=6.02 (6.62); % N=11.17 (11.8)
High-Resolution Mass Spectrometry (ESI+):
Empirical formula: C.sub.35H.sub.39N.sub.5O.sub.4
[M+H].sup.+ calculated: 594.3100
[M+H].sup.+ measured: 594.3083
EXAMPLE 37
5-(4-{[(Benzylcarbamoyl)amino]methyl}-2-{[(3R)-3-methyl-3,4-dihydroisoquin-
olin-2(1H)-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-N,1,2-trimethyl-1H-pyrr-
ole-3-carboxamide
The title compound is obtained in accordance with the process of
Example 32 using benzyl isocyanate as acylating agent in Step
D.
Elemental Microanalysis: (%, Measured(Theoretical))
% C=73.21 (73.26); % H=5.98 (6.3); % N=10.23 (10.68)
High-Resolution Mass Spectrometry (ESI+):
Empirical formula: C.sub.40H.sub.41N.sub.5O.sub.4
[M+H].sup.+ calculated: 656.3239
[M+H].sup.+ measured: 656.3256
EXAMPLE 38
5-(5-Chloro-2-{[(3S)-3-(hydroxymethyl)-3,4-dihydroisoquinolin-2(1H)-yl]car-
bonyl}phenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-phenyl-1H-pyrrole-3-carbo-
xamide
Elemental Microanalysis: (%, Measured(Theoretical))
% C=70.97 (71.34); % H=5.2 (5.32); % N=6.96 (6.93)
EXAMPLE 39
N-(4-Hydroxyphenyl)-1,2-dimethyl-5-(6-{[(3R)-3-methyl-3,4-dihydroisoquinol-
in-2(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-N-(1-methyl-1H-pyrazol-4-yl)-1-
H-pyrrole-3-carboxamide
Elemental Microanalysis: (%, Measured(Theoretical))
% C=69.81 (69.64); % H=5.6 (5.51); % N=11.55 (11.6)
High-Resolution Mass Spectrometry (ESI+):
Empirical formula: C.sub.35H.sub.34N.sub.5O.sub.5
[M+H].sup.+ calculated: 604.2554
[M+H].sup.+ measured: 604.2565
EXAMPLE 40
Phenyl
(3-{4-[(4-hydroxyphenyl)(methyl)carbamoyl]-1,5-dimethyl-1H-pyrrol-2-
-yl}-4-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}benzyl)-ca-
rbamate
Step A:
N-(4-Benzyloxyphenyl)-N,1,2-trimethyl-pyrrole-3-carboxamide
The process is analogous to that described in Step A of Example
45.
Step B:
5-[5-(Aminomethyl)-2-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)--
yl]-carbonyl}phenyl]-N-[4-(benzyloxy)phenyl]-N,1,2-trimethyl-1H-pyrrole-3--
carboxamide hydrochloride
The compound of Preparation III (1.84 g; 3.99 mmol) and the
compound of Step A (1.60 g; 4.48 mmol) are dissolved in
dimethylacetamide (20 mL) and then nitrogen is bubbled through the
solution for 5 minutes. Potassium acetate (0.78 g; 7.48 mmol) and
bis(triphenylphosphine)palladium(II) dichloride (0.28 g; 0.4 mmol)
are added to the mixture which is then heated to 105.degree. C.
and, after stirring for 10 minutes, water (11 .mu.L) is added.
Stirring at 105.degree. C. under a nitrogen atmosphere is continued
for 6 hours more. The reaction mixture is allowed to cool to
ambient temperature, the resulting mixture is filtered over a short
Celite column and is then purified by preparative HPLC using
water-TFA and acetonitrile as eluants. The pH of the appropriate
fractions is adjusted to 7 with NaHCO.sub.3 and then the
acetonitrile is evaporated off under reduced pressure. The solid
precipitate is removed by filtration and then dried (5 mbar,
45.degree. C., 16 hours) to form tert-butyl
[3-(4-{[4-(benzyloxy)phenyl](methyl)carbamoyl}-1,5-dimethyl-1H-pyrrol-2-y-
l)-4-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}benzyl]carba-
mate which is dissolved/suspended in 4M HCl in dioxane (35 mL). The
heterogeneous mixture is stirred for 30 minutes at ambient
temperature and then evaporated to dryness to yield the title
compound which is used in the next Step without purification.
High-Resolution Mass Spectrometry (ESI+):
Empirical formula: C.sub.39H.sub.40N.sub.4O.sub.3
[M+H].sup.+ calculated: 613.3180
[M+H].sup.+ measured: 613.3194
IR: .nu.: N--H+: 2854 cm.sup.-1; >C.dbd.O: 1621 cm.sup.-1;
C--O--C: 1234, 1120, 1011 cm.sup.-1
Step C: Phenyl
(3-{4-[(4-hydroxyphenyl)(methyl)carbamoyl]-1,5-dimethyl-1H-pyrrol-2-yl}-4-
-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}benzyl)carbamate
The title compound is obtained starting from the compound of the
above Step in accordance with the process of Step D of Example
45.
Elemental Microanalysis: (%, Measured(Theoretical))
% C=73.2 (72.88); % H=5.83 (5.96); % N=8.13 (8.72)
High-Resolution Mass Spectrometry (ESI+):
Empirical formula: C.sub.39H.sub.38N.sub.4O.sub.5
[M+H].sup.+ calculated: 643.2922
[M+H].sup.+ measured: 643.2902
EXAMPLE 41
N-(3-Fluorophenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-5-(6-{[(3R)-3-methyl-3-
,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-1H-pyrrole--
3-carboxamide
Elemental Microanalysis: (%, Measured(Theoretical))
% C=71.44 (71.95); % H=4.95 (5.22); % N=6.8 (6.8)
High-Resolution Mass Spectrometry (ESI+):
Empirical formula: C.sub.37H.sub.33FN.sub.3O.sub.5
[M+H].sup.+ calculated: 618.2399
[M+H].sup.+ measured: 618.2392
EXAMPLE 42
N-(4-Hydroxyphenyl)-1,2-dimethyl-5-(6-{[(3R)-3-methyl-3,4-dihydroisoquinol-
in-2(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-N-(1-methyl-1H-pyrrolo[2,3-b]p-
yridin-5-yl)-1H-pyrrole-3-carboxamide
Elemental Microanalysis: (%, Measured(Theoretical))
% C=71.32 (71.65); % H=5.17 (5.4); % N=10.67 (10.71)
High-Resolution Mass Spectrometry (ESI+):
Empirical formula: C.sub.39H.sub.36N.sub.5O.sub.5
[M+H].sup.+ calculated: 654.2711
[M+H].sup.+ measured: 654.2710
EXAMPLE 43
N-(4-Hydroxyphenyl)-1,2-dimethyl-5-(6-{[(3R)-3-methyl-3,4-dihydroisoquinol-
in-2(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-N-phenyl-1H-pyrrole-3-carboxam-
ide
Elemental Microanalysis: (%, Measured(Theoretical))
% C=73.9 (74.11); % H=5.16 (5.55); % N=6.81 (7.01)
High-Resolution Mass Spectrometry (ESI+):
Empirical formula: C.sub.37H.sub.34N.sub.3O.sub.5
[M+H].sup.+ calculated: 600.2493
[M+H].sup.+ measured: 600.2495
EXAMPLE 44
N-(4-Hydroxyphenyl)-1,2-dimethyl-N-(1-methyl-1H-pyrrolo[2,3-b]-pyridin-5-y-
l)-5-(6-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]ca-
rbonyl}-1,3-benzodioxol-5-yl)-1H-pyrrole-3-carboxamide
hydrochloride
Elemental Microanalysis: (%, Measured(Theoretical))
% C=66.41 (66.62); % H=5.08 (5.59); % N=10.85 (10.84); % Cl--=4.68
(4.57)
High-Resolution Mass Spectrometry (ESI+):
Empirical formula: C.sub.43H.sub.42N.sub.6O.sub.6
[M+H].sup.+ calculated: 739.3239
[M+H].sup.+ measured: 739.3246
EXAMPLE 45
Phenyl
[2-(3-{4-[(4-hydroxyphenyl)(methyl)carbamoyl]-1,5-dimethyl-1H-pyrro-
l-2-yl}-4-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-phenyl-
)ethyl]carbamate
Step A:
N-(4-Benzyloxyphenyl)-N,1,2-trimethyl-pyrrole-3-carboxamide
To a suspension of 1,2-dimethylpyrrole-3-carboxylic acid (2.085 g;
15 mmol) in 1,2-dichloroethane (40 mL) there is added
1-chloro-N,N,2-trimethyl-prop-1-en-1-amine (2.37 mL; 17.9 mmol),
and the solution formed is stirred for 1 hour. To the resulting
solution there is added, dropwise, an ice-cold solution of
4-benzyloxy-N-methyl-aniline (3.73 g; 15 mmol) and
N-ethyl-N-isopropyl-propan-2-amine (7.75 mL; 45 mmol) in
1,2-dichloroethane (40 mL). The reaction mixture is stirred at
ambient temperature for 1 hour; it is then diluted with
dichloromethane (250 mL) and washed with water (2.times.30 mL),
dried over Na.sub.2SO.sub.4 and evaporated. The crude product is
triturated with diethyl ether and the solid formed is filtered off
to yield the title compound.
IR: .nu.: >C.dbd.O: 1616 cm.sup.-1; amide: 1508 cm.sup.-1;
C--O--C: 1230, 1172, 1009 cm.sup.-1
Step B: tert-Butyl
{2-[3-(4-{[4-(benzyloxy)phenyl](methyl)carbamoyl}-1,5-dimethyl-1H-pyrrol--
2-yl)-4-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}phenyl]et-
hyl}-carbamate
The compound of Preparation I (0.869 g; 1.67 mmol) and the compound
of Step A (0.558 g; 1.67 mmol) are dissolved in dimethylacetamide
(8 mL) and then nitrogen is bubbled through the solution for 5
minutes. Potassium acetate (0.33 g; 3.34 mmol) and
bis(triphenylphosphine)palladium(II) dichloride (0.117 g; 0.167
mmol) are added to the mixture which is then heated to 140.degree.
C. and, after stirring for 10 minutes, water (80 .mu.L) is added.
Stirring at 140.degree. C. under a nitrogen atmosphere is continued
for 16 hours more. The reaction mixture is allowed to cool to
ambient temperature and then evaporated. The residue is partitioned
between dichloromethane (100 mL) and water (20 mL). The organic
phase is washed with water (20 mL), dried over Na.sub.2SO.sub.4 and
evaporated. The residue was purified by preparative HPLC using
water-TFA and acetonitrile as eluants. The pH of the appropriate
fractions is adjusted to 12 using aqueous NaOH solution and then
the acetonitrile is evaporated off under reduced pressure. The
aqueous residue is extracted with dichloromethane (2.times.100 mL).
The organic phase is dried over Na.sub.2SO.sub.4 and evaporated to
dryness to yield the title compound.
High-Resolution Mass Spectrometry (ESI+):
Empirical formula: C.sub.45H.sub.50N.sub.4O.sub.5
[M+H].sup.+ calculated: 727.3861
[M+H].sup.+ measured: 727.3852
IR: .nu.: >C.dbd.O: 1705, 1618 cm.sup.-1; amide: 1509 cm.sup.-1;
C--O--C: 1242, 1166, 1012 cm.sup.-1
Step C:
5-[5-(2-Aminoethyl)-2-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-
-yl]-carbonyl}phenyl]-N-[4-(benzyloxy)phenyl]-N,1,2-trimethyl-1H-pyrrole-3-
-carboxamide hydrochloride
The compound of Step B (0.35 g; 0.48 mmol) was dissolved/suspended
in 4M HCl in dioxane (3 mL). The heterogeneous mixture is stirred
for 30 minutes at ambient temperature and then evaporated to
dryness to yield the title compound which is used in next Step
without being otherwise purified.
High-Resolution Mass Spectrometry (ESI+):
Empirical formula: C.sub.40H.sub.42N.sub.4O.sub.3
[M+H].sup.+ calculated: 627.3337
[M+H].sup.+ measured: 627.3309
IR: .nu.: C--H: 2931 cm.sup.-1; >C.dbd.O: 1608 cm.sup.-1; amide:
1508 cm.sup.-1; C--O--C: 1233, 1012 cm.sup.-1
Step D: Phenyl
2-(3-{4-[(4-hydroxyphenyl)(methyl)carbamoyl]-1,5-dimethyl-1H-pyrrol-2-yl}-
-4-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}phenyl)ethyl]--
carbamate
The compound of Step C (0.10 g; 0.15 mmol) is dissolved in
dichloromethane. Phenyl chloroformate (0.027 g; 0.17 mmol) and
diisopropylethylamine (0.097 g, 0.75 mmol) are added thereto. The
reaction mixture is stirred at ambient temperature for 30 minutes.
After dilution with dichloromethane (100 mL), the organic phase is
washed with water (20 mL), evaporated and concentrated. The residue
is then dissolved in ethanol and a Pd/C catalyst is added (10 mg).
The reaction mixture is hydrogenated at atmospheric pressure at
ambient temperature. When the reaction is complete, the catalyst is
removed by filtration, the filtrate is concentrated and the crude
product is purified by chromatography over silica gel using
dichloromethane and methanol as eluants, to yield the title
product.
Elemental Microanalysis: (%, Measured(Theoretical))
% C=72.36 (73.15); % H=6.15 (6.14); % N=8.14 (8.53)
High-Resolution Mass Spectrometry (ESI+):
Empirical formula: C.sub.4H.sub.40N.sub.4O.sub.5
[M+H].sup.+ calculated: 657.3077
[M+H].sup.+ measured: 657.3062
EXAMPLE 46
N-(4-Hydroxyphenyl)-N,1,2-trimethyl-5-(2-{[(3R)-3-methyl-3,4-dihydroisoqui-
nolin-2(1H)-yl]carbonyl}-5-{2-[(phenoxyacetyl)amino]ethyl}phenyl)-1H-pyrro-
le-3-carboxamide
The title compound is obtained in accordance with the process of
Example 45 using 2-phenoxyacetyl chloride as acylating agent in
Step D.
Elemental Microanalysis: (%, Measured(Theoretical))
% C=72.74 (73.41); % H=6.38 (6.31); % N=7.65 (8.35)
High-Resolution Mass Spectrometry (ESI+):
Empirical formula: C.sub.41H.sub.42N.sub.4O.sub.5
[M+H].sup.+ calculated: 671.3235
[M+H].sup.+ measured: 671.3226
EXAMPLE 47
N-(4-Hydroxyphenyl)-1,2-dimethyl-N-(1-methyl-1H-pyrazol-4-yl)-5-(6-{[(3S)--
3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-1,3-ben-
zodioxol-5-yl)-1H-pyrrole-3-carboxamide hydrochloride
Elemental Microanalysis: (%, Measured(Theoretical))
% C=64.25 (64.59); % H=5.4 (5.7); % N=11.41 (11.59); % Cl--=4.93
(4.89)
EXAMPLE 48
N-(4-Hydroxyphenyl)-N-(2-methoxypyrimidin-5-yl)-1,2-dimethyl-5-(6-{[(3R)-3-
-methyl-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-1H-
-pyrrole-3-carboxamide
Elemental Microanalysis: (%, Measured(Theoretical))
% C=68.07 (68.45); % H=5 (5.27); % N=10.74 (11.09)
EXAMPLE 49
N-(4-Hydroxyphenyl)-1,2-dimethyl-N-(1-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]-
pyridin-5-yl)-5-(6-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin--
2(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-1H-pyrrole-3-carboxamide
dihydrochloride
Step A:
N-(4-{[tert-Butyl(dimethyl)silyl]oxy}phenyl)-1,2-dimethyl-N-(1-met-
hyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-5-(6-{[(3S)-3-(morpholin-4-ylmethyl)-3,-
4-dihydroisoquinolin-2(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-1H-pyrrole-3-
-carboxamide
The title compound is obtained in accordance with the process of
Example 1 using the acid of Preparation 11 and
(3S)-3-(4-morpholinylmethyl)-1,2,3,4-tetrahydroisoquinoline (see
Preparation 3') in Step A, and the compound of Preparation 11'' in
Step C.
Step B:
N-(4-Hydroxyphenyl)-1,2-dimethyl-N-(1-methyl-2,3-dihydro-1H-pyrrol-
o[2,3-b]pyridin-5-yl)-5-(6-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoq-
uinolin-2(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-1H-pyrrole-3-carboxamide
dihydrochloride
To a solution of 0.21 g (0.2 mmol) of the compound of Step A in 3
mL of acetic acid there are added 85 mg of sodium cyanoborohydride
(5 equivalents). The reaction mixture is stirred for 3 hours at
ambient temperature and then overnight at 50.degree. C. There are
then added 2.6 equivalents of sodium cyanoborohydride and the
reaction mixture is heated at 50.degree. C. for 3 hours. The
operation is repeated for a second time (addition of 2.6
equivalents of sodium cyanoborohydride and then heating at
50.degree. C. for 3 hours). After coevaporation of the acetic acid
in the presence of toluene, the residue is taken up in 3 mL of
methanol. The pH of the solution is adjusted to 12 using 1M
methanolic potassium hydroxide solution. After stirring overnight
at ambient temperature, the reaction mixture is poured into
saturated aqueous sodium bicarbonate solution and extracted with
dichloromethane. The resulting organic phase is washed with brine,
dried over Na.sub.2SO.sub.4, filtered and concentrated under
reduced pressure. The product obtained is purified by
chromatography over silica gel (dichloromethane/ethanol/ammonia
94/6/0.6) and then over a Lichroprep RP18 column
(water/acetonitrile/trifluoroacetic acid). After evaporation of the
acetonitrile, the product is neutralised with sodium bicarbonate.
It is then extracted with ethyl acetate. The organic phase is dried
over Na.sub.2SO.sub.4, filtered and concentrated under reduced
pressure. The residue obtained is dissolved in acetonitrile and
converted into salt form with 1M aqueous HCl solution. After
lyophilisation, the title product is obtained in the form of a
solid.
High-Resolution Mass Spectrometry (ESI+):
Empirical formula: C.sub.43H.sub.44N.sub.6O.sub.6
[M+H].sup.+ calculated: 741.3395
[M+H].sup.+ measured: 741.3400
EXAMPLE 50
N-(4-Hydroxyphenyl)-N-(2-methoxypyrimidin-5-yl)-1,2-dimethyl-5-(6-{[(3S)-3-
-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-1,3-benz-
odioxol-5-yl)-1H-pyrrole-3-carboxamide hydrochloride
High-Resolution Mass Spectrometry (ESI+):
Empirical formula: C.sub.40H.sub.40N.sub.6O.sub.7
[M+H].sup.+ calculated: 717.3031
[M+H].sup.+ measured: 717.3031
EXAMPLE 51
5-(5-{[(Benzylcarbamoyl)amino]methyl}-2-{[(3R)-3-methyl-3,4-dihydroisoquin-
olin-2(1H)-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-N,1,2-trimethyl-1H-pyrr-
ole-3-carboxamide
The title compound is obtained in accordance with the process of
Example 40 using benzyl isocyanate as acylating agent in Step
C.
Elemental Microanalysis: (%, Measured(Theoretical))
% C=73.39 (73.26); % H=6.16 (6.3); % N=10.08 (10.68)
High-Resolution Mass Spectrometry (ESI+):
Empirical formula: C.sub.40H.sub.41N.sub.5O.sub.4
[M+H].sup.+ calculated: 656.3239
[M+H].sup.+ measured: 656.3226
EXAMPLE 52
5-(5-{[(Ethylcarbamoyl)amino]methyl}-2-{[(3R)-3-methyl-3,4-dihydroisoquino-
lin-2(1H)-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-N,1,2-trimethyl-1H-pyrro-
le-3-carboxamide
The title compound is obtained in accordance with the process of
Example 40 using ethyl isocyanate as acylating agent in Step C.
Elemental Microanalysis: (%, Measured(Theoretical))
% C=71.4 (70.8); % H=6.41 (6.62); % N=11.24 (11.8)
High-Resolution Mass Spectrometry (ESI+):
Empirical formula: C.sub.35H.sub.39N.sub.5O.sub.4
[M+H].sup.+ calculated: 594.3082
[M+H].sup.+ measured: 594.3069
EXAMPLE 53
N-(4-Hydroxyphenyl)-N,1,2-trimethyl-5-(2-{[(3R)-3-methyl-3,4-dihydroisoqui-
nolin-2(1H)-yl]carbonyl}-5-{[(phenoxyacetyl)amino]methyl}phenyl)-1H-pyrrol-
e-3-carboxamide
The title compound is obtained in accordance with the process of
Example 40 using 2-phenoxyacetyl chloride as acylating agent in
Step C.
Elemental Microanalysis: (%, Measured(Theoretical))
% C=72.32 (73.15); % H=6.21 (6.14); % N=7.84 (8.53)
High-Resolution Mass Spectrometry (ESI+):
Empirical formula: C.sub.40H.sub.40N.sub.4O.sub.5
[M+H].sup.+ calculated: 657.3079
[M+H].sup.+ measured: 657.3105
EXAMPLE 54
N-(4-Hydroxyphenyl)-1,2-dimethyl-5-(2-{[(3R)-3-methyl-3,4-dihydroisoquinol-
in-2(1H)-yl]carbonyl}-5-{[(phenoxyacetyl)amino]methyl}phenyl)-N-(1-methyl--
1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide
Elemental Microanalysis: (%, Measured(Theoretical))
% C=73.87 (73.04); % H=5.47 (5.74); % N=10.26 (10.87)
EXAMPLE 55
5-(5-[2-({[2-(4-Fluorophenyl)ethyl]sulphonyl}amino)ethyl]-2-{[(3R)-3-methy-
l-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-N,1-
,2-trimethyl-1H-pyrrole-3-carboxamide
The title compound is obtained in accordance with the process of
Example 45 using 2-(4-fluorophenyl)ethanesulphonyl chloride as
acylating agent in Step D.
Elemental Microanalysis: (%, Measured(Theoretical))
% C=67.42 (68.12); % H=5.76 (6); % N=7.27 (7.75); S=3.68 (4.44)
High-Resolution Mass Spectrometry (ESI+):
Empirical formula: C.sub.41H.sub.43FN.sub.4O.sub.5S
[M+H].sup.+ calculated: 723.3018
[M+H].sup.+ measured: 723.3011
EXAMPLE 56
5-(5-{2-[(Benzylcarbamoyl)amino]ethyl}-2-{[(3R)-3-methyl-3,4-dihydroisoqui-
nolin-2(1H)-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-N,1,2-trimethyl-1H-pyr-
role-3-carboxamide
The title compound is obtained in accordance with the process of
Example 45 using benzyl isocyanate as acylating agent in Step
D.
Elemental Microanalysis: (%, Measured(Theoretical))
% C=71.14 (73.52); % H=6.47 (6.47); % N=9.42 (10.46)
High-Resolution Mass Spectrometry (ESI+):
Empirical formula: C.sub.41H.sub.43N.sub.5O.sub.4
[M+H].sup.+ calculated: 670.3395
[M+H].sup.+ measured: 670.3390
EXAMPLE 57
N-(4-Hydroxyphenyl)-N,1,2-trimethyl-5-(2-{[(3R)-3-methyl-3,4-dihydroisoqui-
nolin-2(1H)-yl]carbonyl}-5-{2-[(phenylacetyl)amino]ethyl}phenyl)-4H-pyrrol-
e-3-carboxamide
The title compound is obtained in accordance with the process of
Example 45 using phenylacetyl chloride as acylating agent in Step
D.
Elemental Microanalysis: (%, Measured(Theoretical))
% C=75.46 (75.21); % H=6.11 (6.46); % N=8.31 (8.56)
High-Resolution Mass Spectrometry (ESI+):
Empirical formula: C.sub.41H.sub.42N.sub.4O.sub.4
[M+H].sup.+ calculated: 655.3286
[M+H].sup.+ measured: 655.3285
EXAMPLE 58
N-(4-Hydroxyphenyl)-N,1,2-trimethyl-5-(2-{[(3R)-3-methyl-3,4-dihydroisoqui-
nolin-2(1H)-yl]carbonyl}-5-{2-[(phenylcarbamoyl)amino]ethyl}phenyl)-1H-pyr-
role-3-carboxamide
The title compound is obtained in accordance with the process of
Example 45 using phenyl isocyanate as acylating agent in Step
D.
Elemental Microanalysis: (%, Measured(Theoretical))
% C=71.25 (73.26); % H=6.12 (6.3); % N=9.61 (10.68)
High-Resolution Mass Spectrometry (ESI+):
Empirical formula: C.sub.40H.sub.41N.sub.5O.sub.4
[M+H].sup.+ calculated: 656.3239
[M+H].sup.+ measured: 656.3226
EXAMPLE 59
5-(4-[({[2-(4-Fluorophenyl)ethyl]sulphonyl}amino)methyl]-2-{[(3R)-3-methyl-
-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-N,1,-
2-trimethyl-1H-pyrrole-3-carboxamide
The title compound is obtained in accordance with the process of
Example 32 using 2-(4-fluorophenyl)ethanesulphonyl chloride as
sulphonylation agent in Step D.
Elemental Microanalysis: (%, Measured(Theoretical))
% H=5.19 (5.83); % N=7.28 (7.9); S=4.45 (4.52); % C=66.17
(67.78)
High-Resolution Mass Spectrometry (ESI+):
Empirical formula: C.sub.40H.sub.41FN.sub.4O.sub.5S
[M+H].sup.+ calculated: 709.2866
[M+H].sup.+ measured: 709.2866
EXAMPLE 60
5-(5-Chloro-2-{[(3S)-3-{[2-(dimethylamino)ethoxy]methyl}-3,4-dihydroisoqui-
nolin-2(1H)-yl]carbonyl}phenyl)-N-(4-hydroxy
phenyl)-1,2-dimethyl-N-phenyl-1H-pyrrole-3-carboxamide
hydrochloride
The process of Example 29 is used, on the one hand replacing the
4-(2-bromoethyl)morpholine hydrobromide used in Step B by
2-chloroethyldimethylamine hydrochloride and on the other hand
adding a catalytic amount of tetrabutylammonium iodide.
High-Resolution Mass Spectrometry (ESI+):
Empirical formula: C.sub.40H.sub.41ClN.sub.4O.sub.4
[M+H].sup.+ calculated: 677.2890
[M+H].sup.+ measured: 677.2887
EXAMPLE 61
N-(4-Hydroxyphenyl)-1,2-dimethyl-5-(6-{[(3R)-3-methyl-3,4-dihydroisoquinol-
in-2(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-N-(pyridin-4-yl)-pyrrole-3-car-
boxamide hydrochloride
High-Resolution Mass Spectrometry (ESI+):
Empirical formula: C.sub.36H.sub.32N.sub.4O.sub.5
[M+H].sup.+ calculated: 601.2445
[M+H].sup.+ measured: 601.2424
EXAMPLE 62
5-(5-Fluoro-4-methoxy-2-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]ca-
rbonyl}phenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-(1-methyl-1H-pyrazol-4-y-
l)-1H-pyrrole-3-carboxamide
Elemental Microanalysis: (%, Measured(Theoretical))
% C=68.99 (69.18); % H=5.89 (5.64); % N=11.35 (11.52)
High-Resolution Mass Spectrometry (ESI+):
Empirical formula: C.sub.35H.sub.34FN.sub.5O.sub.4
[M+H].sup.+ calculated: 608.2668
[M+H].sup.+ measured: 608.2640
EXAMPLE 63
5-(5-Chloro-2-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]-carbonyl}ph-
enyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-(1-methyl-1H-pyrrolo[2,3-b]-pyrid-
in-5-yl)-1H-pyrrole-3-carboxamide
Elemental Microanalysis: (%, Measured(Theoretical))
% C=70.48 (70.85); % H=5.67 (5.32); % N=11.2 (10.87)
High-Resolution Mass Spectrometry (ESI+):
Empirical formula: C.sub.38H.sub.34ClN.sub.5O.sub.3
[M+H].sup.+ calculated: 666.2242
[M+H].sup.+ measured: 666.2235
EXAMPLE 64
N,1,2-Trimethyl-N-(1-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-5-(6-{[(3S)-3-(-
morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-1,3-benzod-
ioxol-5-yl)-1H-pyrrole-3-carboxamide hydrochloride
High-Resolution Mass Spectrometry (ESI+):
Empirical formula: C.sub.38H.sub.40N.sub.6O.sub.5
[M+H].sup.+ calculated: 661.3133
[M+H].sup.+ measured: 661.3125
EXAMPLE 65
1,2-Dimethyl-N-(1-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-5-(6-{[(3S)-3-(mor-
pholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-1,3-benzodiox-
ol-5-yl)-N-phenyl-1H-pyrrole-3-carboxamide hydrochloride
High-Resolution Mass Spectrometry (ESI+):
Empirical formula: C.sub.43H.sub.42N.sub.6O.sub.5
[M+H].sup.+ calculated: 723.3289
[M+H].sup.+ measured: 723.3287
EXAMPLE 66
4-Methylphenyl
(4-{4-[(4-hydroxyphenyl)(methyl)carbamoyl]-1,5-dimethyl-1H-pyrrol-2-yl}-3-
-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]-carbonyl}benzyl)carbamat-
e
The title compound is obtained in accordance with the process of
Example 32 using 4-methylphenyl chloroformate as acylating agent in
Step D.
High-Resolution Mass Spectrometry (ESI+):
Empirical formula: C.sub.40H.sub.40N.sub.4O.sub.5
[M+H].sup.+ calculated: 657.3079
[M+H].sup.+ measured: 657.3076
EXAMPLE 67
5-(5-Fluoro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-(1-methyl-1H-pyraz-
ol-4-yl)-1H-pyrrole-3-carboxamide hydrochloride
Elemental Microanalysis: (%, Measured(Theoretical))
% C=65.69 (65.28); % H=5.38 (5.77); % N=11.18 (12.02); % Cl--=5.61
(5.07)
EXAMPLE 68
5-(5-Fluoro-4-hydroxy-2-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]ca-
rbonyl}phenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-(1-methyl-1H-pyrazol-4-y-
l)-1H-pyrrole-3-carboxamide
A 1N solution of tribromoborane (1.3 equivalents) in
dichloromethane is poured rapidly, at ambient temperature, into a
solution of the compound of Example 62 in dichloromethane. This
operation is repeated twice in order to complete the reaction in 5
hours. The reaction mixture is poured into anhydrous ethanol at
5.degree. C. After stirring for 10 minutes, saturated aqueous
NaHCO.sub.3 solution is added. The mixture is extracted with
dichloromethane, dried over Na.sub.2SO.sub.4 and concentrated to
dryness. The crude product obtained is purified by preparative HPLC
using water, TFA and acetonitrile as eluants. The pH of the
appropriate fractions is adjusted to 12 with saturated aqueous
NaHCO.sub.3 solution, and then the acetonitrile is evaporated off
under reduced pressure. The aqueous residue is extracted with
dichloromethane. The organic phase is dried over Na.sub.2SO.sub.4
and evaporated to dryness to yield the title compound.
High-Resolution Mass Spectrometry (ESI+):
Empirical formula: C.sub.34H.sub.32FN.sub.5O.sub.4
[M+H].sup.+ calculated: 594.2511
[M+H].sup.+ measured: 594.2517
EXAMPLE 69
N-(4-Hydroxyphenyl)-1,2-dimethyl-5-(6-{[(3S)-3-[(4-methylpiperazin-1-yl)me-
thyl]-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-N-(1-
-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide
hydrochloride
High-Resolution Mass Spectrometry (ESI+):
Empirical formula: C.sub.44H.sub.45N.sub.7O.sub.5
[M+H].sup.+ calculated: 752.3555
[M+H].sup.+ measured: 752.3552
EXAMPLE 70
N-(4-Hydroxyphenyl)-1,2-dimethyl-5-(6-{[(3S)-3-[(4-methylpiperazin-1-yl)me-
thyl]-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-N-(p-
yridin-4-yl)-1H-pyrrole-3-carboxamide hydrochloride
High-Resolution Mass Spectrometry (ESI+):
Empirical formula: C.sub.41H.sub.42N.sub.6O.sub.5
[M+H].sup.+ calculated: 699.3289
[M+H].sup.+ measured: 699.3293
EXAMPLE 71
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-(1-methyl-1H-pyrro-
lo[2,3-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide hydrochloride
High-Resolution Mass Spectrometry (ESI+):
Empirical formula: C.sub.42H.sub.41ClN.sub.6O.sub.4
[M+H].sup.+ calculated: 723.3289
[M+H].sup.+ measured: 723.3287
EXAMPLE 72
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-(1-methyl-1H-benzi-
midazol-5-yl)-1H-pyrrole-3-carboxamide
Elemental Microanalysis: (%, Measured(Theoretical))
% C=68.90 (69.17); % H=5.32 (5.67); % N=11.40 (11.52)
EXAMPLE 73
N-(4-Hydroxyphenyl)-1,2-dimethyl-5-(6-{[(3S)-3-(morpholin-4-ylmethyl)-3,4--
dihydroisoquinolin-2(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-N-(pyridin-4-y-
l)-1H-pyrrole-3-carboxamide dihydrochloride
High-Resolution Mass Spectrometry (ESI+):
Empirical formula: C.sub.40H.sub.39N.sub.5O.sub.6
[M+H].sup.+ calculated: 686.2973
[M+H].sup.+ measured: 686.2971
EXAMPLE 74
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-(pyridin-4-yl)-1H--
pyrrole-3-carboxamide hydrochloride
High-Resolution Mass Spectrometry (ESI+):
Empirical formula: C.sub.39H.sub.38ClN.sub.5O.sub.4
[M+H].sup.+ calculated: 676.2685
[M+H].sup.+ measured: 676.2684
EXAMPLE 75
N-(4-Hydroxyphenyl)-1-methyl-N-(1-methyl-1H-pyrazol-4-yl)-5-(6-{[(3S)-3-(m-
orpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-1,3-benzodi-
oxol-5-yl)-2-(trifluoromethyl)-1H-pyrrole-3-carboxamide
hydrochloride
Elemental Microanalysis: (%, Theoretical:Measured)
% C=60.12:59.77; % H=4.92:4.76; % N=10.79:10.39% Cl--=4.55:5.17
High-Resolution Mass Spectrometry (ESI+):
Empirical formula: C.sub.39H.sub.37F.sub.3N.sub.6O.sub.6
[M+H].sup.+ calculated: 743.2799
[M+H].sup.+ measured: 742.2802
EXAMPLE 76
2-(Difluoromethyl)-N-(4-hydroxyphenyl)-1-methyl-N-(1-methyl-1H-pyrazol-4-y-
l)-5-(6-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]ca-
rbonyl}-1,3-benzodioxol-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 77
N-(4-Hydroxyphenyl)-2-(methoxymethyl)-1-methyl-N-(1-methyl-1H-pyrazol-4-yl-
)-5-(6-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]car-
bonyl}-1,3-benzodioxol-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 78
2-(2,2-Difluoroethyl)-N-(4-hydroxyphenyl)-1-methyl-N-(1-methyl-1H-pyrazol--
4-yl)-5-(6-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl-
]carbonyl}-1,3-benzodioxol-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 79
N-(4-Hydroxyphenyl)-1-methyl-N-(1-methyl-1H-pyrazol-4-yl)-5-(6-{[(3S)-3-(m-
orpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-1,3-benzodi-
oxol-5-yl)-2-(2,2,2-trifluoroethyl)-1H-pyrrole-3-carboxamide
EXAMPLE 80
N-(4-Hydroxyphenyl)-2-(2-methoxyethyl)-1-methyl-N-(1-methyl-1H-pyrazol-4-y-
l)-5-(6-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]ca-
rbonyl}-1,3-benzodioxol-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 81
N-(4-Hydroxyphenyl-1-methyl-5-(6-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(-
1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-N-(1-methyl-1H-pyrazol-4-yl)-2-[2-(-
morpholin-4-yl)ethyl]-1H-pyrrole-3-carboxamide hydrochloride
The procedure is in accordance with the general protocol of Example
1 using the compound of Preparation 22 in Step A. The product
obtained is finally dissolved in acetonitrile and converted into
salt form using 0.1M aqueous HCl solution. After a lyophilisation
step, the expected compound is obtained in the form of a solid.
High-Resolution Mass Spectrometry (ESI+):
Empirical formula: C.sub.40H.sub.42N.sub.6O.sub.6
[M+H].sup.+ calculated: 703.3239
[M+H].sup.+ measured: 703.3236
EXAMPLE 82
N-(4-Hydroxyphenyl)-1-methyl-5-(6-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2-
(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-N-(1-methyl-1H-pyrazol-4-yl)-2-(mo-
rpholin-4-ylmethyl)-1H-pyrrole-3-carboxamide
The procedure is in accordance with the general protocol of Example
1 using the compound of Preparation 23 in Step A.
High-Resolution Mass Spectrometry (ESI+):
Empirical formula: C.sub.39H.sub.40N.sub.6O.sub.6
[M+H].sup.+ calculated: 689.3082
[M+H].sup.+ measured: 689.3085
EXAMPLE 83
N-(4-Hydroxyphenyl)-1-methyl-N-(1-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-5--
(6-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbony-
l}-1,3-benzodioxol-5-yl)-2-(trifluoromethyl)-1H-pyrrole-3-carboxamide
EXAMPLE 84
2-(Difluoromethyl)-N-(4-hydroxyphenyl)-1-methyl-N-(1-methyl-1H-pyrrolo[2,3-
-b]pyridin-5-yl)-5-(6-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinol-
in-2(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 85
N-(4-Hydroxyphenyl)-2-(methoxymethyl)-1-methyl-N-(1-methyl-1H-pyrrolo[2,3--
b]pyridin-5-yl)-5-(6-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinoli-
n-2(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 86
2-(2,2-Difluoroethyl)-N-(4-hydroxyphenyl)-1-methyl-N-(1-methyl-1H-pyrrolo[-
2,3-b]pyridin-5-yl)-5-(6-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoqui-
nolin-2(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 87
N-(4-Hydroxyphenyl)-1-methyl-N-(1-methyl-W-pyrrolo[2,3-b]pyridin-5-yl)-5-(-
6-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl-
}-1,3-benzodioxol-5-yl)-2-(2,2,2-trifluoroethyl)-1H-pyrrole-3-carboxamide
EXAMPLE 88
N-(4-Hydroxyphenyl)-2-(2-methoxyethyl)-1-methyl-N-(1-methyl-1H-pyrrolo[2,3-
-b]pyridin-5-yl)-5-(6-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinol-
in-2(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-1H-pyrrole-3-carboxamide
hydrochloride
The procedure is in accordance with the general protocol of Example
1 using the appropriate Preparations. The product obtained is
finally dissolved in acetonitrile and converted into salt form
using 0.1M aqueous HCl solution. After a lyophilisation step, the
expected compound is obtained in the form of a solid.
Elemental Microanalysis: (%, Theoretical:Measured)
% C=65.97:66.15; % H=5.78:5.46; % N=10.26:10.24; %
Cl--=4.33:4.76
High-Resolution Mass Spectrometry (ESI/FIA/HR and MS/MS):
Empirical formula: C.sub.45H.sub.46N.sub.6O.sub.7
[M+H].sup.+ calculated: 783.3501
[M+H].sup.+ measured: 783.3502
EXAMPLE 89
N-(4-Hydroxyphenyl)-1-methyl-N-(1-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-2--
[2-(morpholin-4-yl)ethyl]-5-(6-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H-
)-yl]carbonyl}-1,3-benzodioxol-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 90
N-(4-Hydroxyphenyl)-1-methyl-N-(1-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-2--
(morpholin-4-ylmethyl)-5-(6-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-y-
l]carbonyl}-1,3-benzodioxol-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 91
N-(4-Hydroxyphenyl)-2-methyl-N-(1-methyl-1H-pyrazol-4-yl)-5-(6-{[(3S)-3-(m-
orpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-1,3-benzodi-
oxol-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 92
1-Ethyl-N-(4-hydroxyphenyl)-2-methyl-N-(1-methyl-1H-pyrazol-4-yl)-5-(6-{[(-
3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-1,3-
-benzodioxol-5-yl)-1H-pyrrole-3-carboxamide hydrochloride
The procedure is in accordance with the protocol described in
Example 1, using the compounds from Preparations 20 and 3' in Step
A and the compound from Preparation 1'' in Step C. The product
obtained is finally dissolved in acetonitrile and converted into
salt form using 0.1M aqueous HCl solution. After a lyophilisation
step, the expected compound is obtained in the form of a solid.
Elemental Microanalysis: (%, Theoretical:Measured)
% C=64.99:65.61; % H=5.86:5.39; % N=11.37:11.43; % Cl=4.80:4.42
[M+H].sup.+ measured: 703.3236
EXAMPLE 93
N-(4-Hydroxyphenyl)-1-(2-methoxyethyl)-2-methyl-N-(1-methyl-1H-pyrazol-4-y-
l)-5-(6-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]ca-
rbonyl}-1,3-benzodioxol-5-yl)-1H-pyrrole-3-carboxamide
hydrochloride
Elemental Microanalysis: (%, Theoretical:Measured)
% C=64.01:64.10; % H=5.90:5.63; % N=10.92:10.88; %
Cl--=4.61:4.70.
High-Resolution Mass Spectrometry (ESI+):
Empirical formula: C.sub.41H.sub.44N.sub.6O.sub.7
[M+H].sup.+ calculated: 733.3344
[M+H].sup.+ measured: 733.3345
EXAMPLE 94
1-(2-Fluoroethyl)-N-(4-hydroxyphenyl)-2-methyl-N-(1-methyl-1H-pyrazol-4-yl-
)-5-(6-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]car-
bonyl}-1,3-benzodioxol-5-yl)-1H-pyrrole-3-carboxamide
hydrochloride
The procedure is in accordance with the protocol described in Steps
A-D of Example 1, using the compounds from Preparations 21 and 3'
in Step A and the compound from Preparation 1'' in Step C. The
product obtained is finally dissolved in acetonitrile and converted
into salt form using 0.1M aqueous HCl solution. After a
lyophilisation step, the expected compound is obtained in the form
of a solid.
Elemental Microanalysis: (%, Theoretical:Measured)
% C=63.44:63.25; % H=5.59:5.09; % N=11.10:11.02; % Cl=4.68:4.74
High-Resolution Mass Spectrometry (ESI+):
Empirical formula: C.sub.40H.sub.41FN.sub.6O.sub.6
[M+H].sup.+ calculated: 721.3144
[M+H].sup.+ measured: 721.3147
EXAMPLE 95
1-(2,2-Difluoroethyl)-N-(4-hydroxyphenyl)-2-methyl-N-(1-methyl-1H-pyrazol--
4-yl)-5-(6-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl-
]carbonyl}-1,3-benzodioxol-5-yl)-1H-pyrrole-3-carboxamide
hydrochloride
The title compound is obtained in accordance with the process of
Example 1 using the acid of Preparation 32 and the compound of
Preparation 3' in Step A, and the compound of Preparation 1'' in
Step C. The compound obtained is converted into salt form and
lyophilised as described in the general process to obtain the title
compound.
Elemental Microanalysis: (%, Theoretical:Measured)
% C=61.97:61.89; % H=5.33:5.04; % N=10.84:10.85; %
Cl.sup.-=4.57:4.55
High-Resolution Mass Spectrometry (ESI+/HR, ESI-/LR):
Empirical formula: C.sub.40H.sub.40F.sub.2N.sub.6O.sub.6
[M+H].sup.+ calculated: 739.3050
[M+H].sup.+ measured: 739.3052
EXAMPLE 96
N-(4-Hydroxyphenyl)-2-methyl-5-(6-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2-
(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-N-(1-methyl-1H-pyrazol-4-yl)-1-[2--
(morpholin-4-yl)ethyl]-1H-pyrrole-3-carboxamide hydrochloride
Step A:
N-[4-[tert-Butyl(dimethyl)silyl]oxyphenyl]-2-methyl-5-[6-[(3R)-3-m-
ethyl-3,4-dihydro-1H-isoquinoline-2-carbonyl]-1,3-benzodioxol-5-yl]-N-(1-m-
ethyl-1H-pyrazol-4-yl)-1-(2-morpholinoethyl)pyrrole-3-carboxamide
The compound obtained in Step E of Example 99 is dissolved in 6 mL
of tetrahydrofuran. Sodium iodide (100 mg, 0.67 mmol) is added,
followed by morpholine (0.21 mL, 2.53 mmol) dropwise. The reaction
mixture is heated in a sealed flask at 90.degree. C. for 72 hours.
After cooling, the solution is evaporated to dryness and the
residue is purified by chromatography over silica gel using
dichloromethane and methanol as eluants. The expected product is
obtained in the form of a foam.
.sup.1H NMR (500 MHz, dmso-d6) .delta. ppm: 7.7-7.45 (4 bs, 1H),
7.2-6.9 (m, 4H), 7.1-6.4 (m, 2H), 7.1-6.9 (4 bs, 1H), 7-6.8 (4 m,
2H), 6.75/6.48 (d+bs, 2H), 6.1 (4 bs, 2H), 5.25-4.7 (4 bs, 1H),
5.2-3.8 (m, 2H), 4.9/4.65/3.8 (3 m, 1H), 3.75 (4 s, 3H), 3.5 (bs,
4H), 3-2 (m, 10H), 2.41/2.3 (2 bs, 3H), 1.02/0.95/0.78 (3 bd, 3H),
0.88 (m, 9H), 0.1 (m, 6H)
IR (ATR) cm.sup.-1: 1626 .delta. >C.dbd.O amides
Step B:
N-(4-Hydroxyphenyl)-2-methyl-5-(6-{[(3R)-3-methyl-3,4-dihydroisoqu-
inolin-2(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-N-(1-methyl-1H-pyrazol-4-y-
l)-1-[2-(morpholin-4-yl)ethyl]-1H-pyrrole-3-carboxamide
hydrochloride
The procedure is in accordance with the protocol described in Step
D of Example 1. The product obtained is finally subjected to a step
of conversion into salt form in the presence of HCl in ether. After
filtration and lyophilisation in a mixture of acetonitrile/water,
the expected compound is obtained.
High-Resolution Mass Spectrometry (ESI+):
Empirical formula: C.sub.40H.sub.42N.sub.6O.sub.6
[M+H].sup.+ calculated: 703.3239
[M+H].sup.+ measured: 703.3238
EXAMPLE 97
N-(4-Hydroxyphenyl)-2-methyl-5-(6-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2-
(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-1-[2-(morpholin-4-yl)ethyl]-N-phen-
yl-1H-pyrrole-3-carboxamide hydrochloride
The procedure is in accordance with the protocol described in
Example 96 replacing the compound of Preparation 1'' by that of
Preparation 2''.
Elemental Microanalysis: (%, Theoretical:Measured)
% C=68.61:68.12; % H=5.89:5.23; % N=7.62:7.54; % Cl--=4.82:4.66
High-Resolution Mass Spectrometry (ESI/FIA/HR and MS/MS):
Empirical formula: C.sub.42H.sub.42N.sub.4O.sub.6
[M+H].sup.+ calculated: 699.3177
[M+H].sup.+ measured: 699.3173
EXAMPLE 98
1-[2-(Dimethylamino)ethyl]-N-(4-hydroxyphenyl)-2-methyl-5-(6-{[(3R)-3-meth-
yl-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-N-pheny-
l-1H-pyrrole-3-carboxamide hydrochloride
The procedure is in accordance with the protocol described in
Example 27 replacing the compound of Preparation 1'' by that of
Preparation 2''. The product obtained is finally subjected to a
step of conversion into salt form in the presence of 1M HCl in
ether. After filtration and lyophilisation in a mixture of
acetonitrile/water, the expected compound is obtained.
Elemental Microanalysis: (%, Theoretical:Measured)
% C=69.30:69.20; % H=5.96:5.48; % N=8.08:8.08; % Cl--=5.11:5.03
High-Resolution Mass Spectrometry (ESI/FIA/HR and MS/MS):
Empirical formula: C.sub.40H.sub.40N.sub.4O.sub.5
[M+H].sup.+ calculated: 657.3071
[M+H].sup.+ measured: 657.3066
EXAMPLE 99
N-(4-Hydroxyphenyl)-1-{2-[(2-methoxyethyl)(methyl)amino]ethyl}-2-methyl-5--
(6-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-1,3-benzodiox-
ol-5-yl)-N-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrole-3-carboxamide
hydrochloride
Step A: Ethyl
1-(2-benzyloxyethyl)-2-methyl-5-[6-[(3R)-3-methyl-3,4-dihydro-1H-isoquino-
line-2-carbonyl]-1,3-benzodioxol-5-yl]pyrrole-3-carboxylate
The procedure is in accordance with the protocol described in Step
A of Example 1 replacing the compound of Preparation 1 by that of
Preparation 19.
.sup.1H NMR (500 MHz, dmso-d6) .delta. ppm: 7.35-6.95 (m, 9H),
7-6.8 (several s, 2H), 6.35-5.85 (several s, 1H), 6.15 (several s,
2H), 5.15-3.5 (several m, 4H), 4.9/4.7/3.95 (several m, 1H), 4.4
(m, 2H), 4.2-3.95 (m, 2H), 3.55 (m, 2H), 3.1-2.35 (several m, 2H),
2.5-2.2 (several s, 3H), 1.25-1.1 (several m, 3H), 1.05-0.7
(several d, 3H)
Step B:
1-(2-Benzyloxyethyl)-2-methyl-5-[6-[(3R)-3-methyl-3,4-dihydro-1H-i-
soquinoline-2-carbonyl]-1,3-benzodioxol-5-yl]pyrrole-3-carboxylic
acid
The procedure is in accordance with the protocol described in Step
B of Example 1.
IR (ATR) cm.sup.-1: 3000-2500 .nu. --OH, 1675-1625 .nu. --C.dbd.O
carboxylic acid+amide
Step C:
1-(2-Benzyloxyethyl)-N-[4-[tert-butyl(dimethyl)silyl]oxyphenyl]-2--
methyl-5-[6-[(3R)-3-methyl-3,4-dihydro-1H-isoquinoline-2-carbonyl]-1,3-ben-
zodioxol-5-yl]-N-(1-methyl-1H-pyrazol-4-yl)pyrrole-3-carboxamide
The procedure is in accordance with the protocol described in Step
C of Example 1.
.sup.1H NMR (500 MHz, dmso-d6) .delta. ppm: 7.7-7.5 (several s,
1H), 7.35-6.5 (several m, 11H), 7.1-6.9 (several s, 1H), 6.95-6.5
(several s, 2H), 6.8/6.5 (m, 2H), 6.05 (several s, 2H), 5.25-4.7
(several s, 1H), 5.1-3.6 (several m, 4H), 4.85/4.6/3.75 (several m,
1H), 4.3 (m, 2H), 3.7 (2.times.s, 3H), 3.4 (m, 2H), 3.05-2.4
(several m, 2H), 2.4-2.25 (several s, 3H), 1-0.75 (several d, 3H),
0.9 (several s, 9H), 0.1 (several s, 6H)
IR (ATR) cm.sup.-1: 1629 .nu. >C.dbd.O amides
Step D:
N-[4-[tert-Butyl(dimethyl)silyl]oxyphenyl]-1-(2-hydroxyethyl)-2-me-
thyl-5-[6-[(3R)-3-methyl-3,4-dihydro-1H-isoquinoline-2-carbonyl]-1,3-benzo-
dioxol-5-yl]-N-(1-methyl-1H-pyrazol-4-yl)pyrrole-3-carboxamide
In a hydrogenating reactor, the compound of the above Step is
dissolved in 30 mL of methanol. The solution is degassed by
bubbling argon in, and palladium-on-carbon 10% (550 mg) is added.
The resulting suspension is stirred under a pressure of 1 bar of
hydrogen for 15 hours, and then passed through a Whatman.RTM.
filter. The catalyst is rinsed with methanol and the filtrate is
evaporated in vacuo. The residue thereby obtained is purified by
chromatography over silica gel using dichloromethane and methanol
as eluants. The expected product is obtained in the form of an
oil.
.sup.1H NMR (500 MHz, pyridine-d5) .delta. ppm: 7.7-7.4 (4 s, 1H),
7.3-6.9 (m, 4H), 7.1-6.8 (4 s, 1H), 7-6.7 (m, 2H), 6.9-6.4 (m, 2H),
6.8-6.4 (4 m, 2H), 6.1 (m, 2H), 5.2/5/4.7 (4 s, 1H), 5.15-3.9 (8 d,
2H), 4.9-4.8 (m, 1H), 4.9/4.7/3.85 (3 m, 1H), 3.9-3.7 (m, 2H), 3.75
(2 s, 3H), 3.5-3.2 (m, 2H), 3-2.4 (m, 2H), 2.4-2.3 (4 s, 3H),
1.05/0.95/0.75 (4 d, 3H), 0.85 (bs, 9H), 0.15-0 (m, 6H)
IR (ATR) cm.sup.-1: 3346 .nu. --OH primary alcohol, 1621.nu.
--C.dbd.O amides
Step E:
2-[3-[[4-[tert-Butyl(dimethyl)silyl]oxyphenyl]-(1-methyl-1H-pyrazo-
l-4-yl)-carbamoyl]-2-methyl-5-[6-[(3R)-3-methyl-3,4-dihydro-1H-isoquinolin-
e-2-carbonyl]-1,3-benzodioxol-5-yl]pyrrol-1-yl]ethyl
methanesulphonate
The compound of the above Step (2.37 g, 3.17 mmol) is dissolved in
30 mL of tetrahydrofuran. The reaction mixture is cooled to
0.degree. C. and there are successively added triethylamine (1.8
mL, 13.9 mmol) and, dropwise, methanesulphonyl chloride (0.40 mL,
5.17 mmol). The reaction mixture is stirred for 2 hours at
0.degree. C. The reaction mixture is then poured into saturated
aqueous sodium hydrogen carbonate solution and extracted 3 times
with ethyl acetate. The organic phase is washed 3 times with brine,
dried over MgSO.sub.4, filtered and then evaporated to dryness. The
evaporation residue is used without purification in the next
Step.
.sup.1H NMR (500 MHz, dmso-d6) .delta. ppm: 7.7-7.45 (several s,
1H), 7.25-6.4 (m, 8H), 7.1-6.9 (several s, 1H), 6.95-6.65 (several
s, 2H), 6.1 (several s, 2H), 5.2-4.6 (several s, 1H), 5.05-3.75
(several d, 2H), 4.9/4.6/3.9/3.8 (several m, 1H), 4.3-4.05 (m, 2H),
4.2-3.95 (m, 2H), 3.75/3.7 (2 s, 3H), 3.05-2.5 (several m, 2H), 3
(several s, 3H), 2.45-2.3 (several s, 3H), 1.05-0.75 (several d,
3H), 0.9 (several s, 9H), 0.1 (several s, 6H)
IR (ATR) cm.sup.-1: 1626 .nu. --C.dbd.O, 1349 .nu. --SO.sub.2, 1249
.delta. --CH3, 1172 .nu. --SO.sub.2
Step F:
N-[4-[tert-Butyl(dimethyl)silyl]oxyphenyl]-1-[2-[2-methoxyethyl(me-
thyl)amino]-ethyl]-2-methyl-5-[6-[(3R)-3-methyl-3,4-dihydro-1H-isoquinolin-
e-2-carbonyl]-1,3-benzodioxol-5-yl]-N-(1-methyl-1H-pyrazol-4-yl)pyrrole-3--
carboxamide
The compound of the above Step (1.33 mg, 1.61 mmol) is dissolved in
6 mL of tetrahydrofuran. Sodium iodide (100 mg, 0.67 mmol) is
added, followed by dimethylamine (0.172 g, 1.932 mmol) dropwise.
The reaction mixture is heated in a sealed flask at 60.degree. C.
for 36 hours. After cooling, it is evaporated to dryness and
purified by chromatography over silica gel using dichloromethane
and ammonia-in-methanol as eluants. The expected product is
obtained in the form of a foam.
.sup.1H NMR (500 MHz, dmso-d6) .delta. ppm 7.7-7.45 (4 bs, 1H),
7.2-6.9 (m, 4H), 7.1-6.9 (4 bs, 1H), 7-6.7 (4 m, 2H), 7/6.45 (2 m,
2H), 6.8/6.45 (2 m, 2H), 6.1 (m, 2H), 5.22/5.05/4.7 (4 bs, 1H),
5.2-3.8 (m, 2H), 4.91/4.65/3.9 (3 m, 1H), 3.75 (2 bs, 3H), 3.7 (m,
2H), 3.2 (bs, 3H), 3-2 (m, 2H), 2.7-2 (ml, 6H), 2.7-2 (m, 3H),
2.45/2.35 (2 bs, 3H), 1.05/0.95/0.8 (3 bd, 3H), 0.9 (m, 9H), 0.1
(m, 6H)
IR (ATR) cm.sup.-1: 1628 (shoulder) .delta. --C.dbd.O amides
Step G:
N-(4-hydroxyphenyl)-1-[2-[2-methoxyethyl(methyl)amino]ethyl]-2-met-
hyl-5-[6-[(3R)-3-methyl-3,4-dihydro-1H-isoquinoline-2-carbonyl]-1,3-benzod-
ioxol-5-yl]-N-(1-methyl-1H-pyrazol-4-yl)pyrrole-3-carboxamide
hydrochloride
The procedure is in accordance with the protocol described in Step
D of Example 1. The product obtained is finally subjected to a step
of conversion into salt form in the presence of 1M HCl in ether.
After filtration and lyophilisation in a mixture of
acetonitrile/water, the expected compound is obtained.
IR (ATR) cm.sup.-1: 2000 to 3500 .nu. --NH.sup.+/OH, 1615 .nu.
>C.dbd.O amides, 1237-1161 .delta. >C--O--C<, 745 .nu.
>CH--Ar
High-Resolution Mass Spectrometry (ESI+):
Empirical formula: C.sub.40H.sub.44N.sub.6O.sub.6
[M+H].sup.+ calculated: 705.3395
[M+H].sup.+ measured: 705.3391
EXAMPLE 100
5-(5-Fluoro-4-methoxy-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquin-
olin-2(1H)-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-(1-methy-
l-1H-pyrazol-4-yl)-1H-pyrrole-3-carboxamide hydrochloride
The procedure is in accordance with the general protocol of Example
1 using the appropriate Preparations. The product obtained is
finally dissolved in acetonitrile and converted into salt form
using 0.1M aqueous HCl solution. After a lyophilisation step, the
expected compound is obtained in the form of a solid.
Elemental Microanalysis: (%, Theoretical:Measured)
% C=64.23:64.31; % H=5.80:5.43; % N=11.52:11.46; %
Cl--=4.86:4.95
High-Resolution Mass Spectrometry (ESI+):
Empirical formula: C.sub.39H.sub.41FN.sub.6O.sub.5
[M+H].sup.+ calculated: 693.3195
[M+H].sup.+ measured: 693.3194
EXAMPLE 101
5-(4-Fluoro-5-methoxy-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquin-
olin-2(1H)-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-(1-methy-
l-1H-pyrazol-4-yl)-1H-pyrrole-3-carboxamide hydrochloride
The title compound is obtained in accordance with the process of
Example 1 using the acid of Preparation 27 and the compound of
Preparation 3' in Step A, and the compound of Preparation 1'' in
Step C. The compound obtained is converted into salt form and
lyophilised as described in the general process to obtain the title
compound.
Elemental Microanalysis: (%, Theoretical:Measured)
% C=64.23:63.12; % H=5.80:5.20; % N=11.52:11.38. %
Cl.sup.-=4.86:5.03
High-Resolution Mass Spectrometry (ESI+/HR, ESI-/LR):
Empirical formula: C.sub.39H.sub.41FN.sub.6O.sub.5
[M+H].sup.+ calculated: 693.3195
[M+H].sup.+ measured: 693.3195
EXAMPLE 102
5-(5-Chloro-2-{[(3S)-3-[(4-methylpiperazin-1-yl)methyl]-3,4-dihydroisoquin-
olin-2(1H)-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-(1-methy-
l-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide
trihydrochloride
High-Resolution Mass Spectrometry (ESI+):
Empirical formula: C.sub.43H.sub.44ClN.sub.7O.sub.3
[M+H].sup.+ calculated: 742.3267
[M+H].sup.+ measured: 742.3268
EXAMPLE 103
5-(5-Chloro-2-{[(3S)-3-[(4-methylpiperazin-1-yl)methyl]-3,4-dihydroisoquin-
olin-2(1H)-yl]carbonyl}phenyl)-1,2-dimethyl-N-(1-methyl-1H-pyrrolo[2,3-b]p-
yridin-5-yl)-N-phenyl-1H-pyrrole-3-carboxamide
EXAMPLE 104
N-(4-Hydroxyphenyl)-1,2-dimethyl-N-(1-methyl-1H-pyrazolo[3,4-b]-pyridin-5--
yl)-5-(6-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]c-
arbonyl}-1,3-benzodioxol-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 105
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-(1-methyl-2,3-dihy-
dro-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 106
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-1,2-dimethyl-N-(1-methyl-1H-pyrrolo[2,3-b]pyridin-5-y-
l)-N-phenyl-1H-pyrrole-3-carboxamide
The procedure is in accordance with the general protocol of Example
1 using the appropriate Preparations, it being understood that Step
D is not carried out. The expected product is obtained in free base
form.
Elemental Microanalysis: (%, Theoretical:Measured)
% C=70.72:69.77; % H=5.79:5.96; % N=11.78:11.43
High-Resolution Mass Spectrometry (ESI+):
Empirical formula: C.sub.42H.sub.41ClN.sub.6O.sub.3
[M+H].sup.+ calculated: 713.3001
[M+H].sup.+ measured: 713.2998
EXAMPLE 107
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(4-fluorophenyl)-1,2-dimethyl-N-(1-methyl-1H-pyrrol-
o[2,3-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 108
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(5-cyano-1-methyl-1H-pyrrol-3-yl)-N-(4-hydroxypheny-
l)-1,2-dimethyl-1H-pyrrole-3-carboxamide hydrochloride
The title compound is obtained in accordance with the process of
Example 1 using the acid of Preparation 1 and
(3S)-3-(4-morpholinylmethyl)-1,2,3,4-tetrahydroisoquinoline (see
Preparation 3') in Step A, and the compound of Preparation 19'' in
Step C. The product obtained is finally subjected to a step of
conversion into salt form in the presence of HCl in ether. After
filtration and lyophilisation in a mixture of acetonitrile/water,
the expected compound is obtained.
Elemental Microanalysis: (%, Theoretical:Measured)
% C=64.95:65.09; % H=5.45:5.20; % N=11.36:11.26; %
Cl--=4.79:4.62
High-Resolution Mass Spectrometry (ESI/+):
Empirical formula: C.sub.40H.sub.39ClN.sub.6O.sub.4
[M+H].sup.+ calculated: 703.2794
[M+H].sup.+ measured: 703.2789
EXAMPLE 109
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(6-cyanopyridin-2-yl)-N-(4-hydroxyphenyl)-1,2-dimet-
hyl-1H-pyrrole-3-carboxamide hydrochloride
The title compound is obtained in accordance with the process of
Example 1 using the acid of Preparation 1 and the compound of
Preparation 3' in Step A, and the compound of Preparation 23'' in
Step C. The compound obtained is converted into salt form and
lyophilised as described in the general process to obtain the title
compound.
High-Resolution Mass Spectrometry (ESI+-/FIA/HR, ESI-/FIA):
Empirical formula: C.sub.40H.sub.37ClN.sub.6O.sub.4
[M+H].sup.+ calculated: 701.2638
[M+H].sup.+ measured: 701.2639
EXAMPLE 110
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(4-cyanopyridin-2-yl)-N-(4-hydroxyphenyl)-1,2-dimet-
hyl-1H-pyrrole-3-carboxamide hydrochloride
Elemental Microanalysis: (%, Theoretical:Measured)
% C=65.13:65.72; % H=5.19:4.76; % N=11.39:12.04; %
Cl.sup.-=4.81:4.45
High-Resolution Mass Spectrometry (ESI+-/FIA/HR, ESI-/FIA):
Empirical formula: C.sub.40H.sub.37ClN.sub.6O.sub.4
[M+H].sup.+ calculated: 701.2638
[M+H].sup.+ measured: 701.2643
EXAMPLE 111
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(4-cyanopyrimidin-2-yl)-N-(4-hydroxyphenyl)-1,2-dim-
ethyl-1H-pyrrole-3-carboxamide
EXAMPLE 112
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-[2-(dimethylamino)pyridin-4-yl]-N-(4-hydroxyphenyl)-
-1,2-dimethyl-1H-pyrrole-3-carboxamide
EXAMPLE 113
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-(1-methyl-1H-benzi-
midazol-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 114
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-(pyrazolo[1,5-a]py-
rimidin-6-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 115
5-(5-Chloro-2-{[(3S)-3-[(9aS)-hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl-
methyl]-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}phenyl)-N-(4-hydroxypheny-
l)-1,2-dimethyl-N-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrole-3-carboxamide
dihydrochloride
The title compound is obtained in accordance with the process of
Example 1 using the acid of Preparation 1 and the compound of
Preparation 7' in Step A, and the compound of Preparation 1'' in
Step C. The compound obtained is converted into salt form and
lyophilised as described in the general process to obtain the title
compound.
Elemental Microanalysis: (%, Theoretical:Measured)
% C=61.01:60.17; % H=5.74:5.09; % N=12.15:12.02; %
Cl.sup.-=8.78:9.81
High-Resolution Mass Spectrometry (ESI+-/FIA/HR, ESI-/FIA):
Empirical formula: C.sub.41H.sub.44ClN.sub.7O.sub.4
[M+H].sup.+ calculated: 734.3216
[M+H].sup.+ measured: 734.3220
EXAMPLE 116
5-(5-Chloro-2-{[(3S)-3-[(9aR)-hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl-
methyl]-3,4-dihydroisoquinolin-2(1H-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl-
)-1,2-dimethyl-N-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrole-3-carboxamide
dihydrochloride
The title compound is obtained in accordance with the process of
Example 1 using the acid of Preparation 1 and the compound of
Preparation 9' in Step A, and the compound of Preparation 1'' in
Step C. The compound obtained is converted into salt form and
lyophilised as described in the general process to obtain the title
compound.
Elemental Microanalysis: (%, Theoretical:Measured)
% C=61.01:61.90; % H=5.74:5.65; % N=12.15:12.14; %
Cl=13.15:11.51
High-Resolution Mass Spectrometry (ESI/FIA/HR and MS/MS):
Empirical formula: C.sub.41H.sub.44ClN.sub.7O.sub.4
[M+H].sup.+ calculated: 734.3216
[M+H].sup.+ measured: 734.3218
EXAMPLE 117
5-(5-Chloro-2-{[(3S)-3-(fluoromethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carb-
onyl}phenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-(1-methyl-1H-pyrazol-4-yl)-
-1H-pyrrole-3-carboxamide
EXAMPLE 118
5-(5-Chloro-2-{[(3S)-3-(difluoromethyl)-3,4-dihydroisoquinolin-2(1H)-yl]ca-
rbonyl}phenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-(1-methyl-1H-pyrazol-4-y-
l)-1H-pyrrole-3-carboxamide
EXAMPLE 119
5-(5-Chloro-2-{[(3S)-3-(trifluoromethyl)-3,4-dihydroisoquinolin-2(1H)-yl]c-
arbonyl}phenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-(1-methyl-1H-pyrazol-4--
yl)-1H-pyrrole-3-carboxamide
EXAMPLE 120
5-(5-Chloro-2-{[(3S)-3-[(3-cyanoazetidin-1-yl)methyl]-3,4-dihydroisoquinol-
in-2(1H)-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-(1-methyl--
1H-pyrazol-4-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 121
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(1-ethyl-1H-pyrazol-4-yl)-N-(4-hydroxyphenyl)-1,2-d-
imethyl-1H-pyrrole-3-carboxamide
EXAMPLE 122
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(1-cyclopropyl-1H-pyrazol-4-yl)-N-(4-hydroxyphenyl)-
-1,2-dimethyl-1H-pyrrole-3-carboxamide
The title compound is obtained in accordance with the process of
Example 1 using the acid of Preparation 1 and the compound of
Preparation 3' in Step A, and the compound of Preparation 28'' in
Step C.
Elemental Microanalysis: (%, Theoretical:Measured)
% C=68.12:67.94; % H=5.86:5.77; % N=11.92:11.65
High-Resolution Mass Spectrometry (ESI+/HR, ESI-/LR):
Empirical formula: C.sub.40H.sub.41ClN.sub.6O.sub.4
[M+H].sup.+ calculated: 705.2951
[M+H].sup.+ measured: 705.2952
EXAMPLE 123
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-[1-(trifluoromethy-
l)-1H-pyrazol-4-yl]-1H-pyrrole-3-carboxamide
EXAMPLE 124
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-[1-(difluoromethyl)-1H-pyrazol-4-yl]-N-(4-hydroxyph-
enyl)-1,2-dimethyl-1H-pyrrole-3-carboxamide
EXAMPLE 125
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-N-[1-(2-methoxyethyl)-1H-pyrazol--
4-yl]-1,2-dimethyl-4H-pyrrole-3-carboxamide
EXAMPLE 126
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-[1-(oxetan-3-yl)-1-
H-pyrazol-4-yl]-1H-pyrrole-3-carboxamide
The title compound is obtained in accordance with the process of
Example 1 using the acid of Preparation 1 and the compound of
Preparation 3' in Step A, and the compound of Preparation 26'' in
Step C.
High-Resolution Mass Spectrometry (ESI+/HR, ESI-/LR):
Empirical formula: C.sub.40H.sub.41ClN.sub.6O.sub.5
[M+H].sup.+ calculated: 721.2900
[M+H].sup.+ measured: 721.2902
EXAMPLE 127
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-[1-(tetrahydrofura-
n-3-yl)-1H-pyrazol-4-yl]-1H-pyrrole-3-carboxamide hydrochloride
The title compound is obtained in accordance with the process of
Example 1 using the acid of Preparation 1 and the compound of
Preparation 3' in Step A, and the compound of Preparation 22'' in
Step C. The compound obtained is converted into salt form and
lyophilised as described in the general process to obtain the title
compound.
Elemental Microanalysis: (%, Theoretical:Measured)
% C=63.81:63.63; % H=5.75:5.74; % N=10.89:10.71; %
Cl.sup.-=4.59:4.52
High-Resolution Mass Spectrometry (ESI+/HR, ESI-/LR):
Empirical formula: C.sub.41H.sub.43ClN.sub.6O.sub.5
[M+H].sup.+ calculated: 735.3056
[M+H].sup.+ measured: 735.3061
EXAMPLE 128
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-[1-(2-hydroxy-2-methylpropyl)-1H-pyrazol-4-yl]-N-(4-
-hydroxyphenyl)-1,2-dimethyl-1H-pyrrole-3-carboxamide
EXAMPLE 129
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-1,2-dimethyl-N-(1-methyl-2,3-dihydro-1H-pyrrolo[2,3-b-
]-pyridin-5-yl)-N-phenyl-1H-pyrrole-3-carboxamide
The title compound is obtained in accordance with the process
described in Step B of Example 49 using Example 106 as starting
material, it being understood that the product is not subjected to
the step of conversion into salt form.
Elemental Microanalysis: (%, Theoretical:Measured)
% C=70.53:70.51; % H=6.06:5.81; % N=11.75:11.71
High-Resolution Mass Spectrometry (ESI+-/FIA):
Empirical formula: C.sub.42H.sub.43ClN.sub.6O.sub.3
[M+H].sup.+ calculated: 715.3158
[M+H].sup.+ measured: 715.3159
EXAMPLE 130
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(4-fluorophenyl)-1,2-dimethyl-N-(1-methyl-2,3-dihyd-
ro-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 131
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-N,1,2-trimethyl-1H-pyrrole-3-carb-
oxamide
EXAMPLE 132
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(2-hydroxypyrimidin-5-yl)-1,2-dimethyl-N-phenyl-1H--
pyrrole-3-carboxamide
EXAMPLE 133
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(2-hydroxypyrimidin-5-yl)-1,2-dimethyl-N-(1-methyl--
1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 134
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(2-hydroxypyrimidin-5-yl)-1,2-dimethyl-N-(1-methyl--
2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 135
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(2-hydroxypyrimidin-5-yl)-1,2-dimethyl-N-(1-methyl--
1H-pyrazol-4-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 136
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-2-methyl-N-(1-methyl-1H-pyrazol-4-
-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 137
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-2-methyl-N-(1-methyl-1H-pyrrolo[2-
,3-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 138
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-2-methyl-N-(1-methyl-2,3-dihydro--
1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 139
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1-methyl-N-(1-methyl-1H-pyrazol-4-
-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 140
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1-methyl-N-(1-methyl-1H-pyrrolo[2-
,3-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 141
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1-methyl-N-(1-methyl-2,3-dihydro--
1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 142
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-1-ethyl-N-(4-hydroxyphenyl)-2-methyl-N-(1-methyl-1H-p-
yrazol-4-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 143
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-1-ethyl-N-(4-hydroxyphenyl)-2-methyl-N-(1-methyl-1H-p-
yrrolo[2,3-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 144
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-1-ethyl-N-(4-hydroxyphenyl)-2-methyl-N-(1-methyl-2,3--
dihydro-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 145
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1-(2-methoxyethyl)-2-methyl-N-(1--
methyl-1H-pyrazol-4-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 146
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1-(2-methoxyethyl)-2-methyl-N-(1--
methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 147
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1-(2-methoxyethyl)-2-methyl-N-(1--
methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 148
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-1-(2-fluoroethyl)-N-(4-hydroxyphenyl)-2-methyl-N-(1-m-
ethyl-1H-pyrazol-4-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 149
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-1-(2-fluoroethyl)-N-(4-hydroxyphenyl)-2-methyl-N-(1-m-
ethyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 150
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-1-(2-fluoroethyl)-N-(4-hydroxyphenyl)-2-methyl-N-(1-m-
ethyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 151
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-1-(2,2-difluoroethyl)-N-(4-hydroxyphenyl)-2-methyl-N--
(1-methyl-1H-pyrazol-4-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 152
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-1-(2,2-difluoroethyl)-N-(4-hydroxyphenyl)-2-methyl-N--
(1-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 153
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-1-(2,2-difluoroethyl)-N-(4-hydroxyphenyl)-2-methyl-N--
(1-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrrole-3-carboxam-
ide
EXAMPLE 154
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-2-methyl-N-(1-methyl-1H-pyrazol-4-
-yl)-1-(2,2,2-trifluoroethyl)-1H-pyrrole-3-carboxamide
EXAMPLE 155
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-2-methyl-N-(1-methyl-1H-pyrrolo[2-
,3-b]pyridin-5-yl)-1-(2,2,2-trifluoroethyl)-1H-pyrrole-3-carboxamide
EXAMPLE 156
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-2-methyl-N-(1-methyl-2,3-dihydro--
1H-pyrrolo[2,3-b]pyridin-5-yl)-1-(2,2,2-trifluoroethyl)-1H-pyrrole-3-carbo-
xamide
EXAMPLE 157
5-(5-Chloro-2-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}phe-
nyl)-N-(4-hydroxyphenyl)-2-methyl-N-(1-methyl-1H-pyrazol-4-yl)-1-[2-(morph-
olin-4-yl)ethyl]-1H-pyrrole-3-carboxamide
EXAMPLE 158
5-(5-Chloro-2-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}phe-
nyl)-N-(4-hydroxyphenyl)-2-methyl-N-(1-methyl-1H-pyrrolo[2,3-b]pyridin-5-y-
l)-1-[2-(morpholin-4-yl)ethyl]-1H-pyrrole-3-carboxamide
EXAMPLE 159
5-(5-Chloro-2-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}phe-
nyl)-N-(4-hydroxyphenyl)-2-methyl-N-(1-methyl-2,3-dihydro-1H-pyrrolo[2,3-b-
]pyridin-5-yl)-1-[2-(morpholin-4-yl)ethyl]-1H-pyrrole-3-carboxamide
EXAMPLE 160
5-(5-Chloro-2-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}phe-
nyl)-N-(4-hydroxyphenyl)-2-methyl-1-[2-(morpholin-4-yl)ethyl]-N-phenyl-1H--
pyrrole-3-carboxamide
EXAMPLE 161
5-(5-Chloro-2-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}phe-
nyl)-1-[2-(dimethylamino)ethyl]-N-(4-hydroxyphenyl)-2-methyl-N-(1-methyl-1-
H-pyrazol-4-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 162
5-(5-Chloro-2-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}phe-
nyl)-1-[2-(dimethylamino)ethyl]-N-(4-hydroxyphenyl)-2-methyl-N-phenyl-1H-p-
yrrole-3-carboxamide
EXAMPLE 163
5-(5-Chloro-2-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}phe-
nyl)-1-[2-(dimethylamino)ethyl]-N-(4-hydroxyphenyl)-2-methyl-N-(1-methyl-1-
H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 164
5-(5-Chloro-2-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}phe-
nyl)-1-[2-(dimethylamino)ethyl]-N-(4-hydroxyphenyl)-2-methyl-N-(1-methyl-2-
,3-dihydro-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 165
5-(5-Chloro-2-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]-carbonyl}ph-
enyl)-N-(4-hydroxyphenyl)-1-{2-[(2-methoxyethyl)(methyl)amino]ethyl}-2-met-
hyl-N-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 166
5-(5-Chloro-2-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]-carbonyl}ph-
enyl)-N-(4-hydroxyphenyl)-1-{2-[(2-methoxyethyl)(methyl)amino]ethyl}-2-met-
hyl-N-(1-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 167
5-(5-Chloro-2-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]-carbonyl}ph-
enyl)-N-(4-hydroxyphenyl)-1-{2-[(2-methoxyethyl)(methyl)amino]ethyl}-2-met-
hyl-N-(1-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrrole-3-ca-
rboxamide
EXAMPLE 168
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1-methyl-N-(1-methyl-1H-pyrazol-4-
-yl)-2-(trifluoromethyl)-1H-pyrrole-3-carboxamide
EXAMPLE 169
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1-methyl-N-(1-methyl-1H-pyrrolo[2-
,3-b]pyridin-5-yl)-2-(trifluoromethyl)-1H-pyrrole-3-carboxamide
EXAMPLE 170
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1-methyl-N-(1-methyl-2,3-dihydro--
1H-pyrrolo[2,3-b]pyridin-5-yl)-2-(trifluoromethyl)-1H-pyrrole-3-carboxamid-
e
EXAMPLE 171
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-2-(difluoromethyl)-N-(4-hydroxyphenyl)-1-methyl-N-(1--
methyl-1H-pyrazol-4-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 172
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-2-(difluoromethyl)-N-(4-hydroxyphenyl)-1-methyl-N-(1--
methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 173
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-2-(difluoromethyl)-N-(4-hydroxyphenyl)-1-methyl-N-(1--
methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 174
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-2-(methoxymethyl)-1-methyl-N-(1-m-
ethyl-1H-pyrazol-4-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 175
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-2-(methoxymethyl)-1-methyl-N-(1-m-
ethyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 176
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-2-(methoxymethyl)-1-methyl-N-(1-m-
ethyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 177
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1-methyl-N-(1-methyl-1H-pyrazol-4-
-yl)-2-(2,2,2-trifluoroethyl)-1H-pyrrole-3-carboxamide
EXAMPLE 178
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1-methyl-N-(1-methyl-1H-pyrrolo[2-
,3-b]pyridin-5-yl)-2-(2,2,2-trifluoroethyl)-1H-pyrrole-3-carboxamide
EXAMPLE 179
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1-methyl-N-(1-methyl-2,3-dihydro--
1H-pyrrolo[2,3-b]pyridin-5-yl)-2-(2,2,2-trifluoroethyl)-1H-pyrrole-3-carbo-
xamide
EXAMPLE 180
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-2-(2,2-difluoroethyl)-N-(4-hydroxyphenyl)-1-methyl-N--
(1-methyl-1H-pyrazol-4-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 181
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-2-(2,2-difluoroethyl)-N-(4-hydroxyphenyl)-1-methyl-N--
(1-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 182
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-2-(2,2-difluoroethyl)-N-(4-hydroxyphenyl)-1-methyl-N--
(1-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrrole-3-carboxam-
ide
EXAMPLE 183
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-2-(2-methoxyethyl)-1-methyl-N-(1--
methyl-1H-pyrazol-4-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 184
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-2-(2-methoxyethyl)-1-methyl-N-(1--
methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 185
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-2-(2-methoxyethyl)-1-methyl-N-(1--
methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 186
5-(5-Chloro-2-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}phe-
nyl)-N-(4-hydroxyphenyl)-1-methyl-N-(1-methyl-1H-pyrazol-4-yl)-2-(morpholi-
n-4-ylmethyl)-1H-pyrrole-3-carboxamide
EXAMPLE 187
5-(5-Chloro-2-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}phe-
nyl)-N-(4-hydroxyphenyl)-1-methyl-N-(1-methyl-1H-pyrrolo[2,3-b]pyridin-5-y-
l)-2-(morpholin-4-ylmethyl)-1H-pyrrole-3-carboxamide
EXAMPLE 188
5-(5-Chloro-2-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}phe-
nyl)-N-(4-hydroxyphenyl)-1-methyl-N-(1-methyl-2,3-dihydro-1H-pyrrolo[2,3-b-
]pyridin-5-yl)-2-(morpholin-4-ylmethyl)-1H-pyrrole-3-carboxamide
EXAMPLE 189
5-(5-Chloro-2-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}phe-
nyl)-N-(4-hydroxyphenyl)-1-methyl-N-(1-methyl-1H-pyrazol-4-yl)-2-[2-(morph-
olin-4-yl)ethyl]-1H-pyrrole-3-carboxamide
EXAMPLE 190
5-(5-Chloro-2-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}phe-
nyl)-N-(4-hydroxyphenyl)-1-methyl-N-(1-methyl-1H-pyrrolo[2,3-b]pyridin-5-y-
l)-2-[2-(morpholin-4-yl)ethyl]-1H-pyrrole-3-carboxamide
EXAMPLE 191
5-(5-Chloro-2-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}phe-
nyl)-N-(4-hydroxyphenyl)-1-methyl-N-(1-methyl-2,3-dihydro-1H-pyrrolo[2,3-b-
]pyridin-5-yl)-2-[2-(morpholin-4-yl)ethyl]-1H-pyrrole-3-carboxamide
EXAMPLE 192
5-(5-Chloro-2-{[(3S)-3-(trifluoromethyl)-3,4-dihydroisoquinolin-2(1H)-yl]c-
arbonyl}phenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-(1-methyl-1H-pyrrolo[2,-
3-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 193
5-(5-Chloro-2-{[(3S)-3-(trifluoromethyl)-3,4-dihydroisoquinolin-2(1H)-yl]c-
arbonyl}phenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-(1-methyl-2,3-dihydro-1-
H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 194
5-(5-Chloro-2-{[(3S)-3-(difluoromethyl)-3,4-dihydroisoquinolin-2(1H)-yl]ca-
rbonyl}phenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-(1-methyl-1H-pyrrolo[2,3-
-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 195
5-(5-Chloro-2-{[(3S)-3-(difluoromethyl)-3,4-dihydroisoquinolin-2(1H)-yl]ca-
rbonyl}phenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-(1-methyl-2,3-dihydro-1H-
-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 196
5-(5-Chloro-2-{[(3S)-3-(fluoromethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carb-
onyl}phenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-(1-methyl-1H-pyrrolo[2,3-b-
]pyridin-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 197
5-(5-Chloro-2-{[(3S)-3-(fluoromethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carb-
onyl}phenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-(1-methyl-2,3-dihydro-1H-p-
yrrolo[2,3-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 198
5-(5-Chloro-2-{[(3S)-3-[(9aS)-hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl-
methyl]-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}phenyl)-N-(4-hydroxypheny-
l)-1,2-dimethyl-N-(1-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrrole-3-ca-
rboxamide
EXAMPLE 199
5-(5-Chloro-2-{[(3S)-3-[(9aS)-hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl-
methyl]-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}phenyl)-N-(4-hydroxypheny-
l)-1,2-dimethyl-N-(1-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H--
pyrrole-3-carboxamide
EXAMPLE 200
5-(5-Chloro-2-{[(3S)-3-[(9aR)-hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl-
methyl]-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}phenyl)-N-(4-hydroxypheny-
l)-1,2-dimethyl-N-(1-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrrole-3-ca-
rboxamide
EXAMPLE 201
5-(5-Chloro-2-{[(3S)-3-[(9aR)-hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl-
methyl]-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}phenyl)-N-(4-hydroxypheny-
l)-1,2-dimethyl-N-(1-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H--
pyrrole-3-carboxamide
EXAMPLE 202
5-(2-{[(3S)-3-(Aminomethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-5-ch-
lorophenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-(1-methyl-1H-pyrazol-4-yl)--
1H-pyrrole-3-carboxamide
EXAMPLE 203
5-(2-{[(3S)-3-(Aminomethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-5-ch-
lorophenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-(1-methyl-1H-pyrrolo[2,3-b]-
pyridin-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 204
5-(2-{[(3S)-3-(Aminomethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-5-ch-
lorophenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-(1-methyl-2,3-dihydro-1H-py-
rrolo[2,3-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 205
5-(5-Chloro-2-{[(3S)-3-[(3-cyanoazetidin-1-yl)methyl]-3,4-dihydroisoquinol-
in-2(1H)-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-(1-methyl--
1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 206
5-(5-Chloro-2-{[(3S)-3-[(3-cyanoazetidin-1-yl)methyl]-3,4-dihydroisoquinol-
in-2(1H)-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-(1-methyl--
2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 207
5-(5-Chloro-2-{[(3S)-3-(1-oxa-6-azaspiro[3.3]hept-6-ylmethyl)-3,4-dihydroi-
soquinolin-2(1H)-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-(1-
-methyl-1H-pyrazol-4-yl)-1H-pyrrole-3-carboxamide
The title compound is obtained in accordance with the process of
Example 1 using the acid of Preparation 1 and the compound of
Preparation 8' in Step A, and the compound of Preparation 1'' in
Step C.
High-Resolution Mass Spectrometry (ESI+-/FIA/HR, ESI-/FIA):
Empirical formula: C.sub.39H.sub.39ClN.sub.6O.sub.4
[M+H].sup.+ calculated: 691.2794
[M+H].sup.+ measured: 691.2796
EXAMPLE 208
5-(5-Chloro-2-{[(3S)-3-(1-oxa-6-azaspiro[3.3]hept-6-ylmethyl)-3,4-dihydroi-
soquinolin-2(1H)-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-(1-
-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 209
5-(5-Fluoro-4-methoxy-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquin-
olin-2(1H)-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-(1-methy-
l-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide
hydrochloride
The procedure is in accordance with the general protocol of Example
1 using the appropriate Preparations. The product obtained is
finally dissolved in acetonitrile and converted into salt form
using 0.1M aqueous HCl solution. After a lyophilisation step, the
expected compound is obtained in the form of a solid.
Elemental Microanalysis: (%, Theoretical:Measured)
% C=66.27:66.84; % H=5.69:5.15; % N=10.78:10.71; %
Cl--=4.55:4.46
High-Resolution Mass Spectrometry (ESI+-/FIA):
Empirical formula: C.sub.43H.sub.43FN.sub.6O.sub.5
[M+H].sup.+ calculated: 743.3352
[M+H].sup.+ measured: 743.3353
EXAMPLE 210
5-(5-Fluoro-4-methoxy-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquin-
olin-2(1H)-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-(1-methy-
l-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide
hydrochloride
Step A:
5-(5-Fluoro-4-methoxy-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydr-
oisoquinolin-2(1H)-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N--
(1-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide
The title compound is obtained in accordance with the process of
Example 1 using the compound of Preparation 14 and
(3S)-3-(4-morpholinylmethyl)-1,2,3,4-tetrahydroisoquinoline (see
Preparation 3') in Step A, and the compound of Preparation 11'' in
Step C.
Step B:
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinol-
in-2(1H)-yl]carbonyl}phenyl)-1,2-dimethyl-N-(1-methyl-2,3-dihydro-1H-pyrro-
lo[2,3-b]pyridin-5-yl)-N-phenyl-1H-pyrrole-3-carboxamide
hydrochloride
The title compound is obtained in accordance with the process
described in Step B of Example 49 starting from compound of the
above Step, it being understood that the product is finally
subjected to a step of conversion into salt form in the presence of
1M HCl in ether. After filtration and lyophilisation in a mixture
of acetonitrile/water, the expected product is obtained.
Elemental Microanalysis: (%, Theoretical:Measured)
% C=60.12:59.77; % H=4.92:4.76; % N=10.79:10.39; %
Cl--=4.55:5.17
High-Resolution Mass Spectrometry (ESI/FIA/HR and MS/MS):
Empirical formula: C.sub.40H.sub.40N.sub.4O.sub.5
[M+H].sup.+ calculated: 657.3071
[M+H].sup.+ measured: 657.3066
EXAMPLE 211
5-(4-Fluoro-5-methoxy-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquin-
olin-2(1H)-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-(1-methy-
l-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 212
5-(4-Fluoro-5-methoxy-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquin-
olin-2(1H)-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-(1-methy-
l-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 213
N-(1-Ethyl-1H-pyrazol-4-yl)-5-(5-fluoro-2-{[(3S)-3-(morpholin-4-ylmethyl)--
3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1,2-d-
imethyl-1H-pyrrole-3-carboxamide
EXAMPLE 214
N-(1-Cyclopropyl-1H-pyrazol-4-yl)-5-(5-fluoro-2-{[(3S)-3-(morpholin-4-ylme-
thyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-
-1,2-dimethyl-1H-pyrrole-3-carboxamide hydrochloride
The title compound is obtained in accordance with the process of
Example 1 using the acid of Preparation 8 and the compound of
Preparation 3' in Step A, and the compound of Preparation 28'' in
Step C. The compound obtained is converted into salt form and
lyophilised as described in the general process to obtain the title
compound.
Elemental Microanalysis: (%, Theoretical:Measured)
% C=66.24:66.53; % H=5.84:5.39; % N=10.59:10.92%
Cl.sup.-=4.89:5.68
EXAMPLE 215
5-(5-Fluoro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-[1-(trifluoromethy-
l)-1H-pyrazol-4-yl]-1H-pyrrole-3-carboxamide
EXAMPLE 216
N-[1-(Difluoromethyl)-1H-pyrazol-4-yl]-5-(5-fluoro-2-{[(3S)-3-(morpholin-4-
-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}phenyl)-N-(4-hydroxyph-
enyl)-1,2-dimethyl-1H-pyrrole-3-carboxamide
EXAMPLE 217
5-(5-Fluoro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-N-[1-(2-methoxyethyl)-1H-pyrazol--
4-yl]-1,2-dimethyl-1H-pyrrole-3-carboxamide
EXAMPLE 218
5-(5-Fluoro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-[1-(oxetan-3-yl)-1-
H-pyrazol-4-yl]-1H-pyrrole-3-carboxamide
EXAMPLE 219
5-(5-Fluoro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-[1-(tetrahydrofura-
n-3-yl)-1H-pyrazol-4-yl]-1H-pyrrole-3-carboxamide
EXAMPLE 220
5-(5-Fluoro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-[1-(2-hydroxy-2-methylpropyl)-1H-pyrazol-4-yl]-N-(4-
-hydroxyphenyl)-1,2-dimethyl-1H-pyrrole-3-carboxamide
EXAMPLE 221
5-(5-Fluoro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-1,2-dimethyl-N-(1-methyl-1H-pyrrolo[2,3-b]pyridin-5-y-
l)-N-phenyl-1H-pyrrole-3-carboxamide
EXAMPLE 222
5-(5-Fluoro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-1,2-dimethyl-N-(1-methyl-2,3-dihydro-1H-pyrrolo[2,3-b-
]pyridin-5-yl)-N-phenyl-1H-pyrrole-3-carboxamide
EXAMPLE 223
5-(5-Fluoro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(4-fluorophenyl)-1,2-dimethyl-N-(1-methyl-1H-pyrrol-
o[2,3-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 224
5-(5-Fluoro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(4-fluorophenyl)-1,2-dimethyl-N-(1-methyl-2,3-dihyd-
ro-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 225
5-(5-Fluoro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-N,1,2-trimethyl-1H-pyrrole-3-carb-
oxamide
EXAMPLE 226
5-(5-Fluoro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(2-hydroxypyrimidin-5-yl)-1,2-dimethyl-N-phenyl-1H--
pyrrole-3-carboxamide
EXAMPLE 227
5-(5-Fluoro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(2-hydroxypyrimidin-5-yl)-1,2-dimethyl-N-(1-methyl--
1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 228
5-(5-Fluoro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(2-hydroxypyrimidin-5-yl)-1,2-dimethyl-N-(1-methyl--
2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 229
5-(5-Fluoro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(2-hydroxypyrimidin-5-yl)-1,2-dimethyl-N-(1-methyl--
1H-pyrazol-4-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 230
N-(5-Cyano-1-methyl-1H-pyrrol-3-yl)-5-(5-fluoro-2-{[(3S)-3-(morpholin-4-yl-
methyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}phenyl)-N-(4-hydroxypheny-
l)-1,2-dimethyl-1H-pyrrole-3-carboxamide hydrochloride
The title compound is obtained in accordance with the process of
Example 1 using the acid of Preparation 8 and the compound of
Preparation 3' in Step A, and the compound of Preparation 19'' in
Step C. The compound obtained is converted into salt form and
lyophilised as described in the general process to obtain the title
compound.
Elemental Microanalysis: (%, Theoretical:Measured)
% C=66.43:67.09; % H=5.57:5.21; % N=11.62:11.48%
Cl.sup.-=4.90:4.75
High-Resolution Mass Spectrometry (ESI+):
Empirical formula: C.sub.40H.sub.39FN.sub.6O.sub.4
[M+H].sup.+ calculated: 687.3097
[M+H].sup.+ measured: 687.3073
EXAMPLE 231
5-(5-Fluoro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-2-methyl-N-(1-methyl-1H-pyrazol-4-
-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 232
5-(5-Fluoro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-2-methyl-N-(1-methyl-1H-pyrrolo[2-
,3-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 233
5-(5-Fluoro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-2-methyl-N-(1-methyl-2,3-dihydro--
1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 234
5-(5-Fluoro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1-methyl-N-(1-methyl-1H-pyrazol-4-
-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 235
5-(5-Fluoro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1-methyl-N-(1-methyl-1H-pyrrolo[2-
,3-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 236
5-(5-Fluoro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1-methyl-N-(1-methyl-2,3-dihydro--
1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 237
1-Ethyl-5-(5-fluoro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinol-
in-2(1H)-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-2-methyl-N-(1-methyl-1H-p-
yrazol-4-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 238
1-Ethyl-5-(5-fluoro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinol-
in-2(1H)-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-2-methyl-N-(1-methyl-1H-p-
yrrolo[2,3-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 239
1-Ethyl-5-(5-fluoro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinol-
in-2(1H)-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-2-methyl-N-(1-methyl-2,3--
dihydro-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 240
5-(5-Fluoro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1-(2-methoxyethyl)-2-methyl-N-(1--
methyl-1H-pyrazol-4-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 241
5-(5-Fluoro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1-(2-methoxyethyl)-2-methyl-N-(1--
methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 242
5-(5-Fluoro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1-(2-methoxyethyl)-2-methyl-N-(1--
methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 243
1-(2-Fluoroethyl)-5-(5-fluoro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydr-
oisoquinolin-2(1H)-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-2-methyl-N-(1-m-
ethyl-1H-pyrazol-4-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 244
1-(2-Fluoroethyl)-5-(5-fluoro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydr-
oisoquinolin-2(1H)-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-2-methyl-N-(1-m-
ethyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 245
1-(2-Fluoroethyl)-5-(5-fluoro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydr-
oisoquinolin-2(1H)-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-2-methyl-N-(1-m-
ethyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 246
1-(2,2-Difluoroethyl)-5-(5-fluoro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-di-
hydroisoquinolin-2(1H)-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-2-methyl-N--
(1-methyl-1H-pyrazol-4-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 247
1-(2,2-Difluoroethyl)-5-(5-fluoro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-di-
hydroisoquinolin-2(1H)-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-2-methyl-N--
(1-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 248
1-(2,2-Difluoroethyl)-5-(5-fluoro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-di-
hydroisoquinolin-2(1H)-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-2-methyl-N--
(1-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrrole-3-carboxam-
ide
EXAMPLE 249
5-(5-Fluoro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-2-methyl-N-(1-methyl-1H-pyrazol-4-
-yl)-1-(2,2,2-trifluoroethyl)-1H-pyrrole-3-carboxamide
EXAMPLE 250
5-(5-Fluoro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-2-methyl-N-(1-methyl-1H-pyrrolo[2-
,3-b]pyridin-5-yl)-1-(2,2,2-trifluoroethyl)-1H-pyrrole-3-carboxamide
EXAMPLE 251
5-(5-Fluoro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-2-methyl-N-(1-methyl-2,3-dihydro--
1H-pyrrolo[2,3-b]pyridin-5-yl)-1-(2,2,2-trifluoroethyl)-1H-pyrrole-3-carbo-
xamide
EXAMPLE 252
5-(5-Fluoro-2-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}phe-
nyl)-N-(4-hydroxyphenyl)-2-methyl-N-(1-methyl-1H-pyrazol-4-yl)-1-[2-(morph-
olin-4-yl)ethyl]-1H-pyrrole-3-carboxamide
EXAMPLE 253
5-(5-Fluoro-2-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}phe-
nyl)-N-(4-hydroxyphenyl)-2-methyl-N-(1-methyl-1H-pyrrolo[2,3-b]pyridin-5-y-
l)-1-[2-(morpholin-4-yl)ethyl]-1H-pyrrole-3-carboxamide
EXAMPLE 254
5-(5-Fluoro-2-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}phe-
nyl)-N-(4-hydroxyphenyl)-2-methyl-N-(1-methyl-2,3-dihydro-1H-pyrrolo[2,3-b-
]pyridin-5-yl)-1-[2-(morpholin-4-yl)ethyl]-1H-pyrrole-3-carboxamide
EXAMPLE 255
5-(5-Fluoro-2-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}phe-
nyl)-N-(4-hydroxyphenyl)-2-methyl-1-[2-(morpholin-4-yl)ethyl]-N-phenyl-1H--
pyrrole-3-carboxamide
EXAMPLE 256
1-[2-(Dimethylamino)ethyl]-5-(5-fluoro-2-{[(3R)-3-methyl-3,4-dihydroisoqui-
nolin-2(1H)-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-2-methyl-N-(1-methyl-1-
H-pyrazol-4-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 257
1-[2-(Dimethylamino)ethyl]-5-(5-fluoro-2-{[(3R)-3-methyl-3,4-dihydroisoqui-
nolin-2(1H)-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-2-methyl-N-phenyl-1H-p-
yrrole-3-carboxamide
EXAMPLE 258
1-[2-(Dimethylamino)ethyl]-5-(5-fluoro-2-{[(3R)-3-methyl-3,4-dihydroisoqui-
nolin-2(1H)-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-2-methyl-N-(1-methyl-1-
H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 259
1-[2-(Dimethylamino)ethyl]-5-(5-fluoro-2-{[(3R)-3-methyl-3,4-dihydroisoqui-
nolin-2(1H)-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-2-methyl-N-(1-methyl-2-
,3-dihydro-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 260
5-(5-Fluoro-2-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]-carbonyl}ph-
enyl)-N-(4-hydroxyphenyl)-1-{2-[(2-methoxyethyl)(methyl)amino]ethyl}-2-met-
hyl-N-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 261
5-(5-Fluoro-2-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]-carbonyl}ph-
enyl)-N-(4-hydroxyphenyl)-1-{2-[(2-methoxyethyl)(methyl)amino]ethyl}-2-met-
hyl-N-(1-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 262
5-(5-Fluoro-2-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]-carbonyl}ph-
enyl)-N-(4-hydroxyphenyl)-1-{2-[(2-methoxyethyl)(methyl)amino]ethyl}-2-met-
hyl-N-(1-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrrole-3-ca-
rboxamide
EXAMPLE 263
5-(5-Fluoro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1-methyl-N-(1-methyl-1H-pyrazol-4-
-yl)-2-(trifluoromethyl)-1H-pyrrole-3-carboxamide
EXAMPLE 264
5-(5-Fluoro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1-methyl-N-(1-methyl-1H-pyrrolo[2-
,3-b]pyridin-5-yl)-2-(trifluoromethyl)-1H-pyrrole-3-carboxamide
EXAMPLE 265
5-(5-Fluoro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1-methyl-N-(1-methyl-2,3-dihydro--
1H-pyrrolo[2,3-b]pyridin-5-yl)-2-(trifluoromethyl)-1H-pyrrole-3-carboxamid-
e
EXAMPLE 266
2-(Difluoromethyl)-5-(5-fluoro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihyd-
roisoquinolin-2(1H)-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1-methyl-N-(1--
methyl-1H-pyrazol-4-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 267
2-(Difluoromethyl)-5-(5-fluoro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihyd-
roisoquinolin-2(1H)-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1-methyl-N-(1--
methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 268
2-(Difluoromethyl)-5-(5-fluoro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihyd-
roisoquinolin-2(1H)-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1-methyl-N-(1--
methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 269
5-(5-Fluoro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-2-(methoxymethyl)-1-methyl-N-(1-m-
ethyl-1H-pyrazol-4-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 270
5-(5-Fluoro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-2-(methoxymethyl)-1-methyl-N-(1-m-
ethyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 271
5-(5-Fluoro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-2-(methoxymethyl)-1-methyl-N-(1-m-
ethyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 272
5-(5-Fluoro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1-methyl-N-(1-methyl-1H-pyrazol-4-
-yl)-2-(2,2,2-trifluoroethyl)-1H-pyrrole-3-carboxamide
EXAMPLE 273
5-(5-Fluoro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1-methyl-N-(1-methyl-1H-pyrrolo[2-
,3-b]pyridin-5-yl)-2-(2,2,2-trifluoroethyl)-1H-pyrrole-3-carboxamide
EXAMPLE 274
5-(5-Fluoro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1-methyl-N-(1-methyl-2,3-dihydro--
1H-pyrrolo[2,3-b]pyridin-5-yl)-2-(2,2,2-trifluoroethyl)-1H-pyrrole-3-carbo-
xamide
EXAMPLE 275
2-(2,2-Difluoroethyl)-5-(5-fluoro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-di-
hydroisoquinolin-2(1H)-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1-methyl-N--
(1-methyl-1H-pyrazol-4-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 276
2-(2,2-Difluoroethyl)-5-(5-fluoro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-di-
hydroisoquinolin-2(1H)-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1-methyl-N--
(1-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 277
2-(2,2-Difluoroethyl)-5-(5-fluoro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-di-
hydroisoquinolin-2(1H)-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1-methyl-N--
methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 278
5-(5-Fluoro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-2-(2-methoxyethyl)-1-methyl-N-(1--
methyl-W-pyrazol-4-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 279
5-(5-Fluoro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-2-(2-methoxyethyl)-1-methyl-N-(1--
methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 280
5-(5-Fluoro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-2-(2-methoxyethyl)-1-methyl-N-(1--
methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 281
5-(5-Fluoro-2-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}phe-
nyl)-N-(4-hydroxyphenyl)-1-methyl-N-(1-methyl-1H-pyrazol-4-yl)-2-(morpholi-
n-4-ylmethyl)-1H-pyrrole-3-carboxamide
EXAMPLE 282
5-(5-Fluoro-2-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}phe-
nyl)-N-(4-hydroxyphenyl)-1-methyl-N-(1-methyl-1H-pyrrolo[2,3-b]pyridin-5-y-
l)-2-(morpholin-4-ylmethyl)-1H-pyrrole-3-carboxamide
EXAMPLE 283
5-(5-Fluoro-2-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}phe-
nyl)-N-(4-hydroxyphenyl)-1-methyl-N-(1-methyl-2,3-dihydro-1H-pyrrolo[2,3-b-
]pyridin-5-yl)-2-(morpholin-4-ylmethyl)-1H-pyrrole-3-carboxamide
EXAMPLE 284
5-(5-Fluoro-2-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}phe-
nyl)-N-(4-hydroxyphenyl)-1-methyl-N-(1-methyl-1H-pyrazol-4-yl)-2-[2-(morph-
olin-4-yl)ethyl]-1H-pyrrole-3-carboxamide
EXAMPLE 285
5-(5-Fluoro-2-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}phe-
nyl)-N-(4-hydroxyphenyl)-1-methyl-N-(1-methyl-1H-pyrrolo[2,3-b]pyridin-5-y-
l)-2-[2-(morpholin-4-yl)ethyl]-1H-pyrrole-3-carboxamide
EXAMPLE 286
5-(5-Fluoro-2-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}phe-
nyl)-N-(4-hydroxyphenyl)-1-methyl-N-(1-methyl-2,3-dihydro-1H-pyrrolo[2,3-b-
]pyridin-5-yl)-2-[2-(morpholin-4-yl)ethyl]-1H-pyrrole-3-carboxamide
EXAMPLE 287
5-(5-Fluoro-2-{[(3S)-3-(trifluoromethyl)-3,4-dihydroisoquinolin-2(1H)-yl]c-
arbonyl}phenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-(1-methyl-1H-pyrazol-4--
yl)-1H-pyrrole-3-carboxamide
EXAMPLE 288
5-(5-Fluoro-2-{[(3S)-3-(trifluoromethyl)-3,4-dihydroisoquinolin-2(1H)-yl]c-
arbonyl}phenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-(1-methyl-1H-pyrrolo[2,-
3-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 289
5-(5-Fluoro-2-{[(3S)-3-(trifluoromethyl)-3,4-dihydroisoquinolin-2(1H)-yl]c-
arbonyl}phenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-(1-methyl-2,3-dihydro-1-
H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 290
5-(2-{[(3S)-3-(Difluoromethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-5-
-fluorophenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-(1-methyl-1H-pyrazol-4-y-
l)-1H-pyrrole-3-carboxamide
EXAMPLE 291
5-(2-{[(3S)-3-(Difluoromethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-5-
-fluorophenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-(1-methyl-1H-pyrrolo[2,3-
-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 292
5-(2-{[(3S)-3-(Difluoromethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-5-
-fluorophenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-(1-methyl-2,3-dihydro-1H-
-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 293
5-(5-Fluoro-2-{[(3S)-3-(fluoromethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carb-
onyl}phenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-(1-methyl-1H-pyrazol-4-yl)-
-1H-pyrrole-3-carboxamide
EXAMPLE 294
5-(5-Fluoro-2-{[(3S)-3-(fluoromethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carb-
onyl}phenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-(1-methyl-1H-pyrrolo[2,3-b-
]pyridin-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 295
5-(5-Fluoro-2-{[(3S)-3-(fluoromethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carb-
onyl}phenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-(1-methyl-2,3-dihydro-1H-p-
yrrolo[2,3-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 296
5-(5-Fluoro-2-{[(3S)-3-(fluoromethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carb-
onyl}phenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-(1-methyl-2,3-dihydro-1H-p-
yrrolo[2,3-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 297
5-(5-Fluoro-2-{[(3S)-3-[(9aS)-hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl-
methyl]-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}phenyl)-N-(4-hydroxypheny-
l)-1,2-dimethyl-N-(1-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrrole-3-ca-
rboxamide
EXAMPLE 298
5-(5-Fluoro-2-{[(3S)-3-[(9aS)-hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl-
methyl]-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}phenyl)-N-(4-hydroxypheny-
l)-1,2-dimethyl-N-(1-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H--
pyrrole-3-carboxamide
EXAMPLE 299
5-(5-Fluoro-2-{[(3S)-3-[(9aR)-hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl-
methyl]-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}phenyl)-N-(4-hydroxypheny-
l)-1,2-dimethyl-N-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 300
5-(5-Fluoro-2-{[(3S)-3-[(9aR)-hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl-
methyl]-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}phenyl)-N-(4-hydroxypheny-
l)-1,2-dimethyl-N-(1-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrrole-3-ca-
rboxamide
EXAMPLE 301
5-(5-Fluoro-2-{[(3S)-3-[(9aR)-hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl-
methyl]-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}phenyl)-N-(4-hydroxypheny-
l)-1,2-dimethyl-N-(1-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H--
pyrrole-3-carboxamide
EXAMPLE 302
5-(2-{[(3S)-3-(Aminomethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-5-fl-
uorophenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-(1-methyl-1H-pyrazol-4-yl)--
1H-pyrrole-3-carboxamide
EXAMPLE 303
5-(2-{[(3S)-3-(Aminomethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-5-fl-
uorophenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-(1-methyl-pyrrolo[2,3-b]pyr-
idin-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 304
5-(2-{[(3S)-3-(Aminomethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-5-fl-
uorophenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-(1-methyl-2,3-dihydro-1H-py-
rrolo[2,3-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 305
5-(2-{[(3S)-3-[(3-Cyanoazetidin-1-yl)methyl]-3,4-dihydroisoquinolin-2(1H)--
yl]carbonyl}-5-fluorophenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-(1-methyl--
1H-pyrazol-4-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 306
5-(2-{[(3S)-3-[(3-Cyanoazetidin-1-yl)methyl]-3,4-dihydroisoquinolin-2(1H)--
yl]carbonyl}-5-fluorophenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-(1-methyl--
1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 307
5-(2-{[(3S)-3-[(3-Cyanoazetidin-1-yl)methyl]-3,4-dihydroisoquinolin-2(1H)--
yl]carbonyl}-5-fluorophenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-(1-methyl--
2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 308
5-(5-Fluoro-2-{[(3S)-3-(1-oxa-6-azaspiro[3.3]hept-6-ylmethyl)-3,4-dihydroi-
soquinolin-2(1H)-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-(1-
-methyl-1H-pyrazol-4-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 309
5-(5-Fluoro-2-{[(3S)-3-(1-oxa-6-azaspiro[3.3]hept-6-ylmethyl)-3,4-dihydroi-
soquinolin-2(1H)-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-(1-
-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 310
N-(1-Ethyl-1H-pyrazol-4-yl)-N-(4-hydroxyphenyl)-1,2-dimethyl-5-(6-{[(3S)-3-
-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-1,3-benz-
odioxol-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 311
N-(1-Cyclopropyl-1H-pyrazol-4-yl)-N-(4-hydroxyphenyl)-1,2-dimethyl-5-(6-{[-
(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-1,-
3-benzodioxol-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 312
N-(4-Hydroxyphenyl)-1,2-dimethyl-5-(6-{[(3S)-3-(morpholin-4-ylmethyl)-3,4--
dihydroisoquinolin-2(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-N-[1-(trifluor-
omethyl)-1H-pyrazol-4-yl]-1H-pyrrole-3-carboxamide
EXAMPLE 313
N-[1-(Difluoromethyl)-1H-pyrazol-4-yl]-N-(4-hydroxyphenyl)-1,2-dimethyl-5--
(6-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbony-
l}-1,3-benzodioxol-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 314
N-(4-Hydroxyphenyl)-N-[1-(2-methoxyethyl)-1H-pyrazol-4-yl]-1,2-dimethyl-5--
(6-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbony-
l}-1,3-benzodioxol-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 315
N-(4-Hydroxyphenyl)-1,2-dimethyl-5-(6-{[(3S)-3-(morpholin-4-ylmethyl)-3,4--
dihydroisoquinolin-2(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-N-[1-(oxetan-3-
-yl)-1H-pyrazol-4-yl]-1H-pyrrole-3-carboxamide
EXAMPLE 316
N-(4-Hydroxyphenyl)-1,2-dimethyl-5-(6-{[(3S)-3-(morpholin-4-ylmethyl)-3,4--
dihydroisoquinolin-2(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-N-[1-(tetrahyd-
rofuran-3-yl)-1H-pyrazol-4-yl]-1H-pyrrole-3-carboxamide
EXAMPLE 317
N-[1-(2-Hydroxy-2-methylpropyl)-1H-pyrazol-4-yl]-N-(4-hydroxyphenyl)-1,2-d-
imethyl-5-(6-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)--
yl]carbonyl}-1,3-benzodioxol-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 318
1,2-Dimethyl-N-(1-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-5-(6-{[(3S)-3-(mor-
pholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-1,3-benzodiox-
ol-5-yl)-N-phenyl-1H-pyrrole-3-carboxamide
EXAMPLE 319
1,2-Dimethyl-N-(1-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-5-yl)-5-(6-{-
[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-1-
,3-benzodioxol-5-yl)-N-phenyl-1H-pyrrole-3-carboxamide
EXAMPLE 320
N-(4-Fluorophenyl)-1,2-dimethyl-N-(1-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-
-5-(6-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carb-
onyl}-1,3-benzodioxol-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 321
N-(4-Fluorophenyl)-1,2-dimethyl-N-(1-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]p-
yridin-5-yl)-5-(6-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2-
(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 322
N-(4-Hydroxyphenyl)-N,1,2-trimethyl-5-(6-{[(3S)-3-(morpholin-4-ylmethyl)-3-
,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-1H-pyrrole--
3-carboxamide
EXAMPLE 323
N-(2-Hydroxypyrimidin-5-yl)-1,2-dimethyl-5-(6-{[(3S)-3-(morpholin-4-ylmeth-
yl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-N-phen-
yl-1H-pyrrole-3-carboxamide
EXAMPLE 324
N-(2-Hydroxypyrimidin-5-yl)-1,2-dimethyl-N-(1-methyl-1H-pyrrolo[2,3-b]pyri-
din-5-yl)-5-(6-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H-
)-yl]carbonyl}-1,3-benzodioxol-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 325
N-(2-Hydroxypyrimidin-5-yl)-1,2-dimethyl-N-(1-methyl-2,3-dihydro-1H-pyrrol-
o[2,3-b]pyridin-5-yl)-5-(6-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoq-
uinolin-2(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 326
N-(2-Hydroxypyrimidin-5-yl)-1,2-dimethyl-N-(1-methyl-1H-pyrazol-4-yl)-5-(6-
-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-
-1,3-benzodioxol-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 327
N-(5-Cyano-1-methyl-1H-pyrrol-3-yl)-N-(4-hydroxyphenyl)-1,2-dimethyl-5-(6--
{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}--
1,3-benzodioxol-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 328
N-(4-Hydroxyphenyl)-2-methyl-N-(1-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-5--
(6-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbony-
l}-1,3-benzodioxol-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 329
N-(4-Hydroxyphenyl)-2-methyl-N-(1-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-5--
(6-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbony-
l}-1,3-benzodioxol-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 330
N-(4-Hydroxyphenyl)-1-methyl-N-(1-methyl-1H-pyrazol-4-yl)-5-(6-{[(3S)-3-(m-
orpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-1,3-benzodi-
oxol-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 331
N-(4-Hydroxyphenyl)-1-methyl-N-(1-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-5--
(6-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbony-
l}-1,3-benzodioxol-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 332
N-(4-Hydroxyphenyl)-1-methyl-N-(1-methyl-2,3-dihydro-1H-pyrrolo-[2,3-b]pyr-
idin-5-yl)-5-(6-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1-
H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 333
1-Ethyl-N-(4-hydroxyphenyl)-2-methyl-N-(1-methyl-1H-pyrrolo[2,3-b]-pyridin-
-5-yl)-5-(6-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-y-
l]-carbonyl}-1,3-benzodioxol-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 334
1-Ethyl-N-(4-hydroxyphenyl)-2-methyl-N-(1-methyl-2,3-dihydro-1H-pyrrolo[2,-
3-b]pyridin-5-yl)-5-(6-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquino-
lin-2(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 335
N-(4-Hydroxyphenyl)-1-(2-methoxyethyl)-2-methyl-N-(1-methyl-1H-pyrrolo[2,3-
-b]pyridin-5-yl)-5-(6-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinol-
in-2(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 336
N-(4-Hydroxyphenyl)-1-(2-methoxyethyl)-2-methyl-N-(1-methyl-2,3-dihydro-1H-
-pyrrolo[2,3-b]pyridin-5-yl)-5-(6-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihy-
droisoquinolin-2(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-1H-pyrrole-3-carbo-
xamide
EXAMPLE 337
1-(2-Fluoroethyl)-N-(4-hydroxyphenyl)-2-methyl-N-(1-methyl-1H-pyrrolo[2,3--
b]pyridin-5-yl)-5-(6-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinoli-
n-2(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 338
1-(2-Fluoroethyl)-N-(4-hydroxyphenyl)-2-methyl-N-(1-methyl-2,3-dihydro-1H--
pyrrolo[2,3-b]pyridin-5-yl)-5-(6-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihyd-
roisoquinolin-2(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-1H-pyrrole-3-carbox-
amide
EXAMPLE 339
1-(2,2-Difluoroethyl)-N-(4-hydroxyphenyl)-2-methyl-N-(1-methyl-1H-pyrrolo[-
2,3-b]pyridin-5-yl)-5-(6-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoqui-
nolin-2(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 340
1-(2,2-Difluoroethyl)-N-(4-hydroxyphenyl)-2-methyl-N-(1-methyl-2,3-dihydro-
-1H-pyrrolo[2,3-b]pyridin-5-yl)-5-(6-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-d-
ihydroisoquinolin-2(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-1H-pyrrole-3-ca-
rboxamide
EXAMPLE 341
N-(4-Hydroxyphenyl)-2-methyl-N-(1-methyl-1H-pyrazol-4-yl)-5-(6-{[(3S)-3-(m-
orpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-1,3-benzodi-
oxol-5-yl)-1-(2,2,2-trifluoroethyl)-1H-pyrrole-3-carboxamide
EXAMPLE 342
N-(4-Hydroxyphenyl)-2-methyl-N-(1-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-5--
(6-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbony-
l}-1,3-benzodioxol-5-yl)-1-(2,2,2-trifluoroethyl)-1H-pyrrole-3-carboxamide
EXAMPLE 343
N-(4-Hydroxyphenyl)-2-methyl-N-(1-methyl-2,3-dihydro-1H-pyrrolo-[2,3-b]pyr-
idin-5-yl)-5-(6-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1-
H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-1-(2,2,2-trifluoroethyl)-1H-pyrrole--
3-carboxamide
EXAMPLE 344
N-(4-Hydroxyphenyl)-2-methyl-5-(6-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2-
(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-N-(1-methyl-1H-pyrrolo[2,3-b]pyrid-
in-5-yl)-1-[2-(morpholin-4-yl)ethyl]-1H-pyrrole-3-carboxamide
EXAMPLE 345
N-(4-Hydroxyphenyl)-2-methyl-5-(6-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2-
(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-N-(1-methyl-2,3-dihydro-1H-pyrrolo-
[2,3-b]pyridin-5-yl)-1-[2-(morpholin-4-yl)ethyl]-1H-pyrrole-3-carboxamide
EXAMPLE 346
1-[2-(Dimethylamino)ethyl]-N-(4-hydroxyphenyl)-2-methyl-5-(6-{[(3R)-3-meth-
yl-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-N-(1-me-
thyl-1H-pyrazol-4-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 347
1-[2-(Dimethylamino)ethyl]-N-(4-hydroxyphenyl)-2-methyl-5-(6-{[(3R)-3-meth-
yl-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-N-(1-me-
thyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 348
1-[2-(Dimethylamino)ethyl]-N-(4-hydroxyphenyl)-2-methyl-5-(6-{[(3R)-3-meth-
yl-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-N-(1-me-
thyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 349
N-(4-Hydroxyphenyl)-1-{2-[(2-methoxyethyl)(methyl)amino]ethyl}-2-methyl-5--
(6-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-1,3-benzodiox-
ol-5-yl)-N-(1-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrrole-3-carboxami-
de
EXAMPLE 350
N-(4-Hydroxyphenyl)-1-{2-[(2-methoxyethyl)(methyl)amino]ethyl}-2-methyl-5--
(6-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-1,3-benzodiox-
ol-5-yl)-N-(1-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrrole-
-3-carboxamide
EXAMPLE 351
N-(4-Hydroxyphenyl)-1-methyl-N-(1-methyl-2,3-dihydro-1H-pyrrolo-[2,3-b]pyr-
idin-5-yl)-5-(6-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1-
H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-2-(trifluoromethyl)-1H-pyrrole-3-car-
boxamide
EXAMPLE 352
2-(Difluoromethyl)-N-(4-hydroxyphenyl)-1-methyl-N-(1-methyl-2,3-dihydro-1H-
-pyrrolo[2,3-b]pyridin-5-yl)-5-(6-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihy-
droisoquinolin-2(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-1H-pyrrole-3-carbo-
xamide
EXAMPLE 353
N-(4-Hydroxyphenyl)-2-(methoxymethyl)-1-methyl-N-(1-methyl-2,3-dihydro-1H--
pyrrolo[2,3-b]pyridin-5-yl)-5-(6-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihyd-
roisoquinolin-2(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-1H-pyrrole-3-carbox-
amide
EXAMPLE 354
N-(4-Hydroxyphenyl)-1-methyl-N-(1-methyl-1H-pyrazol-4-yl)-5-(6-{[(3S)-3-(m-
orpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-1,3-benzodi-
oxol-5-yl)-2-(2,2,2-trifluoroethyl)-1H-pyrrole-3-carboxamide
EXAMPLE 355
N-(4-Hydroxyphenyl)-1-methyl-N-(1-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-5--
(6-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbony-
l}-1,3-benzodioxol-5-yl)-2-(2,2,2-trifluoroethyl)-1H-pyrrole-3-carboxamide
EXAMPLE 356
N-(4-Hydroxyphenyl)-1-methyl-N-(1-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyri-
din-5-yl)-5-(6-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H-
)-yl]carbonyl}-1,3-benzodioxol-5-yl)-2-(2,2,2-trifluoroethyl)-1H-pyrrole-3-
-carboxamide
EXAMPLE 357
2-(2,2-Difluoroethyl)-N-(4-hydroxyphenyl)-1-methyl-N-(1-methyl-2,3-dihydro-
-1H-pyrrolo[2,3-b]pyridin-5-yl)-5-(6-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-d-
ihydroisoquinolin-2(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-1H-pyrrole-3-ca-
rboxamide
EXAMPLE 358
N-(4-Hydroxyphenyl)-2-(2-methoxyethyl)-1-methyl-N-(1-methyl-2,3-dihydro-1H-
-pyrrolo[2,3-b]pyridin-5-yl)-5-(6-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihy-
droisoquinolin-2(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-1H-pyrrole-3-carbo-
xamide hydrochloride
The title compound is obtained in accordance with the process
described in Step B of Example 49 using Example 88 as starting
material, it being understood that the product is finally dissolved
in acetonitrile and converted into salt form in 0.1M aqueous HCl
solution. After a lyophilisation step, the expected product is
obtained in the form of a solid.
Elemental Microanalysis: (%, Theoretical:Measured)
% C=65.80:64.71; % H=6.01:5.74; % N=10.23:10.03; %
Cl--=4.32:6.47
High-Resolution Mass Spectrometry (ESI/+):
Empirical formula: C.sub.45H.sub.48N.sub.6O.sub.7
[M+H].sup.+ calculated: 785.3657
[M+H].sup.+ measured: 785.3658
EXAMPLE 359
N-(4-Hydroxyphenyl)-1-methyl-5-(6-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2-
(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-N-(1-methyl-2,3-dihydro-1H-pyrrolo-
[2,3-b]pyridin-5-yl)-2-(morpholin-4-ylmethyl)-1H-pyrrole-3-carboxamide
EXAMPLE 360
N-(4-Hydroxyphenyl)-1-methyl-5-(6-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2-
(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-N-(1-methyl-2,3-dihydro-1H-pyrrolo-
[2,3-b]pyridin-5-yl)-2-[2-(morpholin-4-yl)ethyl]-1H-pyrrole-3-carboxamide
EXAMPLE 361
N-(4-Hydroxyphenyl)-1,2-dimethyl-N-(1-methyl-1H-pyrazol-4-yl)-5-(6-{[(3S)--
3-(trifluoromethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-1,3-benzodio-
xol-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 362
N-(4-Hydroxyphenyl)-1,2-dimethyl-N-(1-methyl-1H-pyrrolo[2,3-b]-pyridin-5-y-
l)-5-(6-{[(3S)-3-(trifluoromethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbony-
l}-1,3-benzodioxol-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 363
N-(4-Hydroxyphenyl)-1,2-dimethyl-N-(1-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]-
pyridin-5-yl)-5-(6-{[(3S)-3-(trifluoromethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}-1,3-benzodioxol-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 364
5-(6-{[(3S)-3-(Difluoromethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-1-
,3-benzodioxol-5-yl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-(1-methyl-1H-pyraz-
ol-4-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 365
5-(6-{[(3S)-3-(Difluoromethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-1-
,3-benzodioxol-5-yl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-(1-methyl-1H-pyrro-
lo[2,3-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 366
5-(6-{[(3S)-3-(Difluoromethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-1-
,3-benzodioxol-5-yl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-(1-methyl-2,3-dihy-
dro-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 367
5-(6-{[(3S)-3-(Fluoromethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-1,3-
-benzodioxol-5-yl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-(1-methyl-1H-pyrazol-
-4-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 368
5-(6-{[(3S)-3-(Fluoromethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-1,3-
-benzodioxol-5-yl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-(1-methyl-1H-pyrrolo-
[2,3-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 369
5-(6-{[(3S)-3-(Fluoromethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-1,3-
-benzodioxol-5-yl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-(1-methyl-2,3-dihydr-
o-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 370
5-(6-{[(3S)-3-[(9aS)-Hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-ylmethyl]-3-
,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-N-(4-hydrox-
yphenyl)-1,2-dimethyl-N-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrole-3-carboxamid-
e
EXAMPLE 371
5-(4-{[(3S)-3-[(9aS)-Hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-ylmethyl]-3-
,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-N-(4-hydrox-
yphenyl)-1,2-dimethyl-N-(1-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrrol-
e-3-carboxamide
EXAMPLE 372
5-(6-{[(3S)-3-[(9aS)-Hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-ylmethyl]-3-
,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-N-(4-hydrox-
yphenyl)-1,2-dimethyl-N-(1-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-5-y-
l)-1H-pyrrole-3-carboxamide
EXAMPLE 373
5-(6-{[(3S)-3-[(9aR)-Hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-ylmethyl]-3-
,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-N-(4-hydrox-
yphenyl)-1,2-dimethyl-N-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrole-3-carboxamid-
e
EXAMPLE 374
5-(6-{[(3S)-3-[(9aR)-Hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-ylmethyl]-3-
,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-N-(4-hydrox-
yphenyl)-1,2-dimethyl-N-(1-methyl-W-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrrole-
-3-carboxamide
EXAMPLE 375
5-(6-{[(3S)-3-[(9aR)-Hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-ylmethyl]-3-
,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-N-(4-hydrox-
yphenyl)-1,2-dimethyl-N-(1-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-5-y-
l)-1H-pyrrole-3-carboxamide
EXAMPLE 376
5-(6-{[(3S)-3-(Aminomethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-1,3--
benzodioxol-5-yl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-(1-ethyl-1H-pyrazol-4-
-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 377
5-(6-{[(3S)-3-(Aminomethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-1,3--
benzodioxol-5-yl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-(1-ethyl-1H-pyrrolo[2-
,3-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 378
5-(6-{[(3S)-3-(Aminomethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-1,3--
benzodioxol-5-yl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-(1-methyl-2,3-dihydro-
-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 379
5-(6-{[(3S)-3-[(3-Cyanoazetidin-1-yl)methyl]-3,4-dihydroisoquinolin-2(1H)--
yl]carbonyl}-1,3-benzodioxol-5-yl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-(1-m-
ethyl-1H-pyrazol-4-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 380
5-(6-{[(3S)-3-[(3-Cyanoazetidin-1-yl)methyl]-3,4-dihydroisoquinolin-2(1H)--
yl]carbonyl}-1,3-benzodioxol-5-yl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-(1-m-
ethyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 381
5-(6-{[(3S)-3-[(3-Cyanoazetidin-1-yl)methyl]-3,4-dihydroisoquinolin-2(1H)--
yl]carbonyl}-1,3-benzodioxol-5-yl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-(1-m-
ethyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 382
N-(4-Hydroxyphenyl)-1,2-dimethyl-N-(1-methyl-1H-pyrazol-4-yl)-5-(6-{[(3S)--
3-(1-oxa-6-azaspiro[3.3]hept-6-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]c-
arbonyl}-1,3-benzodioxol-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 383
N-(4-Hydroxyphenyl)-1,2-dimethyl-N-(1-methyl-1H-pyrrolo[2,3-b]-pyridin-5-y-
l)-5-(6-{[(3S)-3-(1-oxa-6-azaspiro[3.3]hept-6-ylmethyl)-3,4-dihydroisoquin-
olin-2(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-1H-pyrrole-3-carboxamide
EXAMPLE 384
5-(5-Fluoro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-(pyridin-4-yl)-1H--
pyrrole-3-carboxamide hydrochloride
Elemental Microanalysis: (%, Theoretical:Measured)
% C=67.28:67.73; % H=5.65:5.30; % N=10.06:9.41% Cl--=5.09:5.79
EXAMPLE 385
5-(5-Fluoro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-(1-methyl-1H-pyrro-
lo[2,3-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide hydrochloride
High-Resolution Mass Spectrometry (ESI+):
Empirical formula: C.sub.41H.sub.41ClN.sub.6O.sub.4
[M+H].sup.+ calculated: 713.3253
[M+H].sup.+ measured: 713.3272
EXAMPLE 386
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(5-cyano-1,2-dimethyl-1H-pyrrol-3-yl)-N-(4-hydroxyp-
henyl)-1,2-dimethyl-1H-pyrrole-3-carboxamide hydrochloride
Step A:
N-[4-[tert-Butyl(dimethyl)silyl]oxyphenyl]-5-[5-chloro-2-[(3S)-3-(-
morpholinomethyl)-3,4-dihydro-1H-isoquinoline-2-carbonyl]phenyl]-N-(5-cyan-
o-1,2-dimethyl-pyrrol-3-yl)-1,2-dimethyl-pyrrole-3-carboxamide
The title compound is obtained in accordance with the process of
Example 1 using the acid of Preparation 1 and the compound of
Preparation 3' in Step A, and the compound of Preparation 18'' in
Step C.
IR: .nu. --CN--: 2210 cm.sup.-1; .nu. --C.dbd.O--: 1631
cm.sup.-1
Step B:
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinol-
in-2(1H)-yl]carbonyl}phenyl)-N-(5-cyano-1,2-dimethyl-1H-pyrrol-3-yl)-N-(4--
hydroxyphenyl)-1,2-dimethyl-1H-pyrrole-3-carboxamide
hydrochloride
The compound of Step A is deprotected in accordance with the
protocol described in Step D of Example 1. The product thereby
obtained is finally subjected to a step of conversion into salt
form in the presence of HCl in ether. After filtration and
lyophilisation in a mixture of acetonitrile/water, the expected
product is obtained.
.sup.1H NMR (500 MHz, dmso-d6) .delta. ppm: 11.2 (bs, 1H), 9.39
(bs, 1H), 7.83 (d, 1H), 7.54 (d, 1H), 7.33 (s, 1H), 7.14 (m, 2H), 7
(m, 2H), 6.8 (d, 2H), 6.62 (d, 2H), 6.57 (bs, 1H), 5.26 (s, 1H),
5.26 (m, 1H), 4.64/4.03 (AB, 2H), 4.01/3.92 (2m, 4H),
3.75/3.43/3.15/3.02 (4m, 4H), 3.59 (s, 3H), 3.3/3.15 (2m, 2H), 2.97
(s, 3H), 2.69/2.52 (dd+d, 2H), 2.06 (s, 3H), 1.91 (s, 3H)
Elemental Microanalysis: (%, Theoretical:Measured)
% C=65.34:65.50; % H=5.62:5.15; % N=11.15:10.84% Cl--=4.70:4.44
High-Resolution Mass Spectrometry (ESI+):
Empirical formula: C.sub.41H.sub.41ClN.sub.6O.sub.4
[M+H].sup.+ calculated: 717.2952
[M+H].sup.+ measured: 717.2951
EXAMPLE 387
N-(4-Hydroxyphenyl)-1,2-dimethyl-N-(1-methyl-1H-pyrrolo[2,3-c]pyridin-5-yl-
)-5-(6-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]car-
bonyl}-1,3-benzodioxol-5-yl)-1H-pyrrole-3-carboxamide
hydrochloride
Elemental Microanalysis: (%, Theoretical:Measured)
% C=66.62:66.36; % H=5.59:5.62; % N=10.84:10.72% Cl--=4.57:4.55
High-Resolution Mass Spectrometry (ESI+):
Empirical formula: C.sub.43H.sub.42N.sub.6O.sub.6
[M+H].sup.+ calculated: 739.3239
[M+H].sup.+ measured: 739.3241
EXAMPLE 388
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-(1-methyl-2,3-dihy-
dro-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide
dihydrochloride
The title compound is obtained in accordance with the process
described in Step B of Example 49 using Example 71 as starting
material, it being understood that the product is finally subjected
to a step of conversion into salt form in the presence of 1M HCl in
ether. After filtration and lyophilisation in a mixture of
acetonitrile/water, the expected compound is obtained.
Elemental Microanalysis: (%, Theoretical:Measured)
% C=62.73:62.96; % H=5.64:4.95; % N=10.45:10.32; %
Cl=13.23:12.91
High-Resolution Mass Spectrometry (ESI+):
Empirical formula: C.sub.42H.sub.43ClN.sub.6O.sub.4
[M+H].sup.+ calculated: 731.3107
[M+H].sup.+ measured: 731.3111
EXAMPLE 389
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-(1-methyl-1H-pyrro-
lo[2,3-c]pyridin-5-yl)-1H-pyrrole-3-carboxamide hydrochloride
The procedure is in accordance with the general protocol of Example
1 using the appropriate Preparations. The product obtained is
finally dissolved in acetonitrile and converted into salt form
using 0.1M aqueous HCl solution. After a lyophilisation step, the
expected compound is obtained in the form of a solid.
Elemental Microanalysis: (%, Theoretical:Measured)
% C=65.88:66.28; % H=5.53:5.15; % N=10.98:10.95; %
Cl--=4.63:4.47
High-Resolution Mass Spectrometry (ESI/FIA/HR and MS/MS):
Empirical formula: C.sub.42H.sub.41ClN.sub.6O.sub.4
[M+H].sup.+ calculated: 729.2951
[M+H].sup.+ measured: 729.2954
EXAMPLE 390
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-1,2-dimethyl-N-(1-methyl-1H-pyrrolo[2,3-b]pyridin-5-y-
l)-N-phenyl-1H-pyrrole-3-carboxamide
The procedure is in accordance with the general protocol of Example
1 using the appropriate Preparations, it being understood that Step
D is not carried out. The expected product is obtained in free base
form.
Elemental Microanalysis: (%, Theoretical:Measured)
% C=70.72:69.77; % H=5.79:5.96; % N=11.78:11.43
High-Resolution Mass Spectrometry (ESI+):
Empirical formula: C.sub.42H.sub.41ClN.sub.6O.sub.3
[M+H].sup.+ calculated: 713.3001
[M+H].sup.+ measured: 713.2998
EXAMPLE 391
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-(1-methyl-1H-pyrro-
lo[3,2-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide hydrochloride
Elemental Microanalysis: (%, Theoretical:Measured)
% C=65.88:65.69; % H=5.33:4.87; % N=10.98:10.86; %
Cl--=4.63:4.51
High-Resolution Mass Spectrometry (ESI+-/FIA):
Empirical formula: C.sub.42H.sub.41ClN.sub.6O.sub.4
[M+H].sup.+ calculated: 729.2951
[M+H].sup.+ measured: 729.2953
EXAMPLE 392
5-(5-Chloro-2-{[(3R)-3-[3-(morpholin-4-yl)propyl]-3,4-dihydroisoquinolin-2-
(1H)-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-phenyl-1H-pyrr-
ole-3-carboxamide hydrochloride
Elemental Microanalysis: (%, Theoretical:Measured)
% C=68.19:68.33; % H=6.00:5.49; % N=10.78:10.71; % Cl--=4.55:4.46;
% Cl=9.58:9.78
High-Resolution Mass Spectrometry (ESI+-/FIA):
Empirical formula: C.sub.42H.sub.43ClN.sub.4O.sub.4
[M+H].sup.+ calculated: 703.3046
[M+H].sup.+ measured: 703.3042
EXAMPLE 393
5-(5-Chloro-2-{[(3R)-3-[3-(morpholin-4-yl)propyl]-3,4-dihydroisoquinolin-2-
(1H)-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-(1-methyl-1H-p-
yrrolo[2,3-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide
hydrochloride
High-Resolution Mass Spectrometry (ESI+-/FIA):
Empirical formula: C.sub.44H.sub.45ClN.sub.6O.sub.4
[M+H].sup.+ calculated: 757.3264
[M+H].sup.+ measured: 757.3263
EXAMPLE 394
5-(5-Chloro-2-{[(3R)-3-[3-(morpholin-4-yl)propyl]-3,4-dihydroisoquinolin-2-
(1H)-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-(1-methyl-2,3--
dihydro-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide
The title compound is obtained in accordance with the process
described in Step B of Example 49 using Example 393 as starting
material, it being understood that the product is not subjected to
the step of conversion into salt form.
Elemental Microanalysis: (%, Theoretical:Measured)
% C=69.60:69.56; % H=6.21:6.24; % N=11.07:11.08
High-Resolution Mass Spectrometry (ESI+-/FIA):
Empirical formula: C.sub.44H.sub.47ClN.sub.6O.sub.4
[M+H].sup.+ calculated: 759.3420
[M+H].sup.+ measured: 759.3422
EXAMPLE 395
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(3-cyano-4-methoxyphenyl)-N-(4-hydroxyphenyl)-1,2-d-
imethyl-1H-pyrrole-3-carboxamide hydrochloride
The procedure is in accordance with the general protocol of Example
1 using the appropriate Preparations. The product obtained is
finally dissolved in acetonitrile and converted into salt form
using 0.1M aqueous HCl solution. After a lyophilisation step, the
expected compound is obtained in the form of a solid.
High-Resolution Mass Spectrometry (ESI/FIA/HR and MS/MS):
Empirical formula: C.sub.42H.sub.40ClN.sub.5O.sub.5
[M+H].sup.+ calculated: 730.2791
[M+H].sup.+ measured: 730.2790
EXAMPLE 396
N-(3-Fluoro-4-hydroxyphenyl)-1,2-dimethyl-N-(1-methyl-1H-pyrazol-4-yl)-5-(-
6-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl-
}-1,3-benzodioxol-5-yl)-1H-pyrrole-3-carboxamide hydrochloride
The title compound is obtained in accordance with the process of
Example 1 using the acid of Preparation 11 and
(3S)-3-(4-morpholinylmethyl)-1,2,3,4-tetrahydroisoquinoline (see
Preparation 3') in Step A, and the compound of Preparation 20'' in
Step C. The product obtained is finally subjected to a step of
conversion into salt form in the presence of 1M HCl in ether. After
filtration and lyophilisation in a mixture of acetonitrile/water,
the expected compound is obtained.
Elemental Microanalysis: (%, Theoretical:Measured)
% C=65.79:65.43; % H=5.39:5.19; % N=11.31:11.21; %
Cl--=4.77:4.34
High-Resolution Mass Spectrometry (ESI/FIA/HR and MS/MS):
Empirical formula: C.sub.39H.sub.39FN.sub.6O.sub.6
[M+H].sup.+ calculated: 707.2988
[M+H].sup.+ measured: 707.2988
EXAMPLE 397
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-N-(2-methoxypyrimidin-5-yl)-1,2-d-
imethyl-1H-pyrrole-3-carboxamide
High-Resolution Mass Spectrometry (ESI+):
Empirical formula: C.sub.39H.sub.39ClN.sub.6O.sub.5
[M+H].sup.+ calculated: 707.2743
[M+H].sup.+ measured: 707.2746
EXAMPLE 398
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(3-cyanophenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-1H-
-pyrrole-3-carboxamide hydrochloride
Elemental Microanalysis: (%, Theoretical:Measured)
% C=66.85:66.75; % H=5.34:5.42; % N=9.51:9.73; % Cl=9.62:9.67; %
Cl.sup.-=4.81:4.71
High-Resolution Mass Spectrometry (ESI+-/FIA/HR, ESI-/FIA):
Empirical formula: C.sub.41H.sub.38ClN.sub.5O.sub.4
[M+H].sup.+ calculated: 700.2685
[M+H].sup.+ measured: 700.2686
EXAMPLE 399
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(3-fluoro-4-hydroxyphenyl)-1,2-dimethyl-N-(1-methyl-
-1H-pyrazol-4-yl)-1H-pyrrole-3-carboxamide hydrochloride
The title compound is obtained in accordance with the process of
Example 1 using the acid of Preparation 1 and
(3S)-3-(4-morpholinylmethyl)-1,2,3,4-tetrahydroisoquinoline (see
Preparation 3') in Step A, and the compound of Preparation 20'' in
Step C. The product obtained is finally subjected to a step of
conversion into salt form in the presence of 1M HCl in ether. After
filtration and lyophilisation in a mixture of acetonitrile/water,
the expected compound is obtained.
Elemental Microanalysis: (%, Theoretical:Measured)
% C=62.21:61.32; % H=5.36:5.18; % N=11.46:11.14; % Cl=9.66:10.16; %
Cl.sup.-=4.83:5.23
High-Resolution Mass Spectrometry (ESI+-/FIA/HR, ESI-/FIA):
Empirical formula: C.sub.38H.sub.38ClFN.sub.6O.sub.4
[M+H].sup.+ calculated: 697.2700
[M+H].sup.+ measured: 697.2704
EXAMPLE 400
Methyl
2-[{[5-(5-chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoqu-
inolin-2(1H)-yl]carbonyl}phenyl)-1,2-dimethyl-1H-pyrrol-3-yl]carbonyl}(4-h-
ydroxyphenyl)amino]pyridine-4-carboxylate hydrochloride
The title compound is a secondary product which forms in the course
of synthesis of Example 110 (in the final Step before the step of
conversion into salt form) owing to hydrolysis of the nitrile
function into a methyl ester function. The compound is separated
from that of Example 110 by chromatography over silica gel in a
mixture of methanol and dichloromethane.
Elemental Microanalysis: (%, Theoretical:Measured)
% C=63.90:64.43; % H=5.36:5.01; % N=9.09:9.34; %
Cl.sup.-=4.60:4.46
High-Resolution Mass Spectrometry (ESI+/HR and ESI-/LR):
Empirical formula: C.sub.41H.sub.40ClN.sub.5O.sub.6
[M+H].sup.+ calculated: 734.2740
[M+H].sup.+ measured: 734.2743
EXAMPLE 401
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(3-cyano-4-fluorophenyl)-N-(4-hydroxyphenyl)-1,2-di-
methyl-1H-pyrrole-3-carboxamide hydrochloride
Elemental Microanalysis: (%, Theoretical:Measured)
% C=65.25:64.23; % H=5.07:4.71; % N=9.28:9.36; % Cl=9.40:9.59; %
Cl.sup.-=4.70:4.50
High-Resolution Mass Spectrometry (ESI+-/FIA/HR, ESI-/FIA):
Empirical formula: C.sub.41H.sub.37ClFN.sub.5O.sub.4
[M+H].sup.+ calculated: 718.2591
[M+H].sup.+ measured: 718.2593
EXAMPLE 402
5-(5-Fluoro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-{1-[(3S or
R)-tetrahydrofuran-3-yl]-1H-pyrazol-4-yl}-1H-pyrrole-3-carboxamide
hydrochloride
Elemental Microanalysis: (%, Theoretical:Measured)
% C=65.20:65.92; % H=5.87:5.78; % N=11.13:10.36%
Cl.sup.-=4.69:4.79)
High-Resolution Mass Spectrometry (ESI+):
Empirical formula: C.sub.41H.sub.43FN.sub.6O.sub.5
[M+H].sup.+ calculated: 719.3359
[M+H].sup.+ measured: 719.3362
and
EXAMPLE 403
5-(5-Fluoro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-{1-[(3R or
S)-tetrahydrofuran-3-yl]-1H-pyrazol-4-yl}-1H-pyrrole-3-carboxamide
hydrochloride
Elemental Microanalysis: (%, Theoretical:Measured)
% C=65.20:66.04; % H=5.87:5.87; % N=11.13:10.62; %
Cl.sup.-=4.69:4.76
High-Resolution Mass Spectrometry (ESI/+):
Empirical formula: C.sub.41H.sub.43FN.sub.6O.sub.5
[M+H].sup.+ calculated: 719.3359
[M+H].sup.+ measured: 719.3350
The compounds of Examples 402 and 403 are obtained in accordance
with the process of Example 1 using the acid of Preparation 8 and
the compound of Preparation 3' in Step A, and the compound of
Preparation 22'' in Step C. The diastereoisomers obtained are
separated by chiral chromatography and then converted into salt
form and lyophilised as described in the general process to yield
the title compounds.
EXAMPLE 404
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(2-cyanopyrimidin-4-yl)-N-(4-hydroxyphenyl)-1,2-dim-
ethyl-1H-pyrrole-3-carboxamide hydrochloride
EXAMPLE 405
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-1,2-dimethyl-N-(1-methyl-1H-pyrrolo[2,3-b]pyridin-5-y-
l)-N-(pyridazin-4-yl)-1H-pyrrole-3-carboxamide dihydrochloride
The title compound is obtained in accordance with the process of
Example 1 using the acid of Preparation 1 and the compound of
Preparation 3' in Step A, and the appropriate amine in Step C, it
being understood that Step D is not carried out. The compound
obtained is converted into salt form and lyophilised as described
in the general process to obtain the title compound.
High-Resolution Mass Spectrometry (ESI+-/FIA/HR, ESI-/FIA):
Empirical formula: C.sub.40H.sub.39ClN.sub.8O.sub.3
[M+H].sup.+ calculated: 715.2906
[M+H].sup.+ measured: 715.2909
EXAMPLE 406
N-(5-Cyano-1,2-dimethyl-1H-pyrrol-3-yl)-N-(4-hydroxyphenyl)-1,2-dimethyl-5-
-(2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbon-
yl}phenyl)-1H-pyrrole-3-carboxamide hydrochloride
The title compound is obtained in accordance with the process of
Example 1 using the acid of Preparation 25 and the compound of
Preparation 3' in Step A, and the compound of Preparation 18'' in
Step C. The compound obtained is converted into salt form and
lyophilised as described in the general process to obtain the title
compound.
Elemental Microanalysis: (%, Theoretical:Measured)
% C=68.46:68.27; % H=6.03:5.12; % N=11.68:11.75; %
Cl.sup.-=4.93:4.73
High-Resolution Mass Spectrometry (ESI/FIA/HR and MS/MS,
ESI-/FIA):
Empirical formula: C.sub.41H.sub.42N.sub.6O.sub.4
[M+H].sup.+ calculated: 683.3340
[M+H].sup.+ measured: 683.3334
EXAMPLE 407
N-(3-Fluoro-4-hydroxyphenyl)-5-(5-methoxy-2-{[(3S)-3-(morpholin-4-ylmethyl-
)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}phenyl)-1,2-dimethyl-N-(1-methy-
l-1H-pyrazol-4-yl)-1H-pyrrole-3-carboxamide hydrochloride
The title compound is obtained in accordance with the process of
Example 1 using the acid of Preparation 12 and the compound of
Preparation 3' in Step A, and the compound of Preparation 20'' in
Step C. The compound obtained is converted into salt form and
lyophilised as described in the general process to obtain the title
compound.
Elemental Microanalysis: (%, Theoretical:Measured)
% C=64.23:63.94; % H=5.80:5.00; % N=11.52:11.56; %
Cl.sup.-=4.86:4.99
High-Resolution Mass Spectrometry (ESI+-/FIA/HR and MS/MS,
ESI-/FIA):
Empirical formula: C.sub.39H.sub.41FN.sub.6O.sub.5
[M+H].sup.+ calculated: 693.3195
[M+H].sup.+ measured: 693.3191
EXAMPLE 408
N-(5-Cyano-1,2-dimethyl-1H-pyrrol-3-yl)-N-(4-hydroxyphenyl)-5-(5-methoxy-2-
-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-
phenyl)-1,2-dimethyl-1H-pyrrole-3-carboxamide hydrochloride
The title compound is obtained in accordance with the process of
Example 1 using the acid of Preparation 12 and the compound of
Preparation 3' in Step A, and the compound of Preparation 18'' in
Step C. The compound obtained is converted into salt form and
lyophilised as described in the general process to obtain the title
compound.
Elemental Microanalysis: (%, Theoretical:Measured)
% C=67.32:67.30; % H=6.05:5.28; % N=11.22:11.15; %
Cl.sup.-=4.73:4.59
High-Resolution Mass Spectrometry (ESI+-/FIA/HR and ESI-/FIA):
Empirical formula: C.sub.42H.sub.44N.sub.6O.sub.5
[M+H].sup.+ calculated: 713.3446
[M+H].sup.+ measured: 713.3443
EXAMPLE 409
N-(4-Hydroxyphenyl)-1,2-dimethyl-N-(1-methyl-1H-pyrrolo[2,3-b]-pyridin-5-y-
l)-5-(2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]-c-
arbonyl}phenyl)-1H-pyrrole-3-carboxamide hydrochloride
The title compound is obtained in accordance with the process of
Example 1 using the acid of Preparation 25 and the compound of
Preparation 3' in Step A, and the compound of Preparation 11'' in
Step C. The compound obtained is converted into salt form and
lyophilised as described in the general process to obtain the title
compound.
Elemental Microanalysis: (%, Theoretical:Measured)
% C=68.98:68.95; % H=5.93:4.76; % N=11.49:11.43
High-Resolution Mass Spectrometry (ESI/FIA/HR and MS/MS):
Empirical formula: C.sub.42H.sub.42N.sub.6O.sub.4
[M+H].sup.+ calculated: 695.3340
[M+H].sup.+ measured: 695.3341
EXAMPLE 410
N-(4-Hydroxyphenyl)-1,2-dimethyl-N-(1-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]-
pyridin-5-yl)-5-(2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin--
2(1H)-yl]carbonyl}phenyl)-1H-pyrrole-3-carboxamide
hydrochloride
The title compound is obtained in accordance with the process
described in Step B of Example 49 using Example 409 as starting
material. The compound obtained is converted into salt form and
lyophilised as described in the general process to obtain the title
compound.
High-Resolution Mass Spectrometry (ESI/FIA/HR and ESI-/FIA):
Empirical formula: C.sub.42H.sub.44N.sub.6O.sub.4
[M+H].sup.+ calculated: 697.3497
[M+H].sup.+ measured: 697.3497
EXAMPLE 411
5-(5-Chloro-2-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}phe-
nyl)-N-(4-hydroxyphenyl)-2-methyl-N-(1-methyl-1H-pyrazol-4-yl)-1-[2-(morph-
olin-4-yl)ethyl]-1H-pyrrole-3-carboxamide hydrochloride
The title compound is obtained in accordance with the process of
Example 96 using the acid of Preparation 30, the compound of
Preparation 1', and the compound of Preparation 1''. The compound
obtained is converted into salt form and lyophilised as described
in the general process to obtain the title compound.
High-Resolution Mass Spectrometry (ESI/FIA/HR and MS/MS):
Empirical formula: C.sub.39H.sub.41ClN.sub.6O.sub.4
[M+H].sup.+ calculated: 693.2951
[M+H].sup.+ measured: 693.2947
EXAMPLE 412
5-(5-Chloro-2-{[(3R)-3-[3-(morpholin-4-yl)propyl]-3,4-dihydroisoquinolin-2-
(1H)-yl]carbonyl}phenyl)-N-(5-cyano-1,2-dimethyl-1H-pyrrol-3-yl)-N-(4-hydr-
oxyphenyl)-1,2-dimethyl-1H-pyrrole-3-carboxamide hydrochloride
The title compound is obtained in accordance with the process of
Example 1 using the acid of Preparation 1 and the compound of
Preparation 6' in Step A, and the compound of Preparation 18'' in
Step C. The compound obtained is converted into salt form and
lyophilised as described in the general process to obtain the title
compound.
Elemental Microanalysis: (%, Theoretical:Measured)
% C=66.06:65.61; % H=5.93:5.22; % N=10.75:10.69; %
Cl.sup.-=4.53:4.68
High-Resolution Mass Spectrometry (ESI/FIA/HR and MS/MS,
ESI-/FIA):
Empirical formula: C.sub.43H.sub.45ClN.sub.6O.sub.4
[M+H].sup.+ calculated: 745.3264
[M+H].sup.+ measured: 745.3260
EXAMPLE 413
N-(5-Cyano-1,2-dimethyl-1H-pyrrol-3-yl)-N-(4-hydroxyphenyl)-1,2-dimethyl-5-
-(7-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]-carbo-
nyl}-2,3-dihydro-1,4-benzodioxin-6-yl)-1H-pyrrole-3-carboxamide
hydrochloride
The title compound is obtained in accordance with the process of
Example 1 using the acid of Preparation 13 and the compound of
Preparation 3' in Step A, and the compound of Preparation 18'' in
Step C. The compound obtained is converted into salt form and
lyophilised as described in the general process to obtain the title
compound.
Elemental Microanalysis: (%, Theoretical:Measured)
% C=66.44:66.40; % H=5.83:4.84; % N=10.81:10.79; %
Cl.sup.-=4.56:4.22
High-Resolution Mass Spectrometry (ESI/FIA/HR and MS/MS,
ESI-/FIA):
Empirical formula: C.sub.43H.sub.44N.sub.6O.sub.6
[M+H].sup.+ calculated: 741.3395
[M+H].sup.+ measured: 741.3397
EXAMPLE 414
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-(5-methyl-5H-pyrro-
lo[3,2-d]pyrimidin-2-yl)-1H-pyrrole-3-carboxamide hydrochloride
The title compound is obtained in accordance with the process of
Example 1 using the acid of Preparation 1 and the compound of
Preparation 3' in Step A, and the appropriate amine in Step C. The
compound obtained is converted into salt form and lyophilised as
described in the general process to obtain the title compound.
Elemental Microanalysis: (%, Theoretical:Measured)
% C=64.23:64.38; % H=5.39:5.25; % N=12.79:12.62; %
Cl.sup.-=4.62:4.39
High-Resolution Mass Spectrometry (ESI/FIA/HR and MS/MS,
ESI-/FIA):
Empirical formula: C.sub.41H.sub.40ClN.sub.7O.sub.4
[M+H].sup.+ calculated: 730.2903
[M+H].sup.+ measured: 730.2904
EXAMPLE 415
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(5-cyano-1,2-dimethyl-1H-pyrrol-3-yl)-N-(4-hydroxyp-
henyl)-1-methyl-1H-pyrrole-3-carboxamide hydrochloride
The title compound is obtained in accordance with the process of
Example 1 using the acid of Preparation 3 and the compound of
Preparation 3' in Step A, and the compound of Preparation 18'' in
Step C. The compound obtained is converted into salt form and
lyophilised as described in the general process to obtain the title
compound.
Elemental Microanalysis: (%, Theoretical:Measured)
% C=64.95:65.14; % H=5.45:5.34; % N=11.36:11.36; %
Cl.sup.-=4.79:4.67
High-Resolution Mass Spectrometry (ESI+-/FIA/HR, ESI-/FIA):
Empirical formula: C.sub.40H.sub.39ClN.sub.6O.sub.4
[M+H].sup.+ calculated: 703.2794
[M+H].sup.+ measured: 703.2795
EXAMPLE 416
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-[1-(trideuteriomet-
hyl)-1H-pyrazol-4-yl]H-pyrrole-3-carboxamide hydrochloride
The title compound is obtained in accordance with the process of
Example 1 using the acid of Preparation 1 and the compound of
Preparation 3' in Step A, and the compound of Preparation 25'' in
Step C. The compound obtained is converted into salt form and
lyophilised as described in the general process to obtain the title
compound.
Elemental Microanalysis: (%, Theoretical:Measured)
% C=63.51:63.41; % H=5.63:5.42; % N=11.69:11.61; %
Cl.sup.-=4.93:4.85
High-Resolution Mass Spectrometry (ESI+-/FIA/HR, ESI-/FIA):
Empirical formula: C.sub.38H.sub.36ClD.sub.3N.sub.6O.sub.4
[M+H].sup.+ calculated: 682.2982
[M+H].sup.+ measured: 682.2986
EXAMPLE 417
N-(5-Cyano-1,2-dimethyl-1H-pyrrol-3-yl)-N-(4-hydroxyphenyl)-5-(4-methoxy-2-
-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-
phenyl)-1,2-dimethyl-1H-pyrrole-3-carboxamide hydrochloride
The title compound is obtained in accordance with the process of
Example 1 using the acid of Preparation 31 and the compound of
Preparation 3' in Step A, and the compound of Preparation 18'' in
Step C. The compound obtained is converted into salt form and
lyophilised as described in the general process to obtain the title
compound.
Elemental Microanalysis: (%, Theoretical:Measured)
% C=67.32:67.56; % H=6.05:5.84; % N=11.22:11.21; %
Cl.sup.-=4.73:4.71
High-Resolution Mass Spectrometry (ESI/FIA/HR and MS/MS,
ESI-/FIA):
Empirical formula: C.sub.42H.sub.44N.sub.6O.sub.5
[M+H].sup.+ calculated: 713.3446
[M+H].sup.+ measured: 713.3446
EXAMPLE 418
N-(4-Hydroxyphenyl)-5-(4-methoxy-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dih-
ydroisoquinolin-2(1H)-yl]carbonyl}phenyl)-1,2-dimethyl-N-(1-methyl-1H-pyra-
zol-4-yl)-1H-pyrrole-3-carboxamide hydrochloride
The title compound is obtained in accordance with the process of
Example 1 using the acid of Preparation 31 and the compound of
Preparation 3' in Step A, and the compound of Preparation 1'' in
Step C. The compound obtained is converted into salt form and
lyophilised as described in the general process to obtain the title
compound.
Elemental Microanalysis: (%, Theoretical:Measured)
% C=65.86:65.51; % H=6.09:6.09; % N=11.82:11.73; %
Cl.sup.-=4.98:5.14
High-Resolution Mass Spectrometry (ESI/FIA/HR, ESI-/FIA):
Empirical formula: C.sub.39H.sub.42N.sub.6O.sub.5
[M+H].sup.+ calculated: 675.3289
[M+H].sup.+ measured: 675.3286
EXAMPLE 419
N-(3-Cyanophenyl)-5-(5-fluoro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydr-
oisoquinolin-2(1H)-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-1H-
-pyrrole-3-carboxamide hydrochloride
The title compound is obtained in accordance with the process of
Example 1 using the acid of Preparation 8 and the compound of
Preparation 3' in Step A, and the compound of Preparation 41'' in
Step C. The compound obtained is converted into salt form and
lyophilised as described in the general process to obtain the title
compound.
High-Resolution Mass Spectrometry (ESI+):
Empirical formula: C.sub.41H.sub.38FN.sub.5O.sub.4
[M+H].sup.+ calculated: 684.2988
[M+H].sup.+ measured: 684.2975
EXAMPLE 420
5-(5-Fluoro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-[1-(trideuteriomet-
hyl)-1H-pyrazol-4-yl]-1H-pyrrole-3-carboxamide hydrochloride
The title compound is obtained in accordance with the process of
Example 1 using the acid of Preparation 8 and the compound of
Preparation 3' in Step A, and the compound of Preparation 25'' in
Step C. The compound obtained is converted into salt form and
lyophilised as described in the general process to obtain the title
compound.
High-Resolution Mass Spectrometry (ESI/+):
Empirical formula: C.sub.38D.sub.3H.sub.36FN.sub.6O.sub.4
[M+H].sup.+ calculated: 666.3285
[M+H].sup.+ measured: 666.3265
EXAMPLE 421
N-(5-Cyano-1,2-dimethyl-1H-pyrrol-3-yl)-5-(5-fluoro-2-{[(3S)-3-(morpholin--
4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}phenyl)-N-(4-hydroxyp-
henyl)-1,2-dimethyl-1H-pyrrole-3-carboxamide hydrochloride
The title compound is obtained in accordance with the process of
Example 1 using the acid of Preparation 8 and the compound of
Preparation 3' in Step A, and the compound of Preparation 18'' in
Step C. The compound obtained is converted into salt form and
lyophilised as described in the general process to obtain the title
compound.
High-Resolution Mass Spectrometry (ESI/FIA/HR and MS/MS):
Empirical formula: C.sub.41H.sub.41FN.sub.6O.sub.4
[M+H].sup.+ calculated: 701.3246
[M+H].sup.+ measured: 701.3282
EXAMPLE 422
N-(4-Hydroxyphenyl)-1,2-dimethyl-N-(1-methyl-1H-pyrazol-4-yl)-5-(2-{[(3S)--
3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}phenyl)--
1H-pyrrole-3-carboxamide hydrochloride
The title compound is obtained in accordance with the process of
Example 1 using the acid of Preparation 25 and the compound of
Preparation 3' in Step A, and the compound of Preparation 1'' in
Step C. The compound obtained is converted into salt form and
lyophilised as described in the general process to obtain the title
compound.
Elemental Microanalysis: (%, Theoretical:Measured)
% C=67.00:67.47; % H=6.07:5.54; % N=12.34:12.46; %
Cl.sup.-=5.20:4.58
High-Resolution Mass Spectrometry (ESI+-/FIA/HR, ESI-/FIA):
Empirical formula: C.sub.38H.sub.40N.sub.6O.sub.4
[M+H].sup.+ calculated: 645.3184
[M+H].sup.+ measured: 645.3182
EXAMPLE 423
5-(5-Fluoro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-[1-(oxetan-3-yl)-1-
H-pyrazol-4-yl]-1H-pyrrole-3-carboxamide
The title compound is obtained in accordance with the process of
Example 1 using the acid of Preparation 8 and the compound of
Preparation 3' in Step A, and the compound of Preparation 26'' in
Step C.
Elemental Microanalysis: (%, Theoretical:Measured)
% C=68.17:67.82; % H=5.86:5.97; % N=11.92:11.48
High-Resolution Mass Spectrometry (ESI/FIA/HR and MS/MS):
Empirical formula: C.sub.40H.sub.41FN.sub.6O.sub.5
[M+H].sup.+ calculated: 705.3202
[M+H].sup.+ measured: 705.3207
EXAMPLE 424
N-(4-Hydroxyphenyl)-N-(2-methoxypyrimidin-5-yl)-1,2-dimethyl-5-(2-{[(3S)-3-
-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}phenyl)-1-
H-pyrrole-3-carboxamide hydrochloride
The title compound is obtained in accordance with the process of
Example 1 using the acid of Preparation 25 and the compound of
Preparation 3' in Step A, and the compound of Preparation 12'' in
Step C. The compound obtained is converted into salt form and
lyophilised as described in the general process to obtain the title
compound.
Elemental Microanalysis: (%, Theoretical:Measured)
% C=66.05:65.63; % H=5.83:5.45; % N=11.85:11.93; %
Cl.sup.-=5.00:4.91
High-Resolution Mass Spectrometry (ESI+-/FIA/HR, ESI-/FIA):
Empirical formula: C.sub.39H.sub.40N.sub.6O.sub.5
[M+H].sup.+ calculated: 673.3133
[M+H].sup.+ measured: 673.3129
EXAMPLE 425
N-(3-Cyano-5-methoxyphenyl)-5-(5-fluoro-2-{[(3S)-3-(morpholin-4-ylmethyl)--
3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1,2-d-
imethyl-1H-pyrrole-3-carboxamide hydrochloride
The title compound is obtained in accordance with the process of
Example 1 using the acid of Preparation 8 and the compound of
Preparation 3' in Step A, and the appropriate amine in Step C. The
compound obtained is converted into salt form and lyophilised as
described in the general process to obtain the title compound.
Elemental Microanalysis: (%, Theoretical:Measured)
% C=67.25:66.55; % H=5.51:5.28; % N=9.33:8.55%
Cl.sup.-=4.73:4.67
EXAMPLE 426
5-(5-Fluoro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-N-(2-methoxypyrimidin-5-yl)-1,2-d-
imethyl-1H-pyrrole-3-carboxamide
The title compound is obtained in accordance with the process of
Example 1 using the acid of Preparation 8 and the compound of
Preparation 3' in Step A, and the compound of Preparation 12'' in
Step C.
High-Resolution Mass Spectrometry (ESI/FIA/HR and MS/MS):
Empirical formula: C.sub.39H.sub.39FN.sub.6O.sub.5
[M+H].sup.+ calculated: 691.3038
[M+H].sup.+ measured: 691.3060
EXAMPLE 427
N-(3-Cyano-4-methoxyphenyl)-5-(5-fluoro-2-{[(3S)-3-(morpholin-4-ylmethyl)--
3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1,2-d-
imethyl-1H-pyrrole-3-carboxamide hydrochloride
The title compound is obtained in accordance with the process of
Example 1 using the acid of Preparation 8 and the compound of
Preparation 3' in Step A, and the appropriate amine in Step C. The
compound obtained is converted into salt form and lyophilised as
described in the general process to obtain the title compound.
Elemental Microanalysis: (%, Theoretical:Measured)
% C=67.24:66.41; % H=5.51:5.35; % N=9.33:8.97%
Cl.sup.-=4.73:4.81
EXAMPLE 428
N-(5-Cyano-1,2-dimethyl-1H-pyrrol-3-yl)-5-(4-fluoro-2-{[(3S)-3-(morpholin--
4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}phenyl)-N-(4-hydroxyp-
henyl)-1,2-dimethyl-1H-pyrrole-3-carboxamide hydrochloride
The title compound is obtained in accordance with the process of
Example 1 using the acid of Preparation 26 and the compound of
Preparation 3' in Step A, and the compound of Preparation 18'' in
Step C. The compound obtained is converted into salt form and
lyophilised as described in the general process to obtain the title
compound.
Elemental Microanalysis: (%, Theoretical:Measured)
% C=66.79:66.97; % H=5.74:5.36; % N=11.40:11.45; %
Cl.sup.-=4.81:4.53
High-Resolution Mass Spectrometry (ESI+-/FIA/HR, ESI-/FIA):
Empirical formula: C.sub.41H.sub.41FN.sub.6O.sub.4
[M+H].sup.+ calculated: 701.3246
[M+H].sup.+ measured: 701.3245
EXAMPLE 429
N-(5-Cyano-1,2-dimethyl-1H-pyrrol-3-yl)-5-(4-fluoro-5-methoxy-2-{[(3S)-3-(-
morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}phenyl)-N-(-
4-hydroxyphenyl)-1,2-dimethyl-1H-pyrrole-3-carboxamide
hydrochloride
The title compound is obtained in accordance with the process of
Example 1 using the acid of Preparation 27 and the compound of
Preparation 3' in Step A, and the compound of Preparation 18'' in
Step C. The compound obtained is converted into salt form and
lyophilised as described in the general process to obtain the title
compound.
Elemental Microanalysis: (%, Theoretical:Measured)
% C=65.75:65.43; % H=5.78:5.57; % N=10.95:10.81; %
Cl.sup.-=4.62:4.54
High-Resolution Mass Spectrometry (ESI/FIA/HR and MS/MS,
ESI-/FIA):
Empirical formula: C.sub.42H.sub.43FN.sub.6O.sub.5
[M+H].sup.+ calculated: 731.3352
[M+H].sup.+ measured: 731.3351
EXAMPLE 430
5-(5-Chloro-2-{[3-(trifluoromethyl)-3,4-dihydroisoquinolin-2(1H)-yl]-carbo-
nyl}phenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-(1-methyl-1H-pyrrolo[2,3-b]-
-pyridin-5-yl)-1H-pyrrole-3-carboxamide
The title compound is obtained in accordance with the process of
Example 1 using the acid of Preparation 1 and racemic
3-(trifluoromethyl)-1,2,3,4-tetrahydroisoquinoline in Step A, and
the compound of Preparation 11'' in Step C.
High-Resolution Mass Spectrometry (ESI+-/FIA/HR and MS/MS,
ESI-/FIA):
Empirical formula: C.sub.38H.sub.31ClF.sub.3N.sub.5O.sub.3
[M+H].sup.+ calculated: 698.2140
[M+H].sup.+ measured: 698.2144
EXAMPLE 431
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(1,3-dimethyl-1H-pyrazol-4-yl)-N-(4-hydroxyphenyl)--
1,2-dimethyl-1H-pyrrole-3-carboxamide hydrochloride
Elemental Microanalysis: (%, Theoretical:Measured)
% C=64.19:64.37; % H=5.80:5.18; % N=11.52:11.55; %
Cl.sup.-=4.86:4.68
High-Resolution Mass Spectrometry (ESI+-/FIA/HR, ESI-/FIA):
Empirical formula: C.sub.39H.sub.41ClN.sub.6O.sub.4
[M+H].sup.+ calculated: 693.2951
[M+H].sup.+ measured: 693.2952
and
EXAMPLE 432
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(1,5-dimethyl-1H-pyrazol-4-yl)-N-(4-hydroxyphenyl)--
1,2-dimethyl-1H-pyrrole-3-carboxamide hydrochloride
Elemental Microanalysis: (%, Theoretical:Measured)
% C=64.19:64.43; % H=5.80:5.22; % N=11.52:11.60; %
Cl.sup.-=4.86:4.66
High-Resolution Mass Spectrometry (ESI+-/FIA/HR, ESI-/FIA):
Empirical formula: C.sub.39H.sub.41ClN.sub.6O.sub.4
[M+H].sup.+ calculated: 693.2951
[M+H].sup.+ measured: 693.2953
The compounds of Examples 431 and 432 are obtained in accordance
with the process of Example 1 using the acid of Preparation 1 and
the compound of Preparation 3' in Step A, and the mixture of
Preparation 27'' in Step C. At the end of Step D, the isomers are
separated by preparative HPLC using acetonitrile and water-TFA as
eluants. After evaporating off the solvent and neutralising with
sodium bicarbonate, the products are subjected to a step of
conversion into salt form in the presence of 1M HCl in ether. After
filtration and lyophilisation in a mixture of acetonitrile/water,
the title products are obtained.
EXAMPLE 433
N-(5-Cyano-1-methyl-1H-pyrrol-3-yl)-N-(4-hydroxyphenyl)-1,2-dimethyl-5-(2--
{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}p-
henyl)-1H-pyrrole-3-carboxamide hydrochloride
The title compound is obtained in accordance with the process of
Example 1 using the acid of Preparation 25 and the compound of
Preparation 3' in Step A, and the compound of Preparation 19'' in
Step C. The compound obtained is converted into salt form and
lyophilised as described in the general process to obtain the title
compound.
Elemental Microanalysis: (%, Theoretical:Measured)
% C=68.12:68.29; % H=5.86:5.40; % N=11.92:12.05; %
Cl.sup.-=5.03:4.92
High-Resolution Mass Spectrometry (ESI/FIA/HR and MS/MS):
Empirical formula: C.sub.40H.sub.40N.sub.6O.sub.4
[M+H].sup.+ calculated: 669.3184
[M+H].sup.+ measured: 669.3184
EXAMPLE 434
5-(5-Fluoro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-(1-methyl-2,3-dihy-
dro-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide
hydrochloride
The title compound is obtained in accordance with the process
described in Step B of Example 49 using Example 385 as starting
material. The compound obtained is converted into salt form and
lyophilised as described in the general process to obtain the title
compound.
Elemental Microanalysis: (%, Theoretical:Measured)
% C=67.15:68.03; % H=5.90:5.50; % N=11.19:10.59%
Cl.sup.-=4.72:5.55
EXAMPLE 435
N-(4-Cyanopyridin-2-yl)-5-(5-fluoro-4-methoxy-2-{[(3S)-3-(morpholin-4-ylme-
thyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-
-1,2-dimethyl-1H-pyrrole-3-carboxamide hydrochloride
The title compound is obtained in accordance with the process of
Example 1 using the acid of Preparation 14 and the compound of
Preparation 3' in Step A, and the appropriate amine in Step C. The
compound obtained is converted into salt form and lyophilised as
described in the general process to obtain the title compound.
High-Resolution Mass Spectrometry (ESI+-/FIA/HR, ESI-/FIA):
Empirical formula: C.sub.41H.sub.39FN.sub.6O.sub.5
[M+H].sup.+ calculated: 715.3039
[M+H].sup.+ measured: 715.3040
EXAMPLE 436
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(5-cyanothiophen-2-yl)-N-(4-hydroxyphenyl)-1,2-dime-
thyl-1H-pyrrole-3-carboxamide hydrochloride
The title compound is obtained in accordance with the process of
Example 1 using the acid of Preparation 1 and the compound of
Preparation 3' in Step A, and the appropriate amine in Step C. The
compound obtained is converted into salt form and lyophilised as
described in the general process to obtain the title compound.
Elemental Microanalysis: (%, Theoretical:Measured)
% C=63.07:63.09; % H=5.02:4.78; % N=9.43:9.35; % S=4.32:4.09; %
Cl.sup.-=4.77:4.59
High-Resolution Mass Spectrometry (ESI/FIA/HR and MS/MS,
ESI+-/FIA):
Empirical formula: C.sub.39H.sub.36ClN.sub.5O.sub.4S
[M+H].sup.+ calculated: 706.2249:
[M+H].sup.+ measured: 706.2250
EXAMPLE 437
N-(3-Cyano-4-fluorophenyl)-5-(5-fluoro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3-
,4-dihydroisoquinolin-2(1H)-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1,2-di-
methyl-1H-pyrrole-3-carboxamide hydrochloride
The title compound is obtained in accordance with the process of
Example 1 using the acid of Preparation 8 and the compound of
Preparation 3' in Step A, and the appropriate amine in Step C. The
compound obtained is converted into salt form and lyophilised as
described in the general process to obtain the title compound.
High-Resolution Mass Spectrometry (ES+):
Empirical formula: C.sub.41H.sub.37F.sub.2N.sub.5O.sub.4
[M+H].sup.+ calculated: 702.2894
[M+H].sup.+ measured: 702.2886
EXAMPLE 438
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-(pyrazin-2-yl)-1H--
pyrrole-3-carboxamide hydrochloride
The title compound is obtained in accordance with the process of
Example 1 using the acid of Preparation 1 and the compound of
Preparation 3' in Step A, and the appropriate amine in Step C. The
compound obtained is converted into salt form and lyophilised as
described in the general process to obtain the title compound.
Elemental Microanalysis: (%, Theoretical:Measured)
% C=63.95:63.96; % H=5.37:5.17; % N=11.78:11.61; %
Cl.sup.-=4.97:4.57
High-Resolution Mass Spectrometry (ESI+/HR, ESI-/LR):
Empirical formula: C.sub.38H.sub.37ClN.sub.6O.sub.4
[M+H].sup.+ calculated: 677.2638
[M+H].sup.+ measured: 677.2639
EXAMPLE 439
5-(5-Fluoro-4-methoxy-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquin-
olin-2(1H)-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-N-(2-methoxypyrimidin-5-
-yl)-1,2-dimethyl-1H-pyrrole-3-carboxamide hydrochloride
The title compound is obtained in accordance with the process of
Example 1 using the acid of Preparation 14 and the compound of
Preparation 3' in Step A, and the compound of Preparation 12'' in
Step C. The compound obtained is converted into salt form and
lyophilised as described in the general process to obtain the title
compound.
High-Resolution Mass Spectrometry (ESI/FIA/HR and MS/MS,
ESI-/FIA):
Empirical formula: C.sub.40H.sub.41FN.sub.6O.sub.6
[M+H].sup.+ calculated: 721.3144
[M+H].sup.+ measured: 721.3144
EXAMPLE 440
N-(5-Cyano-1,2-dimethyl-1H-pyrrol-3-yl)-5-(5-fluoro-4-methoxy-2-{[(3S)-3-(-
morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-phenyl)-N--
(4-hydroxyphenyl)-1,2-dimethyl-1H-pyrrole-3-carboxamide
hydrochloride
The title compound is obtained in accordance with the process of
Example 1 using the acid of Preparation 14 and the compound of
Preparation 3' in Step A, and the compound of Preparation 18'' in
Step C. The compound obtained is converted into salt form and
lyophilised as described in the general process to obtain the title
compound.
Elemental Microanalysis: (%, Theoretical:Measured)
% C=65.75:65.98; % H=5.78:5.50; % N=10.95:10.87; %
Cl.sup.-=4.62:4.42
High-Resolution Mass Spectrometry (ESI+/HR, ESI-/LR):
Empirical formula: C.sub.42H.sub.43FN.sub.6O.sub.5
[M+H].sup.+ calculated: 731.3352
[M+H].sup.+ measured: 731.3353
EXAMPLE 441
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(5-cyano-1,2-dimethyl-1H-pyrrol-3-yl)-1,2-dimethyl--
N-phenyl-1H-pyrrole-3-carboxamide hydrochloride
The title compound is obtained in accordance with the process of
Example 1 using the acid of Preparation 1 and the compound of
Preparation 3' in Step A, and the compound of Preparation 29'' in
Step C, it being understood that Step D is not carried out. The
compound obtained is converted into salt form and lyophilised as
described in the general process to obtain the title compound.
Elemental Microanalysis: (%, Theoretical:Measured)
% C=66.75:66.44; % H=5.74:5.59; % N=11.39:11.45; %
Cl.sup.-=4.81:4.43
High-Resolution Mass Spectrometry (ESI+/HR, ESI-/LR):
Empirical formula: C.sub.41H.sub.41ClN.sub.6O.sub.3
[M+H].sup.+ calculated: 701.3001
[M+H].sup.+ measured: 701.2998
EXAMPLE 442
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(5-cyanothiophen-3-yl)-N-(4-hydroxyphenyl)-1,2-dime-
thyl-1H-pyrrole-3-carboxamide hydrochloride
The title compound is obtained in accordance with the process of
Example 1 using the acid of Preparation 1 and the compound of
Preparation 3' in Step A, and the compound of Preparation 42'' in
Step C. The compound obtained is converted into salt form and
lyophilised as described in the general process to obtain the title
compound.
Elemental Microanalysis: (%, Theoretical:Measured)
% C=63.07:63.14; % H=5.02:4.87; % N=9.43:9.41; % S=4.32:4.24; %
Cl.sup.-=4.77:4.57
High-Resolution Mass Spectrometry (ESI+/HR, ESI-/LR):
Empirical formula: C.sub.39H.sub.36ClN.sub.5O.sub.4S
[M+H].sup.+ calculated: 706.2249
[M+H].sup.+ measured: 706.2252
EXAMPLE 443
5-(5-Fluoro-4-hydroxy-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquin-
olin-2(1H)-yl]carbonyl}phenyl)-1,2-dimethyl-N-(1-methyl-1H-pyrrolo[2,3-b]p-
yridin-5-yl)-N-phenyl-1H-pyrrole-3-carboxamide
Step A:
5-(5-Fluoro-4-methoxy-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydr-
oisoquinolin-2(1H)-yl]carbonyl}phenyl)-1,2-dimethyl-N-(1-methyl-1H-pyrrolo-
[2,3-b]pyridin-5-yl)-N-phenyl-1H-pyrrole-3-carboxamide
The title compound is obtained in accordance with the process of
Example 1 (Steps A to C) using the acid of Preparation 28 and the
compound from Preparation 3' in Step A, and the compound of
Preparation 30'' in Step C.
Step B:
5-(5-Fluoro-4-hydroxy-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydr-
oisoquinolin-2(1H)-yl]carbonyl}phenyl)-1,2-dimethyl-N-(1-methyl-1H-pyrrolo-
[2,3-b]pyridin-5-yl)-N-phenyl-1H-pyrrole-3-carboxamide
To a solution of the compound of Step A (1 g; 1.37 mmol) in
anhydrous dichloromethane (10 mL) there is added, dropwise at
0.degree. C., a 1M solution of boron tribromide in dichloromethane
(1.8 mL; 1.8 mmol). After stirring for 15 hours at ambient
temperature, the reaction mixture is poured dropwise into a
solution of ethanol (15 mL) at -10.degree. C. After stirring for
one hour, saturated aqueous sodium bicarbonate solution is added,
and the reaction mixture is extracted with dichloromethane. After
drying over MgSO.sub.4, the residue is purified on a silica gel
column using a mixture of dichloromethane and methanol as eluant to
yield the expected product.
High-Resolution Mass Spectrometry (ESI+/HR, ESI-/LR):
Empirical formula: C.sub.42H.sub.41FN.sub.6O.sub.4
[M+H].sup.+ calculated: 713.3246
[M+H].sup.+ measured: 713.3244
EXAMPLE 444
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-N-(5-methoxypyrazin-2-yl)-1,2-dim-
ethyl-1H-pyrrole-3-carboxamide hydrochloride
The title compound is obtained in accordance with the process of
Example 1 using the acid of Preparation 1 and the compound of
Preparation 3' in Step A, and the appropriate amine in Step C. The
compound obtained is converted into salt form and lyophilised as
described in the general process to obtain the title compound.
Elemental Microanalysis: (%, Theoretical:Measured)
% C=62.99:62.72; % H=5.42:5.24; % N=11.30:11.19; %
Cl.sup.-=4.77:4.67
High-Resolution Mass Spectrometry (ESI+/HR, ESI-/LR):
Empirical formula: C.sub.39H.sub.39ClN.sub.6O.sub.5
[M+H].sup.+ calculated: 707.2743
[M+H].sup.+ measured: 707.2747
EXAMPLE 445
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-[1-(trideuteriomet-
hyl)-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-5-yl]-1H-pyrrole-3-carboxamide
hydrochloride
Step A:
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinol-
in-2(1H)-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-[1-(trideu-
teriomethyl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-1H-pyrrole-3-carboxamide
The intermediate is obtained in accordance with the process of
Example 1 using the acid of Preparation 1 and the compound of
Preparation 3' in Step A, and the compound of Preparation 31'' in
Step C.
Step B:
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinol-
in-2(1H)-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-[1-(trideu-
teriomethyl)-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-5-yl]-1H-pyrrole-3-carbo-
xamide hydrochloride
The procedure is in accordance with the protocol described in Step
B of Example 49, it being understood that the product is then
subjected to a step of conversion into salt form in the presence of
1M HCl in ether. After filtration and lyophilisation in a mixture
of acetonitrile/water, the title product is obtained.
Elemental Microanalysis: (%, Theoretical:Measured)
% C=65.45:65.33; % H=5.78:5.59; % N=10.90:10.82; %
Cl.sup.-=4.60:4.28
High-Resolution Mass Spectrometry (ESI+/HR, ESI-/LR):
Empirical formula: C.sub.42H.sub.40ClD.sub.3N.sub.6O.sub.4
[M+H].sup.+ calculated: 734.3295
[M+H].sup.+ measured: 734.3300
EXAMPLE 446
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(5-fluoropyrazin-2-yl)-N-(4-hydroxyphenyl)-1,2-dime-
thyl-1H-pyrrole-3-carboxamide hydrochloride
The title compound is obtained in accordance with the process of
Example 1 using the acid of Preparation 1 and the compound of
Preparation 3' in Step A, and the appropriate amine in Step C. The
compound obtained is converted into salt form and lyophilised as
described in the general process to obtain the title compound.
Elemental Microanalysis: (%, Theoretical:Measured)
% C=62.28:62.16; % H=5.10:4.97; % N=11.04:11.35; %
Cl.sup.-=4.85:4.48
High-Resolution Mass Spectrometry (ESI+/HR, ESI-/LR):
Empirical formula: C.sub.38H.sub.36ClFN.sub.6O.sub.4
[M+H].sup.+ calculated: 695.2543
[M+H].sup.+ measured: 695.2545
EXAMPLE 447
5-(4-Fluoro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-(1-methyl-1H-pyraz-
ol-4-yl)-1H-pyrrole-3-carboxamide hydrochloride
The title compound is obtained in accordance with the process of
Example 1 using the acid of Preparation 26 and the compound of
Preparation 3' in Step A, and the compound of Preparation 1'' in
Step C. The compound obtained is converted into salt form and
lyophilised as described in the general process to obtain the title
compound.
Elemental Microanalysis: (%, Theoretical:Measured)
% C=65.28:65.27; % H=5.77:5.51; % N=12.02:1.90; %
Cl.sup.-=5.07:4.74
High-Resolution Mass Spectrometry (ESI+/HR, ESI-/LR):
Empirical formula: C.sub.38H.sub.39FN.sub.6O.sub.4
[M+H].sup.+ calculated: 663.3090
[M+H].sup.+ measured: 663.3084
EXAMPLE 448
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-[5-cyano-1-(trideuteriomethyl)-1H-pyrrol-3-yl]-N-(4-
-hydroxyphenyl)-1,2-dimethyl-1H-pyrrole-3-carboxamide
hydrochloride
The title compound is obtained in accordance with the process of
Example 1 using the acid of Preparation 1 and the compound of
Preparation 3' in Step A, and the compound of
Preparation 32'' in Step C. The compound obtained is converted into
salt form and lyophilised as described in the general process to
obtain the title compound.
Elemental Microanalysis: (%, Theoretical:Measured)
% C=64.69:64.23; % H=5.45:5.47; % N=11.32:11.16; %
Cl.sup.-=4.77:4.56
High-Resolution Mass Spectrometry (ESI+/HR, ESI-/LR):
Empirical formula: C.sub.40H.sub.36ClD.sub.3N.sub.6O.sub.4
[M+H].sup.+ calculated: 706.2982
[M+H].sup.+ measured: 706.2985
EXAMPLE 449
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-[5-cyano-2-methyl-1-(trideuteriomethyl)-1H-pyrrol-3-
-yl]-N-(4-hydroxyphenyl)-1,2-dimethyl-1H-pyrrole-3-carboxamide
hydrochloride
The title compound is obtained in accordance with the process of
Example 1 using the acid of Preparation 1 and the compound of
Preparation 3' in Step A, and the compound of Preparation 33'' in
Step C. The compound obtained is converted into salt form and
lyophilised as described in the general process to obtain the title
compound.
Elemental Microanalysis: (%, Theoretical:Measured)
% C=65.07:64.55; % H=5.62:5.51; % N=11.11:10.98; %
Cl.sup.-=4.68:4.58
High-Resolution Mass Spectrometry (ESI+/HR, ESI-/LR):
Empirical formula: C.sub.41H.sub.38ClD.sub.3N.sub.6O.sub.4
[M+H].sup.+ calculated: 720.3139
[M+H].sup.+ measured: 720.3143
EXAMPLE 450
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(3-cyano-1-methyl-1H-pyrazol-5-yl)-N-(4-hydroxyphen-
yl)-1,2-dimethyl-1H-pyrrole-3-carboxamide hydrochloride
The title compound is obtained in accordance with the process of
Example 1 using the acid of Preparation 1 and the compound of
Preparation 3' in Step A, and the compound of Preparation 34'' in
Step C. The compound obtained is converted into salt form and
lyophilised as described in the general process to obtain the title
compound.
Elemental Microanalysis: (%, Theoretical:Measured)
% C=63.24:62.62; % H=5.31:5.09; % N=13.24:13.04; %
Cl.sup.-=4.79:4.37
High-Resolution Mass Spectrometry (ESI+/HR, ESI-/LR):
Empirical formula: C.sub.39H.sub.38ClN.sub.7O.sub.4
[M+H].sup.+ calculated: 704.2747
[M+H].sup.+ measured: 704.2747
EXAMPLE 451
5-(5-Fluoro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-(1-methyl-1H-pyraz-
olo[3,4-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide hydrochloride
The title compound is obtained in accordance with the process of
Example 1 using the acid of Preparation 8 and the compound of
Preparation 3' in Step A, and the compound of Preparation 17'' in
Step C. The compound obtained is converted into salt form and
lyophilised as described in the general process to obtain the title
compound.
Elemental Microanalysis: (%, Theoretical:Measured)
% C=65.64:66.28; % H=5.51:5.45; % N=13.07:12.17%
Cl.sup.-=4.73:5.51
EXAMPLE 452
N-(1,3-Dimethyl-1H-pyrazol-4-yl)-5-(5-fluoro-2-{[(3S)-3-(morpholin-4-ylmet-
hyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)--
1,2-dimethyl-1H-pyrrole-3-carboxamide hydrochloride
Elemental Microanalysis: (%, Theoretical:Measured)
% C=65.68:64.77; % H=5.94:5.55; % N=11.78:10.69%
Cl.sup.-=4.97:6.48
and
EXAMPLE 453
N-(1,5-Dimethyl-1H-pyrazol-4-yl)-5-(5-fluoro-2-{[(3S)-3-(morpholin-4-ylmet-
hyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)--
1,2-dimethyl-1H-pyrrole-3-carboxamide hydrochloride
Elemental Microanalysis: (%, Theoretical:Measured)
% C=65.68:65.43; % H=5.94:5.62; % N=11.78:10.95%
Cl.sup.-=4.97:5.60
The compounds of Examples 452 and 453 are obtained in accordance
with the process of Example 1 using the acid of Preparation 8 and
the compound of Preparation 3' in Step A, and the mixture of
Preparation 27'' in Step C. At the end of Step D, the isomers are
separated by preparative HPLC using acetonitrile and water-TFA as
eluants. After evaporating off the solvent and neutralising with
sodium bicarbonate, the products are subjected to a step of
conversion into salt form in the presence of 1M HCl in ether. After
filtration and lyophilisation in a mixture of acetonitrile/water,
the title products are obtained.
EXAMPLE 454
5-(5-Chloro-2-{[3-(trifluoromethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbon-
yl}phenyl)-N-(5-cyano-1,2-dimethyl-1H-pyrrol-3-yl)-N-(4-hydroxyphenyl)-1,2-
-dimethyl-1H-pyrrole-3-carboxamide
The title compound is obtained in accordance with the process of
Example 1 using the acid from Preparation 1 and racemic
3-(trifluoromethyl)-1,2,3,4-tetrahydroisoquinoline in Step A, and
the compound of Preparation 18'' in Step C.
Elemental Microanalysis: (%, Theoretical:Measured)
% C=64.77:64.81; % H=4.55:4.52; % N=10.21:10.33
High-Resolution Mass Spectrometry (ESI+/HR):
Empirical formula: C.sub.37H.sub.31ClF.sub.3N.sub.5O.sub.3
[M+H].sup.+ calculated: 686.2140
[M+H].sup.+ measured: 686.2145
EXAMPLE 455
5-(5-Chloro-2-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]-carbonyl}ph-
enyl)-N-{5-cyano-2-methyl-1-[2-(morpholin-4-yl)ethyl]-1H-pyrrol-3-yl}-N-(4-
-hydroxyphenyl)-1,2-dimethyl-1H-pyrrole-3-carboxamide
hydrochloride
The title compound is obtained in accordance with the process of
Example 1 using the acid of Preparation 1 and the compound of
Preparation 1' in Step A, and the compound of Preparation 35'' in
Step C. The compound obtained is converted into salt form and
lyophilised as described in the general process to obtain the title
compound.
Elemental Microanalysis: (%, Theoretical:Measured)
% C=65.71:66.07; % H=5.78:5.82; % N=10.95:10.66; %
Cl.sup.-=4.62:4.45
High-Resolution Mass Spectrometry (ESI+/HR, ESI-/LR):
Empirical formula: C.sub.42H.sub.43Cl.sub.6O.sub.4
[M+H].sup.+ calculated: 731.3107
[M+H].sup.+ measured: 731.3109
EXAMPLE 456
5-(5-Chloro-2-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]-carbonyl}ph-
enyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-{2-[2-(morpholin-4-yl)-ethoxy]pyr-
imidin-5-yl}-1H-pyrrole-3-carboxamide hydrochloride
The title compound is obtained in accordance with the process of
Example 1 using the acid of Preparation 1 and the compound of
Preparation 1' in Step A, and the compound of Preparation 36'' in
Step C. The compound obtained is converted into salt form and
lyophilised as described in the general process to obtain the title
compound.
Elemental Microanalysis: (%, Theoretical:Measured)
% C=63.41:63.51; % H=5.59:5.26; % N=11.09:11.10; %
Cl.sup.-=4.68:4.46
High-Resolution Mass Spectrometry (ESI+/HR, ESI-/LR):
Empirical formula: C.sub.40H.sub.41ClN.sub.6O.sub.5
[M+H].sup.+ calculated: 721.2900
[M+H].sup.+ measured: 721.2907
EXAMPLE 457
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(6-cyano-5-methoxypyridin-2-yl)-N-(4-hydroxyphenyl)-
-1,2-dimethyl-1H-pyrrole-3-carboxamide hydrochloride
The title compound is obtained in accordance with the process of
Example 1 using the acid of Preparation 1 and the compound of
Preparation 3' in Step A, and the appropriate amine in Step C. The
compound obtained is converted into salt form and lyophilised as
described in the general process to obtain the title compound.
Elemental Microanalysis: (%, Theoretical:Measured)
% C=64.15:63.95; % H=5.25:4.79; % N=10.95:10.97; %
Cl.sup.-=4.62:4.22
High-Resolution Mass Spectrometry (ESI+/HR):
Empirical formula: C.sub.41H.sub.39ClN.sub.6O.sub.5
[M+H].sup.+ calculated: 731.2743
[M+H].sup.+ measured: 731.2746
EXAMPLE 458
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(5-cyano-1,4-dimethyl-1H-pyrrol-3-yl)-N-(4-hydroxyp-
henyl)-1,2-dimethyl-1H-pyrrole-3-carboxamide hydrochloride
The title compound is obtained in accordance with the process of
Example 1 using the acid of Preparation 1 and the compound of
Preparation 3' in Step A, and the compound of Preparation 37'' in
Step C. The compound obtained is converted into salt form and
lyophilised as described in the general process to obtain the title
compound.
Elemental Microanalysis: (%, Theoretical:Measured)
% C=65.34:65.68; % H=5.62:5.31; % N=11.15:11.15; %
Cl.sup.-=4.70:4.33
High-Resolution Mass Spectrometry (ESI+/HR, ESI-/LR):
Empirical formula: C.sub.41H.sub.41ClN.sub.6O.sub.4
[M+H].sup.+ calculated: 717.2951
[M+H].sup.+ measured: 717.2954
EXAMPLE 459
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(5-cyano-1-ethyl-2-methyl-1H-pyrrol-3-yl)-N-(4-hydr-
oxyphenyl)-1,2-dimethyl-1H-pyrrole-3-carboxamide hydrochloride
The title compound is obtained in accordance with the process of
Example 1 using the acid of Preparation 1 and the compound of
Preparation 3' in Step A, and the compound of Preparation 38'' in
Step C. The compound obtained is converted into salt form and
lyophilised as described in the general process to obtain the title
compound.
Elemental Microanalysis: (%, Theoretical:Measured)
% C=65.71:65.29; % H=5.78:5.51; % N=10.95:10.95; %
Cl.sup.-=4.62:4.39
High-Resolution Mass Spectrometry (ESI+/HR, ESI-/LR):
Empirical formula: C.sub.42H.sub.43ClN.sub.6O.sub.4
[M+H].sup.+ calculated: 731.3107
[M+H].sup.+ measured: 731.3109
EXAMPLE 460
5-(5-Chloro-2-{[(3R)-3-[3-(morpholin-4-yl)propyl]-3,4-dihydroisoquinolin-2-
(1H)-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-[1-(tetrahydro-
furan-3-yl)-1H-pyrazol-4-yl]-1H-pyrrole-3-carboxamide
hydrochloride
The title compound is obtained in accordance with the process of
Example 1 using the acid of Preparation 1 and the compound of
Preparation 6' in Step A, and the compound of Preparation 22'' in
Step C. The compound obtained is converted into salt form and
lyophilised as described in the general process to obtain the title
compound.
Elemental Microanalysis: (%, Theoretical:Measured)
% C=64.58:64.24; % H=6.05:5.88; % N=10.51:10.53; %
Cl.sup.-=4.43:4.39
High-Resolution Mass Spectrometry (ESI+/HR, ESI-/LR):
Empirical formula: C.sub.43H.sub.47ClN.sub.6O.sub.5
[M+H].sup.+ calculated: 763.3369
[M+H].sup.+ measured: 763.3371
EXAMPLE 461
5-(5-Chloro-2-{[(3R)-3-[3-(morpholin-4-yl)propyl]-3,4-dihydroisoquinolin-2-
(1H)-yl]carbonyl}phenyl)-N-(5-cyano-1,2-dimethyl-1H-pyrrol-3-yl)-1,2-dimet-
hyl-N-phenyl-1H-pyrrole-3-carboxamide hydrochloride
The title compound is obtained in accordance with the process of
Example 1 using the acid of Preparation 1 and the compound of
Preparation 6' in Step A, and the compound of Preparation 29'' in
Step C, it being understood that Step D is not carried out. The
compound obtained is converted into salt form and lyophilised as
described in the general process to obtain the title compound.
Elemental Microanalysis: (%, Theoretical:Measured)
% C=67.44:66.68; % H=6.05:5.80; % N=10.97:10.95; %
Cl.sup.-=4.63:4.57
High-Resolution Mass Spectrometry (ESI+/HR):
Empirical formula: C.sub.43H.sub.45ClN.sub.6O.sub.3
[M+H].sup.+ calculated: 729.3314
[M+H].sup.+ measured: 729.3316
EXAMPLE 462
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-(5-methyl-1,2-oxaz-
ol-3-yl)-1H-pyrrole-3-carboxamide
The title compound is obtained in accordance with the process of
Example 1 using the acid of Preparation 1 and the compound of
Preparation 3' in Step A, and the appropriate amine in Step C.
Elemental Microanalysis: (%, Theoretical:Measured)
% C=67.10:66.64; % H=5.63:5.40; % N=10.30:10.24
High-Resolution Mass Spectrometry (ESI+/HR, ESI-/LR):
Empirical formula: C.sub.38H.sub.38ClN.sub.5O.sub.5
[M+H].sup.+ calculated: 680.2634
[M+H].sup.+ measured: 680.2637
EXAMPLE 463
N-(2-Ethoxypyrimidin-5-yl)-5-(5-fluoro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3-
,4-dihydroisoquinolin-2(1H)-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1,2-di-
methyl-1H-pyrrole-3-carboxamide
The title compound is obtained in accordance with the process of
Example 1 using the acid of Preparation 8 and the compound of
Preparation 3' in Step A, and the compound of Preparation 39'' in
Step C.
Elemental Microanalysis: (%, Theoretical:Measured)
% C=68.17:67.52; % H=5.86:5.60; % N=11.92:11.43
EXAMPLE 464
5-(5-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(5-hydroxypyridin-2-yl)-1,2-dimethyl-N-(1-methyl-1H-
-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrrole-3-carboxamide
dihydrochloride
The title compound is obtained in accordance with the process of
Example 1 using the acid of Preparation 1 and the compound of
Preparation 3' in Step A, and the compound of Preparation 40'' in
Step C. The compound obtained is converted into salt form and
lyophilised as described in the general process to obtain the title
compound.
High-Resolution Mass Spectrometry (ESI+/HR, ESI-/LR):
Empirical formula: C.sub.41H.sub.40ClN.sub.7O.sub.4
[M+H].sup.+ calculated: 730.2903
[M+H].sup.+ measured: 730.2907
EXAMPLE 465
5-(4-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(5-cyano-1,2-dimethyl-1H-pyrrol-3-yl)-N-(4-hydroxyp-
henyl)-1,2-dimethyl-1H-pyrrole-3-carboxamide hydrochloride
The title compound is obtained in accordance with the process of
Example 1 using the acid of Preparation 29 and the compound of
Preparation 3' in Step A, and the compound of Preparation 18'' in
Step C. The compound obtained is converted into salt form and
lyophilised as described in the general process to obtain the title
compound.
Elemental Microanalysis: (%, Theoretical:Measured)
% C=65.34:64.81; % H=5.62:5.27; % N=11.15:10.95%
Cl.sup.-=4.70:5.09
High-Resolution Mass Spectrometry (ESI+):
Empirical formula: C.sub.41H.sub.41ClN.sub.6O.sub.4
[M+H].sup.+ calculated: 717.2951
[M+H].sup.+ measured: 717.2952
EXAMPLE 466
5-(4-Chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-
-yl]carbonyl}phenyl)-N-(4-hydroxyphenyl)-1,2-dimethyl-N-(1-methyl-1H-pyraz-
ol-4-yl)-1H-pyrrole-3-carboxamide hydrochloride
The title compound is obtained in accordance with the process of
Example 1 using the acid of Preparation 29 and the compound of
Preparation 3' in Step A, and the compound of Preparation 1'' in
Step C. The compound obtained is converted into salt form and
lyophilised as described in the general process to obtain the title
compound.
Elemental Microanalysis: (%, Theoretical:Measured)
% C=66.77:62.82; % H=5.63:5.29; % N=11.74:11.75; %
Cl.sup.-=5.01:5.23
High-Resolution Mass Spectrometry (ESI+/HR, ESI-/LR):
Empirical formula: C.sub.38H.sub.39ClN.sub.6O.sub.4
[M+H].sup.+ calculated: 679.2794
[M+H].sup.+ measured: 679.2796
EXAMPLE 467
5-(5-Chloro-2-{[3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}phenyl)-N-(4-hydr-
oxyphenyl)-1,2-dimethyl-N-phenyl-1H-pyrrole-3-carboxamide
The title compound is obtained in accordance with the process of
Example 1 using the acid of Preparation 1 and
1,2,3,4-tetrahydroisoquinoline in Step A, and the compound of
Preparation 2'' in Step C.
Elemental Microanalysis: (%, Theoretical:Measured)
% C=72.97:72.93; % H=5.25:5.08; % N=7.29:7.34
High-Resolution Mass Spectrometry (ESI/FIA/HR and MS/MS):
Empirical formula: C.sub.35H.sub.30ClN.sub.3O.sub.3
[M+H].sup.+ calculated: 576.2048
[M+H].sup.+ measured: 576.2067
Pharmacological Study
EXAMPLE A
Inhibition of Bcl-2 by the Fluorescence Notarisation Technique
The fluorescence polarisation tests were carried out on microplates
(384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that
Bcl-2 corresponds to the UniProtKB.RTM. primary accession number:
P10415), at a final concentration of 2.50.times.10.sup.-8 M, is
mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY),
at a final concentration of 1.00.times.10.sup.-8M in a buffer
solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the
presence or absence of increasing concentrations of test compounds.
After incubation for 2 hours, the fluorescence polarisation is
measured.
The results are expressed in IC.sub.50 (the concentration of
compound that inhibits fluorescence polarisation by 50%) and are
presented in Table 1 below.
The results show that the compounds of the invention inhibit
interaction between the Bcl-2 protein and the fluorescent peptide
described hereinbefore.
EXAMPLE B
In Vitro Cytotoxicity
The cytotoxicity studies were carried out on the RS4;11 leukaemia
tumour line.
The cells are distributed onto microplates and exposed to the test
compounds for 48 hours.
The cell viability is then quantified by a colorimetric assay, the
Microculture Tetrazolium Assay (Cancer Res., 1987, 47,
939-942).
The results are expressed in IC.sub.50 (the concentration of
compound that inhibits cell viability by 50%) and are presented in
Table 1 below.
The results show that the compounds of the invention are
cytotoxic.
TABLE-US-00001 TABLE 1 IC.sub.50 of Bcl-2 inhibition (fluorescence
polarisation test) and of cytotoxicity for RS4; 11 cells IC.sub.50
(nM) Bcl-2 FP IC.sub.50 (nM) MTT RS4; 11 Example 1 5.0 33.6 Example
2 ND 1660 Example 3 24.6 94.9 Example 4 ND 231 Example 5 21.2 44.8
Example 6 25.2 69 Example 7 25.6 90.6 Example 8 ND 255 Example 9
22.4 87.5 Example 10 16.2 205 Example 11 14.2 202 Example 12 5.5
39.6 Example 13 4.4 19.8 Example 14 3.7 8.23 Example 15 11.1 69.4
Example 16 12.6 22.7 Example 17 8.0 75.2 Example 18 3.9 27.6
Example 19 6.0 65.5 Example 20 4.9 164 Example 21 4.7 79.9 Example
22 6.6 45.7 Example 23 3.6 25.4 Example 24 6.2 79.1 Example 25 4.0
33.3 Example 26 4.1 541 Example 27 5.2 93.4 Example 28 7.5 95.3
Example 29 6.6 47.5 Example 30 4.7 771 Example 31 7.2 89.3 Example
32 13.3 240 Example 33 10.9 57.8 Example 34 8.2 47 Example 35 50.0
560 Example 36 71.4 >600 Example 37 60.4 >600 Example 38 7.5
134 Example 39 7.2 19.7 Example 40 64.4 431 Example 41 10.0 22.6
Example 42 5.2 4.36 Example 43 5.1 28.9 Example 44 3.0 5.41 Example
45 38.9 403 Example 46 76.6 >600 Example 47 5.9 44.5 Example 48
4.4 14.9 Example 49 4.0 14.1 Example 50 5.9 33.1 Example 51 26.7
354 Example 52 28.9 433 Example 53 43.5 293 Example 54 18.0 30.5
Example 55 209.6 >600 Example 56 75.0 >600 Example 57 80.0
>600 Example 58 133.3 >600 Example 59 134.0 >600 Example
60 ND 18.3 Example 61 4.5 37.8 Example 62 14.3 127 Example 63 5.1
11.2 Example 65 21.9 113 Example 66 16.9 241 Example 67 12.5 98.6
Example 68 2.1 20.7 Example 69 5.3 3.68 Example 70 8.5 63.5 Example
71 6.1 12.9 Example 72 7.7 43.6 Example 73 8 42.6 Example 74 4 45.4
Example 75 52.9 367 Example 81 ND 249 Example 82 19.5 427 Example
88 15.9 69.6 Example 92 8.4 37.8 Example 93 19.7 368 Example 94 8.6
104 Example 95 7 174 Example 96 13.5 161 Example 97 19 98 Example
98 7.6 68.3 Example 99 6.4 108 Example 100 22.9 193 Example 101
21.1 743 Example 102 2 6.51 Example 108 3.9 15.4 Example 109 91.5
930 Example 110 8.5 39.5 Example 115 3.6 18.3 Example 116 3.4 47.8
Example 122 3.4 82.4 Example 126 4.2 49.2 Example 127 5.3 111
Example 129 18.1 275 Example 207 4.6 32.2 Example 209 7.4 25.4
Example 210 8.8 47.2 Example 214 6.3 236 Example 230 5.1 18.3
Example 358 14.8 165 Example 384 9.7 216 Example 385 5.7 28.7
Example 386 2.6 9.23 Example 387 20.6 243 Example 388 3.6 16.5
Example 389 14.7 208 Example 390 21.2 173 Example 391 30.3 255
Example 392 3.8 11.4 Example 393 2.1 1.95 Example 394 2.5 2.76
Example 395 3.5 7.57 Example 396 15.7 116 Example 397 4.5 37.1
Example 398 3.9 13.4 Example 399 9.9 155 Example 400 49 469 Example
401 8 24.3 Example 402 26.1 241 Example 403 24.2 289 Example 404
24.4 85.5 Example 406 4.2 10.6 Example 407 20.6 150 Example 408 5.4
4.46 Example 409 12.2 41.9 Example 410 9.9 61.6 Example 411 5.5
32.8 Example 412 3.1 0.398 Example 413 3.1 9.43 Example 415 3.8
29.9 Example 416 2.9 42.5 Example 417 3 11 Example 418 10.1 159
Example 419 2.8 15.8 Example 420 6.1 51.8 Example 421 2.5 3.73
Example 422 9.2 101 Example 423 11.7 344 Example 424 13.6 102
Example 425 4.2 62 Example 426 5.2 139 Example 427 2.2 23.3 Example
428 3.5 59.2 Example 429 3.1 109 Example 430 19.9 328 Example 431 3
89 Example 432 3.4 76.6 Example 433 2.6 48.2 Example 434 3.5 45.7
Example 435 14.9 441 Example 436 49.1 338 Example 437 4.4 70.5
Example 438 11.3 379 Example 439 6.1 329 Example 440 2.6 13.6
Example 441 3.5 132 Example 442 3 42.8 Example 443 ND 57.9 Example
444 5.5 181 Example 445 2 19 Example 446 7.8 249 Example 447 20
>600 Example 448 2.4 12.1 Example 449 1.7 11.9 Example 450 2.7
53.2 Example 451 2.9 102 Example 452 8.3 112 Example 453 6.9 99.9
Example 454 6.5 158 Example 455 1.9 11.8 Example 456 2.7 80.6
Example 457 ND 80.4 Example 458 10.5 197 Example 459 2.5 5.93
Example 460 2.8 22.9 Example 461 3.1 18.6 Example 462 13.3 368
Example 463 ND 40.8 Example 464 36.6 723 Example 465 ND 50.6
Example 466 ND 493 Example 467 19.2 188
ND: not determined
EXAMPLE C
Induction of Caspase Activity In Vivo
The ability of the compounds of the invention to activate caspase 3
is evaluated in a xenograft model of RS4;11 leukaemia cells.
1.times.10.sup.7 RS4;11 cells are grafted sub-cutaneously into
immunosuppressed mice (SCID strain). 25 to 30 days after the graft,
the animals are treated orally with the various compounds. Sixteen
hours after treatment, the tumour masses are recovered and lysed,
and the caspase 3 activity is measured in the tumour lysates.
This enzymatic measurement is carried out by assaying the
appearance of a fluorogenic cleavage product (DEVDase activity,
Promega). It is expressed in the form of an activation factor
corresponding to the ratio between the two caspase activities: the
activity for the treated mice divided by the activity for the
control mice.
The results obtained show that the compounds of the invention are
capable of inducing apoptosis in RS4;11 tumour cells in vivo.
EXAMPLE D
Quantification of the Cleaved Form of Caspase 3 In Vivo
The ability of the compounds of the invention to activate caspase 3
is evaluated in a xenograft model of RS4;11 leukaemia cells.
1.times.10.sup.7 RS4;11 cells are grafted sub-cutaneously into
immunosuppressed mice (SCID strain). 25 to 30 days after the graft,
the animals are treated orally with the various compounds. After
treatment, the tumour masses are recovered and lysed, and the
cleaved (activated) form of caspase 3 is quantified in the tumour
lysates.
The quantification is carried out using the "Meso Scale Discovery
(MSD) ELISA platform" test, which specifically assays the cleaved
form of caspase 3. It is expressed in the form of an activation
factor corresponding to the ratio between the quantity of cleaved
caspase 3 in the treated mice divided by the quantity of cleaved
caspase 3 in the control mice.
The results show that the compounds of the invention are capable of
inducing apoptosis in RS4;11 tumour cells in vivo.
TABLE-US-00002 TABLE 2 Caspase activation factors (cleaved caspase
3 MSD test in the tumours of treated mice versus control mice) in
vivo, after treatment by the oral route (exact doses in brackets)
Time period after Activation Compound which the tumour factor .+-.
SEM tested is removed (T) (versus control) Example 25 2 hours 45.7
.+-. 2.0 (25 mg/kg) Example 28 2 hours 72.3 .+-. 5.4 (12.5 mg/kg)
Example 47 2 hours 12.3 .+-. 2.4 (25 mg/kg) Example 61 2 hours 76.0
.+-. 5.2 (12.5 mg/kg) Example 67 2 hours 29.8 .+-. 4.0 (25 mg/kg)
Example 71 2 hours 46.8 .+-. 16.1 (25 mg/kg) Example 74 2 hours
24.5 .+-. 7.4 (12.5 mg/kg) Example 108 2 hours 22.6 .+-. 2.4 (12.5
mg/kg) Example 230 2 hours 42.2 .+-. 9.3 (25 mg/kg) Example 386 2
hours 52.0 .+-. 8.6 (12.5 mg/kg) Example 388 2 hours 85.7 .+-. 3.7
(25 mg/kg) Example 421 2 hours 38.7 .+-. 10.7 (12.5 mg/kg) Example
449 2 hours 50.5 .+-. 3.4 (12.5 mg/kg)
EXAMPLE E
Anti-Tumour Activity In Vivo
The anti-tumour activity of the compounds of the invention is
evaluated in a xenograft model of RS4;11 leukaemia cells.
1.times.10.sup.7 RS4;11 cells are grafted sub-cutaneously into
immunosuppressed mice (SCID strain). 25 to 30 days after the graft,
when the tumour mass has reached about 150 mm.sup.3, the mice are
treated orally with the various compounds in two different regimes
(daily treatment for five days per week for two weeks, or two
treatments weekly for two weeks). The tumour mass is measured twice
weekly from the start of treatment.
The results obtained accordingly show that the compounds of the
invention are capable of inducing significant tumour regression,
which can be total, during the treatment period.
EXAMPLE F
Pharmaceutical Composition: Tablets
TABLE-US-00003 1000 tablets containing a dose of 5 mg of a 5 g
compound selected from Examples 1 to 467 Wheat starch 20 g Maize
starch 20 g Lactose 30 g Magnesium stearate 2 g Silica 1 g
Hydroxypropylcellulose 2 g
* * * * *